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Prefa ce
The National Aeronautics and Space Administration (NASA) is aware
of the potential toxicological hazards to humans that might be associated
with prolonged spacecraft missions. Despite major engineering ad-
vances in controlling the atmosphere within spacecraft, some contami-
nation of the air appears inevitable. NASA has measured numerous
airborne contaminants during space missions. As the missions increase
in duration and complexity, ensuring the health and well-being of astro-
nauts traveling and working in this unique environment becomes in-
creasingly difficult.
As part of its efforts to promote safe conditions aboard spacecraft,
NASA requested the National Research Council (NRC) to develop
guidelines for establishing spacecraft maximum allowable concentrations
(SMACs) for contaminants, and to review SMACs for various space-
craft contaminants to determine whether NASA's recommended expo-
sure limits are consistent with the guidelines recommended by the sub-
committee.
In response to NASA's request, the NRC organized the Subcommit-
tee on Guidelines for Developing Spacecraft Maximum Allowable Con-
centrations for Space Station Contaminants within the Committee on
Toxicology (COT). In the first phase of its work, the subcommittee
developed the criteria and methods for preparing SMACs for spacecraft
contaminants. The subcommittee's report, entitled Guidelines for De-
veloping Spacecraft Maximum Allowable Concentrations for Space Sta-
tion Contaminants, was published in 1992. The executive summary of
that report is reprinted as Appendix A of this volume.
xi
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In the second phase of the study, the Subcommittee on Spacecraft
Maximum Allowable Concentrations reviewed reports prepared by
NASA scientists and contractors recommending SMACs for approxi-
mately 35 spacecraft contaminants. The subcommittee sought to deter-
mine whether the SMAC reports were consistent with the 1992 guide-
lines. Appendix B of this volume contains the SMAC reports for 12
chemical contaminants that have been reviewed for their application of
the guidelines developed in the first phase of this activity and approved
by the subcommittee. This report is the second volume in the series
Spacecraft McLrimum Allowable Concentrations for Space Station Con-
taminants. The first volume was published in 1994.
The subcommittee gratefully acknowledges the valuable assistance
provided by the following personnel from NASA and its contractors:
Dr. John James, Dr. Martin Coleman, Dr. Lawrence Dietlein, Mr. Jay
Perry, Mr. Kenneth Mitchell (all from NASA), Mr. James Hyde (Jet
Propulsion Laboratory), Dr. King Lit Wong (U.S Department of Com-
merce, Patent and Trademark Office), Dr. Hector Garcia, Dr. Chiu
Wing Lam (both from Krug International), and Mr. Donald Cameron
(Boeing Company). The subcommittee is grateful to astronauts Drs.
Shannon Lucid, Drew Gaffney, Mary Cleave, and Martin Fettman for
sharing their experiences. The subcommittee also acknowledges the
valuable assistance provided by the Johnson Space Center, Houston,
Texas, the Marshall Space Flight Center, Huntsville, Alabama, the
Kennedy Space Center, Cape Canaveral, Florida, and the Space Station
Freedom Program Office, Reston, Virginia, for providing tours of their
facilities. No effort of this kil_d can be accomplished without the hard
work and dedication of Sharon Holzmann, Catherine Kubik, and Mar-
garet McVey. Lucy Fusco was the project assistant. Ruth Crossgrove
edited the report. The subcommittee particularly acknowledges Dr.
Kulbir Bakshi, project director for the subcommittee, whose hard work
and expertise were most effective in bringing the report to completion.
Donald E. Gardner, Chair
Subcommittee on Spacecraft Maximum
Allowable Concentrations
Rogene F. Henderson, Chair
Committee on Toxicology
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Spacecraft Maximum Allowable
Concentrations for Selected
Airborne Contaminants
INTRODUCTION
he space station--a multinational effort--is expected to be
launched in 1997 and, in its present configuration, is expected to
carry a crew of four to eight astronauts for up to 180 days. Be-
cause the space station will be a closed and complex environment, some
contamination of its internal atmosphere is unavoidable. Several hun-
dred chemical contaminants are likely to be found in the closed-loop
atmosphere of the space station, most at very low concentrations. Im-
portant sources of atmospheric contaminants include off-gassing of
cabin materials, operation of equipment, and metabolic waste products
of crew members. Other potential sources of contamination are releases
of toxic chemicals from experiments and manufacturing activities per-
formed on board the space station and accidental spills and fires. The
water recycling system has also been shown to produce chemical con-
taminants that can enter the cabin air. Therefore, the astronauts poten-
tially can be chronically exposed to low levels of airborne contaminants
and occasionally to high levels of contaminants in the event of a leak,
spill, or fire.
The National Aeronautics and Space Administration (NASA) seeks to
ensure the health, safety, and functional abilities of astronauts and seeks
to prevent the exposure of astronauts to toxic levels of spacecraft con-
taminants. Consequently, exposure limits need to be established for
continuous exposure of astronauts to spacecraft contaminants for up to
180 days (for normal space-station operations) and for short-term (1-24
hr) emergency exposures to high levels of chemical contaminants.
Federal regulatory agencies, such as the U.S. Occupational Safety
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and Health Administration (OSHA) and the U.S. Environmental Protec-
tion Agency (EPA), have not promulgated exposure limits for the
unique environment of spacecraft, nor are their existing standards ap-
propriate for this environment. In 1972, the National Research Coun-
cil's Committee on Toxicology (COT) first recommended maximum
levels for continuous and emergency exposures to spacecraft contami-
nants (NRC, 1972). However, that early report did not provide docu-
mentation of toxicity data or the rationale for the recommended expo-
sure levels. Toxicity data for most of the compounds were not well
developed at that time, and the risk-assessment methods were rudimen-
tary. Over the past several years, COT has recommended emergency
exposure guidance levels (EEGLs) and continuous exposure guidance
levels (CEGLs) for several hundred chemical substances for the U.S.
Department of Defense (NRC, 1984a,b,c,d; 1985a,b; 1986; 1987;
1988). However, EEGLs and CEGLs are not available for most space-
craft contaminants. Because of the experience of COT in recommend-
ing EEGLs and CEGLs, NASA requested that COT establish guidelines
for developing spacecraft maximum allowable concentrations (SMACs)
that could be used uniformly by scientists involved in preparing SMACs
for airborne contaminants and review the SMACs for individual con-
taminants to ascertain whether they are consistent with the guidelines.
SMACs are intended to provide guidance on chemical exposures dur-
ing normal operations of spacecraft as well as emergency situations.
Short-term SMACs refer to concentrations of airborne substances (such
as a gas, vapor, or aerosol) that will not compromise the performance
of specific tasks by astronauts during emergency conditions or cause
serious or permanent toxic effects. Such exposures might cause revers-
ible effects, such as mild skin or eye irritation, but they are not expect-
ed to impair judgment or interfere with proper responses to emergen-
cies. Long-term SMACs are intended to avoid adverse health effects
(either immediate or delayed) and to prevent decremental change in
crew performance under continuous exposure to chemicals in the closed
environment of the space station for as long as 180 days.
In response to NASA's request to establish guidelines for developing
SMACs and to review SMAC documents for selected spacecraft con-
taminants, COT organized the Subcommittee on Guidelines for Devel-
oping Spacecraft Maximum Allowable Concentrations for Space Station
Contaminants. The subcommittee comprised experts in toxicology, epi-
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demiology, medicine, physiology, biochemistry, pathology, pharmacol-
ogy, neurotoxicology, industrial hygiene, statistics, and risk assessment.
In the first phase of the study, the subcommittee prepared Guidelines
for Developing Spacecraft Maximum Allowable Concentrations for
Space Station Contaminants (NRC, 1992). That report provided guid-
ance for deriving SMACs from available toxicological and epidemiolog-
ical data. It also provided guidance on what data to use, how to evalu-
ate the data for appropriateness, how to perform risk assessment for
carcinogenic and noncarcinogenic effects, and how to consider the ef-
fects of physiological changes induced by microgravity that might en-
hance the susceptibility of astronauts to certain spacecraft contaminants.
The executive summary of that report is contained in Appendix A of
this volume.
SUMMARY OF REPORT ON
GUIDELINES FOR DEVELOPING SMACS
As described in Appendix A, the first step in establishing SMACs for
a chemical is to collect and review all relevant information available on
a compound. Various types of evidence are assessed in establishing
SMAC values for a chemical contaminant. These include information
from (1) chemical-physical characterizations, (2) structure-activity rela-
tionships, (3) in vitro toxicity studies, (4) animal toxicity studies, (5)
human clinical studies, and (6) epidemiological studies. For chemical
contaminants, dose-response data from human exposure are most appli-
cable and are used when available in preference to data from animal
studies and in vitro studies. Toxicity data from inhalation exposures
are most useful because inhalation is the most likely route of exposure.
For most chemicals, actual human toxicity data are not available.
Therefore, toxicity data from studies conducted in animals are extrapo-
lated to estimate the potential toxicity in humans. Extrapolation re-
quires experienced scientific judgment. The toxicity data from animal
species most representative of humans in terms of pharmacodynamic
and pharmacokinetic properties are used for determining SMACs. If
data are not available on which species best represents humans, the data
from the most sensitive animal species are used to set SMACs. Safety
or uncertainty factors are commonly used when animal data are extrap-
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olated to a safe level for humans. The magnitude of uncertainty factors
depends on the quality of the animal data used to determine the no-
observed-adverse-effect level (NOAEL). Conversion from animals to
humans is done on a body-weight or surface-area basis. When avail-
able, pharmacokinetic data on tissue doses are considered for use in
species interconversion.
Based on the review of the toxicity data and the use of appropriate
safety factors, SMACs for different periods are developed, and a ration-
ale is provided for each recommendation. One- or 24-hr emergency
SMACs are usually derived from acute exposure toxicity studies. De-
velopment of 1- or 24-hr SMACs usually begins with providing a
SMAC for the shortest exposure of 1 hr. Values for 24-hr SMACs
might necessitate using Haber's rule (C x T = k) when applicable.
Detoxification or recovery and data available on 24-hr exposures are
taken into account in modifying Haber's rule.
When data from chronic exposure studies are available, they are used
to derive 7-, 30-, or 180-day SMACs, and safety factors are applied as
needed. For substances that affect several organ systems or have multi-
ple effects, all end points--including reproductive (in both sexes), de-
velopmental, carcinogenic, neurotoxic, respiratory, and other organ-re-
lated effects--are evaluated, the most important or most sensitive effects
receiving the major attention. With carcinogenic chemicals, quantita-
tive carcinogenic assessment is done, and the SMAC is set so that the
estimated lifetime risk of a neoplasm is no more than 1 in 10,000 ex-
posed persons. When a substance is known to cause an effect that will
be aggravated by microgravity, additional safety factors are used.
REVIEW OF SMAC REPORTS
In the second phase of the study, the Subcommittee on Spacecraft
Maximum Allowable Concentrations reviewed reports for approximate-
ly 35 spacecraft contaminants to determine whether the recommended
exposure limits were consistent with the 1992 guidelines (see Appendix
A). The SMAC reports were prepared solely by NASA scientists or
contractors.
These SMAC reports are intended for use by engineers in developing
design criteria for the space station. The SMAC reports will also be
applicable to the space shuttle, because the recommended SMACs will
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cover the exposure times that are of interest to the space-shuttle pro-
gram--l-hr and 24-hr SMACs for emergencies and 7-day and 30-day
SMACs for continuous exposures.
The subcommittee's review of the SMAC reports prepared by
NASA, NASA's contractors, and members of the subcommittee in-
volved both oral and written presentations to the subcommittee by the
authors of the reports. The subcommittee provided advice and recom-
mendations for revisions. The authors of the SMAC reports presented
their revised reports at subsequent meetings until the subcommittee
agreed that the reports followed the guidelines developed in the first
phase of the study (NRC, 1992).
The subcommittee recognizes that many factors, such as the altera-
tions in normal human physiological and biochemical processes associ-
ated with spaceflight, are not fully understood and could warrant revi-
sions of proposed SMAC values as additional scientific data become
available. Because of the enormous amount of data presented in the
SMAC reports, the subcommittee could not verify all the data. The sub-
committee relied on NASA scientists for the accuracy and completeness
of the toxicity data cited in the SMAC reports. Although individual
data points were not verified by the subcommittee, the subcommittee
agrees with the proposed SMAC values.
This report is the second volume in the series Spacecraft Maximum
Allowable Concentrations for Selected Airborne Contaminants. It con-
tains SMAC reports on 12 spacecraft contaminants. The subcommittee
concludes that these reports, presented in Appendix B, are consistent
with the 1992 NRC guidelines. The first report in the series, Spacecraft
Maximum Allowable Concentrations for Selected Airborne Contami-
nants, Volume I, published in 1994, contains SMAC reports on 11 sub-
stances. SMAC reports for additional spacecraft contaminants will be
presented in subsequent volumes.
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Guidelines for Developing Spacecraft
Maximum Allowable Concentrations
for Space Station Contaminants:
Executive Summary
he National Aeronautics and Space Administration (NASA) is
preparing to launch a manned space station by the mid-1990s.
Because the space station will be a closed complex environment,
some contamination of its atmosphere is inevitable. Several hundred
chemicals are likely to be found in the closed atmosphere of the space
station, most in very low concentrations. Important sources of atmos-
pheric contaminants include metabolic waste products of crew members
and off-gassing of cabin materials and equipment. Release of chemicals
from experiments performed on board the space station is also a possi-
ble source of contamination, and the water reclamation system has the
potential to introduce novel compounds into the air. NASA is con-
cerned about the health, safety, and functional abilities of crews ex-
posed to these contaminants.
This report, prepared by the Committee on Toxicology of the
National Research Council's Board on Environmental Studies and Toxi-
cology, is in response to a request from NASA for guidelines to devel-
op spacecraft maximum allowable concentrations (SMACs) for space-
station contaminants. SMACs are used to provide guidance on allow-
able chemical exposures during normal operations and emergency situa-
tions. Short-term SMACs refer to concentrations of airborne substances
(such as gas, vapor, or aerosol) that will not compromise the perfor-
mance of specific tasks during emergency conditions lasting up to 24
hr. Exposure to 1- or 24-hr SMACs will not cause serious or perma-
nent effects but may cause reversible effects that do not impair judg-
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ment or interfere with proper responses to emergencies such as fires or
accidental releases.
Long-term SMACs are intended to avoid adverse health effects (ei-
ther immediate or delayed) and to avoid degradation in crew perform-
ance with continuous exposure in a closed space-station environment for
as long as 180 days. Chemical accumulation, detoxification, excretion,
and repair of toxic insults are thus important in determining 180-day
SMACs.
ENVIRONMENTAL CONTROL AND
LIFE-SUPPORT SYSTEM
The environmental control and life-support system (ECLSS) of the
space station is designed to control temperature, humidity, and compo-
sition of space-station air, including CO2 removal; recover water; dis-
pose of waste; and detect and suppress fires. Fires are a great potential
hazard and much attention has been given to suppressing them. A fire
suppression system is available, but if all else fails, an escape vehicle
can be used. A subsystem of the ECLSS, the atmosphere revitalization
system, which includes a mass spectrometer called the major constituent
analyzer, will analyze cabin air for 02, N2, Hz, CO, H20, and CH 4 in
all areas of the habitation and laboratory modules. A design criterion
for the atmosphere revitalization subsystem is the maintenance of space-
station exposure levels below the 180-day SMACs under normal condi-
tions.
MODIFICATION OF CONTAMINANT
TOXICITY BY ENVIRONMENTAL FACTORS
The special conditions of the space environment must be taken into
account in defining spacecraft contaminant exposure limits. Deposition
of particles is clearly different and lung function and the toxic potential
of inhaled particles may be different under microgravity conditions than
under full gravity conditions, as on earth.
Astronauts will be physically, physiologically, and psychologically
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compromised for the following reasons: loss of muscle and bone mass,
altered immune system, cardiovascular changes, decreased red-blood-
cell mass, altered nutritional requirements, behavioral changes from
stress, fluid shift in the body, altered hormonal status, and altered drug
metabolism. These changes could be important factors in disease sus-
ceptibility.
The physiological changes noted in spaceflight to date demonstrate
that the astronaut is in an altered homeostatic state and thus may be
more susceptible to toxic chemicals. How this altered state modifies
reactions to chemicals in the space-station environment is not fully
known. The physiological changes induced in the space crew are im-
portant and their impact must be taken into account in developing
SMAC values for various contaminants.
SOURCES AND TYPES OF DATA FOR
ESTABLISHMENT OF SMACS
The subcommittee recommends the use of data derived from a num-
ber of sources in establishing SMAC values. These sources provide
information on a variety of health effects including mortality, morbid-
ity, clinical signs and symptoms, pulmonary effects, neurobehavioral
effects, immunotoxicity, reproductive and developmental toxicity, pa-
thology, mutagenicity, carcinogenicity, and biochemical and enzyme
changes.
Chemical-Physical Characteristics of Toxicants
The chemical and physical characteristics of a substance provide
valuable information on potential tissue dosimetry of the compound
within the body and on its likely toxic effects. Preliminary estimates of
the toxic potential of new chemicals also may be derived from known
toxicities of structurally similar, well-investigated compounds. How-
ever, additional uncertainty (safety) factors must be applied to arrive at
safe levels for those congeners that have no dose-response data from
intact animals.
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In Vitro Toxicity Studies
Useful information can be obtained from studies conducted to investi-
gate adverse effects of chemicals on cellular or subcellular systems in
vitro. Systems in which toxicity data have been collected include iso-
lated organ systems, single-cell systems, and tissue cultures from multi-
cellular organisms maintained under defined conditions or from func-
tional units derived from whole cells. In vitro studies can be used to
elucidate the toxic effects of chemicals and to study their mechanism of
action.
Animal Toxicity Studies
The data necessary to evaluate the relationship between exposure to a
toxic chemical and its effects on people are frequently not available
from human experience; therefore, animal toxicity studies must be re-
lied on to provide information on responses likely to occur in humans.
The usefulness of animal data depends in part on the route of expo-
sure and species used. Although inhalation studies are most relevant in
assessing the toxicity of atmospheric contaminants, data from skin ab-
sorption, ingestion, and parenteral studies are also useful. The relevance
of animal data to humans may be limited by the absence of information
on affected target organs and knowledge of metabolic pathways and
pharmacokinetics in animals and humans.
Clinical and Epidemiological Observations
In establishing SMACs for chemicals, dose-response data from hu-
man exposure should be used whenever possible. Data from clinical
inhalation exposures are most useful because inhalation is the most like-
ly route of exposure. Human toxicity data also are available from epi-
demiological studies of long-term industrial exposures, from short-term
high-level exposures following accidents, or from therapeutic uses of
some pharmaceutical agents. Some of these data provide a basis for
estimating a dose-response relationship.
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Epidemiological studies have contributed to our knowledge of the
health effects of many airborne chemical hazards. The limitations of
epidemiology stem from its use of available data. The accuracy of data
on health outcomes varies with the source of the information, and re-
cords documenting historical exposure levels are often sparse. For ex-
ample, mortality information derived from death certificates is some-
times inaccurate, and exposure information collected from administra-
tive purposes is limited. Despite these limitations, if the populations
studied are large enough and have been exposed to high enough doses
over a sufficient period to allow for the expression of disease, epidemi-
ological studies usually provide valuable information on the effects of
exposure in humans without resorting to cross-species extrapolation or
to exposing humans in an experimental situation to possible injuries
from chemical hazards.
Pharmacokinetics and Metabolism
Evaluation of the health effects of any chemical in a given environ-
ment is greatly facilitated by an understanding of its physiological dis-
position in the body. Many chemicals require some form of metabolic
activation to exert their toxic effects. The formation of reactive metab-
olites may depend on the level of exposure and the pharmacokinetics of
the chemical. Modern pharmacokinetic studies can provide physiologi-
cally based models describing disposition of chemicals within organs
and tissues in the body. The space station is a closed system with lim-
ited capacity to clear the air of chemical vapors; the crew contributes to
the removal of the chemicals from the air through sequestration and
metabolism.
Toxic metabolites may be highly reactive chemically. These metabo-
lites are biologically reactive intermediates that may covalently bind to
nucleic acids or proteins that in turn, may alter DNA replication or
transcription. In addition to formation of reactive metabolites, meta-
bolic activity also may lead to formation of species of active oxygen
that may damage nucleic acids or proteins or cause lipid peroxidation.
The resulting health effects may range from direct, short-term target-
organ toxicity to carcinogenesis.
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Biological Markers
Biological markers are indicators of change within an organism that
link exposure to a chemical to subsequent development of adverse
health effects. Biological markers within an exposed individual can
indicate the degree of exposure to a pollutant and may provide evidence
of the initial structural, functional, or biochemical changes induced by
the exposure and, ultimately, the biochemical or physiological changes
associated with adverse health effects.
Biological markers can be divided into three classes:
1. Biological markers of exposure to pollutants may be thought of
as "footprints" that the chemical leaves behind upon interaction with the
body. Such markers contain the chemical itself or a metabolic fragment
of the chemical and thus are usually chemical-specific.
2. Biological markers of the effects of exposure include the totality
of subclinical and clinical signs of chemically induced disease states.
The markers of greatest interest are those that are early predictors of
serious effects or late-occurring effects. Such markers would be useful
in determining what levels of pollutants in the space station can be tol-
erated without causing irreversible deleterious health effects.
3. Biological markers of increased susceptibility to the effects of
exposure to pollutants could be used to predict which persons are most
likely to be at excess risk as space-station crew members.
RISK ASSESSMENT
(DEVELOPMENT OF EXPOSURE CRITERIA)
The assessment of toxicants that do not induce carcinogenic or muta-
genic effects traditionally has been based on the concept that an adverse
health effect will not occur below a certain level of exposure, even if
exposure continues over a lifetime. Given this assumption, a reference
dose intended to avoid toxic effects may be established by dividing the
no-observed-adverse-effect level by an appropriate uncertainty factor or
set of factors.
For carcinogenic effects, especially those known to be due to direct
mutagenic events, no threshold dose may exist. However, when carci-
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nogenesis is due to epigenetic or nongenotoxic mechanisms, a threshold
dose may be considered. Attempts to estimate carcinogenic risks associ-
ated with levels of exposure have involved fitting mathematical models
to experimental data and extrapolating from these models to predict
risks at doses that are usually well below the experimental range. The
multistage model of Armitage and Doll is used most frequently for low-
dose extrapolation. According to multistage theory, a malignant cancer
cell develops from a single stem cell as a result of a number of biologi-
cal events (e.g., mutations) that must occur in a specific order. Recent-
ly, a two-stage model that explicitly provides for tissue growth and cell
kinetics also has been used in carcinogenic risk assessment.
The multistage model, characterized by low-dose linearity, forms the
basis for setting SMACs for carcinogens. Low-dose linearity is gener-
ally assumed for chemical carcinogens that act through direct interaction
with genetic material.
ISSUES IN MAKING RECOMMENDATIONS
FOR THE ESTABLISHMENT OF SMACS
A number of issues need to be considered in developing recommen-
dations for establishing SMACs. These issues include (I) translating
animal toxicity data to predict toxicities in humans; (2) determining 30-
or 180-day SMACs for carcinogens based on toxicological or epidemio-
logical studies that often involve long-term or lifetime exposure; (3)
considering limits set by the Occupational Safety and Health Adminis-
tration, the American Conference of Governmental Industrial Hygien-
ists, and the National Research Council in developing SMACs; (4) eval-
uating the toxicities of mixtures; and (5) modifying risk assessments
based on the altered environment in the microgravity of space.

App en dix B
Reports on Spacecraft Maximum
Allowable Concentrations for
Selected Airborne Contaminants

B1 Acrolein
King Lit Wong, Ph.D.
Johnson Space Center Toxicology Group
Biomedical Operations and Research Branch
Houston, Texas
PHYSICAL AND CHEMICAL PROPERTIES
Acrolein is a colorless or yellowish, volatile, flammable liquid with
an extremely sharp, irritating odor (Sax, 1984).
Synonyms:
Formula:
CAS number:
Molecular weight:
Boiling point:
Melting point:
Vapor pressure:
Conversion factors
at 25°C, 1 atm:
2-Propenal, acrylic aldehyde
CH2CHCHO
107-02-08
56
52.7°C
-87 °C
214 mm Hg at 20°C
1 ppm = 2.29 mg/m 3
1 mg/m 3 = 0.44 ppm
OCCURRENCE AND USE
Acrolein is not used in the spacecraft, but acrolein is a potential at-
mospheric contaminant in spacecraft because it was found to be off-
gassed from the hardware of two Spacelab missions at a rate of 0.007
mg/d (Geiger, 1984).
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PHARMACOKINETICS AND METABOLISM
In dogs, inhaled acrolein is primarily retained by the upper respira-
tory tract (Bowes and Cater, 1968). In the rat, the evidence suggests
that acrolein is oxidized by two pathways. The liver and lung micro-
somes oxidize acrolein in vitro to its epoxide metabolite, glycidaldehyde
(Patel et al., 1980), which is converted to glyceraldehyde by epoxide
hydrase (Hayakawa et al., 1975). Acrolein is also oxidized to acrylic
acid probably involving aldehyde dehydrogenase (Patel et al., 1980).
In rats given acrolein orally, S-carboxyethylmercapturic acid is the me-
tabolite found in urine (Draminski et al., 1983).
TOXICITY SUMMARY
The major toxicity of acrolein is mucosal irritation.
Acute and Short-Term Toxicity
Mucosal Irritation
The NRC's Committee on Toxicology cited a report by the Shell
Chemical Corporation that acrolein produced moderate mucosal irrita-
tion at a concentration as low as 0.25 ppm in humans, but no informa-
tion on the exposure duration was given (Shell Chemical Corp., 1958).
In comparison, Weber-Tschopp et al. (1977) reported that an exposure
to acrolein at 0.3 ppm resulted in only a little eye discomfort in 1.5 min
and moderate eye irritation in 1 h. Darley et al. (1960) demonstrated
that a 5-min exposure to acrolein at 1.3-1.6 ppm was found to produce
only moderate eye irritation in college students. In contrast, Sim and
Pattie (1957) found that 1.2 ppm was extremely irritating to the muco-
sal surfaces in 5 min. Because of these variations in human test results,
comparisons of the qualitative descriptions of acrolein's irritancy in dif-
ferent studies should be made with care.
Some studies show that acrolein's eye irritancy tends to increase pro-
gressively within the first 40 min of the exposure. Stephens et al.
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(1961) showed that an exposure to acrolein at 0.5 ppm resulted in eye
irritation in 10-35% of subjects within 5 min and in 91% within 12 min
(Stephens et al., 1961). Exposure to acrolein at 0.3 ppm produced mild
eye irritation in human subjects in 10 min, mild-to-moderate eye irrita-
tion in 20 min, and moderate eye irritation in 40 min (Weber-Tschopp
et al., 1977). From 40 to 60 min, the degree of eye, nose, and throat
irritation stayed constant (Weber-Tschopp et al., 1977).
The relative sensitivity of human eyes and nose toward acrolein's
irritation depends on the exposure concentration and duration. For ex-
posures lasting about an hour, acrolein is more irritating to the eyes
than the nose; the reverse is true for short exposures at below 0.3 ppm
(Weber-Tschopp et al., 1977). A 40-60 min exposure to acrolein at 0.3
ppm caused moderate eye irritation and slight nose irritation (Weber-
Tschopp et al., 1977). In a 1.5-min exposure of human volunteers to
acrolein, 0.6 ppm produced the same degree of irritation in the eyes
and the nose (somewhat slight irritation) (Weber-Tschopp et al., 1977).
However, in a similar exposure, 0.15 ppm caused a little bit of nose
discomfort, although it was not irritating to the eyes (Weber-Tschopp et
al., 1977).
There are some data on acrolein's dose-response relationship in the
literature. Darley et al. (1960) showed that in a 5-min exposure of hu-
mans to acrolein, the eye irritation was moderate at a concentration of
1.3-1.6 ppm and moderate to severe at 2.0-2.3 ppm. Weber-Tschopp
et al. (1977) reported that in human volunteers exposed to acrolein for
1.5 min, mild irritation to the eyes and nose was detected at 0.60 ppm,
a little bit of discomfort to the eyes and nose was detected at 0.30 ppm,
and a little bit of discomfort to the nose and no effect on the eye was
detected at 0.15 ppm (Weber-Tschopp et al., 1977). Probably because
of the little bit of discomfort to the nose, some of the test subjects ex-
pressed a desire to leave the room when questioned in a survey, and
they characterized the air quality as acceptable, versus good by the con-
trol group (Weber-Tschopp et al., 1977).
The exposure concentration seems to be more important than the ex-
posure duration in causing acute irritating effects in humans. Sim and
Pattie (1957) found that an exposure to acrolein at 0.8 ppm produced
lacrimation in humans in 20 s. However, at a slightly higher concen-
tration of 1.2 ppm, acrolein produced lacrimation in only 5 s. Had ac-
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rolein's mucosal irritancy followed Haber's rule, 1.2 ppm would not be
expected to produce lacrimation until 13 s into an exposure. That
means C x T was not constant in that study.
Respiratory Effects
Like most sensory irritants, acrolein also affects respiration. In
about half of the human volunteers exposed to acrolein at 0.3 ppm, re-
spiratory rates were decreased by 10% after 10 min of exposure
(Weber-Tschopp et al., 1977). A 10-min exposure of Swiss-Webster
mice to acrolein at 0.22 ppm also resulted in a decrease of approximate-
ly 25% in the respiratory rate (Steinhagen and Barrow, 1984). Even an
exposure as low as 0.04 ppm resulted in a decrease of about 10% in the
respiratory rate in the mouse (Steinhagen and Barrow, 1984). In guinea
pigs exposed to acrolein at 0.4-1.0 ppm for 2 h, there were decreases in
the respiratory rate and increases in the total pulmonary resistance
(Murphy et ai., 1963). The respiratory effects of acrolein in both the
mouse and guinea pig are readily reversible when the exposure ends
(Steinhagen and Barrow, 1984; Murphy et al., 1963). In a recent
study, a 2-h exposure of guinea pigs to acrolein at 0.3 ppm increased
the pulmonary resistance and bronchial responsiveness (Leikauf et al.,
1989). In the lung lavage fluid, the exposure also increased the amount
of thromboxane B2 and prostaglandin F2 immediately after exposure and
the number of neutrophils 24 h after exposure (Leikauf et al., 1989).
Miscellaneous Effects
Acrolein readily reacts with sulfhydryl groups. As a result, a 3-h in-
halation exposure of rats to acrolein at 2.5 ppm decreased mucosal glu-
tathione in the respiratory region of the nose (Lam et al., 1985). A 6-h
exposure of rats to acrolein at 2 ppm did not cause DNA-protein cross-
links in the respiratory mucosa of the nose (Lam et al., 1985).
Finally, acrolein exposures at a sufficiently high concentration could
be lethal. The 6-tl LCs0 of acrolein in mice was 66 ppm (Philippin et
al., 1970) and one man died 10 min after exposure at 150 ppm
(Prentiss, 1937).
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Subchronic and Chronic Toxicity
Mucosal Irritation and Effects
on the Respiratory System
Subchronic exposures to acrolein generally produced signs of muco-
sal irritation and pathology of the respiratory system. An exposure of
mice to acrolein at 6 ppm for 2 w, 6 h/d, 5 d/w caused atelectasis, in-
flammation, and edema in the lung and body-weight reduction
(Philippin et al., 1970). When the acrolein exposure was extended to
6 w, 8 h/d, 5 d/w, Lyon et al. (1970) found that 3.7 ppm produced eye
irritation, squamous metaplasia, and basal-cell hyperplasia in the trachea
of monkeys. Dogs, rats, and guinea pigs were similarly exposed in the
same study, but the rats and guinea pigs appeared to be less susceptible
to acrolein than the monkeys; the rats and guinea pigs did not show any
gross sign of irritation, tracheal metaplasia, or tracheal hyperplasia
(Lyon et al., 1970). Only two dogs were used in each exposure group,
and in general the clinical signs of eye and nose irritation as well as
lung injury in the dogs were similar to those in the monkeys. An expo-
sure of acrolein at 0.7 ppm for 6 w, 8 h/d, 5 d/w caused chronic peri-
bronchial inflammation in all exposed animals, indicating chronic bron-
chial irritation (Lyon et al., 1970).
Unfortunately, the nose was not examined microscopically in any of
the experimental animals in either of the subchronic studies reviewed
above. Feron et al. (1978) were the first to look for any nasal histopa-
thology produced by acrolein. In an exposure of hamsters, rats, and
rabbits to acrolein for 13 w, 6 h/d, 5 d/w, Feron et al. found that the
rat was the most susceptible species, and the rabbit appeared to be the
least susceptible. The 13-w exposure at 1.4 ppm resulted in metaplasia
and inflammation of the nasal mucosa in the rats, only minimal nasal
inflammation in the hamsters, and no adverse effects in the rabbits
(Feron et al., 1978). The no-observed-adverse-effect level (NOAEL)
was 0.4 ppm for this exposure of hamsters and rats to acrolein for 13
w, 6 h/d, 5 d/w (Feron et al., 1978).
In a 6-w exposure of mice, acrolein at 2 ppm for 6 h/d had no effect
on the body-weight gain and the wet-to-dry lung-weight ratio in the
mice (Northrop, 1985). However, it is of interest that a 6-w exposure
of mice to acrolein at 4 ppm for 3 h/d or at 8 ppm for 1.5 h/d also did
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not affect the wet-to-dry lung-weight ratio, but it did reduce the body-
weight gain (Northrop, 1985). These results show that, in subchronic
exposures to acrolein, the exposure concentrations seem to be more im-
portant than the exposure times. As discussed above, a similar conclu-
sion was drawn for the acute mucosal irritancy of acrolein in humans.
Lyon et al. (1970) exposed monkeys, dogs, rats, and guinea pigs to
acrolein continuously for 90 d, but no nasal microscopic examinations
were conducted. Lyon et al. did observe that exposure to acrolein at
1.0 ppm produced ocular and nasal discharge, squamous metaplasia,
and basal-cell hyperplasia in the tracheas of the monkeys. The effects
from the exposure on the internal organs of the monkeys might not be
reliable, because parasitic infestation was found in the lungs, livers,
hearts, and brains of these monkeys (Lyon et al., 1970). The 1.0-ppm
exposure did not cause any exposure-related histopathological changes
in the tracheas or lungs of the guinea pigs and rats (Lyon et al., 1970).
Lyon et al. used only two dogs in the 1.0-ppm exposure group, and the
dogs reacted to acrolein exposure similarly to the monkeys. A 90-d
continuous exposure of four dogs to acrolein at 0.22 ppm led to emphy-
sema and lung congestion in two dogs.
Miscellaneous Effects
In the 90-d continuous exposure of four dogs to acrolein conducted
by Lyon et al. (1970), an exposure at 0.22 ppm resulted in splenic
hemorrhage in two dogs and thyroid hyperplasia in the other two dogs.
However, no exposure-related histopathological changes were detected
in the internal organs of the monkeys, guinea pigs, and rats. (Lyon et
al. did not examine the trachea in the 0.22-ppm exposure groups.) A
similar exposure at 1.0 ppm was found to cause focal liver necrosis in
guinea pigs and rats. The meaning of the finding of liver necrosis is
uncertain, because a 90-d continuous exposure at a higher concentration
of 1.8 ppm failed to induce liver necrosis in the guinea pigs and rats
(Lyon et al., 1970).
In addition to the Lyon et al. investigation, Sinkuvene (1970) investi-
gated the toxic effects of a continuous subchronic exposure to acrolein.
The latter study showed that a 16-d continuous exposure of rats to acro-
lein at 0.056 ppm produced some changes, but they were not specified
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(Sinkuvene, 1970). A similar exposure at 0.011 ppm failed to change
the blood cholinesterase activity, the "chronaxy" of antagonistic mus-
cles, and body-weight gain (Sinkuvene, 1970).
Carcinogenicity
The U.S. Environmental Protection Agency (EPA) classified acrolein
as a possible human carcinogen on the basis of limited animal carcino-
genicity data, mutagenicity in bacteria, and structural similarity with
two probable human carcinogens, formaldehyde and acetaldehyde
(EPA, 1990). A 1-y exposure of hamsters to acrolein at 4 ppm failed
to cause any increase in tumor incidence (Feron and Kruysse, 1977).
However, the hamster study did not prove that acrolein is noncarcino-
genic in laboratory animals for two reasons. First, it is likely that 1 y
is not of sufficient duration for exposure. Second, the hamster has not
been shown to be the most sensitive test species, at least on the basis of
noncarcinogenic end points, to the toxicity of acrolein in subchronic
exposures (Feron et al., 1978). Lijinski and Reuber (1987) found an
increased incidence of adrenal cortical adenomas in female rats given
acrolein at a concentration of 625 ppm in drinking water for 5 d/w for
100 w, but the increase was not statistically significant. (Evidence of
the carcinogenicity of acrolein in this study is inconclusive, however,
because of the p difference and the small number of rats, 20 in each
group used.) It should be noted that there is no evidence of the carci-
nogenicity of acrolein in humans (EPA, 1990). The International Agen-
cy for Research on Cancer (IARC) characterized acrolein as a com-
pound with inadequate evidence of carcinogenicity in both humans and
animals (IARC, 1987).
Genotoxicity
There are some indications that acrolein might be genotoxic. It in-
duced mutations in Salmonella typhimurium strain TA104 but not in
strains TA98, TA1535, TA1537, and TA1538 (Lutz et al., 1982;
Hales, 1982; Marnett et al., 1985). Acrolein induced recessive lethal
mutations in Drosophila melanogaster (Zimmering et al., 1985) and
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sister chromatid exchange in Chinese hamster ovary cells (Au et al.,
1980). However, acrolein failed to affect the dominant lethal assay in
mice after an intraperitoneai injection (Epstein et al., 1972).
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TABLE 1-2 Exposure Limits Set by Other Organizations
Organization Concentration, ppm
ACGIH's TLV 0.1 (TWA)
ACGIH's STEL 0.3
OSHA's PEL 0.1 (TWA)
NIOSH's IDLH 5
NRC's 10-min EEGL 0.1
NRC's 60-min EEGL 0.05
NRC's 24-h EEGL 0.01
NRC's 90-d CEGL 0.01
TLV = threshold limit value. TWA = time-weighted average. STEL =
short-term exposure limit. PEL = permissible exposure limit. IDLH = im-
mediately dangerous to life and health. EEGL = emergency exposure guid-
ance level. CEGL = continuous exposure guidance level.
TABLE 1-3 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m 3 Target Toxicity
1 h 75 170
24 h 35 80
7 d _ 15 30
30 d 15 30
180 d 15 30
Mucosal irritation
Mucosal irritation
Mucosal irritation
Mucosal irritation
Mucosal irritation
_Former 7-d SMAC = 50 ppm.
RATIONALE FOR
ACCEPTABLE CONCENTRATIONS
Mucosal irritation is the most important toxic end point to be used in
setting SMACs for acrolein because mucosal irritation was detected in
humans and mice after exposure to concentrations lower than those that
produced histopathological changes in the respiratory systems of various
laboratory animal species (Weber-Tschopp et al., 1977; Steinhagen and
Barrow, 1984; Lyon et al., 1970; Feron et al., 1978). The eyes and
nose differ in their sensitivities to acrolein's irritation. Weber-Tschopp
et al. found that a l-h exposure of human volunteers to acrolein at 0.3
ppm caused moderate eye irritation and only slight nose irritation
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(Weber-Tschopp et ai., 1977). Because the eye appears to be more
sensitive than the nose, SMACs for acrolein are set on the basis of eye
irritation.
The 1-h and 24-h SMACs are designed for contingency scenarios, so
they are aimed at preventing irreversible injuries and significant perfor-
mance decrements. It is acceptable that these short-term SMACs might
not protect against slight mucosal irritation.
1-h SMAC
The goal is to find an exposure concentration that would produce
only slight eye irritation in 1 h. A 1-h exposure to acrolein at 0.3 ppm
produced, on the average, moderate eye irritation in humans (Weber-
Tschopp et ai., 1977). Darley et al. (1960) showed that, after a 5-min
exposure to acrolein, eye irritancy in humans decreased by half a grade,
from moderate-to-severe to moderate, when the concentration was re-
duced 35-40% (from 2.0-2.3 ppm to 1.3-1.6 ppm). According to Fig-
ure 4 in the report of Weber-Tschopp et al. (1977), as the concentration
of acrolein was reduced from 0.6 ppm to 0.3 ppm in a 1.5-min expo-
sure of human volunteers to acrolein, the effect on the eye was reduced
from being mild irritation to a little bit of discomfort. There was no
effect on the eye when the concentration was further reduced to 0.15
ppm. From the data of Darley et al. and Weber-Tschopp et al., lower-
ing the 1-h exposure concentration of 0.3 ppm, which was moderately
irritating to the eye, fourfold should result in a concentration that is
only mildly irritating to the eye.
l-h SMAC based on eye irritation
= 1-h moderately irritating concentration x 1/extrapolation factor
= 0.3ppm x 1/4
= 75 ppb.
24-h SMAC
Because Weber-Tschopp et al. (1977) showed that the mucosal irri-
tancy caused by exposure to acrolein at 0.3 ppm stayed constant from
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40 min to 60 min, the irritancy concentration should remain unchanged
when extending the exposure from 1 h to 24 h. Therefore, theoreti-
cally, the 24-h SMAC could be set equal to the 1-h SMAC. However,
to reduce the degree of mucosal irritation that the astronauts have to
endure in a 24-h emergency, the 24-h SMAC is derived by dividing the
1-h SMAC by two. The factor of two is selected because Weber-
Tschopp et al. (1977) demonstrated that, when the concentration of
acrolein in a 1.5-min exposure was lowered twofold (from 0.6 ppm to
0.3 ppm), the severity of the eye irritation was reduced from slight
irritation to only a little bit of discomfort. As a result, dividing the
mildly irritating 1-h SMAC by two should yield a concentration that
will cause only a little eye discomfort.
24-h SMAC based on eye irritation
= 1-h slightly irritating concentration
= 75ppb x 1/2
= 35 ppb.
x l/extrapolation factor
7-d, 30-d, and 180-d SMACs
If the irritancy of acrolein at 24 h is likely to be the same as that at 1
h, it stands to reason that the irritancy would not worsen when exposure
is extended to 180 d. That is because mucosal irritation is a surface
phenomenon and is generally not considered to be exposure-duration-
dependent after the initial exposure period. Acute eye-irritation effects
of exposure to acrolein in humans (Sim and Pattie, 1957) and subchron-
ic depressive effects on body-weight gain in mice (Northrop, 1985) are
more dependent on the exposure concentration than on the exposure
duration (Northrop, 1985). Moreover, in dogs exposed repetitively or
continuously to acrolein, the signs of mucosal irritation were found to
diminish after the first week, indicating the development of reduced
susceptibility as acrolein exposure is lengthened (Lyon et al., 1970).
Therefore, long-term SMACs could be established by basing an
estimate for a nonirritating concentration of acrolein on data of 1-h
exposures.
As discussed above, a l-h exposure at 75 ppb is expected to be only
slightly irritating to the eye. To estimate a 1-h exposure concentration
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that is nonirritating to the eye, an extrapolation factor of 4 is applied on
75 ppb. This factor of 4 was derived from the data of Weber-Tschopp
et al. (1977), who showed that, in a 1.5-min exposure of human
subjects to acrolein, 0.60 ppm produced a slight eye irritation, 0.30
ppm caused a little eye discomfort, and 0.15 ppm resulted in no adverse
effects on the eye (going from 0.60 ppm to 0.15 ppm is a factor of 2 ×
2, or 4). With a lack of data, the concentration-response relationship of
acrolein exposure and mucosal irritation in a l-h exposure is assumed to
be the same as that in a 1.5-rain exposure. An additional safety factor
of 10/(square root of n) is applied for the potential differences among
individuals in a human population.
7-d, 30-d, and 180-d SMACs based on eye irritation
= l-h slightly irritating concentration x 1/extrapolation factor
× l/small n factor
= 75 ppb x i/4 x (square root of n)/10
= 75 ppb × 1/4 x (square root of 53)/10
= 15 ppb.
The Establishment of SMAC Values
Consequently, the l-h, 24-h, 7-d, 30-d, and 180-d SMACs are set at
75, 35, 15, 15, and 15 ppb, respectively, to prevent mucosal irritation.
Because mucosal irritation is not expected to be significantly influenced
by physiological changes caused by microgravity, the SMAC values are
not adjusted for any microgravity-induced physiological changes.
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B2 Benzene
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Houston, Texas
PHYSICAL AND CHEMICAL PROPERTIES
Benzene is a clear, colorless, highly flammable liquid with an odor
characteristic of aromatic hydrocarbons (Sandmeyer, 1981; ATSDR,
1989). The odor threshold is 4-5 ppm (ATSDR, 1989).
Synonym: Benzol
Chemical
structure:
Formula:
CAS number:
Molecular weight:
Boiling point:
Melting point:
Specific gravity:
Vapor pressure:
Solubility:
Conversion factors
at 25°C, 1 atm:
C6H_
71-43-2
78.11
80.1 °C
5.5°C
0.88 (20°C)
95 torr (25°C)
Slightly soluble in water, very
soluble in organic solvents
1 ppm = 3.26 mg/m 3
1 mg/m 3 = 0.31 ppm
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OCCURRENCE AND USE
Benzene is a natural constituent of crude oil, coal tar, and other fos-
sil fuels (Sandmeyer, 1981). Most of the millions of gallons of benzene
that are used in the United States each year are produced by petroleum
refining. A major use of benzene is as a component in gasoline, partic-
ularly in unleaded fuels, because of its antiknock properties (ATSDR,
1989). Its content in gasoline is estimated to range from 1% to 2% in
the United States and up to 5 % in European countries. Large quantities
are also used to synthesize chemicals for the manufacture of various
plastics, resins, elastomers, dyes, and pesticides (Marcus, 1987). Mini-
mal amounts are now used as a solvent in paints, cements, adhesives,
and paint removers. Sources of atmospheric contamination include fu-
gitive emissions from gasoline handling, thermal degradation of plas-
tics, solid waste gasification, and tobacco smoke (Sandmeyer, 1981;
Marcus, 1987).
Benzene has been detected in approximately 10% of recent air sam-
ples in the space-shuttle cabin and in Spacelab at concentrations of
0.01-0.1 mg/m3 (James et al., 1994). Benzene has not been used as a
payload or system chemical aboard the space shuttle; hence, the low
concentrations observed are due to materials out-gassing. Benzene has
been found as a pyrolysis product of electronic components identical to
ones that failed in data-display units aboard STS-35 (J. Boyd, NASA,
unpublished data).
PHARMACOKINETICS AND METABOLISM
Absorption
In humans, benzene vapor is rapidly absorbed by the lungs in
amounts equivalent to about 50% of the doses inhaled over several
hours of exposure to concentrations of 50-100 ppm (Nomiyama and
Nomiyama, 1974a,b; Sato and Nakajima, 1979; R. Snyder et al., 1981;
IARC, 1982). In men and women exposed to 52-62 ppm for 4 h,
respiratory uptake was 47%, with little difference between the sexes
(Nomiyama and Nomiyama, 1974a,b; IARC, 1982). Absorption was
greatest during the first 5 min of exposure and reached a constant level
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between 15 min (Srbova et al., 1950) and 3 h (Nomiyama and Nomi-
yama, 1974a,b; IARC, 1982). Respiratory retention (the difference
between respiratory uptake and excretion) was estimated as 30% of the
inhaled dose (Nomiyama and Nomiyama, 1974a,b; IARC, 1982).
Benzene can also be absorbed through the skin, but the rate of
absorption is lower than that for inhalation exposure (ATSDR, 1989).
It has been calculated that an adult working in ambient air containing
benzene at 10 ppm would absorb 7.5 tzL/h from inhalation versus 1.5
#L/h from whole-body dermal absorption (Blank and McAuliffe, 1985).
Absorption of benzene vapor by animals also is rapid, but retention of
absorbed benzene might be affected by exposure concentration. In rats
and mice, the percentage of inhaled vapor that was retained decreased
from 33% to 15% during a 6-h exposure and from 50% to 10%,
respectively, as the concentration was increased from approximately I0
ppm to 1000 ppm (Sabourin et al., 1987).
Distribution
Once benzene is absorbed into the blood, it is rapidly distributed to
tissues; the relative uptake is dependent on the perfusion rate of tissues
(ATSDR, 1989). Because of its high lipophilicity, benzene tends to
accumulate in fatty tissues. In experimental human exposures, lower
blood concentrations and slower elimination in females than in males
were attributed primarily to relatively higher fat content of females
(Sato et al., 1975). Tissue levels of benzene in accidental- or intention-
al-exposure victims are variable but generally indicate higher
concentrations in brain, fat, and liver (Winek et al., 1967; Winek and
Collom, 1971). About 60% of the absorbed benzene was found in bone
marrow, adipose tissue, and liver of humans exposed to unspecified
concentrations (Duvoir et ai., 1946).
Distribution of benzene in animals also is rapid; the relative uptake
and accumulation in tissues appear to be dependent on perfusion rate
and lipid content (Schrenk et al., 1941; Ghantous and Danielsson,
1986). Following a 10-min inhalation exposure of mice, benzene was
present in well-perfused tissues, such as liver and kidney, and in lipid-
rich tissues, such as brain and fat (Ghantous and Danielsson, 1986). In
rats exposed to 500 ppm, steady-state concentrations were highest in
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fat, bone marrow, and blood (15:5.5:1 ratio) and lower in kidney, lung,
liver, brain, and spleen (Rickett et al., 1979). Female rats and male
rats with large body fat content stored benzene longer and eliminated it
more slowly than lean animals (Sato et al., 1974).
Excretion
Following inhalation, benzene is eliminated from the body by hu-
mans and animals in unchanged form in the exhaled air and in metabo-
lized form in the urine (ATSDR, 1989). Estimates of the fraction of
absorbed benzene excreted in the expired air of humans range from
12% to 50% (Srbova et al., 1950; Teisinger et al., 1952; Nomiyama
and Nomiyama, 1974a,b; IARC, 1982). The respiratory elimination is
described as triphasic--an initial fast component having a half-life of
0.9 h and two slower components having half-lives of 3 and 15 h,
respectively (Nomiyama and Nomiyama, 1974a,b; IARC, 1982). No
differences in respiratory elimination were observed between men and
women (Nomiyama and Nomiyama, 1974a,b; IARC, 1982).
In rats exposed to 500 ppm for 6 h, a biphasic pattern of respiratory
elimination of benzene was observed, with half-lives of 0.7 and 13.1 h
(Rickert et al., 1979). Respiratory elimination might be increased as a
result of saturation of metabolic pathways by high doses of benzene.
At lower concentrations (10-130 ppm), less than 6% of inhaled _4C-
benzene was exhaled by rats and mice, whereas at concentrations of 260
and 870 ppm (rats) and 990 ppm (mice), exhaled radioactivity increased
from 11% to 48% (Sabourin et ai., 1987).
Metabolism
The metabolism of benzene is complex and not completely eluci-
dated. It is well established that most of the absorbed benzene is
metabolized through a variety of major and minor pathways in humans
and animals and excreted as metabolites in the urine (Snyder, 1987).
The major site of metabolism is the liver, although mixed-function oxi-
dases that catalyze the oxidation of benzene also occur in bone marrow,
the target organ of benzene toxicity (Snyder, 1987). Benzene is
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metabolized mostly by oxidation to the major metabolites--phenol,
catechol, and hydroquinone, which are excreted in the urine as sulfate
and glucuronide conjugates (Snyder, 1987). Many minor metabolites
also are formed, of which phenylmercapturic acid and trans, trans-
muconic acid are the most important.
In the initial metabolic step, benzene is thought to be oxidized by
hepatic microsomal mixed-function oxidase to a reactive intermediate,
benzene oxide (Erexson et ai., 1985; Yardley-Jones et al., 1991). Most
of the benzene oxide rearranges spontaneously to phenol. Phenol is
mostly conjugated and excreted as sulfate ester and glucuronide, but
some can be further oxidized to catechol and hydroquinone (Erexson et
al., 1985; ATSDR, 1989). The latter compound spontaneously oxidizes
to form 1,4-benzoquinone. The remaining benzene oxide can be conju-
gated with glutathione to produce phenylmercapturic acid, which is ex-
creted in the urine, or it can be converted to benzene glycol (ATSDR,
1989; Erexson et al., 1985). The latter compound can undergo dehy-
drogenation to form catechol or further oxidation and ring breakage to
produce trans, trans-muconic acid. Most of the catechol is conjugated
and excreted, but a small amount is oxidized to the trihydroxybenzene
1,2,4-benzenetrioi.
In humans, the major urinary metabolite of benzene is phenol
(Teisinger et al., 1952). Most of the phenol is excreted as sulfate ester
(Teisinger et al., 1952), but significant amounts of glucuronide can be
formed, especially after exposure to high concentrations of benzene
(Sherwood, 1972). In an inhalation study with human subjects, 28.8%
of the absorbed benzene was excreted in the urine as phenol, 2.9% as
catechol, and 1.1% as hydroquinone (Teisinger et al., 1952). Urinary
excretion was highest within the first 24 h following exposure and was
essentially complete within 48 h.
In workers exposed for 7 h to benzene at 1-76 ppm, the correlation
between exposure concentration and urinary phenol excretion was 0.891
(Inoue et al., 1986). A urinary phenol concentration of 75 mg/L indi-
cates an 8-h (time-weighted average) exposure at 10 ppm (NIOSH,
1974) and a concentration of 100 mg/L indicates an 8-h exposure at 25
ppm (Sandmeyer, 1981). The ACGIH biological exposure index (BEI)
for benzene exposure is a urinary concentration of phenol at 50 mg/g of
creatinine at the end of a workshift, but ACGIH notes that phenol is
usually present in unexposed individuals and also might result from ex-
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posure to other chemicals (ACGIH, 1991). Recently, S-phenylmercap-
turic acid in urine (Stommel et al., 1989) and benzene hemoglobin ad-
ducts in blood (Sun et al, 1990) were evaluated as possible biomarkers
of benzene exposure.
In a study in which radiolabeled benzene was administered to rabbits
by oral intubation, 43 % of the radioactivity was recovered as exhaled,
unmetabolized benzene and 1.5% was recovered as carbon dioxide
(Parke and Williams, 1953). Urinary metabolites (representing 35% of
the dose) were mainly in the form of phenolic sulfates and glucuronides
and included phenol (23%), hydroquinone (4.8%), catechol (2.2%),
trans, trans-muconic acid (1.3 %), phenylmercapturic acid (0.5 %), and
1,2,4-trihydroxybenzene (0.3%). This same general profile was also
found in rats (Cornish and Ryan, 1965), mice (Longacre et al., 1981),
and cats and dogs (Oehme, 1969).
Benzene metabolism appears to be qualitatively similar but quantita-
tively different among species. Mice metabolized the largest fraction of
benzene (67%) to hydroquinone conjugates and muconic acid metabo-
lites, followed by monkeys (31%), rats (17%), and chimpanzees (14%)
(Sabourin et al., 1992). Urinary-metabolite data from workers exposed
for about 7 h to benzene at 50 ppm suggest that the metabolism of ben-
zene to hydroquinone compounds in humans is quantitatively compara-
ble to that in mice, whereas the metabolism to muconic acid is compa-
rable to that in rats and one-third of that in mice (Henderson et al.,
1992).
Metabolic pathways leading to putative toxic metabolites, such as
hydroquinone and muconic acid metabolites, have been designated
"toxification pathways" in contrast to "detoxification pathways," which
lead to the less toxic metabolites, such as phenyl conjugates and phenyl-
mercapturic acid products (Henderson et al., 1992). In mice, rats, and
monkeys, the toxification pathways appear to be low-capacity, high-
affinity pathways that become saturated at relatively low concentrations,
resulting in proportionately less formation of hydroquinone and mucon-
ic acid at higher concentrations (Henderson et al., 1992).
Stimulation or inhibition of hepatic mixed-function oxidase activity
by benzene, other chemicals, or dietary factors might alter the rate of
metabolism of benzene. Exposure of mice to benzene enhanced the in
vitro metabolism of benzene by hepatic microsomes from these animals,
but exposure to phenolic metabolites did not (Dean, 1978; Gonasun et
BENZENE 45
al., 1973). In contrast, repeated inhalation exposure of mice and rats to
benzene at 600 ppm for 6 h/d, 5 d/w, for 3 w had minimal effects on
urinary-metabolite profiles (Sabourin et ai., 1990). Ethanol ingestion as
well as food deprivation and carbohydrate restriction enhanced the me-
tabolism of benzene in rats (Sato and Nakajima, 1985).
Three physiologically based pharmacokinetic (PBPK) models were
recently proposed to describe the pharmacokinetics and metabolism of
benzene in animals (Medinsky et al., 1989; Woodruff et al., 1989;
Travis et al., 1990). The models are herein arbitrarily referred to by
the name of the first author as the Medinsky model (Medinsky et al.,
1989), the Travis model (Travis et al., 1990), and the Woodruff model
(Woodruff et al., 1989). The Medinsky model was adjusted to data ob-
tained experimentally with mice and rats (Medinsky et al., 1989), the
Travis model with data on mice, rats, and humans (Travis et al., 1990),
and the Woodruff model with data on rats (Woodruff et al., 1989).
The models have similar structures but differ in the parameter values
used for the same species. In a comparison and evaluation of the mod-
els, the investigators concluded that PBPK models are useful for investi-
gating the mechanism of toxicity of benzene but not for risk assessment
of cancer (Bois et al., 1991).
TOXICITY SUMMARY
Acute and Short-Term Toxicity
Neurotoxicity
In humans, acute inhalation of benzene produces CNS effects, includ-
ing euphoria, giddiness, nausea and drowsiness at lower concentrations,
and ataxia, narcosis, delirium, convulsions, unconsciousness, and even
death at high concentrations (Sandmeyer, 1981). Recovery is usually
rapid, but, in some cases, symptoms have persisted for weeks.
The symptoms, and their severity, vary with concentration and dura-
tion of exposure. It is estimated (without supporting data) that exposure
at 25 ppm for 8 h has no effects; 50-150 ppm for 5 h produces head-
ache, lassitude, and weakness, symptoms that are exaggerated at 500
ppm; 3000 ppm for 0.5-1.0 h can be tolerated; 7500 ppm for 30 min is
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dangerous to life: and 19,000-20,000 ppm can be fatal in 5-10 min
(Gerarde, 1962; Von Oettingen, 1940). The rapid development of CNS
effects, including death in some cases, suggests that benzene, not a me-
tabolite, is responsible for the acute toxicity and that the cause of sud-
den death is asphyxiation, respiratory arrest, CNS depression, or car-
diac arrhythmia (Sandmeyer, 1981).
Acute inhalation exposure to benzene also causes CNS effects in ani-
mals. In mice, exposure at 2200 ppm produced narcosis, and at 4600
ppm and 11,800 ppm produced narcosis in 51 min and 8 min, respec-
tively (Von Oettingen, 1940). At 11,800 ppm, deaths occurred in 38-
295 min, and at 24,000 ppm, deaths occurred in 50 min. About 4000
ppm was the narcotic concentration threshold for laboratory animals,
and more than 10,000 ppm was fatal after several hours of exposure
(Leong, 1977). At 35,000-45,000 ppm, anesthesia occurred in about 4
min, with excitation and tremors after 5 min, loss of pupillary reflexes
after 6.5 min, involuntary blinking after 15 rain, and death after 22-71
min (Carpenter, et al., 1944).
Lethality data of rats confirm the low potential tbr benzene to cause
death via inhalation. A 4-h exposure at 16,000 ppm resulted in the
deaths of four of six rats (Smyth et al., 1962). An LCs0 value of 13,700
ppm was determined for a 4-h exposure of rats (Drew and Fouts,
1974). Respiratory paralysis followed by ventricular fibrillation was ob-
served in male rats exposed to lethal concentrations (Sandmeyer, 1981).
A limited number of animal studies measured electroencephalograph-
ic and behavioral changes to investigate the CNS effects of benzene. In
cats, exposure to benzene at a concentration of 12,000 ppm for 10 min
caused restlessness, rapid respiration, and head nodding, accompanied
by hypersynchronous amygdaloid EEG activity (Contreras et al., 1979).
Ataxia and postural collapse occurred when concentrations were in-
creased to 52,000 ppm. With repeated daily 10-min exposures, a 3-Hz
spike-wave activity in the gyrus cinguli developed and generalized
tonic-clonic seizures developed after a sensitization period. Behavioral
disturbances, characterized by increased milk-licking, were evident in
C57BL mice after the first week of exposure to 100 or 300 ppm
(Dempster et al., 1984). Less sensitive parameters, home-cage food
intake and hind-limb grip strength, were reduced at 1000 and 3000
ppm, but not at 100 or 300 ppm, even when exposure durations were
adjusted to yield a minimum Ct (concentration x time) product of 3000
ppm.
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Cardiac Sensitization
Acute inhalation of high concentrations of benzene by cats and mon-
keys induced ventricular dysrhythmias, which were abolished by remov-
al of the adrenals and the stellate ganglia, and were restored by injec-
tions of epinephrine (Nahum and Hoff, 1934). The effects were attrib-
uted to the sensitization of the myocardium to epinephrine by benzene.
In Wistar rats, previous inhalation of benzene at 3000 and 7000 ppm,
but not at 1500 ppm, for 15 rain increased the number of ectopic ven-
tricular beats induced by coronary ligation or intravenous administration
of aconitine (Magos et al., 1990). With an increased dose of aconitine,
ventricular fibrillation developed rapidly at 7000 ppm, and progressed
to asystole and death after 16 min.
Hematotoxicity and lmmunotoxicity
Although benzene-induced hematotoxicity and immunotoxicity are
generally associated with prolonged exposure, abnormal hematological
parameters have been observed in some workers exposed to low con-
centrations for short periods (ATSDR, 1989). These observations are
consistent with the results of animal studies showing hematological
changes after short-term, and even acute, exposures. After an 8-h inha-
lation exposure of mice to 4680 ppm, a significant depletion of bone-
marrow colony-forming cells was evident in an in vitro cell culture
(Uyeki et al., 1977). In mice, continuous exposure at 100 ppm for 2 d
produced leukocytopenia (Gill et al., 1980) and a 1-w exposure (6 h/d,
5 d/w) at 300 ppm decreased peripheral blood erythrocyte and lympho-
cyte counts (Snyder et al., 1978). Continuous exposure of NMRI mice
at a concentration of 21 ppm for 4-10 d significantly decreased cellular-
ity (number of nucleated cells) and colony-forming granulopoietic stem
cells (CFU-C) in tibia bone marrow (Toft et al., 1982). Intermittent
exposure (8 h/d, 5 d/w) for 2 w at 21 ppm reduced the number of
CFU-C cells.
In female Wistar rats exposed 8 h/d for 7 d, peripheral leukocyte
counts were depressed significantly after exposures at 50-300 ppm but
not at 20 ppm (Li et al., 1986). Leukocyte alkaline phosphatase (LAP)
concentrations were significantly increased at 300 ppm, marginally in-
creased at 100 ppm, and not affected at 20 or 50 ppm.
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Short-term exposures of animals at low concentrations might produce
hematological changes that can affect immune-associated processes. In
male C57BL mice exposed at 10 ppm for 6 h/d for 6 d, femoral
lipopolysaccharide (LPS)-induced B-lymphocyte-colony-forming ability
was significantly depressed, but total numbers of B lymphocytes were
not (Rozen et al., 1984). At 30 ppm, splenic phytohemagglutinin
(PHA)-induced blastogenesis was significantly depressed, but there was
no concomitant significant depression in numbers of T lymphocytes.
After six exposures at 300 ppm, mitogen-induced proliferation of bone
marrow and splenic B and T lymphocytes was depressed, and numbers
of T lymphocytes in thymus and spleen were reduced (Rozen and
Snyder, 1985).
Genotoxicity
Benzene is not mutagenic in most in vitro test systems, including
both Sahnonella _'phimurium (five strains) and Saccharomyces cerevi-
siae with and without metabolic activation, Drosophila melanogaster,
mouse lymphoma cells, various human, mouse, and Chinese hamster
cells, and others (ATSDR, 1989; Marcus, 1987). In vitro studies of
chromosomal aberrations and other genotoxic effects of benzene yielded
positive, negative, or mixed results, depending on the end point and test
system. Positive results were obtained in studies of DNA binding in
rabbit bone marrow and rat liver mitoblasts; negative results were ob-
tained in studies of DNA breaks in rat hepatocytes, Chinese hamster
V79 cells, and mouse L5178Y cells; and mixed results were obtained in
studies of chromosomal aberrations and sister chromatid exchange
(SCE) in human lymphocytes (ATSDR, 1989). Benzene did not in-
crease SCE frequency in human lymphocytes stimulated by phytohe-
magglutinin (Morimoto and Wolff, 1980) or in human lymphocytes in-
cubated without rat liver S-9 (Morimoto, 1983). Delaying addition of
benzene, however, to 24 h after mitogen stimulation produced signifi-
cant concentration-related increases in SCE frequency, decreases in mi-
totic indices, and inhibition of cell-cycle kinetics without S-9 (Erexson
et al., 1985).
In contrast to in vitro results, benzene-induced cytogenetic effects,
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including chromosomal and chromatid aberrations, SCE, and micronu-
clei, were consistently found in in vivo animal studies (ATSDR, 1989).
Acute inhalation studies have shown cytogenetic effects in animals, even
at low exposure concentrations. Exposure of mice at 10 ppm for 6 h
induced SCE in peripheral blood lymphocytes and bone marrow as well
as micronuclei in bone-marrow polychromatic erythrocytes (Erexson et
al., 1985). Exposure of DBA/2 mice at 3100 ppm for 4 h significantly
increased SCE frequency in bone-marrow cells in both sexes and inhib-
ited marrow cellular proliferation in males only, but did not affect the
frequency of chromosomal aberrations (Tice et al., 1980).
Subchronic and Chronic Toxicity
Prolonged inhalation of benzene by humans can result in CNS,
hematotoxic, myelotoxic, immunotoxic, genotoxic, or carcinogenic ef-
fects. These effects are well established for chronic exposure, but less
is known about some of these effects as a result of subchronic ex-
posure. Limited information exists on the potential of benzene to cause
adverse effects on reproductive function and pre- and postnatal develop-
ment in humans.
Neurotoxicity
Involvement of the CNS might be an important effect of chronic in-
halation exposure of humans and animals to benzene, but it can be
masked by other more-visible effects (Sandmeyer, 1981). Workers ex-
posed even to low concentrations (e.g., 50 ppm) reported symptoms of
headaches, dizziness, fatigue, anorexia, dyspnea, and visual disturban-
ces (Sandmeyer, 1981). Some workers also exhibited signs of CNS
lesions, such as abnormal caloric labyrinth irritability and impairment
of hearing. Although there are reports of polyneuritis associated with
exposure to benzene, other chemicals were also involved (Sandmeyer,
1981). Exposure of rats for 5.5 mo to 20 ppm resulted in a delay in
conditioned reflex response time; however, the effect was not seen at 4
ppm (Novikov, 1956).
50 SMACs FOR SELECTED AIRBORNE CONTAMINANTS
Hematotoxicity and Myelotoxicity
The effects of benzene on the hematopoietic system have been known
for many years. Prolonged exposure causes hypoplasia and depressed
function of bone marrow, resulting in leukopenia, anemia, or thrombo-
cytopenia (Sandmeyer, 1981; ATSDR, 1989). With continued expo-
sure, bone-marrow aplasia results in pancytopenia and aplastic anemia;
bone-marrow aplasia might progress and develop into myelogenous leu-
kemia or other types of leukemia. These are not distinct diseases but
rather are a continuum of changes reflecting the severity of damage to
the bone marrow.
The cytopenias, which can occur as a group or in various combina-
tions, can manifest themselves as specific adverse health effects
(ATSDR, 1989). For example, thrombocytopenia induces capillary fra-
gility, petechiae, and hemorrhage, which might result in death. De-
creased circulating granuiocytes decrease defenses against infection,
which might have been responsible for deaths of some benzene-exposed
individuals. Also, lymphocytopenia and eosinophilia, which might be
related to impaired immune function, were observed in some workers.
A high prevalence and wide range of hematological responses to ben-
zene are evident in the numerous epidemiological studies and case re-
ports of occupationally exposed workers. Of 332 rotogravure workers
exposed to benzene at 11-1060 ppm for 6-60 mo, 23 had severe cytope-
nia (23 of 23, leukopenia; 15 of 23, erythropenia; 18 of 23, thrombocy-
topenia) (Goldwater, 1941). In a rubber factory, 25 of 1104 workers
exposed at up to 500 ppm (100 ppm average) developed severe pancyto-
penia (9 of the 25 were hospitalized), and 83 others had mild hemato-
logical disorders (Wilson, 1942). The relationship between pancytope-
nia, preleukemia and acute leukemia was reviewed by Goldstein (1977).
Pancytopenia also was diagnosed in 6 of 217 apparently healthy shoe-
factory workers exposed at 30-210 ppm for 3 mo to 17 y; 45 others had
some hematological abnormalities (Aksoy et al., 1971). There also are
numerous reports of aplastic anemia in occupationally exposed workers
(Aksoy et al., 1972; Vigliani and Forni, 1976). Of 32 cases of aplastic
anemia among workers exposed at 150-650 ppm for 4 mo to 15 y, there
were eight deaths due to thrombocytopenic hemorrhage and infection
(Aksoy et al., 1972). In a 10-y followup of 216 workers in a study of
282 workers, four had persistent cytopenias and one died of aplastic
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anemia 9 y after cessation of exposure (Guberan and Kocher, 1971).
The exposure level associated with development of noncarcinogenic he-
matological effects of benzene has not been established (ATSDR,
1989). A threshold of about 10 ppm for cytopenia was suggested on
the basis of observations of minimal hematotoxicity in workers exposed
at 20 ppm (Chang, 1972).
There is evidence that benzene-induced pancytopenia or aplastic ane-
mia is associated with the later development of leukemia (ATSDR,
1989). In 44 patients with pancytopenia (exposure at 150-650 ppm for
4 mo to 15 y), six developed leukemia within 6 y of followup (Aksoy
and Erdem, 1978). Leukemia also occurred in workers with aplastic
anemia either during exposure to high concentrations or shortly after
cessation of exposure; however, in a few cases the latency period was
long (Aksoy et al., 1976; Aksoy, 1978). Benzene-induced leukemia is
discussed in more detail in the section on carcinogenicity.
The hematotoxic effects observed in humans have been reproduced
experimentally in animals; however, the response depends on species,
strain, sex, and intermittent vs. continuous exposure, in addition to ex-
posure concentration and duration (ATSDR, 1989).
Exposure of rats to benzene at concentrations of 831, 65, or 61 ppm
produced a significant leukopenia within 2 to 4 w, and a less severe
leukopenia after 5-8 w at concentrations of 47 or 44 ppm (Deichmann
et al., 1963). Leukocyte counts were not affected by 31 ppm for 4 mo,
29 ppm for 3 mo, or 15 ppm for 7 mo. In CD-1 mice, 300 ppm for 6
h/d, 5 d/w for 13 w increased mean cell volume and mean cell hemo-
globin and decreased hematocrit, hemoglobin, erythrocyte, leukocyte,
and platelet counts and percentage of lymphocytes (Ward et al., 1985).
Histopathological changes, including bone-marrow hypoplasia, lymph-
oid depletion in lymph nodes and tissue, and increased splenic extra-
medullary hematopoiesis, were more prevalent and severe in males than
females. No effects were evident at 1, 10, or 30 ppm.
Sprague-Dawley rats were less severely affected by the same expo-
sure regimen than mice. The rats exhibited no effects at 1, 10, or 30
ppm and significant decreases only in leukocyte counts and percentage
of lymphocytes at a concentration of 300 ppm (Ward et al., 1985). The
only histological lesion was slightly decreased femoral-marrow cellular-
ity. Repeated inhalation exposures at 80-85 ppm for 136 exposures of
rats, 175 exposures of rabbits, and 193 exposures of guinea pigs in-
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duced leukopenia, increased spleen weights, and histopathological
changes in bone marrow in the rats, guinea pigs, or rabbits (Wolf et
al., 1956).
Several animal studies indicate that benzene induces its hematotox-
icity by acting on early progenitor cells in the bone marrow and spleen.
In CD-1 mice, 103 ppm and higher exposures for 6 h/d for 5 d reduced
marrow and spleen cellularity and decreased granulocyte macrophage
colony-forming units (GM-CFU-C) in spleen but not in marrow (Green
et al., 1981a). At concentrations of 302 ppm for 26 w, marrow and
spleen cellularity, colony-forming units in spleen (CFU-S), and marrow
GM-CFU-S were decreased. Depression of CFU-S also was reported
in C57BL mice exposed at 400 ppm for 6 h/d intermittently for 9 d or
consecutively for 11 d (Harigaya et al., 1981). Bone-marrow cellular-
ity and pluripotential stem cells were significantly reduced in C57BL
mice exposed for 2 w at 100 ppm, but not at 10 or 25 ppm (Cronkite et
al., 1985). At 300 ppm, 2 w were required for recovery of stem-cell
numbers after 2- or 4-w exposures, and 25 w were required for recov-
ery to 92% of control values after a 16-w exposure. Peripheral blood
lymphocyte counts were not affected at 10 ppm (2 w), but exhibited a
dose-related decrease at 25-400 ppm.
Other investigators also observed depletions in pluripotential stem-
cell numbers (Gill et al., 1980) and reductions in granulocyte and mac-
rophage progenitor cells (C.A. Snyder et al., 1981) in mice. In studies
of the erythroid cell line, repeated exposures to benzene at 10 ppm re-
duced the number of progenitor red blood cells, i.e., erythroid colony-
forming units (CFU-E) in mice (Baarson et al., 1984; Valle-Paul and
Snyder, 1986). The effects of benzene at concentrations of 100, 300,
and 900 ppm (6 h/d, 5 d/w, for up to 16 w) on hematopoietic stem-cell
compartments were investigated in a series of studies with female BDF1
mice (Seidel et al., 1989a,b, 1990). The CFU-E was the most sensitive
compartment, showing significant concentration-dependent decreases
and a marked decrease at 100 ppm as early as 1 w after the start of ex-
posure (Seidel et al., 1990). The BFU-E (burst-forming units), CFU-S,
and CFU-C compartments of progenitor cells showed dose-related de-
creases at 300 and 900 ppm. Recovery of stem-cell compartments was
slow, requiring 73-185 d after exposure at 300 ppm.
Potential mechanisms for the development of pancytopenia and its
variants in humans and animals exposed to benzene include destruction
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of bone-marrow stem cells, impairment of the differentiation of these
cells, and destruction of more mature hematopoietic cell precursors and
circulating cells (Goldstein, 1977). Numerous studies have shown that
benzene-induced bone-marrow depression is the result of inhibitory ef-
fects on proliferation, maturation, or replication of pluripotential stem
cells or early proliferating committed cells in either the erythroid or
myeloid lines (ATSDR, 1989). Several molecular mechanisms have
been proposed to explain the hematotoxicity and myelotoxicity, as well
as other toxicities, of benzene. These include suppression of RNA and
DNA synthesis, alkylation of cellular sulfhydryl groups, disruption of
the cell cycle, oxygen activation (or free radical formation), and cova-
lent building of benzene metabolites to cellular macromolecules
(ATSDR, 1989). These mechanisms will be reviewed in greater detail
in the section on carcinogenicity.
Although the exact mechanism is unknown, it is generally accepted
that benzene must be metabolized before its toxic effects (other than
neurotoxicity and cardiac sensitization) are manifest (ATSDR, 1989).
Evidence for a primary role for benzene metabolites in inducing myelo-
suppression and hematotoxicity is provided by studies showing that
agents that alter benzene metabolism modify its toxicity. Partial hepa-
tectomy alleviated benzene-induced depression of erythropoiesis, and
decreased urinary levels of benzene metabolites and covalent binding of
reactive metabolites to bone-marrow protein (Sammett et al., 1979).
The apparent decrease in toxicity provided by phenobarbital and
Arochlor-1254 was attributed to increased detoxifying metabolism of
benzene in the liver (Ikeda and Ohtsuji, 1971; ATSDR, 1989); the
decrease provided by toluene and aminotriazole was attributed to inhibi-
tion of metabolism resulting in a decreased rate of toxic metabolite for-
mation (Hirokawa and Nomiyama, 1962). On the other hand, ethanol
ingestion generally increases benzene-induced hematotoxicity, possibly
by increasing the rate of formation of toxic metabolites (Driscoll and
Snyder, 1984).
Also supporting a causative role of benzene metabolites in bone-mar-
row suppression and hematotoxicity are studies showing the accumula-
tion of metabolites in bone marrow. Although benzene can be metabo-
lized in bone marrow, mixed-function oxidase activity appears to be
insufficient to account for the high concentrations of phenol, hydroqui-
none, and catechol in bone marrow (ATSDR, 1989). It is postulated,
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therefore, that one or more metabolites formed in the liver are trans-
ported to the bone marrow where they accumulate and produce a meta-
bolic impairment expressed as bone-marrow depression (Marcus, 1987).
Finally, metabolites of benzene, including benzene oxide, hydroqui-
none, catechol, and trans, trans-muconaldehyde (a precursor of muconic
acid), have been shown to be hematotoxic to animals (Marcus, 1987;
ATSDR, 1989).
Immunotoxicity
It has long been suspected that benzene might adversely affect human
immune functions. Studies in the early 1900s demonstrated an in-
creased susceptibility of benzene-treated rabbits to tuberculosis and
pneumonia (Marcus, 1987). Later, depression of lymphocytes and in-
creased susceptibility to infection became increasingly associated with
exposure of workers to benzene. With advances in immunology, alter-
ations in serum immunoglobulin and complement levels were detected
in occupationally exposed workers (Marcus, 1987). In 35 painters ex-
posed to benzene, along with toluene and xylene, at concentrations of
3.4-48 ppm, serum IgG and IgA levels were significantly decreased
compared with controls, and IgM levels were increased (Lange et al.,
1973). Leukocyte agglutinins also were increased in some workers,
leading to the suggestion that benzene might cause an allergic blood
dyscrasia in some individuals. Other findings in workers, including
eosinophilia and leukocyte agglutination associated with granulocytope-
nia, also suggest that autoimmunity or allergy is responsible for ben-
zene-induced effects on immune function (Goldstein, 1977). Further-
more, auto-immune phenomena and reticulosis were implicated in the
pathogenesis of bone-marrow disease.
In C57BL mice, 300-ppm exposures for 6 h/d for 6, 30, or 115 d
reduced mitogen-induced proliferation of bone-marrow and splenic B
and T lymphocytes and markedly reduced the number of B lymphocytes
in bone marrow and spleen and the number of T lymphocytes in thymus
and spleen (Rozen and Snyder, 1985). Increased bone-marrow cellular-
ity and numbers of thymic T cells between the 6th and 30th exposure
suggested a compensating proliferative response. Thymic lymphoma
was observed after 115 exposures. Significant suppression of the pri-
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mary antibody response to fluid (FTT) and adsorbed (APTT) tetanus
toxoid was observed in Swiss albino mice exposed at 200 ppm for 6 h/d
for 10-20 d but was not observed at 50 ppm (Stoner et al., 1981). At
concentrations of 400 ppm for 5, 12, or 22 exposures, the primary anti-
body response to FTT was reduced by 74-89% and that to APTT by
8%, 36%, and 85%, respectively. The secondary antibody response
was unaffected at 50, 200, or 400 ppm.
In a study of cell-mediated immunity, host resistance to Listeria
monocytogenes was measured in mice exposed to benzene for either 5 d
prior to infection (pre-exposure regimen) or for 5 d prior to and 7 d
after infection (continuous regimen) (Rosenthal and Snyder, 1985). The
pre-exposure regimen at 300 ppm increased splenic bacterial counts
(730% of controls) on day 4 but had no effect at 10, 30, or 100 ppm.
With the continuous-exposure regimen, bacterial counts were increased
at 30, 100, and 300 ppm to 490%, 750%, and 720% of controls, re-
spectively, and were unaffected at 10 ppm. On day 7, bacterial counts
were not increased by either regimen, indicating recovery of the im-
mune response. At concentrations of 30 ppm and higher, a concen-
tration-dependent decrease in T and B lymphocytes was observed, with
B lymphocytes showing a greater decrease. Tumor resistance, another
parameter of cell-related immunity, also is adversely affected by ben-
zene. In male C57BL mice exposed at 100 ppm for 6 h/d, 5 d/w, for
20 exposures and then injected with cells from a virus-induced tumor,
90% developed lethal tumors, compared with 30% of controls
(Rosenthal and Snyder, 1986).
Several metabolites of benzene are suspect in benzene's immunotoxi-
city, but the identity of the causative agent or agents and the mechanism
of action have not been established. Catechol, hydroquinone, benzoqui-
none, and 1,2,4-benzenetriol are cytotoxic to spleen cells, reduce the
number of progenitor cells from the spleen and bone marrow, or sup-
press T- and B-lymphocyte mitogen responses (Irons and Neptun, 1980;
Pfeifer and Irons, 1981). Suppression of cell growth and function in
the lymphoid system, as in the bone marrow, correlates with the con-
centration of hydroquinone and catechol, which accumulate in lymphoid
tissue following exposure to benzene (Greenlee et al., 1981; Wierda
and Irons, 1982; Irons et al., 1982). Also, hydroquinone, benzoqui-
none, phenol, and catechol suppress microtubule assembly and progeni-
tor cells (Kalf et al., 1987). Inhibition of microtubule function might
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result in suppression of phytohemagglutinin-stimulated lymphocyte acti-
vation; the inactivation correlates with the ability of the metabolites to
undergo sulfhydryi-dependent autoxidation (Irons and Neptun, 1980;
Pfeifer and Irons, 1981). It has been suggested that hydroquinone or its
terminal oxidation product, p-benzoquinone, might be responsible for
these effects (Irons and Neptun, 1980).
Mutagenicity and Genotoxicity
Evidence that benzene is genotoxic to humans comes from epidemio-
logical studies of occupationally exposed workers. These studies show
that workers with benzene-induced blood disorders consistently exhib-
ited an increased prevalence of chromosomal aberrations; in workers
who were without overt signs of toxicity or were exposed to benzene at
low concentrations, the results were less consistent (ATSDR, 1989).
There are extensive reviews of epidemiological studies and case re-
ports of benzene-induced chromosomal aberrations in workers (Snyder
et al., 1977; White et al., 1980; Van Raalte and Grasso, 1982; Dean,
1985). A significantly higher number of lymphocytes with unstable
chromosomal aberrations were found in 20 men (many with neutrope-
nia) exposed to benzene for 1-20 y than were found in unexposed con-
trols (1.4% exposed vs. 0.6% controls) (Tough and Brown, 1965). In
rotogravure workers exposed at 125-532 ppm for 1-22 y, unstable and
stable chromosomal aberrations in lymphocytes were significantly in-
creased, compared with controls (Forni et al., 1971a). Similar results
were reported in 25 persons (13 men and 12 women), even after recov-
ery from hemopathy (Forni et al., 1971b).
Even at low concentrations, chromosomal aberrations were increased;
for example, increases were found in 52 workers exposed at < 10 ppm
(estimated time-weighted-average exposure 2.1 ppm) for 5 y (Picciano,
1979) and in 22 healthy workers exposed at 13 ppm for 11 y (Sarto et
al., 1984). In other studies, significant increases were not found when
exposures were <25 ppm (Austin et al., 1988). Some investigators
reported increases in the frequency of chromosomal damage and of sis-
ter chromatid exchange (SCE) in peripheral blood lymphocytes of work-
ers exposed to concentrations as low as 1 ppm (Dean, 1985). Others
failed to detect a statistically significant increase in SCE frequency in
BENZENE 5 7
workers exposed to higher concentrations (Watanabe et al., 1980;
Clarke et al., 1984; Sarto et al., 1984).
Exposure of CD-1 mice for 22 h/d, 7 d/w for 6 w at 0.04 ppm or
0.01 ppm increased the frequencies of spleen lymphocytes with muta-
tions at the hypoxanthine-guanine phosphoribosyl transferase (hrpt) lo-
cus and the frequencies of chromosomal aberrations (chromatid breaks)
(Au et al., 1991; Ward et al., 1992). Reduced effects at 1 ppm were
attributed possibly to increased glutathione-S-transferase levels at higher
doses, resulting in more detoxification metabolites and less putative
toxic compounds (Ward et al., 1992). Female mice were found to be
more sensitive than males in the Au et al. (1991) and the Ward et al.
(1992) studies, but in studies using high doses, male mice were more
sensitive than female mice (Uyeki et al., 1977; Choy et al., 1985). Ex-
posure of mice (DBA/2, B6C3F_, and C57BL mice) at 300 ppm for 6
h/d, 5 d/w (regimen 1) or 3 d/w (regimen 2) for 13 w induced a highly
significant increase in the frequency of micronucleated polychromatic
erythrocytes (Luke et al., 1988a). The magnitude of the increase was
strain-specific, with DBA/2 greater than C57BL, and C57BL equal to
B6C3F_ mice, but independent of exposure regimen and, except for
B6C3F_ mice, independent of exposure duration. In DBA/2 mice, this
genotoxic injury to the bone marrow was accompanied by a decreased
percentage of polychromatic erythrocytes, indicating depression of
erythropoiesis (Luke et al., 1988b).
Carcinogenicity
Epidemiological studies and case reports provide convincing evidence
of the carcinogenic (leukemogenic) effects of benzene inhalation
(Vigliani, 1976; Infante et al., 1977; Ott et al., 1978; Rinsky et al.,
1981; Maltoni et al., 1989). The first epidemiological study of ben-
zene, published in 1974, reported a leukemia incidence during 1967-
1973 of 13/100,000 among 28,500 Turkish shoe workers exposed to
benzene at concentrations of 150-650 ppm for 4 mo to 15 y (Aksoy et
al., 1974). This incidence was significantly higher than the estimated
6/100,000 for the general population, and the incidence decreased after
use of benzene was discontinued in 1969 (Aksoy, 1980). A mortality
study and continued followup studies of rubber-industry workers ex-
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posed at 10-100 ppm for up to 10 y or more reported excessive mortal-
ity from myelogenous leukemia and reported a direct correlation be-
tween benzene exposure and other forms of leukemia (Infante et al.,
1977; Infante, 1978; Rinsky et al., 1981, 1987). Epidemioiogical
studies or case reports of chemical workers or other workers suggested
a direct or possible correlation between exposure and excess mortalities
from, or the development of, one or more tbrms of leukemia (Aksoy,
1978; Infante, 1978; Bond et al., 1986; Rinsky et al., 1987). Some of
these studies, however, were criticized for inappropriate sampling tech-
niques, exposure determinations, mortality standards, and experimental
design (Van Raalte and Grasso, 1982).
IARC (1982), EPA (1989), NIOSH (1977), and others (ATSDR,
1989) concluded that benzene is carcinogenic to humans and is associ-
ated with an increased incidence of myelogenous leukemia. The data,
however, do not establish an association with other types of leukemia.
Several risk-assessment models were developed to estimate the probabil-
ity of developing leukemia from a particular exposure level, utilizing
data from the major epidemiological studies. A number of these assess-
ments, including the Crump and Allen, the Rinsky et al. (and vari-
ations), and the White, Infante, and Chu assessments, were critically
reviewed (Brett et al., 1989). The models yield widely varying risk
estimates, depending on the particular model, the data selected for the
model, and the exposure assumptions. In 1987, OSHA established an
8-h permissible exposure limit (PEL) of 1.0 ppm for benzene, relying
on the Crump and Allen linear risk assessment, which was based on
combined data from three high-quality epidemiological studies (Brett et
al., 1989). The assessment projects a risk of 10 excess leukemia deaths
per 1000 workers as a result of a 45-y occupational exposure to
benzene at 1 ppm.
In 1990, the ACGIH proposed revision of its threshold limit value
(TLV) for benzene from 10 ppm to 0.1 ppm, with a skin notation and
designation as an A1 carcinogen (confirmed human carcinogen)
(ACGIH, 1991). The ACGIH based its proposal on: (l) leukemia risk
assessments emphasizing NIOSH case control data; (2) exposure levels
in a cohort mortality study of leukemia in chemical workers; and (3)
exposure levels associated with chromosomal breakage. Recently, the
proposed lower limit was defended on the basis of the need to consider
effects other than leukemia, chromosomal aberrations in workers at low
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exposure levels, and increased toxicity from dermal and intermittent
exposures (Infante, 1992).
In animals, benzene by inhalation or gavage is a multipotent carcino-
gen, capable of producing a variety of neoplasms at several sites. Ele-
vated incidences of tumors are reported in the Zymbal gland, oral cav-
ity, preputial gland, harderian gland, liver, mammary gland, lungs, and
ovaries, in addition to lymphomas and leukemias (Huff et al., 1988;
Maltoni et al., 1989). Many attempts to induce leukemia in animals
yielded negative or debatable results because of difficulties in establish-
ing a suitable animal model (ATSDR, 1989). In an early study of 40
C57BL/6 mice, occurrences of leukemia (1), thymic lymphoma (6),
plasmacytoma (1), and bone-marrow hyperplasia (13) were reported
after exposures at 300 ppm for 6 h/d, 5 d/w, for life, as compared with
the occurrence of two iymphomas (nonthymic) in controls (Snyder et
al., 1980). A similar exposure of AKR mice caused bone-marrow hy-
poplasia, but did not alter the incidence or induction time of viral-
induced lymphomas common in this strain.
In subsequent studies by the same laboratory, myelogenous leukemia
occurred in 1 of 40 CD-1 mice exposed at 100 ppm and in 2 of 40
exposed at 300 ppm for 6 h/d, 5 d/w for life (Goldstein et al., 1982); it
also occurred in 1 of 40 Sprague-Dawley rats similarly exposed at 100
ppm (Snyder et al., 1984). Liver tumors (4 in 40 rats) and Zymbal-
gland carcinomas (2 in 40 rats) also were observed. The investigators
suggested a causative role for benzene because spontaneous myeloge-
nous leukemia had not been observed in these strains. However, the
results might be of questionable significance because of the small num-
bers of animals and marginally increased incidences (Maltoni et al.,
1989).
More convincing evidence of the leukemogenicity of benzene was
provided by a major series of studies in which animals were exposed 6
h/d, 5 d/w, for 16 w to approximate the average exposure duration of
workers (15% of lifetime). In C57BL/6 mice, exposure at 300 ppm
resulted in a highly significant increase in lymphoma-leukemia, from
0% (0/90) in controls to 8% (8/90) (Cronkite et al., 1984). The expo-
sure produced a definite pattern of lymphoma and mortality, with the
first wave of deaths at 330-390 d of age primarily due to thymic lym-
phoma and the second wave beginning at 570 d of age due to nonthy-
mic lymphoma and solid tumors. In a recent study from the same labo-
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ratory, exposure at 300 ppm 6 h/d, 5 d/w, for 16 w significantly in-
creased the incidence of myelogenous leukemia from 0% in controls to
19.3% in male CBA/Ca mice and of nonhematopoietic nonhepatic neo-
plasms (Zymbai, harderian, mammary) from 21.7% to 52.6% in males
and from 35.0% to 79.6% in females (Cronkite et al., 1989). A simi-
lar exposure at 100 ppm did not affect the incidence of myelogenous
neoplasms, but did increase the incidence of nonhematopoietic
nonhepatic tumors from 20.0% to 44.7% in males.
The Bologna Institute of Oncology conducted several chronic expo-
sure studies in which benzene was administered by inhalation or gavage
to various strains of rats and mice (Maltoni et al., 1989). Sprague-
Dawley rats were exposed by inhalation either at 200 ppm for 15 w or
at 200 ppm for 19 w followed by 300 ppm for 85 w (total of 104 w).
Although extensive data from the studies were presented, the data do
not appear to be complete for all tumor sites. Positive results were
summarized as an increase or marginal increase in the incidence of the
various tumor types or sites without statistical analysis. In the
Sprague-Dawley rat, inhalation of benzene was reported to be "associ-
ated" with an increase in the incidence of total malignant tumors and
carcinomas of the Zymbal glands and oral cavity and with a marginal
increase in the incidence of hepatomas and carcinomas of the nasal cav-
ities and mammary gland (Maltoni et al., 1989). At an exposure of 200
ppm, 4-7 h/d, 5 d/w, for 19 w, followed by an exposure at 300 ppm, 7
h/d, 5 d/w, for 85 w, with exposure started in embryonal life, the inci-
dence of malignant tumors increased from 17.3% in male and female
controls to 43.6%, Zymbal gland carcinomas increased from 0.7% to
10.0%, and hepatomas increased from 0.3% to 6.4%. In females,
mammary gland tumors increased from 5.4% in controls to 13.8%.
The investigators concluded that the carcinogenic effects of benzene
increased with increasing doses (daily dose and length of treatment) and
that the carcinogenic effect is enhanced when exposure is started during
embryonal life (Maltoni et al., 1989).
Many mechanisms have been suggested for the carcinogenicity of
benzene. One involves modification by benzene or its metabolites of
"immune surveillance," thereby allowing development of unusual cellu-
lar species that cause leukemia and other neoplasms in humans (Leong,
1977). Another suggestion is that benzene or its metabolites might act
as a promoter, rather than an initiator, by forcing compensatory hema-
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topoiesis (regenerative hyperplasia), with the resultant appearance of
preleukemic and leukemogenic clones from stem cells exposed to
leukemogenic-initiating agents prior to benzene exposure (Harigaya et
ai., 1981).
One of the favored mechanisms involves the covalent binding of ben-
zene metabolites to cellular macromolecules. Covalent binding to DNA
was observed in the livers of rats exposed to benzene vapor (Lutz and
Schlatter, 1977). In mice, radiolabeled metabolites were covalently
bound to liver, bone marrow, kidney, spleen, blood, and fat; the label
was bound to nucleic acids of hematopoietic cells and to nucleic acids
and other macromolecules of mitochondria (Gill and Ahmed, 1981).
Also, bioactivation of benzene by mitochrondia caused adduct formation
with DNA and inhibited the ability of RNA polymerase to transcribe
the genome (Kalf et al., 1982).
A recent review of the molecular pathology of benzene points out
that its carcinogenic, hematotoxic, cytotoxic, and genotoxic effects are
the consequences of highly complex, interactive biological processes
(Yardley-Jones et al., 1991). Possible processes include increased pro-
duction of hydroxyl radicals, generation of oxygen radicals, depletion
of endogenous glutathione, activation of protein kinase c (an enzyme in-
volved in cell transformation and tumor promotion), covalent binding to
glutathione, protein and other cellular macromolecules, DNA damage,
and induction of micronuclei.
Reproductive Toxicity
Studies of the effects of benzene on reproductive functions in humans
are limited in number and scope but suggest a possible association be-
tween chronic exposure and adverse effects in females. In a study of
30 employed women with symptoms of benzene toxicity (indicative of
higher exposure levels than currently allowed), 12 had menstrual disor-
ders (Vara and Kinnunen, 1946). There were two spontaneous abor-
tions and no births during employment, even though no contraceptive
measures were taken by the 12 women, 10 of whom were married.
Gynecological examinations revealed that the scanty menstruations in
five of the women were due to hypoplasia of the ovaries.
Two European studies reported menstrual disturbances (heavy
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bleeding) in workers exposed to benzene at concentrations of 31 ppm
(Michon, 1965) and ovarian hypofunction in workers in another factory
(Pushkina et al., 1968). In another European study of 360 gluing oper-
ators, all of whom were women who were exposed to petroleum (con-
taining benzene) and chlorinated hydrocarbons both dermally and by
inhalation, no significant difference in fertility between exposed workers
and unexposed controls was found, but spontaneous abortion and pre-
mature birth increased (Mukhametova and Vozovaya, 1972).
Inhalation studies with animals have demonstrated adverse effects of
benzene on the reproductive systems of both sexes, but particularly of
males. In CD-1 mice exposed at 1, 10, 30, or 300 ppm, 6 h/d, 5 d/w,
for 13 w, exposure at 300 ppm resulted in histopathological changes to
the testes and ovaries (Ward et al., 1985). Changes to the testes includ-
ed atrophy and degeneration, decreases in spermatozoa, and moderate
increases in abnormal sperm forms. Pathological changes to the ovaries
were less severe and consisted of bilateral cysts. In chronic exposure
studies of rabbits and guinea pigs, slight increases in average testicular
weight occurred in guinea pigs at 88 ppm 7-8 h/d, 5 d/w, for up to 6
mo and slight histopathological changes to the testes (degeneration of
the germinal epithelium) occurred in rabbits at 80 ppm (Wolf et al.,
1956).
Developmental Toxicity
There is little information on the developmental toxicity of benzene
in humans. It is known, however, that benzene crosses the human pla-
centa and is present in cord blood in amounts equal to those in maternal
blood (Dowty et al., 1976).
A few case reports and epidemiological studies of benzene-exposed
pregnant workers are available in the literature. The results generally
are mixed or inconclusive and do not provide direct evidence of the
developmental toxicity or the teratogenicity of benzene. One study re-
ports on two infants with no evidence of chromosomal alterations deliv-
ered from a worker who had severe pancytopenia and increased
chromosomal aberrations and who had been exposed to benzene during
her entire pregnancy (Forni et al., 1971b). In another study, an in-
creased frequency of chromatid and isochromatid breaks and SCE was
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found in lymphocytes from 14 children of female workers exposed to
benzene during pregnancy; however, the workers were also exposed to
other organic solvents (Funes-Cravioto et al., 1977). Other epidemio-
logical studies of pregnant women occupationally exposed to undefined
organic solvents or living near waste dumps contaminated with benzene
and other carcinogens found no evidence of developmental toxicity or
teratogenicity (ATSDR, 1989).
Numerous inhalation studies have shown that benzene is embryotoxic
and fetotoxic in animals, as evidenced by increased incidences of re-
sorption, reduced fetal weight, skeletal variation, and altered fetal he-
matopoiesis (ATSDR, 1989). However, no studies have shown benzene
to be teratogenic or embryolethal in animals, even at concentrations that
are toxic (reduced weight gain) to the mother. Exposure to benzene
vapor adversely affected pregnant rabbits and rats at concentrations
above 100 ppm (Green et al., 1978). Maternal toxicity was evidenced
by a decrease in maternal-weight gain; the decrease was accompanied
by retarded fetal growth. Some investigators found no increase in re-
sorption in rats exposed at 100, 300, or 2200 ppm (Green et al., 1978),
or at 10, 50, or 500 ppm (Murray et al., 1979), but others reported
increased resorption in rodents, mostly at concentrations above 150 ppm
(ATSDR, 1989). Exposures of mice at 500 ppm 7 h/d on gestation
days 6-15 (Murray et al., 1979) and at 156 or 313 ppm 24 h/d or 4 h/d
on gestation days 6-15 and exposures of rabbits at 313 ppm 24 h/d
(Ungvary and Tatrai, 1985) resulted in growth retardation and increased
skeletal variants in fetuses, but no malformations. In rats, concentra-
tions of 50-2200 ppm caused decreased fetal weight, but numbers of
skeletal variants increased significantly at 125 ppm and higher (Green et
al., 1978). No pregnancies were reported in 10 female rats exposed to
benzene at 210 ppm for 10-15 d and then joined by two unexposed
males (Gofmekler, 1968). Changes in the weights of body organs were
also reported at lower exposures, but the data are difficult to interpret
because of a lack of any dose-response relationship. Hematopoietic
alterations were reported in the fetuses and offspring of pregnant Swiss-
Webster mice exposed by inhalation to benzene. At concentrations of
5, 10, or 20 ppm 6 h/d on gestation days 6-15, the number of erythroid
colony-forming cells of progeny was markedly decreased, and at 10 and
20 ppm, granulocytic colony-forming cells also were reduced (Keller
and Snyder, 1986).
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Interaction with Other Chemicals
Ethanol has been shown to consistently increase the hematotoxicity of
benzene in animals. In mice, decreased blood cell counts and bone-
marrow cellularity induced by benzene were further reduced by ethanol
administration (Seidei et al., 1990). The administration of ethanol in-
creased the depression of hematopoietic progenitor cells, CFU-E,
BFU-E, and CFU-C, induced by exposure to benzene at 300 or 900
ppm in BDFI mice (Seidel et al., 1990).
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TABLE 2-2 Exposure Limits Set by Other Organizations
Organization Concentration, ppm
ACGIH's TLV
OSHA's PEL
OSHA's STEL
N1OSH's REL
NIOSH's STEL
NIOSH's IDLH
NRC's 1-h EEGL
NRC's 24-h EEGL
0.1 (TWA, proposed; skin, A1 carcinogen)
1 (TWA)
5 (ceiling limit; carcinogen)
0.1 (TWA)
1 (ceiling limit; carcinogen)
3O00
5O
2
TLV = threshold limit value. TWA = time-weighted average. PEL =
permissible exposure limit. STEL = short-term exposure limit. REL = rec-
ommended exposure limit. IDLH = immediately dangerous to life and health.
EEGL = emergency exposure guidance level.
TABLE 2-3 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m 3 Target Toxicity
1 h 10 35 Immune system
24 h 3 10 Immune system
7 d 0.5 1.5 Immune system
30 d 0.1 0.3 Immune system
180 d 0.07 0.2 Immune system
(leukemia)
RATIONALE FOR
ACCEPTABLE CONCENTRATIONS
Because a large database exists on benzene's toxicity to animals and
humans, multiple toxic effects must be considered in setting safe expo-
sure concentrations. The immediate effects of benzene exposure are
thought to be due to benzene itself, whereas the delayed effects are
caused by toxic metabolites reaching target cells, particularly in the
bone marrow. The most important threshold-type effect induced by ben-
zene itself is CNS depression; however, mucosal irritation and cardiac
effects also will be considered briefly. The clinical diseases associated
with myelotoxicity are caused by benzene metabolites that injure cells in
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the bone marrow; the weight of evidence indicates that these effects are
more severe with either increasing benzene concentration or increasing
exposure time (cumulative-type effects).
Species Extrapolation
Based on work by Sabourin et al. (1992), it appears that mice are the
best model for studying the effects induced by benzene metabolites.
Analyses of urinary metabolites indicated that both humans and mice
have a higher propensity to metabolize benzene to its toxic metabolites,
muconic acid and hydroquinone, than do rats, monkeys, or chimpan-
zees. The ratio of hydroquinone or muconic acid to phenol in the urine
of mice was 80% and 300%, respectively, as compared with concentra-
tions in human urine (Henderson et al., 1992). Mice are also the most
sensitive rodent species to metabolite-mediated effects, but do not seem
to show leukemogenic changes similar to those found in industrial
workers (see below). The usual species-extrapolation factor of 10 will
not be used because that factor compensates for species differences in
both metabolism and target-tissue susceptibility. Although the compara-
tive tissue susceptibility of mice and humans is unknown, mice seem to
produce more toxic metabolites; hence, a species factor of 3 will be
used to extrapolate metabolite-induced effects in mice to human esti-
mates. A factor of 10 will still be used for CNS effects thought to be
caused directly by benzene itself. This factor is chosen because of po-
tential differences in tissue susceptibility and in the reduced sensitivity
of CNS tests in animals compared with the sensitivity of CNS tests in
humans (e.g., performance decrements).
Benzene-Induced Toxicity
The acute irritancy and cardiac arrhythmogenic effects of benzene
occur only at concentrations that induce significant CNS effects. In ro-
dents, aconitine-induced cardiac arrhythmias were induced by preadmin-
istration of benzene at a few thousand parts per million for 15 min;
however, narcotic effects were pronounced in the animals exposed to
benzene (Magos et al., 1990). Likewise, in monkeys and cats, cardiac
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rhythm disturbances occurred primarily during induction of narcosis
(Nahum and Hoff, 1934). Protection against CNS effects should pro-
tect against any sort of cardiac sensitization similar to that observed in
the experimental models. Benzene apparently is not very irritating; hu-
mans have been reported to tolerate a concentration of 3000 ppm for up
to 1 h (Flury, 1928), whereas CNS effects (headache, lassitude, and
weariness) are estimated to occur in the range of 50-150 ppm (Gerarde,
1960). Concentrations low enough to protect against CNS effects will
protect against irritation from benzene vapor.
Metabolite-lnduced Toxicity
During longer exposures that are below the CNS threshold, the me-
tabolites of benzene may induce several toxic effects that are mediated
through damage to stem cells (and other cells) in the bone marrow.
Each toxic effect will be analyzed separately; they include hematologi-
cal, immunological, and neoplastic effects. The first two effects are
particularly important because spaceflight causes loss of red-blood-cell
mass and reduced immune function in some cells.
Benzene has also been reported to cause reproductive toxicity, devel-
opmental toxicity, and genotoxicity. High (but unknown) concentra-
tions of benzene apparently caused menstrual disorders in 12 of 30 fe-
male workers exhibiting other signs of benzene toxicity (Vara and
Kinnunen, 1946); however, other studies in humans have not confirmed
this finding (Barlow and Sullivan, 1982). Animal studies have shown
ovarian and testicular changes in mice after subchronic exposure at 300
ppm, but nonreproductive effects (e.g., hematological) occurred much
earlier in the same study (Ward et al., 1985). Benzene concentrations
low enough to protect against myelogenic toxicity also are not likely to
produce any reproductive effects. No convincing human or animal data
exist to show that inhalation exposures to benzene cause developmental
abnormalities except at concentrations that are toxic to the mother.
Benzene is clearly a genetic toxicant; however, the clinically recognized
effects that it causes (hematotoxicity, immunotoxicity, and leukemia)
are largely mediated through genetic mechanisms; hence, the genotoxic
effects of benzene will not be analyzed separately.
BENZENE 75
Nervous System Effects
The early literature contains reports on the CNS effects induced by
inhaling high concentrations of benzene for brief periods (Flury, 1928;
Von Oettingen, 1940). Unfortunately, these human data are not suffi-
ciently specific in terms of exposure concentrations, number of test sub-
jects, and sensitivity of end points to be useful in setting acceptable
concentrations for benzene. Animal studies typically focus on the my-
elogenic effects; however, Demster et al. (1984) reported that hind-limb
grip strength was diminished 12% in mice exposed for 6 hr to benzene
at 1000 ppm, but ten 6-hr exposures at 300 ppm produced no signifi-
cant effect. Using 300 ppm as the no-observed-adverse-effect level
(NOAEL) and applying a species extrapolation factor of 10, gave an
acceptable concentration (AC) for benzene exposure of 30 ppm. This
value seems to be below the estimated threshold (50-150 ppm) for in-
duction of CNS effects in humans; therefore, it was adopted for all ex-
posure times from 1 hr to 180 d. (See Table 2-5 at the end of this sec-
tion.)
Hematological Effects
The hematological effects of benzene (e.g., hemorrhage of skin and
mucous membranes and anemia) have been known for almost a century;
however, quantitative human data on benzene's ability to induce these
effects are not available. Most human studies have focused on the leu-
kemogenic properties of benzene (considered below). Suitable data
from three studies of mice were used to estimate safe human exposure
limits to protect against hematological effects. For reasons cited above,
the species extrapolation factor was 3; however, because a 10% loss in
red-blood-cell mass is typical during spaceflight, a spaceflight factor of
3 was also applied. From the study by Dempster et ai. (1984), two 6-h
exposures at 300 ppm did not induce hematological effects. The human
limits were calculated as follows:
AC (1 h) = 300 ppm x 1/3 x 1/3 = 33 ppm.
AC(24h) = 300ppm x 1/3 x !/3 x 12/24 = 16ppm.
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Extrapolation to longer exposures is not reasonable from these data; for
longer exposures, the data of Green et al. (1981b) were used. They
found that 50 6-h exposures at 10 ppm did not induce hematological
effects. This information was used to estimate human exposure limits
as follows:
AC(7d) = 10ppm x t/3 x 1/3 = 1.1 ppm.
AC(30d) = 10ppm x 1/3 x 1/3 x 50 x 6/720 = 0.5ppm.
Extrapolation to 180 d was not necessary because data from Toft et al.
(1982) show that an 8-w continuous exposure at 10 ppm caused no
measurable changes in bone-marrow cellularity. From this 56-d expo-
sure, the human limit was estimated as follows:
AC(180d) = 10ppm x 1/3 x 1/3 x 56/180 = 0.3ppm.
This estimate was only slightly below the 30-d AC, suggesting that con-
centrations in the few tenths of a parts-per-million range approach a no-
effect level even when exposures are very long.
Immunological Effects
Dempster et al. (1984) reported that five 6-h exposures to benzene at
a concentration of 100 ppm induced a 30% reduction in circulating
lymphocytes in mice. No significant change was detected after a single
6-h exposure; hence, the NOAEL was 100 ppm for 6 h. From this
finding, the short-term ACs were derived as follows:
AC(1 h) = 100ppm x 1/3 x 1/3 = 11 ppm.
AC(24h) = 100ppm x 1/3 x 1/3 x 6/24 = 3ppm.
Since the immunological effects, which are similar (or greater) in mice
and humans, were presumably induced by benzene's toxic metabolites,
the species factor was only 3. Likewise, it was concluded that a space-
flight factor of 3 was appropriate because of the numerous reports of
spaceflight effects on immune function in rats and, to a lesser extent, in
astronauts (Lesnyak et al., 1993; Taylor, 1993). At landing, shuttle
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astronauts show depression in blast-cell transformation, changes in cyto-
kine function, and depression of peripheral T-inducer, T-cytotoxic, and
natural-killer cells (Taylor, 1993). The changes noted in animals in-
clude altered lymphocyte blastogenesis, cytokine function, killer-cell
activity, and colony-stimulating factors (Lesnyak et al., 1993).
Rosenthal and Snyder (1985) showed that 12 6-h exposures (72 h
total) to benzene at 10 ppm did not increase the susceptibility of mice to
infection by Listeria monocytogenes. This observation was used to cal-
culate ACs for 7 d and 30 d of exposure as follows:
AC(7d) = 10 x 1/3 x 1/3 x 72/168 = 0.5ppm.
AC (30 d) = 10 ppm x 1/3 x 1/3 x 72/720 = 0.1 ppm.
These were the lowest of the immunotoxicity ACs and were also the
lowest for any toxic effect known to be caused by benzene.
Data were available to set 7-d and 30-d ACs from Green et al.
(1981b). They found that mice exposed to benzene at 9.6 ppm for 6
h/d for 50 d (300 h = 12.5 d total) showed no changes in peripheral
blood or bone marrow. Although splenic cellularity and weight
changed, these changes are considered adaptive rather than adverse ef-
fects, because the direction of splenic changes in heavily exposed mice
was opposite to the changes noted in mice exposed at 9.6 ppm. This
information was used to calculate ACs as follows:
AC (7 d) = 9.6 ppm x 1/3 x 1/3 = 1.1 ppm.
AC (30 d) = 9.6 ppm x 1/3 x 1/3 x 300/720 = 0.4 ppm.
No long-term exposure data are available on the immunological ef-
fects of benzene exposure; however, Haber's rule can be used to ex-
trapolate a value of 0.07 ppm for continuous exposures of 180 d.
Risk of Leukemia
The risk of death from leukemia induced by occupational and envi-
ronmental exposure to benzene vapor has been estimated by many in-
vestigators. Most estimates have been based on positive epidemiologi-
cal findings from relatively high industrial exposures; however, other
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estimates have been based on "detection limits" of negative epidemio-
logical studies or extrapolation from animal data. Numerous controver-
sial issues affect the outcome of the risk estimates. These may be cate-
gorized as follows:
1. The spectrum of neoplasms that can be ascribed to benzene expo-
sure.
2. The concentrations found in industrial workers exposed at high
concentrations.
3. The most appropriate model to extrapolate risk from high- to low-
concentration exposures.
4. The most appropriate control population from which to judge
excess leukemia risk.
The only point of agreement among investigators seems to be that
cumulative benzene exposures above 300 ppm-y induce a significant
increase in the occurrence of leukemia in workers. This observation is
based on the results of a thorough epidemiological study of 1165 work-
ers exposed at two industrial sites in Ohio (Infante et al., 1977). In that
study, standard mortality ratios (SMRs) were not statistically above 100
except for the group with an exposure at the highest concentration
(> 400 ppm-y) and the group with a cumulative exposure at 200-400
ppm-y. In the group exposed at 40-200 ppm-y, the SMR was 322
(95% confidence interval 36-1165). Using such observations to predict
a benzene concentration to which crew members could be continuously
exposed for 180 d with no more than a 0.01% increase in leukemia is
not simple. At the end of this section, there is a chronological sum-
mary in Table 2-4 of risk assessments that have been published since
the late 1970s for benzene inhalation exposure. The concentrations cal-
culated in this document and shown in Table 2-4 are for continuous
0.5-y exposures and are typically determined from the long-term
intermittent-exposure predictions provided by the original risk asses-
sors. The values are not the 95% confidence limits; for ease of com-
parison, only mean or maximum-likelihood values are calculated.
Since the mid-1970s, when the threshold limit value (TLV) for ben-
zene was lowered from 25 ppm to 10 ppm (ACGIH, 1991), thought
concerning the leukemogenic properties of benzene has evolved. In
1979, the U.S. Environmental Protection Agency (EPA) estimated that
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the risk of dying from leukemia as a result of a 70-y exposure to ben-
zene at 1 ppm was 0.024 (EPA, 1979). This value was based on the
geometric mean of three risk estimates that varied from 0.014 to 0.046
(Aksoy et al., 1974; lnfante et al., 1977; Ott et al., 1978). However,
these risk estimates were based on epidemiological studies that had sub-
stantial shortcomings. In 1986, the National Research Council's Com-
mittee on Toxicology used the EPA values to estimate that a 0.004-ppm
lifetime exposure would impart a risk of 0.01% (NRC, 1986). Simi-
larly, the EPA conclusions can be used to calculate a 180-d (0.5-y) ex-
posure concentration (C) that would impart a 0.01% risk:
C (0.5 y) = 1 ppm x 70/0.5 x 0.0001/0.024 = 0.6 ppm.
This value is not the upper confidence limit of a 0.01% risk; it is the
most likely value estimated from the cited studies.
In the mid-1980s, the preliminary epidemiological investigations of
the rubber workers in Ohio (Infante et al., 1977) were reexamined
(Rinsky et al., 1981) and updated (Rinsky et al., 1987). These data
have been interpreted in several ways, and several shortcomings have
been indicated. The interpretations will be described below; however,
no attempt will be made to refine the original author's conclusions.
One of the major shortcomings of the positive epidemiological find-
ings is that worker exposures to benzene must be estimated; hence, the
leukemia risk varies depending on variations in the exposure estimates.
In 1985, the 5-y occupational-exposure (about 1 y of continuous expo-
sure) risk of exposure to benzene at 1 ppm was estimated to range from
0.5/1000 to 2/1000. The range is due to uncertainty about the concen-
trations of benzene in the exposures of workers in the cohort (Infante
and White, 1985). The Ohio cohort and a Michigan cohort (Ott et al.,
1978) gave essentially the same risk estimate when the one-hit linear
model was applied to the leukemia incidence. Using the geometric av-
erage of the range (1/1000), the concentration yielding a risk of 0.01%
after a continuous exposure for 0.5 y was calculated as follows:
C (0.5 y) = 1 ppm × 0.0001/0.001 × 1/0.5 = 0.2 ppm.
This value does not take into account statistical uncertainty from the
incidence of leukemia or possibly inappropriate modeling.
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The question of the link between benzene and cancer was subjected
to cancer modeling in which the increase in cancers relative to the back-
ground incidence was estimated. One model, based on the concept that
both initiation and promotion mechanisms must be considered (the lin-
ear nonthreshold model does not model epigenetic cancer mechanisms),
predicted that 2 ppb would yield an incidence of 0.00001 for all cancers
based on extrapolation from the most sensitive orally dosed rodents
(Albert, 1988). This estimate assumes that a concentration that doubled
malignant tumors in exposed animals would double the natural inci-
dence of all cancers in humans (0.02). If this calculation is applied to
a working lifetime of 45 y (10 y continuous exposure), then the half-
year concentration can be calculated for a 0.0001 risk as follows:
C (0.5 y) = 0.002 ppm × 10/0.5 × 0.0001/0.00001 = 0.4 ppm.
This is not an upper limit, and it applies, in principle, to all benzene-
induced cancers.
In a somewhat similar relative-risk approach, epidemiological data
were used to predict the odds ratio of benzene-exposed workers dying
of leukemia relative to unexposed workers dying of leukemia (Rinsky et
ai., 1987). Using a linear low-dose extrapolation, the ratio was esti-
mated to be 1.05 (range 1.01 to 1.09) for lifetime industrial exposure to
benzene at 0.1 ppm. Because the odds of males dying of myelogenous
leukemia is about 0.002, a 1/20 increase in this value is 0.0001. The
half-year continuous-exposure concentration would be calculated as fol-
lows:
C (0.5 y) = 0.1 ppm × 0.0001/0.0001 × 10/0.5 = 2.0 ppm.
This number is the most likely value; however, the concentration would
be nearly halved if the upper 95% limit of the odds ratio (1.09) were
used.
At about the same time as the above analyses were published, the use
of a linear low-dose extrapolation was questioned (Grilli et al., 1987).
The authors concluded from animal metabolism data that the tumor risk
from exposures at 10 ppm seemed to be 2-3 times the risk that would
be predicted from incidence data on exposures at 100 ppm. This in-
crease stems from a flattening of the dose-response curve above about
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40 ppm, where the high-affinity, low-capacity metabolic activation path-
ways start to become saturated.
Using a weighted average from four epidemiological studies, Austin
et al. (1988) concluded that a 30-y lifetime occupational exposure (6.6
continuous years) to benzene at 1 ppm would impart an excess risk of
death from leukemia of 0.005. Again the authors used a linear extrapo-
lation to lower concentrations from conclusions reached at much higher
concentrations. The prediction for the condition of 0.5 y of continuous
exposure is as follows:
C (0.5 y) = 1 ppm x 6.6/0.5 × 0.0001/0.005 = 0.3 ppm.
Again, this value is not based on the upper-confidence interval of the
risk; if it were, the value would be about 0.1 ppm. It includes only
deaths from leukemia, even though the analysis by Rinsky et al. (1987)
suggested that multiple myeloma might also be an outcome of benzene
exposure.
In an analysis of data on hematopoietic neoplasms in C57BL mice
(Snyder et al., 1980), Beliles and Totman (1989) concluded that the
maximum likelihood estimate for neoplasm risk in humans was 0.014
for lifetime occupational exposure at 10 ppm. This result was derived
by noting that the mice were exposed experimentally to benzene for
15% of their lifetimes and humans working for 45 y (10 y continuous
exposure) in a benzene-contaminated environment would be exposed for
14% of their lifetimes. Species extrapolation was done by allometric
equations based on surface area or metabolic-rate analyses. It was
found that body-weight ratios to the exponent 0.74 provided the best fit
to mouse and human data. The half-year risk calculation from this esti-
mate was as follows:
C (0.5 y) = 10 ppm × 10/0.5 × 0.0001/0.014 = 1.4 ppm.
The actual production of myelogenous leukemia in mice by benzene in-
halation has not been achieved by any investigator (Farris et al., 1993).
Using both positive and negative epidemiological data and a linear
model, Swaen and Meijers (1989) estimated five to six excess deaths
from nonlymphatic leukemia per 1000 deaths in workers exposed at 300
ppm-y of benzene (10 ppm x 30 y work exposure, or 6.6 y continuous
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exposure). The positive data were from Rinsky et al. (1987) and the
negative data were from several massive studies of 34,000-38,000
workers presumably exposed to low concentrations of benzene (and
many other chemicals). The authors of the latter studies used the un-
proven assumption that the low-concentration exposures averaged 50
ppm-y. From their analysis of the positive epidemioiogical data, the
half-year concentration is as follows:
C (0.5 y) = 10 ppm × 6.6/0.5 × 0.0001/0.006 = 2.2 ppm.
This result is similar to the value derived from the original work by
Rinsky.
Recognizing the wide range of risk estimates for benzene, Byrd and
Barfield (1989) asked whether this uncertainty was due to differences in
data, methods, or concept. They concluded that methodological differ-
ences contributed most to the uncertainty. As an example, Parodi et al.
(1989) argued that benzene lacks promoting potential below 10 ppm;
hence, a sublinear response at low-concentration exposures might be
predicted relative to exposures in the range of 10-30 ppm. However,
they noted that a leveling-off appears in the range of 50-100 ppm, re-
sulting in a sigmoidal dose-response curve.
Brett et al. (1989) examined various assumptions about the concen-
trations of benzene that the Ohio rubber workers were exposed to and
the matching to control populations. Variations in control matching
with Rinsky's exposure assumptions gave predicted increases in leuke-
mia death rates in the range of 4.2-6.4/1000 after 45 ppm-y of exposure
(equivalent to 10 y continuous exposure at 1 ppm), whereas the expo-
sure assumptions of Crump and Allen (1984) gave a range of leukemia
death rates of 0.5-1.6/1000 for the same variations in control matching.
Clearly, the exposure assumptions have a larger effect on the estimates
of leukemia risk than the control-matching choices. The authors' pref-
erence, using conditional logistic regression, gave leukemia death rates
of 1.2-1.6/1000 workers (45 ppm-y of exposure) based on the three
control-matching options (Brett et al., 1989). Using the average of this
range, gives the following half-year continuous exposure limit:
C (0.5 y) = 1 ppm × 10/0.5 × 0.0001/0.0014 = 1.4 ppm.
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This value falls between the low-concentration exposure group (<0.6
ppm) and the high-concentration exposure group (> 2 ppm).
In 1990, the ACGIH proposed a TLV of 0.1 ppm for benzene
(ACGIH, 1991) and that value has been defended on scientific grounds
(Infante, 1992). In particular, inhalation exposures at 1 ppm have been
noted to induce cytogenic effects in animals and humans. In addition,
Infante asserts that the Michigan cohort has provided evidence that low
cumulative exposures of benzene can increase the risk of leukemia.
Using the TLV (45 working y = 10 y continuous exposure) as a start-
ing point without any quantitative specification of leukemia risk, the
half-year concentration can be calculated as follows:
C (0.5 y) = 0.1 x 10/0.5 = 2 ppm.
This value is at the high end of the allowable concentrations and sug-
gests that the proposed TLV is not especially conservative.
Factors affecting the outcome of benzene risk estimates have been
considered by a panel whose general conclusions have been published
(Voytek and Thorslund, 1991). The panel preferred the epidemiologi-
cal data over the animal data for risk assessment; however, the animal
data were considered a valuable adjunct to the human exposure results.
It was not clear whether updating (for new leukemia deaths) and com-
bining epidemiological studies would provide a more powerful basis for
risk assessment. The panel felt that it was important to focus on spe-
cific disease entities (e.g., myelogenous leukemia) rather than on more
general categories (e.g., leukemia). The linear quadratic model was
preferred over linear models based on leukemia and bone-cancer risks
from radiation exposure, provided the former was found to be a "sensi-
tive" model at low concentrations. A preference for absolute risk over
relative risk was expressed by the panel.
Review of the risk assessments described above shows that they pre-
dict a half-year exposure concentration range of 0.2-2.2 ppm to cause a
0.01% increase in the risk of death due to leukemia. Yardley-Jones et
al. (1991) concluded, not surprisingly, that without the three highest
exposure cases in the Rinsky study, the model was statistically insigni-
ficant in predicting leukemia risks at low concentrations. Furthermore,
in the parts-per-billion range, the largest degree of uncertainty is due to
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dose-response extrapolation rather than to uncertainties in worker expo-
sures in the parts-per-billion range (Snyder et al., 1993a). Moreover,
factoring in the four multiple myeloma cases (one expected) found by
Rinsky should be considered. The problem is that three-fourths of the
cases occurred in the lowest-concentration exposure group (< 40 ppm-
y) with a very long latency period. It is difficult to understand why the
multiple myeloma cases occurred in the lowest-concentration exposure
group with such a preference if the myelomas were caused by exposure
to benzene. It was decided not to include these neoplasms in the pres-
ent risk analysis.
The average of the nine estimates, which are not independent of each
other, is 1.2 ppm. As a conservative measure, the lowest of the con-
centrations expected to impart a risk of no more than 0.01% was se-
lected-that is 0.2 ppm. Higher radiation exposures during spaceflight
are inevitable when compared with earth environments. The radiomi-
metic properties of benzene are well known; hence, it would be prudent
to consider the effects as interacting, probably in an additive way. The
degree of radiation protection that will be provided to crews is un-
known; hence, a reduction by a factor of 3 in benzene's leukemogenic
allowable concentration was selected somewhat arbitrarily. Therefore,
the AC to protect against excess leukemia for a continuous exposure of
180 d is 0.07 ppm. Using linear extrapolation to shorter times, the
ACs for 30, 7, and 1 d were found to be 0.4 ppm, 1.7 ppm, and 12
ppm, respectively. An estimate for 1 h was not considered suitable be-
cause the value would be well into the dangerous range based on other
toxic effects.
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Summary of Toxic Effects
The analysis of toxic effects induced by benzene generally followed
guidelines provided to NASA by the NRC Committee on Toxicology
(NRC, 1992). A summary of the analysis has been provided in Table
2-5. Important deviations from past practices were the following: (1)
A species extrapolation factor of 3 was used rather than 10 for effects
caused by metabolites of benzene. (2) For the first time, a spaceflight
factor was applied to an immunotoxicant because of the immune-modu-
lating effects of spaceflight. (3) A radiation uncertainty factor was ap-
plied because of the leukemogenic properties of benzene and the rela-
tively high radiation exposure of astronauts. (4) Finally, the present
analysis of leukemogenic effects deviated from the NRC-recommended
linearized multistage model because of uncertainty involving the human
epidemiology database and variations in low-dose extrapolation methods
used by investigators.
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RECOMMENDATIONS
Benzene ranks among the most well-studied chemicals known to
cause toxic effects in humans. Nonetheless, during our efforts to set
exposure limits for astronauts, important limitations in the database be-
came apparent; these limitations should be targets of further research on
benzene's toxicity. The acceptable concentration for protection from
neurotoxicity induced by short-term benzene exposures was based on
rodent data. That was because the reported effects in humans appeared
to be based on impressions from industrial experience rather than on
specific human data. Well-controlled short-term human exposures to
assess neurotoxicity (e.g., performance decrements) are needed to place
the acceptable concentrations for such effects on a more reliable founda-
tion. Ethical constraints could limit the scope of studies involving
controlled human exposures to benzene.
Continuation of scientific investigations into the role of various en-
zymes and cofactors in the activation of benzene to its myelotoxic prod-
ucts should continue (Snyder et al., 1993b). Discovery of new poten-
tially toxic metabolites, such as 6-hydroxy-trans, trans-2,4-hexadienoic
acid, will further elucidate the mechanism of benzene toxicity (Kline et
al., 1993). Refinement of toxicokinetic models will lead to better defi-
nition of research aims and facilitate comparative toxicity study (Wood-
ruff and Bois, 1993). Taken together, such scientific investigations will
result in an improved definition of time and concentration dynamics,
particularly in the areas of continuous-vs.-intermittent exposure and
low-concentration extrapolation.
The uncertainty factors selected to compensate for "target-organ"
effects common to both benzene and spaceflight were arbitrarily as-
signed. Experiments designed to assess the interaction of chemical tox-
icity and spaceflight-induced changes would be valuable in evaluating
the accuracy of such selections. For example, rodent experiments in-
volving concomitant exposure to benzene and spaceflight (or a model of
spaceflight) could be designed to show whether spaceflight modulates
benzene's hematotoxicity or immunotoxicity. Findings in such experi-
ments would improve the risk assessment and circumvent the need to
make arbitrary choices in uncertainty factors.
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PHYSICAL AND CHEMICAL PROPERTIES
Carbon dioxide is an odorless and colorless gas (Sax, 1984).
Synonym:
Formula:
CAS number:
Molecular weight:
Boiling point:
Melting point:
Vapor pressure:
Conversion factors
at 25°C, 1 atm:
Carbonic anhydride
CO2
124389
44
Not applicable
Sublime at-78°C
Not applicable
1 ppm = 1.80 mg/m 3
1 mg/m 3 = 0.56 ppm
OCCURRENCE AND USE
CO2 normally exists in the atmosphere at 0.03% (Morey and Shat-
tuck, 1989). In a Danish study, the maximal CO2 concentrations inside
14 town-hall buildings (6 had natural and 8 had mechanical ventilation)
were measured to be 0.05-0.13% (Skov et al., 1987). Wang (1975) re-
ported that the CO2 concentration inside a university auditorium built up
to about 0.06-0.09% during a lecture. COz is not used in space shut-
ties, but it will be used as a fire extinguishant in the space station.
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Metabolism is a source of CO2 in spacecraft, and thermodegradation
of organic materials is a potential source of CO2 (Coleman et al., 1968;
Terrill et al., 1978; Wooley et al., 1979). Humans produce CO2 via
oxidative metabolism of carbohydrates, fatty acids, and amino acids; the
production rate is dependent on the caloric expenditure of the individual
(Baggott, 1982; Diamondstone, 1982: LeBaron, 1982; Olson, 1982). A
young adult male produces about 22,000 meq of CO2 per day (Baggott,
1982). For a 70-kg adult doing light work in spaceflight, the amount of
CO_, exhaled was estimated to be 500 L/d (Clamann, 1959). The
amount of CO, exhaled by a group of normal male subjects, aged
18-45, inside a steel chamber was measured at 469 L/d per person
(Consolazio et al., 1947). During a 7-d shuttle mission with seven
crew members, the mean CO2 concentration in the cabin was about 2
mm Hg, which was equivalent to 0.26% in an atmosphere of 760 mm
Hg, with a 5-h peak of 9 mm Hg or 1.2% (NASA, 1984).
PHARMACOKINETICS AND METABOLISM
When inhaled, CO2 freely penetrates cellular membranes (Baggott,
1982). The diffusion rate of CO2 through the alveolar membrane into
blood is about 20 times that of 02 (West, 1979). CO2 is carried in
blood in three forms, the bicarbonate being the major form. Ninety
percent of the CO2 in blood reacts with water, under the catalysis of
carbonic anhydrase inside the erythrocytes, to form carbonic acid,
which in turn is ionized to bicarbonate (Baggott, 1982). This reaction
also takes place in serum in the absence of carbonic anhydrase, but it
proceeds much more slowly than with catalysis (Baggott, 1982).
The other two forms of CO2 transport in blood are relatively minor.
About 5% of the CO2 in blood is dissolved in serum and cytoplasm
(Baggott, 1982). The solubility of CO,, in water is approximately 20
times that of O2, so that CO : dissolved in plasma is a more important
form of transport in blood than dissolved 02 (West, 1979). CO2 is
present in blood in the third form as carbamino compounds, which are
formed from the reaction of CO2 with uncharged amino groups in he-
moglobin (Baggott, 1982). The carbamino form accounts for about 5%
of the CO, in blood (Baggott, 1982).
CARBON DIOXIDE 107
Normally, CO2 is eliminated from the body via exhalation. A
healthy man exhales CO2 at about 220 mL/min at rest and 1,650 mL/
min during moderate exercise (Cotes, 1979, pp. 266, 276, 384).
The CO2-bicarbonate system functions as the major buffering system
in blood (Baggott, 1982). In acidosis, an individual is exposed to a
high concentration of CO2. Hyperventilation increases the CO2 exhala-
tion, which raises the pH in blood (Baggott, 1982). In alkalosis, the
individual will hypoventilate to reduce CO2 exhalation and the kidney
will excrete bicarbonate ions into the urine, both of which lower the pH
in blood (Baggott, 1982).
TOXICITY SUMMARY
Acute and Short-Term Toxicity
Miscellaneous Signs and Symptoms
Both hearing and vision can be impaired by CO2. A 6-min exposure
to 6.1-6.3% CO2 resulted in a 3-8% decrease in hearing threshold in six
human subjects (Gellhorn and Spiesman, 1935). For CO2 exposures of
six human subjects lasting 5-22 min, 3-4% CO2 was the threshold for
causing slight hearing impairment and 2.5% was the no-observed-
adverse-effect level (NOAEL) (Gellhorn and Spiesman, 1934, 1935).
Because the amount of hearing impairment produced by about 6% CO2
is very small and because the SMACs are expected to be much lower
than 6%, hearing impairment is not considered in setting the SMACs
for CO2. Acute exposures to 6% CO2 affected vision by reducing vi-
sual intensity discrimination in 1-2 min (Gellhorn, 1936) and by causing
visual disturbances in several hours in an unspecified number of men
(Schulte, 1964).
CO2 exposures can cause other symptoms, such as tremor, discom-
fort, dyspnea, headache, and intercostal pain. Tremor was produced in
human subjects exposed to 6% CO2 for several hours (number of sub-
jects unknown) (Schulte, 1964) or 7-14% CO2 for 10-20 min (12 sub-
jects) (Sechzer et al., 1960). Exposures of six volunteers to 6% CO2
for 20.5-22 min led to discomfort (Gellhorn and Spiesman, 1935).
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Dyspnea
Available data indicate that acute exposures to CO2 at concentrations
higher than 3 % definitely could produce dyspnea. For instance, White
et al. (1952) found that, in a 16-min exposure to 6% CO s in 02, 19 of
24 volunteers had slight or moderate dyspnea, and the dyspneic sensa-
tion was severe in the remaining five subjects. A 17-32 min exposure
of 16 human subjects to 4-5% COs (Schneider and Truesdale, 1922) or
a 2.5-10 min exposure to 7.6% COs (Dripps and Comroe, 1947) result-
ed in dyspnea.
There were conflicting data on whether 2.8-3% CO2 would cause
dyspnea. On one hand, Menn et al. (1970) found that, in a 30-min ex-
posure to 2.8% CO2, dyspnea was detected in three of eight human sub-
jects during maximal exercise, but not during half-maximal or two-
thirds-maximal exercises. On the other hand, Sinclair et al. (1971)
showed that a 1-h or 15- to 20-d exposure of four volunteers to 2.8%
CO2 failed to produce any dyspnea during steady strenuous exercise.
However, Schulte (1964) reported that an exposure to CO2 at concentra-
tions as low as 2% for several hours resulted in dyspnea on exertion in
an unknown number of human subjects. In the study conducted by
Menn et al., 1.1% CO2 failed to cause dyspnea in eight subjects even
during maximal exercise in 30 min. There were also conflicting data
on CO2's dyspneic effect in resting subjects. Brown (1930a) showed
that 3.2% CO2 or 2.5-2.8% CO2 did not produce dyspnea in five rest-
ing human subjects. In contrast, Schulte (1964) reported that an expo-
sure to 3 % CO2 for several hours resulted in dyspnea even at rest, with-
out specifying the number of human subjects on which he based his
conclusion. The bulk of the data indicate that the NOAEL for CO2 ex-
posures based on dyspnea appears to be 2.8% because astronauts will
engage in moderate, but not maximal, exercise.
Headaches
In addition to dyspnea, acute CO2 exposures could produce head-
aches. Without specifying the size of population he based his conclu-
sion on, Schulte (1964) reported that human subjects exposed to 2% or
3% CO2 for several hours developed headaches on mild exertion; the
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headache was more severe at 3% COz than 2%. Sinclair et al. (1971)
showed that a l-h exposure of four human subjects to 2.8% CO2 result-
ed in occasional mild headaches during strenuous steady-state exercise.
Menn et al. (1970) found that mild-to-moderate frontal headaches devel-
oped in six of eight human subjects exposed to 3.9% CO2 for 30 min
while doing two-thirds-maximal exercise. A similar exposure to 1.1%
or 2.8% CO2 failed to cause headaches (Menn et al., 1970). Therefore,
there is conflicting evidence whether 2.8% CO2 produces headaches
during exertion.
In a comparison of the data on exercising subjects (Schulte, 1964;
Menn et al., 1970; Sinclair et al., 1971) and on subjects at rest (Schnei-
der and Truesdale, 1922; Brackett et al., 1965), CO2 appears to cause
more headaches at a lower concentration during exercise than at rest.
White et al. (1952) showed that, soon after a 16-min exposure of 24
subjects to 6% CO2, one developed a severe headache and nine devel-
oped mild headaches of very short durations. In a study of five or six
resting human subjects conducted by Brown (1930a), an exposure to
3.2% CO 2 in 13.4% 02 for several hours produced headache and giddi-
ness, but an exposure to 2.5-2.8% CO 2 in 14.6-15% 02 was devoid of
any symptoms. Schneider and Truesdale (1922) showed that, in 16
resting volunteers exposed to 1-8% CO2 for 17-32 min, headaches de-
veloped only at a CO2 concentration of 5 % or more and the headache
could be intense. In a study by Brackett et al. (1965), 7% CO2 caused
mild headache in approximately seven resting volunteers in 40-90 min.
CO2 exposures do not cause headaches immediately. Menn et al.
(1970) reported that headaches mostly developed near the end of a 30-
min exposure to 3.9% CO2 while the subjects were performing
two-thirds-maximal exercise. Glatte et al. (1967a) found that, in a 5-d
exposure to 3% CO2, mild-to-moderate throbbing frontal headaches
were detected in four of seven human subjects in the first day. A simi-
lar response was found in human subjects exposed to 4% CO2 (Glatte et
al., 1967b; Menn et al., 1968). The headaches usually began in the
first few hours of exposure.
The headaches produced by CO2 are not long lasting. In a 30-min
exposure to 3.9% COz, the headaches disappeared an hour after the
exposure (Menn et al., 1970). In human subjects exposed to 3% or 4%
CO2 for 5 d, they recovered from the headaches in 3 d (Glatte et al.,
1967b; Menn et ai., 1968). Menn et al. (1970) postulated that the
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headaches are caused by CO2-induced dilation of cerebral blood vessels
(Patterson et al., 1955). The disappearance of the headaches soon after
an acute exposure or disappearing beginning on the third day of a 5-d
exposure suggests, as another possibility, that the headaches are due to
CO2-induced acidosis.
As discussed above, it is not certain whether 2.8% CO2 could cause
headaches. Similarly, there is conflicting evidence on 2% CO2. With-
out specifying the size of the study population, Schulte (1964) reported
that headaches were detected in human subjects exposed to 2% CO: for
several hours on mild exertion. In contrast, Radziszewski et al. (1988)
showed that a 30-d exposure of six human subjects to 2% COz rarely
produced headaches, even when they exercised.
Intercostal Pain
Acute COe exposures can produce intercostal pain. Menn et al.
(1970) reported that a 30-rain exposure to 2.8% CO 2 caused intercostal
muscle pain during maximal exercise in two of eight human subjects.
They did not report any intercostal pain in the subjects during two-
thirds- or half-maximal exercise. However, Sinclair et al. (1971)
showed that a t-h exposure to 2.8% CO2 failed to produce intercostal
muscle pain in four volunteers during steady strenuous exercise. It is
possible that the test subjects in Sinclair's stud)' did not exercise maxi-
mally during the exposure to 2.8% CO2, so that they did not experience
the intercostal pain that was reported by those in Menn's study. Menn
et al. failed to detect intercostal muscle pain in eight human subjects
exposed to 1.1% CO2 for 30 min even during maximal exercise. Be-
cause astronauts will not be exercising maximally in the spacecraft,
2.8% is chosen as the NOAEL for intercostal muscle pain resulting
from acute CO2 exposures.
Acid-Base Balance
An exposure to CO2 at concentrations much higher than the normal
value of 0.03% increases the pCO2 in blood (Mines, 1981). The in-
creased pCO2 in blood lowers the blood pH, although the lowering is
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reduced somewhat by the bicarbonate and protein buffers in blood
(Mines, 1981). Acidosis is known to occur in humans after a 1-h expo-
sure to 2.8% CO z (Sinclair et al., 1971). Both the CO 2 absorption and
acidosis happen very rapidly. During a 1-h exposure of volunteers to
7% CO 2, the arterial pCO 2 and HCO 3 concentrations were raised, while
the arterial plasma pH dropped from 7.40 to 7.30 as early as 10 min
into the exposure (Brackett et al., 1965). These arterial parameters re-
mained at a plateau from min 10-60 during the CO 2 exposure. The de-
creases in arterial plasma pH in humans resulting from acute CO2 expo-
sures are tabulated as follows.
TABLE 3-1 Arterial pH Decreases After Acute CO2 Exposures
Concen- Exposure Arterial pH
tration, % Duration Drop Reference
1.5 1 d 0.05
2 2h 0
2 2-3 d 0.01
2.8 1 d 0.02
3.0 6-24 h 0.025
7 10-60 min 0.10
10 10-60 min 0.22
Schaefer, 1963b
Guillerm and Radziszewski, 1979
Guillerm and Radziszewski, 1979
Glatte et al., 1967a
Sinclair et al., 1969
Brackett et al., 1965
Brackett et al., 1965
Electrolyte Levels
Messier et al. (1976) reported some electrolyte changes in 7-15 hu-
man subjects in 57-d submarine patrols, the atmosphere of which was
maintained at 0.8-1.2% CO 2, 19-21% 02, and CO at <25 ppm. On
the first day of a patrol, the plasma levels of calcium decreased, with
no change in plasma phosphorus levels, but the erythrocyte level of cal-
cium increased.
Respiratory System
The most obvious effect of CO 2 exposures is increased alveolar venti-
lation, which is not a toxic effect per se, but it and other physiological
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changes inducible by CO2 will be described in the Toxicity Summary.
If 02 is maintained at a constant concentration, alveolar ventilation of
humans varies linearly with the CO2 concentration at ventilation up to
about 60 L/min (Cotes, 1979, pp. 149, 258, 363). The amounts of
ventilatory increase during an acute exposure of normal human subjects
to CO2 at various concentrations are summarized in Table 3-2.
The hyperventilatory response is due mainly to a tidal volume in-
crease, although the respiratory rate was tbund to increase in one study
but not in another (Schaefer, 1963b; Giatte et al., 1967a; Guillerm and
Radziszewski, 1979). The hyperventilatory response to inhaled CO2 is
triggered by COt's effect on chemoreceptors in the brain and the
carotid chemoreceptors (Cotes, 1979, pp. 149, 258, 363; Phillipson et
al., 1981). When the CO2 exposure terminates, residual hyperventila-
tion helps to lower the pCOz in blood, and thus the hyperventilation
plays a role in restoring the normal blood pH.
Three studies show that human subjects acclimate somewhat to the
hyperventilatory effect of CO2 (Chapin et al., 1955; Schaefer, 1958;
Radziszewski et al., 1988). The alveolar ventilation at rest was 15.1
L/min shortly after an exposure to 3% CO: began, but it was lowered
to 12.9 L/min near the end of the 78-h exposure (Chapin et al., 1955).
Schaefer (1958) also reported acclimation to CO2's ventilatory effect.
He presented evidence that diving instructors, who had held their
breaths daily for long durations under water (resulting in CO2 accumu-
lation in their bodies), showed a smaller hyperventilatory response to-
ward acute CO2 challenges than other volunteers who were not accus-
tomed to CO2 retention. Some of the data from Radziszewski et al.
(1988), summarized in Table 3-2 showed that the hyperventilatory re-
sponse to CO2 was diminished about one fifth at 24 h compared with 2
h in a continuous CO2 exposure.
Some evidence indicates that CO2 can stimulate or depress ventilation
depending on the concentration. As mentioned above, CO2 stimulates
respiration at a concentration as low as 1%. CO2 at concentrations
higher than 8% has been reported to depress respiration in humans
(Cotes, 1979, pp. 149, 258, 363). However, a 3.8-min exposure of
human subjects to 10.4% CO2 is known to stimulate respiration (Dripps
and Comroe, 1947). So the exact CO2 concentration required to consis-
tently depress respiration is unknown and it might be much higher than
8%.
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TABLE 3-2 Hyperventilatory Responses to Acute C02 Exposures
Increase in Mini-
Concen- Exposure mum Volume, %
tration, % No. Duration (mean + SD) Reference
0.5-0.6 5 10 min 14 +4 Campbell et al., 1913
0.5 6 24 h --" Radziszewski et al., 1988
1 16 17-32 min 32 Schneider and Truesdale, 1922
1 6 24 h 19 Radziszewski et al., 1988
2 16 17-32 min 80 Schneider and Truesdale, 1922
2 6 2 h 60 Radziszewski et al., 1988
2 6 24 h 45 Radziszewski et al., 1988
2.1-2.5 3 10 min 63 +13 Campbell et al., 1913
2.2 3 10 min 36 +21 Eldridge and Davis, 1959
2.5 3 10-20 min 30 + 9 Brown et al., 1948
2.5 9 _20 min 33 _ 21 Tashkin and Simmons, 1972
3 16 17-32 min 148 Schneider and Truesdale, 1922
3 5 2 h 70 Radziszewski et al., 1988
3 5 24 h 50 Radziszewski et al., 1988
3.8 5 2 h 160 Radziszewski ec al., 1988
3.8 5 24 h 130 Radziszewski et al., 1988
4 16 17-32 min 208 Schneider and Truesdale, 1922
4.2 3 10 min 184 + 110 Eldridge and Davis, 1959
4.3 5 2 h 240 Radziszewski et al., 1988
4.3 5 24 h 180 Radziszewski et al., 1988
5 3 10-20 min 130 __+30 Brown et al., 1948
5 9 =20 min 91 ___60 Tashkin and Simmons, 1972
5 16 17-32 min 309 Schneider and Truesdale, 1922
5.7-6.1 5 10 min 413 + 57 Campbell et al., 1913
5.9 7 5 min 184 Brown, 1930a
6 3 20.5-22 min 203 Brown, 1930a
6 23 16 min 200 White et al., 1952
6 16 17-32 min 419 Schneider and Truesdale, 1922
7 16 17-32 min 512 Schneider and Truesdale, 1922
7.5 3 10-20 min 474 __+242 Brown et al., 1948
7.5 9 =20 min 269 + 123 Tashkin and Simmons, 1972
8 16 17-32 min 640 Schneider and Truesdale, 1922
8.8 5 7-10 rain 228 Brown, 1930a
10 9 _20 rain 456 ± 189 Tashkin and Simmons, 1972
12.4 7 0.75-2 rain 153 Brown, 1930a
aStatistically not significant.
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Exposures to CO2 are also known to affect lung functions. CO2 in-
halation for 2 h at 5 % or 7.5% decreased specific airway conductance
in volunteers, but 2.5% CO2 did not change the conductance (Tashkin
and Simmons, 1972). A 120% increase in the total lung resistance was
detected in human subjects who inhaled 8% CO_ in 19% 02 for 3-6 min
(Nadel and Widdicombe, 1962).
There are no data on the structural effect of CO2 on the lungs of hu-
man beings. However, Schaefer and his colleagues reported that acute
exposures to CO2 injured the lungs of guinea pigs (Niemoeller and
Schaefer, 1962; Schaefer et al., 1964a). In some of the guinea pigs ex-
posed to 15% CO 2 in 21% 02, Schaefer's group detected subpleurai
atelectasis, an increase of lamellar bodies in alveolar lining cells, con-
gestion, edema, and hemorrhage in the lungs in l or 6 h (Schaefer et
al., 1964a). When the exposure was extended to 1 or 2 d, they report-
ed that hyaline membranes were seen in the lungs, in addition to the
pulmonary injuries seen at 1 and 6 h. As the exposure was further ex-
tended to 7 or 14 d, they described a decline in incidences of atelecta-
sis, edema, hemorrhages, and hyaline membranes in the lung. In that
1964 study, Schaefer's group looked at a total of six time points, with
4-14 guinea pigs exposed to CO2 per time point. However, they used
only 13 guinea pigs as controls, and they did not specify how many
control guinea pigs were sacrificed per time point. That means, on the
average, only two control guinea pigs were sacrificed at each time point
and that is grossly inadequate. In another study, Niemoeller and
Schaefer (1962) reported that CO 2 exposures at 1.5% or 3% could pro-
duce similar lung injuries as 15% CO2. In this study, the same prob-
lem existed. They used only /our control guinea pigs in the 1.5%-CO2
experiment in which a group of exposed guinea pigs was examined at
four time points. Similarly, in the 3 %-CO2 experiment, they used seven
guinea pigs to control for examinations of exposed guinea pigs at five
time points. Consequently, their findings that CO2 exposures produced
lung injuries in guinea pigs might not be reliable. Therefore, their
findings in the lungs of guinea pigs (Niemoeller and Schaefer, 1962;
Schaefer et al., 1964a) are disregarded in setting SMACs.
Cardiovascular System
CO2 exposures are known to affect the heart and the circulatory sys-
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tem. A 17-32-min exposure of humans to 1% or 2% CO2 is known to
cause slight increases of systolic and diastolic pressure (Schneider and
Truesdale, 1922). In another human study, a 15-30-min exposure to
5 % or 7% CO2 caused increases in blood pressure and cerebral blood
flow and a decrease in cerebrovascular resistance (Kety and Schmidt,
1948). In the same study, no change in cardiac output was detected,
but in another study, a 4-25-min exposure of volunteers to 7.5% CO2
increased the cardiac output and blood pressure (Grollman, 1930). In
addition to changing the cardiac output, CO2 can increase the heart rate.
A 10-15-min exposure to 5.4% CO2 or a 4-25-min exposure to 7.5%
CO2 increased the pulse rate in humans (Grollman, 1930; Schaefer,
1958).
Acute CO2 exposures can result in some EKG changes. Nodal and
atrial premature systoles, premature ventricular contractions, inversion
of P waves, low P waves, and increased T-wave voltage were observed
in psychiatric patients exposed to 30% CO2 in 70% 02 for 38 s (Mac-
Donald and Simonson, 1953). Similarly, McArdle (1959) exposed psy-
chiatric patients to 30% CO 2 in 70% 02 for 10-15 breaths, and he de-
tected acidosis, marked increases in systolic and diastolic pressures,
atrial extrasystoles, atrial tachycardia (but no ventricular extrasystole),
increased P-wave voltage, low or inverted P waves, spiked T waves
with a broad base, increased T-wave voltage, slight increases in PR
intervals and QRS intervals, and a marked increase in the QT interval,
which was the most consistent finding. The fact that it took only 35-45
breaths of the mixture of 30% CO 2 in 70% 02 to produce narcosis in
these patients suggests that the CO2 concentration used was very high.
In CO2 exposures at lower concentrations, lower incidences of abnor-
mal cardiac rhythm result. For instance, in human subjects breathing
7-14% CO2, balance 02, for 10-20 min at rest, premature nodal con-
traction was detected in only 2 of 27 subjects (versus 0 of 27 before the
exposure) and premature ventricular contraction was found in only 3 of
27 subjects (versus 1 of 27 before the exposure) (Sechzer et al., 1960).
At even lower CO2 concentrations, only minor EKG changes were
produced without any abnormal rhythm. In human subjects, a 6-8 min
exposure to 6% CO2 depressed the amplitude of the QRS complex and
T wave, but there were no T-wave inversions or changes in the S-T
segment (Okajima and Simonson, 1962). These EKG changes were
more severe in men of about 60 years of age than in men in their twen-
ties. In volunteers doing moderate or maximal exercise while exposed
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to 2.8% or 3.9% CO2 for 30 min, Menn et al. (1970) found no signifi-
cant increase in premature atrial or ventricular contractions over the
incidences normally seen in exercising individuals in room air.
These data indicate that, in acute exposures, CO2 can produce clini-
cally unimportant abnormal cardiac rhythm at a fairly high concentra-
tion of 7-14% and requires a very high concentration of 30% to pro-
duce atrial tachycardia. Therefore, COz's EKG effects are not used in
setting the SMACs for CO2.
The mechanism of EKG changes produced by CO/ is unknown.
Altschule and Sulzbach (1947) postulated that the COz-induced EKG
changes were due to COz-induced acidosis because the changes were
seen with acidosis in a 45-90-min exposure of two patients at 5 % CO2
in 95 % 02 and the changes disappeared within 30 min of terminating
the C02 exposure.
Nervous System
Exposures to CO2 at the appropriate concentrations could cause CNS
depression. Consolazio et al. (1947) discovered a decrease in hand-arm
steadiness, but no change in the ability to compute, translate, check
numbers, and discriminate pitch and loudness in four volunteers ex-
posed to 5-6.75% CO 2 in 19.2% 02 for 37 h. Schulte reported that an
exposure of an unspecified number of human subjects to 5% CO2 for
several hours produced CNS depression (Schulte, 1964). An exposure
of fighter pilots to 5% CO2 for a unspecified duration degraded their
performance in landing maneuvers, such as lengthened flight time
between gear down and touch down and unacceptable increases in
touch-down sink rates (Wamsley et al., 1969). Therefore, these studies
indicate that 5 % CO2 is depressive to the CNS.
Brown (1930a) conducted a study with five human subjects in a static
exposure chamber for 8 h with the CO: concentration measured at 4.1%
and 5.3% at the end of the fourth and seventh hours, respectively.
Brown showed that the number of numbers canceled in a cancellation
test dropped 24% at the end of the seventh hour when the CO2 concen-
tration was 5.3% with 21% O2. Using the data provided by Brown, the
24% reduction is found to be statistically significant from the pre-expo-
sure number. However, Brown commented that the reduction was not
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serious deterioration. It should be noted that the same CO2 exposure
caused no changes on the scores in Army Alpha intelligence and arith-
metic tests, attention, and muscular coordination (Brown, 1930a).
Whether the 24 % reduction in the cancellation test score was due to the
concentration of CO2 at 5.3% in the exposure chamber or due to bore-
dom from confinement in the exposure chamber is unknown because
there was no sham-exposed control group.
Data on CNS depression resulting from exposure to CO2 at concen-
trations below 5% were inconsistent. In the study of five human volun-
teers conducted by Brown, the number of numbers canceled in the can-
cellation test decreased by 13 % at the end of the fourth hour when the
atmosphere contained 4.1% CO2 in 21% 02 (Brown, 1930a). Although
the 13% reduction is statistically significant (based on a paired t test
using Brown's data), Brown did not consider it a serious deterioration.
There were no effects observed in the Army Alpha intelligence and
arithmetic tests, attention, and muscular coordination (Brown, 1930a).
Because Brown did not have a sham-exposed control group in assessing
the CNS effects of CO2, interpretation of Brown's CNS data is difficult.
Schaefer et al. (1958, 1959, 1963a) reported that some crew mem-
bers on board a German submarine that contained 3-3.5% CO2 in 15-
17% 02, suffered impaired attentiveness in a 2-mo underwater patrol in
World War 1I. Nevertheless, as noted by Glatte et al. (1967b) and
Menn et ai. (1968), the submarine atmosphere was not tightly con-
trolled, so that simultaneous exposure of the crew to other con-
taminants, such as carbon monoxide, could not be ruled out. It is,
therefore, possible that the CNS depression suffered by the crew was
due to the relatively low oxygen concentration, carbon monoxide, or
certain organic solvents instead of the 3-3.5% CO2. Brown's test pro-
duced giddiness and headache in four human subjects exposed to 3.2%
CO2 for several hours (Brown, 1930b). Unfortunately, the subjects
were also exposed to a relatively low 02 concentration of 13.4%, which
makes interpretation of the finding of giddiness difficult.
In contrast to the findings of Schaefer et al. and Brown, other evi-
dence shows that exposures to CO2 in the range of 2-4 % do not depress
the CNS. For instance, Glatte et al. showed that a 5-d exposure of
seven human subjects to 3 % or 4 % CO2 failed to influence hand steadi-
ness, vigilance, auditory monitoring, memory, and arithmetic and prob-
lem solving performance (Glatte et al., 1967a,b; Menn et al., 1968).
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Storm and Giannetta (1974) showed that there were no changes in aim-
ing ability, closure flexibility, visualization, perceptual speed, and num-
ber facility in 12 human volunteers who were tested everyday during a
2-w exposure to 4% CO2. Schulte (1964) reported no mental depres-
sion in subjects exposed to 2% or 3% CO2 for a few hours. The num-
ber of subjects is not known. From these data, the NOAEL for CNS
depression is estimated to be 4 %.
At a CO2 concentration higher than 5%, CO2's effect on the CNS is
not purely depressive. Restlessness and dizziness have been detected in
human subjects exposed to 7.5% CO2 for 15 min, 10% CO2 for 15-25
min, and 10.4% CO2 for 3.8 min (Dripps and Comroe, 1947; Schaefer,
1963a; Brackett et ai., 1965). Some studies have shown that acute ex-
posures to CO2 at high concentrations produced purely depressive signs
and symptoms. For instance, unconsciousness was detected in human
subjects exposed to 10% CO2 for several hours (Schulte, 1964) and
drowsiness and near stupor were found in individuals who had inhaled
12.4% CO2 for 0.75-2 min (Brown, 1930b). In contrast, some investi-
gators have presented evidence that CO2 exposures excite the CNS.
Psychomotor excitation, eye flickering, myoclonic twitches, increased
muscle tone, and restlessness were produced by exposures to 10% COs
for 1.5 min and 15% CO2 for 3 min in a study by Lambersten (1971).
At even higher CO2 concentrations, the CNS effects of CO2 are
mostly depressive. Unconsciousness was the predominant finding in
human subjects exposed to 17% CO2 in 17.3% 02 for 20-52 s (Aero
Medicat Association, 1953) or 18.6% CO2 in 17% 02 for <2 min
(Dalgaard et al., 1972). Of course, at such high CO2 concentrations, it
is difficult to separate the CO,. effect from the hypoxic effect. The
CNS effects of acute CO2 exposures are summarized in Table 3-3.
At CO2 concentrations much higher than 17%, the CNS depression
could result in death. Several workers in a ship carrying fish were
found dead in the holding tank with a CO2 concentration at 20-22%
(Dalgaard et al., 1972). Similarly, CO2 could be the cause of death in
some fires. Gormsen et al. (1984) examined the causes of death in fire
victims. They concluded that CO2 poisoning or oxygen deficiency or
both is the second most common cause of death, carbon monoxide poi-
soning being the most common.
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TABLE 3-3 CNS Effects Resulting from Acute CO2 Exposures
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Concen-
tration, % CNS Effects Reference
1.5
3-4.5
5
6
7.5-15
No effect Schaefer, 1959
No effect or marginal depres- Glatte et al., 1967a; Deitrick et
sion
Depression
Subjective feelings of speech
and movement difficulties
that did not exist when deter-
mined objectively
Mixture of depression and
excitation
> 17 Unconsciousness
al., 1948; Brown, 1930a
Wamsley et al., 1969;
Consolazio et al., 1947
White et al., 1952
Brown, 1930a; Dripps and
Comroe, 1947; Lambertsen,
1971
Aero Medical Association, 1953;
Dalgaard et al., 1972
Kidneys
CO2 exposures might produce physiological changes in the kidney.
A 30-min exposure of human subjects to 5 % CO2 produced increases in
renal blood flow, glomerular filtration rate, and renal venous pressure,
as well as decreased renal vascular resistance (Yonezawa, 1968). These
physiological changes in the kidney probably represent renal compensa-
tion for the CO2-induced acidosis because the plasma HCO 3 level was
increased. Due to their innocuous nature, the SMACs are not set to
prevent these renal physiological changes.
Male Reproductive System
Acute CO2 exposures might affect some of the mature cell types in
the testis of laboratory animals. Vandemark et al. (1972) showed that a
4- or 8-h exposure to 2.5% CO2 resulted in a disappearance of mature
spermatids in rats. The disappearance was apparently due to sloughing
of mature spermatids and Sertoli cells in the seminiferous tubules, re-
suiting in cellular debris in the lumen. The degenerative change
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showed a concentration response, with the testis responding more to 5 %
CO2 and even more at 10%. The testicular degenerative change was re-
versible because the testis appeared completely normal histologically 36
h after the CO2 exposure. Although acute CO2 exposures could affect
the mature spermatids and Sertoli cells in the rat, they did not affect the
weight of the testis and seminal vesicles. The response in the testis to
CO 2 was somewhat affected by the exposure duration. An acute expo-
sure to 2.5%, 5%, or 10% CO2 did not affect the testis in 1 or 2 h, but
it caused a similar degree of sloughing of mature spermatids in 4 or 8
h.
Even though Vandemark et al. (1972) found no testicular changes
immediately after a 1-h exposure to 2.5% COz, it does not mean that
the 1-h exposure absolutely would not cause any testicular change. It is
possible that had the rats been sacrificed at a later time rather than im-
mediately after exposure, some testicular degeneration could show up.
However, the key point is that the testicular degeneration produced by
acute COz exposures is transient, with complete structural recovery in
36 h (Vandemark et al., 1972). Therefore, the l-h and 24-h SMACs
are not set according to COfs testicular toxicity.
Finally, Mukherjee and Singh (1967) observed spermatozoa with
smaller head and midpiece in the vas deferens of mice exposed alterna-
tively to 2 h of 36% CO 2 in 13.4% 02 and 0.5 h of air for a total of 6
h. In another experiment, they exposed male mice to about 4 h of CO2
at the same concentration per day (two CO2 exposure periods of 2 h
each separated by an air exposure of 0.5 h) for 6 d. The fertility was
reduced in these male mice. However, the meaning of Mukherjee and
Singh's findings is uncertain due to the very high CO 2 concentration and
very low 02 concentration used.
Intestine and Spleen
Other than injuring the lung and testes, there was a report that acute
exposures of guinea pigs to high concentrations of CO2 might also dam-
age other tissues. Schaefer et al. (1971) present evidence that in 1-d
exposure of guinea pigs to 15 % CO2 led to hemorrhages in the intestine
and the spleen. Unfortunately, as discussed above, due to an inade-
quate number of control animals used in that study, it appeared that
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they did not adequately control their experiments. That casts doubt on
the meaning of their positive findings. As a result, the SMACs are not
set based on any intestinal or splenic end point.
Subchronic and Chronic Toxicity
Dyspnea and Intercostal Pain
Acute CO2 exposures could cause headaches, dyspnea, and intercostal
muscle pain, especially during exercise or exertion. However, Sinclair
et al. (1971) showed that a 15-20 d exposure to 2.8% CO2 failed to
produce any dyspnea or intercostal muscle pain in four human subjects,
who performed, twice daily, 45-min of continuous steady state exercises
on a bicycle ergometer at a low, moderate, or heavy level. Radziszew-
ski and his colleagues reported no dyspnea or intercostal pain in six
human subjects who were exposed to 2% CO2 for 30 d or 2.9% for 8 d
and who performed, twice a week, a 10-min exercise with a bicycle
ergometer at a 150-watt workload (Guillerm and Radziszewski, 1979;
Radziszewski et al., 1988).
Headaches
Subchronic CO2 exposures are known to produce headaches at a con-
centration of 3% or higher. In a 30-d exposure of six human volun-
teers to CO2 conducted by Radziszewski et al. (1988), the subjects rare-
ly developed headaches to 2% CO2, but slight headaches were detected
to 2.9% COy Sinclair et al. (1969, 1971) showed that four subjects
exposed to 2.8% CO2 for 15-30 d or 3.9% CO2 for 11 d occasionally
developed mild headaches during heavy exertion, but the headaches dis-
appeared after the first day of exposure. Glatte et al. (1967a,b) and
Menn et al. (1968) reported that, in the 5-d exposure to 3% or 4%
CO2, mild-to-moderate throbbing frontal headaches started to appear in
the first day in about 60% of seven human subjects and the headaches
disappeared in the third day. They claimed that the headaches were not
severe enough to interfere with normal activities. However, because
75% of the subjects who were inflicted with headaches felt that the
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headache was sufficiently prominent to request an analgesic, headaches
are considered in setting the long-term SMACs.
The above data are summarized in Table 3-4 to provide a glimpse of
the COz's concentration-response relationship based on headaches devel-
oped in repetitive CO2 exposures.
TABLE 3-4 Data on COz-Induced Headaches
Concen- Exposure
tration, % Duration Intensity of Headache Reference
2 30 d Rare headache even during exercise Radziszewski et ai.,
1988
2.8 15-30 d Occasional mild transient headache Sinclair et al.,
during heavy exertion 1969, 1971
2.9 30 d Slight headache Radziszewski et al.,
1988
3 5 d Mild-to-moderate throbbing frontal Glatte et ai., 1967;
headache that disappeared in 2 d Menn et al., 1968
3.8 30 d Intense and annoying headache Radziszewski et al.,
1988
3.9 11 d Occasional mild transient headache Sinclair et al.,
during heavy exertion 1969, 1971
4 5 d Mild-to-moderate throbbing frontal Glatte et al., 1967a;
headache that disappeared in 2 d Menn et al., 1968
4.3 30 d Intense and annoying headache Radziszewski et al.,
1988
Nervous System
As discussed in the Acute Toxicity subsection, it is questionable
whether acute CO2 exposures at less than 5% cause CNS depression.
Similarly, there are conflicting data on the CNS effects of subchronic
CO2 exposures at 3-5%. Schaefer (1949a,b) reported that, in an 8-d
exposure of human subjects to 3% COz, mild excitement (euphoria,
troubled sleep with frequent dreams and nightmares) was seen in d 1,
followed by inattentiveness, erratic behavior, exhaustion, and confusion
in d 2-8. However. no behavioral changes were found by Glatte et al.
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in seven human volunteers exposed to 3 % or 4 % CO2 for 5 d (Glatte et
al., 1967a,b; Menn et al., 1968).
Although Schaefer (1949a,b) found that human subjects suffered
motor skill impairment on d 2-8 of an 8-d exposure to 3% CO2, Glatte
et al. (1967a,b), Menn et al. (1968), and Storm and Giannetta (1974)
did not find any psychomotor impairment in volunteers exposed to 3 %
or 4% CO2. Glatte et al. exposed seven volunteers to 3 % or 4% CO2
for 5 d, and Storm and Giannetta exposed 12 volunteers to 4% CO2 for
2 w. Both Giatte et al. and Storm and Giannetta used a battery of tests
called the Repetitive Psychometric Measures, which tested hand steadi-
ness, visualization, the arithmetical ability to add, the ability to find
four-letter words in rows of letters, the speed of canceling letters in a
row of letters, and the speed of perception. Glatte et al. also tested the
subjects' ability to solve arithmetical problems involving multiplication
and memory, compensatory tracking maneuvers, pitch, roll, and yaw
maneuvers, simple visual vigilance (monitoring the on and off of a
light), complex auditory monitoring, and memory (counting and re-
membering the number of flashes of a light for l-min periods, as well
as listening and remembering combinations of letters and numbers).
Neither Glatte et al. nor Storm and Giannetta found any effect on these
tests with exposures to 3% or 4% CO2. Due to the extensive psycho-
metric testing done by these two groups of investigators in the Air
Force, an exposure of humans to 3% CO2 is not likely to impair the
CNS or the motor ability.
The data available indicate that a subchronic CO2 exposure at less
than 2% definitely has no CNS impairment effect. In a summary report
of a 42-d study of 23 human volunteers exposed to 1.5% CO2 in a sub-
marine, Schaefer (1961) reported that there were no effects on immedi-
ate memory, problem-solving abilities, a letter-canceling test, the Min-
nesota Manual Dexterity test, a complex coordination test, the Mc-
Quarrie test of mechanical ability, strength, visual accommodation,
visual acuity, depth perception, and pitch discrimination. There were,
however, moderate increases in anxiety, apathy, increased uncoopera-
tiveness, a desire to leave, and increased sexual desire. In a study spon-
sored by NASA, Jackson et al. (1972) showed that there were no
changes in psychomotor performances, as determined with a Langley
Complex Coordinator, in four human volunteers continuously exposed
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to CO 2 for 90 d (0.6% CO 2 in the first 46 d and 0.8% in the remain-
der).
Acid-Base Balance
Similar to acute CO2 exposures, subchronic CO2 exposures also
lower the blood pH. Table 3-5 summarizes the effect of CO 2 exposure
on the acid-base balance of human subjects. Tile amount of plasma pH
drop caused by CO_ varied somewhat with the CO: exposure concentra-
tion. In a subchronic exposure of human subjects to CO2 at 5 mm Hg
(equivalent to 0.7% at sealevel) or 1.5% CO2, a plasma pH drop of
0.05 unit was detected in the first 20 or so days (Schaefer, 1963b;
Messier et al., 1971). However, Guillerm and Radziszewski (1979)
showed that a 3-d exposure to 2% CO 2 lowered the plasma pH by 0.01
unit. In comparison, Glatte et al. (1967a) found that an exposure of
seven humans to CO2 at 21 mm Hg (equivalent to 2.8% at sealevel)
lowered the plasma pH by 0.02 unit in 2-3 d and 0.01 unit in 4-5 d, but
these pH drops were not statistically significant.
TABLE 3-5 Plasma pH Decreases During CO2 Exposures
Concen- Exposure Plasma pH
tration, % No. Duration Drop Reference
0.85 15 56 d a
0.7 12 3-24 d 0.05
0.7 12 31-38 d --
1 15 44 d 0.02
1.5 21 1-20 d 0.05
1.5 21 24-42 d --
2 6 3 d 0.01
2 6 8-30 d --
2.8 7 1-5 d 0.01-0.02
3.9 3-4 1-2 d 0.02
3.9 3-4 5 d --
Peck, 1971
Messier et al., 1971
Messier et al., 1971
Pingree, 1977
Schaefer, 1958
Schaefer, 1958
Guillerm and Radziszewski, 1979
Guillerm and Radziszewski, 1979
Glatte et al., 1967a
Sinclair et al., 1969
Sinclair et al., 1969
_Not significant.
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During subchronic hypercapnia, the kidney compensates for the aci-
dosis by increasing the secretion of H + in urine and conserving HCO3 +
(Kryger, 1981). The renal compensation of the acidosis is, however,
rather slow; it takes days before its effect is manifested (Kryger, 1981).
The data summarized in Table 3-5 show that the body compensated for
the respiratory acidosis in 5-8 d in two studies (Sinclair et al., 1969;
Guillerm and Radziszewski, 1979) and in about 30 d in two other stud-
ies (Schaefer, 1963a; Messier et al., 1971).
The CO2-induced acid-base change in animals is similar to that in
humans. Schaefer et al. (1964a) reported that the arterial pCO2 in-
creased maximally as early as 1 h into a 14-d exposure of guinea pigs
to 15% CO2. The arterial pCO 2 remained higher than controls all
through the 14-d CO2 exposure period, but it gradually declined with
time starting at 1 h, which was the first sampling point in that study
(Schaefer et al., 1964). Schaefer et al. (1964) showed that the time
course of arterial pH changes in guinea pigs exposed to 15% CO2
followed that of pCO 2 quite closely. Barbour and Seevers (1943)
showed that, in rats exposed to 11% CO2 for 17 d, the arterial pH
dropped below the pre-exposure level as early as 0.5 h (the first
sampling point) into the CO 2 exposure. Starting at 0.5 h, the arterial
pH gradually rose, but it remained lower than the pre-exposure level
throughout the 17-d exposure.
Electrolyte Levels
Similar to acute CO2 exposures, subchronic CO2 exposures might
also change the electrolyte levels in the body. The data on plasma total
calcium levels and urinary total calcium excretion gathered in humans
are summarized in Table 3-6.
In a 57-d submarine-patrol study, with an atmosphere of 0.8-1.2%
CO 2 and less than 25-ppm CO, Messier et al. (1976) detected that
calcium levels decreased in plasma, but increased in erythrocytes, in
7-15 human subjects. Because there were no changes in the parathyroid
hormone and calcitonin plasma levels, the calcium changes detected by
Messier et al. were not due to parathyroid hormone or calcitonin. A
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TABLE 3-6 CO2-Induced Calcium Changes
Concen-
tration, Exposure Plasma Calcium
% No. Duration Level
Urinary Calcium
Excretion Reference
0.5 6 13 d Not measured
4 90 d d 1-53: No change
0.6 d 54-90: 4%
0.8 decrease
0.7 15 49 d
0.65 14 56 d
d 5: 3% increase w 1: No change
d 12, 19: No change w 2-7: 24-37%
d 26: 2% increase
d 33: No change
d 40: 5% increase
d 47: 3% increase
Not measured
1 7 57 d d 7-57: 10%
decrease
1.5 20 42 d d 3-21: 6% decrease
d 30-42: No
decrease
3 7 5 d No change
No change Davies et al.,
1978a
No higher than the Jackson et
range of normal al., 1972;
Schaefer,
1979
Gray et al.,
1973
decrease
d 2: No change Peck, 1971
d 9, t7: 35-42%
decrease
d 30: No decrease
d 42, 56: 23-40%
decrease
d 1-57: 30-40% Messier et
decrease al., 1976
d 1-42: 47% Schaefer et
decrease al., 1963b
No change Glatte et al.,
1967a
group in the United Kingdom's Institute of Naval Medicine also dis-
counted the role of a reduction in vitamin D, which promotes intestinal
calcium absorption, because the reduction in urinary calcium excretion
occurred fairly rapidly (Davies and Morris, 1979).
Similarly, Schaefer et al. (1963b) found that, in 20 human subjects
exposed to 1.5% CO2 for 42 d, the plasma calcium levels were lowered
in the first 3 w of the exposure, but they returned to the pre-exposure
levels in the last 3 w. Taking the data from a 90-d study performed by
Jackson et al. (1972) under NASA's sponsorship, paired t-tests show
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that there was no significant change in the serum calcium levels in four
human volunteers exposed to a median CO2 concentration of 0.6% in
the first 53 d. The serum calcium levels, however, dropped 4% in
54-90 d when the median C02 concentration was at 0.8%.
There were, however, other studies that tended to dispute that CO2
has any effect on the plasma level of calcium. For instance, Glatte et
al. (1967a) found no changes in the plasma and urinary calcium levels
in humans exposed to 3% CO2 for 5 d. Davies et al. (1978a) also
found no changes in the urinary excretion of calcium, phosphorus, so-
dium, potassium, and magnesium in humans exposed to 0.5% CO2 for
13 d. Davies et al. (1978b) showed that the reduction in urinary excre-
tion of minerals found by other investigators might be artifacts of urine
collection methodology.
To further complicate the picture, Schaefer et al. (1979a,b) found
that subchronic exposures of guinea pigs to CO2 also resulted in time-
dependent changes in plasma levels of calcium, but in an opposite direc-
tion compared with the human data of Schaefer et al. and Messier et al.
discussed above. In guinea pigs exposed to 1% CO2 for 6 w, Schaefer
et al. (1979a) detected increases in the plasma calcium levels in w 6,
but the plasma calcium levels did not differ from the control in w 1-4.
In another study conducted by Schaefer et al. (1979b) with guinea pigs
exposed to 0.5 % CO2 for 8 w, no change in plasma calcium levels was
detected in w 4 and an increase was detected in w 8. Because the data
indicate that CO2 increases the plasma calcium levels in guinea pigs
(Schaefer et al., 1979a,b), but CO2 either decreases or causes no change
in the plasma calcium levels in humans (Schaefer et al., 1963b; Glatte
et al., 1967a; Messier et al., 1976), the meaning of these data gathered
from guinea pigs is doubtful.
Gray et al. (1973) reported that the serum levels of calcium, magne-
sium, and inorganic phosphorus were raised during a 7-w exposure of
15 submariners exposed to 0.7% CO2. During the CO2 exposure, the
urinary excretions of these three electrolytes were reduced. Because the
inverse relationship between the serum levels of calcium and urinary
excretion of calcium also existed during the pre-exposure period, Gray
et ai. admitted that the renal handling of calcium in these subjects was
unusual. Gray et al. speculated that, when the 15 submariners took part
in the 7-w exposure, they had not completely recovered from a 3-w
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exposure to 1% CO2 in a submarine patrol 3 m earlier. That cast doubt
on whether the findings of Gray et al. in the 7-w study were representa-
tive of the responses in normal individuals exposed to CO2.
The effect of CO2 on urinary excretion of calcium has also been
studied. In the 20 human subjects exposed to 1.5% CO2 for 42 d,
Schaefer et al. (1963b) found that the amount of calcium excreted in
the urine per day was reduced by about 45-50% throughout the CO2
exposure. Since the daily urine volume was reduced by only about
one-third during the 42-d CO2 exposure, that means the calcium con-
centration in the urine must have been reduced during the CO2 exposure
(Schaefer et al., 1963). Schaefer et al. reported that the urine pH
dropped in the first 23 d of CO2 exposure, but it returned to the
pre-exposure value in the last 19 d of the exposure. Similarly, Messier
et al. (1976) showed that the amount of calcium excreted in the urine
per day was lower in the 7-15 human subjects in a 57-d submarine pa-
trol exposed to about 1% CO2. However, Messier et al. failed to find
any changes in the daily urine volume during the CO2 exposure. So
one can infer that the concentration of calcium in the urine was reduced
during the 57-d exposure to 1% CO2. Unlike the finding of Schaefer et
al., Messier et al. detected that the urine pH was elevated during the
CO2 exposure. Davies et al. (1978a) exposed six men to fresh air for 9
d followed by 0.5% CO2 for 13 d with intensive physical training dur-
ing the chamber stay. They found no changes in the daily urine volume
and the urinary and fecal excretions of calcium.
There were two studies in which the amounts of urinary calcium ex-
cretion were reported, but the investigators were silent about the daily
urine volume. The first study was a 90-d study sponsored by NASA in
which four volunteers were exposed to a median CO2 concentration of
0.7% (Jackson et al., 1972). Schaefer (1979) displayed urinary data
gathered in that 90-d study. According to the data, the amounts of
daily urinary calcium excretion, averaged among the four volunteers,
ranged from 95 mg to 170 mg in the 90-d exposure. Unfortunately,
Schaefer did not present the pre-exposure data. Nevertheless, the 90-d
exposure to 0.7% CO2 most likely did not increase the urinary calcium
excretion because the values were all below the maximum limit of uri-
nary calcium excretion of, 250 mg/d determined by Pak et al. (1985,
1989) in at least 77 normal volunteers without kidney stones. The sec-
ond study was conducted by Peck on 15 healthy male Navy servicemen
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in a 56-d submarine patrol (Peck, 1971). These 15 men were exposed
to a mean CO2 concentration of 0.85%, with a range of 0.72% to
0.95%. Peck did not measure the pre-exposure daily urinary calcium
excretion, but all values measured during the entire 56 d fell within
normal limits.
The results of the studies conducted by Messier et al. (1976) and
Schaefer et al. (1963b) did not agree on CO2's effect on phosphorus
levels. Messier et al. showed that a 57-d exposure to 1% CO2 caused
no change in the plasma phosphorus levels in seven human subjects dur-
ing the exposure, but it reduced urinary excretion of phosphorus. In
contrast, Schaefer et al. found that the plasma phosphorus levels were
raised during a 42-d exposure of 20 human subjects to 1.5% CO 2, and
that, while the urinary phosphorus excretion was increased in the first 2
d, it declined with time so that it was lower than the pre-exposure level
in the last 3 w of the CO,, exposure. In 15 men exposed to 0.7% CO2
for 52 d, Gray et al. (1973) reported that the urinary excretion of phos-
phorus was raised in d 1-2, but it was below the control value from d
3-52. The serum phosphorus levels in these 15 subjects were raised
from d 5-47. However, Glatte et al. (1967a) did not detect any change
in the plasma and urinary levels of phosphorus in seven human subjects
exposed to 3% CO2 for 5 d. Similarly, Davies et al. (1978a) found no
changes in urinary and fecal excretion of phosphorus in six men ex-
posed to 0.5% CO2 for 13 d. The sum findings of these studies seem
to indicate that CO_'s effect on the body levels of phosphorus varies.
Messier et al. (1976) also found increased sodium in the plasma ev-
ery week during the 57-d submarine-patrol study with exposure to 0.8-
1.2% CO2. A decrease in the plasma levels of potassium started to ap-
pear in the third week. Opposite changes in the erythrocyte levels of
these electrolytes were detected.
Bones and Kidneys
The changes in plasma calcium levels discovered by Schaefer et al.
(1979a) in guinea pigs seem to be related somewhat to renal calcifica-
tion, which might be assessed either histologically or biochemically.
Histological evidence of renal calcification, in the form of focal calcifi-
cation primarily in tubules in the renal cortex, was presented by
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Schaefer et al. in guinea pigs exposed to 1.5% CO2 for 35-42 d and in
rats exposed to 1.5% CO2 for 35 or 91 d. Meessen (1948) also showed
renal tubular necrosis with calcification in rabbits exposed to 4.5 % CO2
for 13 d. The presence of renal calcification can be determined bio-
chemically by measuring the renal calcium concentration. Schaefer et
al. (1979a,b) defined renal calcification as any rise in renal calcium
concentration larger than 25%. An 8-w exposure of guinea pigs to
0.5% CO2 resulted in an increase in the plasma calcium level and a
larger than 25 % rise in the renal calcium levels with no change in bone
calcium levels in w 8 (but not in w 4-6) (Schaefer et at., 1979b). Simi-
larly, in a 6-w exposure of guinea pigs to 1% CO2, Schaefer et al.
found an increase in plasma calcium levels and a decrease in bone cal-
cium levels in w 1 and 6, as well as a larger than 25 % rise in the renal
calcium levels in w 2-6 (Schaefer et al., 1979a). These changes in the
calcium levels in the bone, plasma, and kidneys support the theory that
CO2-induced renal calcification in these animals was due to the mobili-
zation of calcium from the bone.
There is no evidence of subchronic CO2 exposures causing renal cal-
cification in humans. In guinea pigs, CO,-induced renal calcification
appeared to be associated with a rise in plasma calcium level (Schaefer
et al., 1979a,b, 1980). In contrast, subchronic exposures to CO2 at
about 1-3% are known to decrease or cause no change in plasma cal-
cium levels in humans (Schaefer et al., 1963b; Glatte et al., 1967a;
Messier et al., 1976). It is, therefore, doubtful that subchronic expo-
sures to CO2 at low concentrations produce renal calcification in hu-
mans. As a result, the renal calcification data gathered in animals are
not relied on in setting the SMACs of CO2. The unchanged or lower
plasma calcium levels in human subjects exposed to CO2 (Schaefer et
al., 1963b; Glatte et al., 1967a; Messier et al., 1976) also discount the
possibility of CO2 causing bone demineralization.
Tansey et al. (1979) compared the medical records of the crew in
over 1000 Polaris submarine patrols in two periods: 1963-1967 and
1968-1973. Each patrol lasted about 60 d with a crew of 140. Data on
submariners in these two periods are summarized in Table 3-7 as fol-
lows.
The CO2concentration onboard was higher in 1963-1967 than in
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TABLE 3-7 Information on Submarine Patrols a
1963-1967 1968-1973
CO2 concentration > 1% 70-90% of the
time (0.9-1.2% in 1966-
1967)
44 ppm (1961)
347
CO concentration
Submarine personnel,
no.
Smokers, % 73
Man-days 3,240,000
Cases of ureteral 0.007
calculi per 1000
man-days
Workdays lost to 0.030
ureteral calculi per
1000 man-days
>1% <20% of the time
(0.8-0.9% in 1968-1971)
15-20 ppm (1969)
225
60
4,410,000
0.004
0.010
aData from Tansey et al. (1979).
1968-1973, with the concentration higher than 1% CO2 70-90% of the
time in 1963-1967, but less than 20% of the time in 1968-1973. Tan-
sey et ai. did not report any pre-1963 CO2 concentration data. Citing
data from other studies, Tansey et ai. reported that the CO2 concentra-
tions onboard submarines were 0.9% to 1.2% in 1966-1967 and that
they were 0.8% to 0.9% in 1968-1971. The rate of crewmen taking
sick leave on board due to ureteral calculi in the 1963-1967 period was
almost twice that in the 1968-1973 period. The number of workdays
lost to ureteral calculi, after normalization by the number of man-days,
was three times higher in 1963-1967 than in 1968-1973.
The question is whether the larger number of workdays lost to ure-
teral calculi in 1963-1967 was due to the higher CO2 concentrations
onboard. In other words, could subchronic CO,, exposures cause ure-
teral calculi in humans? Three lines of reasoning tend to cast doubt that
the larger number of workdays lost to ureteral calculi was caused by
subchronic CO2 exposures. First, Tansey et al. admitted that the sub-
marine atmosphere contained contaminants such as CO2, CO, hydrocar-
bons, and aerosols in low concentrations. Even though the CO2 con-
centrations in 1963-1967 appeared to be higher than those in 1968-
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1973, there were no data on the concentrations of hydrocarbons and
aerosols in these two periods. Although Tansey et al. did not measure
the CO concentration, they presented data gathered by others showing
that CO concentrations in the submarine declined about 50% from 1961
to 1969, and they declined another 50% from 1969 to 1972 (Tansey et
al., 1979). These declines in CO concentrations illustrate the possibil-
ity that, other than reductions in CO2 and CO concentrations in the two
periods studied, there could be reductions in the concentrations of other
air contaminants onboard the Polaris submarines. The difference in the
number of workdays lost to genitourinary diseases between 1963-1967
and 1968-1973 might be due to an air contaminant other than CO2.
The second reason is that kidney stone formation is affected by a
number of risk factors, such as the oxalate contents of food (Schwille
and Herrmann, 1992), hypocitraturia (Goldberg et al., 1989; Hofbauer
et al., 1990), low urine volume (Thun and Schober, 1991), low testos-
terone concentration in urine (van Aswegen et al, 1989), and dietary
protein intakes (Breslau et al., 1988; Trinchieri et al., 1991). There
could be dietary differences in oxalate contents or protein intakes in
these two periods and the dietary differences could play a role in caus-
ing the difference in the rate of workdays lost to ureteral calculi.
The third reason, which is the most convincing one, relates to the
mechanism of nephrolithiasis formation in humans. According to Coe
and Favus (1987), 75% to 85% of kidney stones are calcium oxalate
and calcium phosphate stones. Calcium phosphate stones usually con-
sist of hydroxyapatite. Urinary excretion of calcium is the major risk
factor for calcium stone formation (Wasserstein et al., 1987; Goldberg
et al., 1989). Urinary stones are usually formed when calcium salts
become supersaturated in the urine (Coe and Favus, 1987). Since CO2
exposures have been shown to either lower or not change urinary cal-
cium excretion (Schaefer et al., 1963b; Glatte et al., 1967a; Davies et
al., 1978a) and to reduce the urinary calcium concentration (Schaefer et
al., 1963b; Messier et al., 1976), the chance of CO2 exposures causing
calcium supersaturation is low. In addition, the lower urinary pH de-
tected in CO2 exposures (Schaefer et al., 1963b; Radziszewski et al.,
1976) disfavors kidney stone formation because the solubility of calcium
oxalate is independent of pH and the deposition of apatite and octocal-
cium phosphate is disfavored in acidic urine (Coe and Favus, 1987).
Therefore, it is highly unlikely that CO1 exposures produce kidney
stones in humans.
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Tansey et ai. (1979) stated that the rate of ureteral calculi aboard the
1968-1973 submarine patrols was "exactly the same as that for the gen-
eral population." It stands to reason that even if all the ureteral calculi
cases detected in the 1968-1973 submarine patrols were due to 0.8-
0.9% CO2 in the submarine, exposures to 0.8-0.9% CO2 does not in-
crease the risk of ureteral calculi in human subjects. It will be shown
in the latter part of this document that the long-term SMACs for CO2
are recommended at 0.7% based on other toxic end points. So the
long-term SMACs will not be associated with any increased risk of ure-
teral calculi according to the submarine patrol data of Tansey et al.
Schaefer et al. (1980) showed that an 8-w exposure of guinea pigs to
1% CO2 increased the CO2 content in the bone, in the fourth to the
eighth week, with the increases in the sixth and eighth weeks due main-
ly to an increase in the bicarbonate contents of the bone. Commensurate
with the bicarbonate content increase in the bone, they saw an increase
in plasma calcium levels in the sixth and eighth week of the CO2 expo-
sure. Schaefer et al. hypothesized that the increase in plasma calcium
levels was due to CO2 binding to the bone and releasing calcium from
the bone in guinea pigs. As a result of this hypothesis, several scien-
tists in NASA raised their concerns on the potential of CO2 in releasing
calcium from the bone of astronauts in the space station and causing
kidney stones. However, according to an analysis of this potential
given below, it is unlikely that their concerns would become reality.
First, CO2's effects on calcium in human beings differ from those in
guinea pigs. All available data showed that continuous CO2 exposures
lasting from 13 to 90 d at concentrations ranging from 0.5% to 1.5%
either lowered or did not change urinary calcium excretion in human
subjects (Schaefer et al., 1963b; Jackson et al., 1972; Gray et al.,
1973; Messier et al., 1976; Davies et al., 1978a). Four studies showed
that exposures of volunteers to 0.6-3 % CO2 lasting from 5 to 90 d ei-
ther decreased or did not change the plasma calcium levels (Schaefer et
al., 1963b; Glatte et al., 1967a; Jackson et al., 1972; Messier et al.,
1976). Only one study by Gray et al. (1973) showed that a 7-w expo-
sure of 15 submariners to 0.7% CO2 increased the serum level of cal-
cium. However, because these submariners excreted less calcium in the
urine, Gray et al. admitted that the increase in serum calcium levels in
these submariners was an anomaly. All in all, because plasma calcium
levels are usually not raised in humans exposed to CO2, it is unlikely
that CO2 would displace calcium from bones in humans.
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Because bone demineralization is associated with calcium changes in
astronauts in space (Whedon et al., 1977; Leach and Rambaut, 1977,
pp. 204-216), it is of interest to examine the CO2 effect, if any, on cal-
cium in space. Calcium data, in means and standard deviations, gath-
ered by Leach arid Rambaut (1977), Whedon et al. (1977), and Whedon
(1984) in three Skylab missions are plotted by the solid lines in Figure
3-1. According to Hopson et al. (1974), the CO2 partial pressures in
Skylab missions ranged from 4.8 to 5.5 mm Hg, with a mean of 5.3
mm Hg, time-weighted average (TWA). The Skylab data showed that,
in three to nine astronauts exposed to microgravity and CO2 at 5.3 mm
Hg for up to 82 d, the plasma calcium levels increased 4-5% and the
daily urinary calcium excretion increased 60-80% starting from d 12
(Figure 3-1). Vogel (1975) reported bone losses in three of the nine
Skylab crew members. Because immobilization bed-rest studies per-
formed by Donaldson et al. (1970) and Deitrick et al. (1948) showed
increases in urinary calcium excretion of approximately the same level
as that seen in the Skylab crew, the increase in urinary calcium excre-
tion detected in Skylab missions was associated with bone demineraliza-
tion in microgravity. The exposure to CO2 at 5.3 mm Hg in these Sky-
lab astronauts probably played no role in the calcium changes. These
Skylab data also showed that both the plasma calcium levels and urinary
calcium excretion in space missions lasting up to 84 d were quite stable
once a plateau was reached. The plasma calcium levels reached a pla-
teau at about 5 d, and the urinary calcium excretion reached a plateau
in about 20 d.
To prove that CO2 exposures in spacecraft play no important role in
calcium changes in astronauts, calcium data from a space mission with
CO2 concentrations at much less than 5.3 mm Hg, but of a similar du-
ration as Skylab missions, is needed as control data. Unfortunately,
there is no such "control" mission, lnflight calcium plasma data are,
nevertheless, available from the Spacelab 2 mission, which lasted for 8
d with a CO2 partial pressure of 2.4 mm Hg, TWA (Shih, 1987). So
the plasma calcium data of Spacelab 2, reported by Morey-Holton et al.
(1988), reflect the plasma calcium concentrations in four astronauts who
stayed for several days in microgravity with less CO2 than those in Sky-
lab. The inflight calcium plasma data from the Spacelab 2 mission are
plotted by the dashed line in Figure 3-1. Compared with the plasma
calcium data of Skylab missions in Figure 3-1 (the solid line), the plas-
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ma calcium concentration in microgravity appeared to be independent of
CO2 for at least 7 d. This lends credence to the belief that CO 2 expo-
sures in spacecraft do not seem to play a major role in causing the cal-
cium changes in microgravity. It should be noted that partial pressures
of 5.3 mm Hg and 2.4 mm Hg are equivalent to concentrations of 0.7%
and 0.3%, respectively, in an atmosphere of 760 mm Hg.
Respiratory System
Similar to acute CO2 exposures, subchronic CO2 exposures could also
cause hyperventilation. Table 3-8 shows the amounts of ventilatory in-
crease attained, after a plateau has been reached, in human subjects ex-
posed to CO2 for more than a day. The sum of the data shows that it
takes at least 1% CO2 to increase, with statistical significance, the min-
ute volume after the hyperventilatory response reaches a plateau after
the first few hours in a subchronic exposure. At 0.5% CO2, the slight
increase in minute volume at the plateau was masked by the physiologi-
cal noise (Radziszewski et al., 1988).
In subchronic CO2 exposure, the hyperventilatory response could di-
minish somewhat in human subjects after the first few days of expo-
sure, indicative of a reduced sensitivity to CO2's stimulation on respi-
ration. Pingree (1977) showed that, in a 44-d exposure of 15 human
subjects to 1% CO2, the minute volume increased about 30% on the
fourth day, but it returned to the control value starting on the eighth
day. In contrast, Schaefer (1963b) reported that, at exposure to 1.5%
CO2, the respiratory ventilation was raised about 30% in normal volun-
teers throughout a 42-d exposure.
However, in a 30-d exposure of humans to 2% CO2, the minute vol-
ume increase was diminished about one-third after 9 d of exposure and
remained constant in the remaining 21 d of the CO2 exposure (Guiilerm
and Radziszewski, 1979). Similarly, in a 30-d exposure to 2.7% CO2,
the minute volume increase was reduced after 4 d and the minute vol-
ume increase remained constant from d 5 to d 14 (Clark et al., 1971).
On the thirtieth day of exposure to 2.7% CO2, the hyperventilatory re-
sponse recovered fully, so that the minute volume equaled that in the
first day of CO2 exposure (Clark et al., 1971).
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TABLE 3-8 Hyperventilatory Responses to CO2 Exposures
Minimum
Concen- Exposure Volume
tration, % No. Duration Increase, % Reference
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1 15 4 d 30 Pingree, 1977
1 15 8-40 d 0 Pingree, 1977
1.5 21 1-42 d 30 Schaefer et al., 1963a; Schafer,
1963b
2 6 9-30 d 44 Guillerm and Radziszewski, 1979
2.8 7 5 d 25 Glatte et al., 1967a
3.9 3-4 3-11 d 130 Sinclair et al., 1969
The reduction in CO, hyperventilatory response during subchronic
exposures appeared to occur sooner at higher CO/exposure concentra-
tions. In an ll-d exposure of humans to 3.9% CO2, the hyperventila-
tory response was diminished about one-third after two days of expo-
sure (Sinclair et al., 1969). Another piece of evidence that humans de-
veloped reduced sensitivity toward CO2's hyperventilatory effect was
obtained by Schaefer (1963b). Schaefer showed that, after 35-40 d of
continuous exposure of human subjects to 1.5% COz, the subjects did
not increase their minute volume upon a 15-rain challenge with 5 % CO2
as much as they did before the subchronic exposure to 1.5% CO2.
An Air Force study showed that a 5-d exposure of seven human vol-
unteers to 3 % CO2 resulted in no changes in maximum breathing capac-
ity, vital capacity, and 1-s vital capacity (Glatte et al., 1967a). It is of
interest that several studies done by the Navy indicate that subchronic
CO2 exposures might affect lung function. Schaefer et al. showed that
a 42-d exposure to 1.5% CO_ increased the anatomic dead space of the
lung by about 40% and the physiologic dead space by 60% in 20-21
human subjects (Schaefer et al., 1963a; Schaefer, 1963b). An exposure
of human subjects to 0.8-0.9% CO2 raised the physiological dead space
50-60% in 20 d, which returned to normal soon after the exposure, in-
dicating that the effect was reversible (Gude and Schaefer, 1969). The
data on CO2-induced increase in physiological dead space are not relied
on in setting the SMACs. This is because the size of the decrease in
physiological dead space caused by CO2 exposures is similar to that
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caused by aging in a normal individual going from age 20 years to age
40 (Cotes, 1979, pp. 149, 358, 363).
There is no evidence of subchronic CO2 exposures causing lung inju-
ries in humans. However, based on electron microscopic studies of gui-
nea pigs, subchronic CO2 exposures are known to cause changes in type
II pneumocytes. Schaefer et al. (1979b) reported, in guinea pigs ex-
posed to 1% COz, increases in the size and number of type II pneumo-
cytes, increases in the size and number of osmiophilic lamellar bodies
inside type II pneumocytes, and clustering of 2-4 type II pneumocytes
starting after 4 w of exposure (Douglas et al., 1979). These uitrastruc-
tural changes were also observed after 6 w of exposure. In comparison,
an 8-w exposure to 0.5% CO2 failed to cause any change in type II
pneumocytes (Schaefer et al., 1979b). Schaefer et al. hypothesized that
the proliferation of type II pneumocytes was a compensatory reaction to
CO2's impairment on type I pneumocytes (Douglas et al., 1979).
However, there was no evidence that type I pneumocytes were dam-
aged by CO2 (Schaefer et al., 1979b; Douglas et al., 1979). So there
seems to be no support for the hypothesis of Schaefer et al. The type II
pneumocyte changes probably represent a metabolic adaptation of the
lung to CO 2challenges because, among the alveolar lining cells, type II
pneumocytes are the more metabolically active cell type (West, 1979).
Since type II pneumocytes are thicker than type I pneumocytes (West,
1979), a potential adverse consequence of type I! pneumocyte prolifera-
tion is impaired gas exchanges. Due to the fact that there was no dif-
ference between the arterial pO2 in the guinea pigs with CO2-induced
type II pneumocyte changes and the control guinea pigs (Douglas et al.,
1979), the proliferation of type II pneumocytes caused by 1% CO2 in
guinea pigs did not impair gas exchanges.
Another potential consequence of type II pneumocyte proliferation is
the higher amount of lung surfactants that are synthesized by type II
pneumocytes (Wright and Clements, 1987). Lung surfactants have been
postulated to perform three functions: to help maintain a low lung
compliance, to stabilize alveoli, and to reduce the chance of pulmonary
edema (Notter and Finkeistein, 1984). Quite a bit is known about the
biological effects of a lack of lung surfactants via studies of respiratory
distress syndromes, but practically nothing is known about the biologi-
cal effects of a higher than usual amount of lung surfactants. The only
dose-response information gathered in a recent literature search is that,
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in the treatment of premature infants with respiratory distress syn-
drome, increasing the dose of surfactant given intratracheally by 300%
up to 400 mg/kg body weight could improve the treatment (Gortner et
al., 1990; Dunn et al., 1990). Since premature infants are deficient in
lung surfactants to begin with, the dose-response data obtained from
these infants probably do not reflect the biological effects of a higher
than usual amount of lung surfactant in normal subjects. However,
However, Douglas et al., 1979 showed that exposure to 1% CO2 in-
creased the number and size of lamellar bodies by only 30-50% in type
II pneumocytes of guinea pigs. Assuming that the amount of lung sur-
factants secreted by type II pneumocytes in these guinea pigs was also
increased by 30-50%, increases of such magnitude are not expected to
have any harmful effect in the lung because any resultant decreases in
surface tension would be of little clinical significance.
By considering the potential effects on gas exchanges and lung sur-
factants, it is safe to assume that the type II pneumocyte changes caused
by subchronic exposures to 1% CO 2 are functionally insignificant.
Therefore, type II pneumocyte changes are not a toxic end point used in
setting SMACs for CO2.
Finally, it should be noted that hyaline membranes and distended
alveoli and alveolar ducts were seen in rabbits exposed to 4.5 % CO2 for
13 d by Meessen (1948). However, Meessen did not use a control
group in the study, so the meaning of the findings is unclear.
Cardiovascular System
As discussed above, acute CO2 exposures produced clinically signifi-
cant arrhythmia in human subjects only at very high concentrations
(30%). All the subchronic studies with EKG evaluations were per-
formed with CO2 concentrations of 4% or less and there are conflicting
data on whether these concentrations of CO2 cause arrhythmia. Glatte
et al. (1967a) found no EKG problems in individuals exposed to 3% or
4 % CO 2for 5 d, in which they exercised an hour daily and were moni-
tored with a 12-lead EKG. Sinclair et al. (1971) showed no increase in
premature ventricular contractions in individuals exposed to 2.8% CO_
for 15-20 d during near-maximal or maximal exercises. In another re-
port, Sinclair et al. (1969) stated that a few individuals exposed to
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3.9% CO2 for 11 d or 2.7% CO 2 for 30 d developed "ectopic foci ac-
tivities," presumably premature ventricular contractions (PVCs), during
exercises. However, some of the ectopic foci were associated with ex-
ercises when breathing air (Sinclair et al., 1969). In addition, the ecto-
pic foci activities during CO2 breathing did not show a concentration-
response relationship. The data of Glatte et al. and Sinclair et al. seem
to suggest that subchronic exposures to 3-4% CO2 are devoid of ar-
rhythmia effects. In contrast, in two French studies, an exposure of
human subjects to 2.9% or 3.8% CO2 for 8 or 9 d resulted in extrasys-
toles (PVCs), but no extrasystoles were detected in a 30-d exposure to
1% or 1.9% COz (Radziszewski et al., 1988; Guillerm and Radziszew-
ski, 1979). Because extrasystoles are of little clinical significance
(Massie and Sokolow, 1990), CO2's SMACs are not set based on the
EKG effects of CO2.
Subchronic CO2 exposures might affect heart morphology. In a 7-d
exposure of guinea pigs to 15% CO2, fat deposition in the myocardium
was detected in d 7, but not at 1 h or d 1 (Schaefer et al., 1971).
Other than fat deposition, there were no other changes in cardiac histol-
ogy. According to the investigators, the experiment "failed to demon-
strate any signs of myocardial damage in guinea pigs exposed for peri-
ods up to 7 days to 15% CO2" (Schaefer et al., 1971). The fat deposi-
tion probably represents only a metabolic change in the heart and not
any serious damage. For comparison, no cardiac histopathology was
found in rats exposed to 8% CO2 for 32 d (Pepelko, 1970). Due to the
relatively minor nature of the myocardial changes, these findings are
not relied on in setting the SMACs.
Structural Effects on Other Tissues
Other than affecting the kidney and lungs, subchronic CO2 exposures
might affect the liver. In rabbits exposed to 4.5% CO 2 in 21% O2 for
13 d, necrosis was seen scattered throughout the liver lobules (Meessen,
1948). Unfortunately, no control group was used in this study, so its
results are not relied on in setting SMACs. A 32-d exposure of rats to
8% CO2 failed to cause any histological lesions in the liver, lungs, kid-
neys, adrenals, spleen, thyroid, and heart (Pepelko, 1970). Similarly,
Schaefer et ai. (1971) showed that exposures of guinea pigs to 3% CO2
for 42 d or 15% CO 2 in 21% 02 for 7 d failed to produce any histopa-
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thology in the liver. Schaefer et al. however, found a decrease in gly-
cogen granules and an increase in fat granules in the liver of guinea
pigs exposed to 3% CO2 for 7 d. The granular changes recovered in 1
d after the end of the exposure. These changes in the granules were
interpreted by the investigators to reflect functional changes in liver
metabolism. Because these changes are not actual damages, they are
not relied on in setting SMACs.
As mentioned above, 4- or 8-h exposures of CO2 are known to pro-
duce injuries in the testis of rats (Vandemark et al., 1972). However,
it is unclear whether subchronic CO2 exposures could damage the testis.
In a study without an adequate number of control animals, Schaefer et
al. (1971) observed in the testis a marked reduction of mature sperma-
tocytes with a concomitant increase in the precursor cells of spermato-
cytes in guinea pigs exposed to 15% CO2 for 2 d. When the exposure
was extended to 7 d, multinucleated giant cells were observed in the
testis. Because on the average only about two control animals were
examined per time point, it is not certain whether the testicular changes
observed by Schaefer et al. in the 15% CO2 group were due to CO2 or
whether they were artifacts. Nevertheless, some of the data gathered
by Schaefer et al. in that subchronic study are of value in setting the
SMACs. Schaefer et al. (1971) reported that the testes of the guinea
pigs and rats exposed to 3% C02 for 42 d or to 1.5% C02 for 6 mo
appeared normal histologically, it can be concluded that a subchronic
exposure to 3% C02 is not toxic to the testis.
Hematological Changes
Guillerm and Radziszewski (1979) reported that a 10% reduction in
hematocrit and a 9 % reduction in red blood cell count were detected in
six human subjects exposed to 2% CO2 for 16-30 d. Because they
failed to observe these reductions in humans exposed to 4% CO2, they
discounted hypercapnia as the cause of the hematological changes. In-
stead, they hypothesized that prolonged confinement might be the
cause. Similarly, the Navy found that prolonged hypercapnia might not
always produce hematological changes. Wilson and Schaefer (1979)
showed that, in Polaris submarine patrols with CO2 levels maintained
between 0.7% and 1.2% and a CO level between 15 and 20 ppm, the
hematological responses in smokers differed from that in nonsmokers.
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In nine smokers in the patrol, the red blood cell count increased by
12% and the hematocrit increased by 4% on the sixth day, but not on
the 32nd and 52nd day. However, these two hematological parameters
did not change in 11 nonsmokers in the patrol on the sixth, 32nd, and
52nd day. Because astronauts will not be allowed to smoke cigarettes
in spacecraft and most of them are nonsmokers, the hematological data
are not relied on in setting CO2 SMACs.
Carcinogenicity
No traditional carcinogenic bioassay has been known to be conducted
with CO2. However, Goldsmith et al. (1980) discovered that infusion
of humidified 99.99% CO2 into the peritoneal cavity of 4- to 6-mo-old
BALB/c mice for 10-12 d led to lymphoma after a latent period of
about 8 mo (the incidence in the air-exposed control group was 0% and
that in the CO2-exposed control group was about 60%) and a doubling
of the incidence of pulmonary adenocarcinoma (from 15% in the con-
trol group to about 30% in the CO2-exposed group). Due to the highly
artificial nature of the CO2 exposure, the practical meaning of the tu-
morigenic findings is uncertain.
Epidemiological Data
Only one epidemiological study involving CO2 was found. In a crite-
ria document for CO2, NIOSH cited, an unpublished report submitted to
NIOSH by the United States Brewers Association, Inc. (Riley and
Barnea-Bromberger, 1976). The report concerned the acid-base effect
of CO2 exposures in brewery workers. In these workers, exposed to
1.1% CO2 TWA with 3-min excursions up to 8%, the blood HCO3- lev-
els did not differ from the control values (Riley and Barnea-Brom-
berger, 1976).
Genetic Toxicity
No genotoxic data of C02 have been found.
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Developmental Toxicity
An exposure of rabbits to 10-13% COz for 4-10 h on d 2 or 3 be-
tween d 7 and d 12 of pregnancy resulted in congenital hypoplasias in
the vertebral column (Grote, 1965). The value of this teratogenic study
was limited because only three pregnant rabbits were exposed to CO2.
In another teratogenic study, 71 pregnant rats were exposed to 6% CO/
in 20% O2 for 24 h between d 5 and d 21 of pregnancy (Haring, 1960).
More increased incidences of cardiac and skeletal malformations were
detected in the CO2-exposed group than in the control group (Haring,
1960).
Interaction with Other Chemicals
Only one report of synergism involving CO2 was found. Levin et al.
(1987) reported that the amount of acidosis produced by a combined
exposure of rats to 5% CO2 and 2500 ppm CO was larger than that pro-
duced by either agent alone. The addition of CO2 to an exposure atmo-
sphere containing CO decreased the mean survival time of rats, com-
pared with rats exposed to only CO (Rodkey and Collison, 1979). This
potentiation of CO's lethal effect by CO2 is thought to be due to CO2's
hyperventilatory effect (Rodkey and Collison, 1979). Indeed, co-expo-
sures of rats to 5% CO2 in 2500 ppm CO are known to increase the
rate of COHb rise in blood compared with CO exposures alone (Levin
et al., 1987). However, it should be noted that co-exposures to 5%
CO2 in CO do not always result in potentiation of CO's toxicity. For
instance, exposure to CO2 at 5% did not potentiate the incapacitation
effect of 3500 ppm CO on the rat (Hartzell and Switzer, 1985). Final-
ly, just as other substances might potentiate the effect of CO2, the re-
verse is also true. A subcutaneous injection of naioxone at 5 mg/kg has
been shown to increase the hyperventilatory response to CO2 in rats
because naloxone displaced endogenous endorphins from central opioid
receptors (Isom and Elshowihy, 1982).
In addition to interacting with CO, CO2 is known to interact with
NOv Exposures of rats to 200 ppm NO2 for 30 min resulted in an in-
crease in methemoglobin level in blood (Levin et al., 1989). A co-
exposure with 5 % CO2 led to a larger increase in methemoglobin than
with 200 ppm NO2 alone (Levin et al., 1989).
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TABLE 3-10 Exposure Limits Set by Other Organizations
Organization Concentration, ppm
ACGIH's TLV 5000 (TWA)
ACGIH's STEL 30,000
OSHA's PEL 5000 (TWA)
N|OSH's REL 10,000 (TWA)
30,000 (ceiling)
NIOSH's IDLH 50,000
Navy's 90-d limit 5000"
Navy's 24-h limit 40,000
Navy's l-h limit 40,000
aAccording to the Navy (1988), long-term exposures at 5000-8000 ppm
probably have no significan health effect.
TLV = threshold limit value. TWA = time-weighted average. STEL =
short-term exposure limit. PEL = permissible exposure limit. REL = rec-
ommended exposure limit. IDLH = immediately dangerous to life and health.
TABLE 3-11 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m 3 Target Toxicity
1 h 13,000 23,400 CNS depression,
visual disturbance
24 h 13,000 23,400 CNS depression,
visual disturbance
7 d_ 7000 12,600 Hyperventilation
30 d 7000 12,600 Hyperventilation
180 d 7000 12,600 Hyperventilation
1"here was no 7-d SMAC. Space-shuttle flight rules require mission termi-
nation at 2% or above and flight surgeon's evaluation at 1-2% (NASA, 1988).
RATIONALE FOR
ACCEPTABLE CONCENTRATIONS
To set the SMACs, guidelines developed by a subcommittee of the
Committee of Toxicology are consulted (NRC, 1992). First, an accept-
able concentration (AC) is estimated lbr each relevant toxic end point
based on data gathered from an exposure of the appropriate duration.
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The lowest AC is then selected as the SMAC for that exposure dura-
tion.
The finding by Zink and Reinhardt (1975) that an exposure to 1-2%
CO2 for 5 h killed all the mice was not used in setting the SMACs.
The reason is that no mortality was found in human subjects exposed to
2% or 2.7% CO2 for 30 d (Zharov et al., 1963; Sinclair et ai., 1969).
The mortality finding of Zink and Reinhardt on the mouse is obviously
of no value in setting exposure limits for humans.
In humans, subchronic C02 exposures are known to either decrease
the plasma levels of calcium and phosphorus (Schaefer, 1961a,
1963a,b; Schaefer et al., 1963a,b, 1964a; Messier et al., 1976) or
cause no change (Glatte et al., 1967a). One group of investigators even
suggested that the decrease in urinary excretion of calcium and phos-
phorus during subchronic CO2 exposures could be an artifact (Davies et
al., 1978a,b). Therefore, subchronically CO2 has no or only weak ef-
fects on calcium and phosphorus levels. Even if CO2 does affect cal-
cium and phosphorus plasma levels, the effects are opposite to those
seen in space missions (Schaefer et al., 1963b), so the long-term
SMACs are not set to prevent the calcium and phosphorus changes.
Visual Impairments, Tremors, and CNS Depression
An exposure of human subjects to 6% CO2 for several hours pro-
duced visual disturbances and tremors (Schulte, 1964). Similarly, vi-
sual intensity discrimination was also found to be reduced in a 1-2 rain
exposure of human subjects to 6% CO2 (Gellhorn, 1936). Both visual
impairments and tremors are toxic end points that should be prevented
because they might interfere with the astronauts in dealing with a con-
tingency.
Several studies showed that the NOAEL for visual impairments and
tremors is about 3-4%. Both Storm and Giannetta (1974) and Glatte et
al. (1967a) used a battery of tests, called Repetitive Psychometric Mea-
sures, to evaluate the effects of CO2 on vision, hand steadiness, and
CNS functions. Storm and Giannetta exposed 12 volunteers to 4% CO2
for 2 w and they detected no visual or tremor problems in the volun-
teers. Glatte et al. found that a 5-d exposure of seven subjects to 3%
CO2 had no effects on vision and hand steadiness.
There are other investigators who used methods other than the Repet-
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itive Psychometric Measures to evaluate the effects of CO2. For in-
stance, Radziszewski et al. (1988) did not find any visual problems or
tremors in six human subjects exposed to 2.9% CO,, for 30 d. Simi-
larly, Sinclair et al. (1971) lbund that 2.8% CO2 did not produce visual
problems or tremors in four human subjects after an exposure of 1 h or
15-20 d. Menn et al. (1970) also failed to detect visual problems or
tremors in eight human subjects exposed to 2.8% CO2 for 30 min.
The mechanisms of CO2-induced visual disturbances and tremors are
unknown. It is possible that they are related to the effect of CO2-
induced acidosis on the eye or the nervous system. Because there are
indications that acidosis develops rapidly during CO2 exposures, the
visual impairments and tremors are assumed not to increase in severity
with exposure duration. In rats, an exposure to 11% CO2 resulted in
acidosis as soon as 0.5 h into the exposure (the earliest blood pH deter-
mination in that study) and the blood pH gradually rose afterward
(Barbour and Seevers, 1943). During a 1-h exposure of human subjects
to 7% CO2, the arterial plasma pH decreased as early as 10 min into
the exposure and stayed constant from rain 10-60 (Brackett et al.,
1965). Due to the rapid development of acidosis and the fact that there
is no evidence that the visual problems and tremors are exposure-dura-
tion dependent, the same AC is derived for an exposure lasting 1 h, 24
h, 7 d, 30 d, or 180 d.
As concluded in the Toxicity Summary section, 5 % CO2 causes mild
CNS depression in acute exposures. Based on a 5-d exposure of seven
human subjects conducted by Glatte et al. (1967a) and a 2-w exposure
of 12 human subjects done by Storm and Giannetta (1974), 3% CO2 is
the NOAEL for the CNS effect of CO,,. Because the same method,
Repetitive Psychometric Measures, was used to evaluate CO2's effects
on vision, hand steadiness, and CNS functions, the data of Glatte et al.
and Storm and Giannetta are combined in deriving the ACs for the pre-
vention of visual disturbances, tremors, and CNS impairment.
l-h, 24-h, 7-d, 30-d, and 180-d AC based on visual disturbances,
tremors, and CNS depression
= NOAEL x 1/small n factor
= NOAEL × (square root of n)/10
= 3% × (square root of(7 + 12))/10
=3% ×0.44
= 1.3%.
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Headaches
Acute CO2 exposures might also produce other symptoms, such as
headaches, dyspnea, and intercostal muscle pain, especially during exer-
cise or exertion (Schulte, 1964; Glatte et al., 1967b; Menn et al., 1968,
1970). Because CO2-induced headaches are usually transient (Glatte et
al., 1967a; Sinclair et al., 1969; Glatte et al., 1967b; Menn et al.,
1968; Mines, 1981) and because Radziszewski et al. showed that an
exposure to 2% CO2 rarely produced headaches in 30 d in six human
subjects who exercised twice weekly for l0 rain each at a 150-watt
workload (Radziszewski et al., 1988; Guillerm and Radziszewski,
1979), 2% CO2 is chosen to be the ACs for headaches.
Dyspnea and Intercostal Pain
CO2 has been shown to produce dyspnea and intercostal pain during
exercise or exertion (Schulte, 1964; Menn et al., 1970). Menn et al.
showed that exposure to 2.8% CO2 did not produce dyspnea and inter-
costal pain in eight human subjects in 30 min. Similarly, Sinclair et ai.
(1971) did not detect dyspnea and intercostal pain in four human sub-
jects who were exposed to 2.8% CO2 tot 1 h or 15-20 d. These indi-
viduals performed a 45-min continuous steady state exercise at low,
moderate, or heavy load once during the 1-h exposure and twice daily
during the 15-20 d of CO2 exposure. Radziszewski and his colleagues
reported no dyspnea or intercostal pain in six human subjects exposed
to 2.9% CO2 and who exercised at a 150-watt workload for 10 min
twice a week (Radziszewski et al., 1988). Because there is no evidence
that the production of dyspnea and intercostal pain by hypercapnia is
time-dependent, the data of Menn et al. and Sinclair et al. are combined
in deriving the 1-h and 24-h ACs for dyspnea and intercostal pain. The
1-h and 24-h ACs are derived without any adjustment for the small
number of human subjects used since a large safety margin is not need-
ed in short-term contingencies, in which astronauts can tolerate a little
bit of dyspnea or intercostal pain on exertion for a short time.
1-h and 24-h ACs for dyspnea and intercostal pain
= 30-min or 1-h NOAEL
= 2.8%.
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In deriving the 7-d, 30-d, and 180-d ACs for dyspnea and intercostal
pain, the data of Sinclair et al. (1971) and Radziszewski et al. (1988)
are combined. Because the six subjects in the study of Radziszewski et
al. did not develop dyspnea and intercostal pain when exposed to 2.9%
CO:, the NOAEL of 2.8% obtained by Sinclair et al. should also be a
NOAEL for these six subjects.
7-d, 30-d, and 180-d ACs for dyspnea and intercostal pain
= 15-20 d NOAEL × 1/small n factor
= 15-20 d NOAEL x (square root of n)/10
= 2.8% x (square root of (4 + 6))/10
= 2.8% × 0.32
= 0.9%.
Hyperventilation
The NRC subcommittee on SMACs advised NASA to consider the
hyperventilatory effect in setting COz's SMACs. Because the 1-h and
24-h SMACs are designed for contingencies, it is acceptable for the
astronauts to tolerate some hyperventilation. Therelore, the 1-h and
24-h SMACs are not set based on CO2-induced hyperventilation.
The hyperventilatory effect is considered in establishing the 7-d,
30-d, and 180-d SMACs. Unlike other end points, the acceptable con-
centrations for a 7-d, 30-d, or 180-d exposure are not set at levels that
will prevent any hyperventilation. Doing otherwise will be too conser-
vative because CO2-induced hyperventilation is not harmful per se. Un-
der most situations, CO2-induced hyperventilation is a protective re-
sponse for the body when oxygen is displaced by CO2 at an abnormally
high level. The situation is different, however, in spacecraft. Since
oxygen is artificially maintained in spacecraft at a level sufficiently high
for metabolic needs, CO2-induced hyperventilation is of lesser impor-
tance in spacecraft than on earth. In setting the acceptable CO2 concen-
trations, toxic effects secondary to CO2-induced hyperventilation should
be taken into consideration. There are three potential secondary effects
of CO2-induced hyperventilation:
1. Discomfort associated with extreme hyperventilation.
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2. Impairment of the ability to exercise or take on heavy workload.
3. Increased inhalation of airborne toxicants.
Consideration of the discomfort associated with extreme hyperventi-
lation overlaps somewhat with that of the miscellaneous symptoms,
such as dyspnea and intercostal muscle pain, discussed above. The lev-
els set to prevent dyspnea and intercostal muscle pain will not be re-
peated here. Sinclair et al. in an Air force study stated that, "with the
exception of occasional mild headaches and awareness of increased ven-
tilation during the first 24 hours" of a 30-d exposure of four subjects to
2.8% CO2 or a ll-d exposure of another four subjects to 3.9% CO2,
the humans subjects tolerated the hypercapnia "without apparent diffi-
culty" (Sinclair et al., 1969). In a French study, there was no report of
any symptoms or complaints in six human volunteers exposed for 30 d
to 2% CO2, which increased the minute volume by 45% in d 8-30
(Radziszewski et al., 1988; Guillerm and Radziszewski; 1979). So the
Air Force and French studies indicate that humans can tolerate 2-3.9%
CO2; the low end of the range, 2%, appears to be a prudent choice as
the NOAEL based on tolerability. The number of test subjects used in
the Air Force and French studies are pooled, 4 + 4 + 6 = 14, in cal-
culating acceptable concentrations based on tolerability.
7-d, 30-d, and 180-d ACs based on tolerability
= NOAEL x 1/small n factor
= NOAEL x (square root of n)/10
= 2% × (square root of 14)/10
= 2% × 0.37
= 0.7%.
Another factor to be considered is whether a subchronic exposure to
CO2 will impair the ability of astronauts to exercise daily, which is very
important in conditioning the muscle in microgravity. The French
group showed that, in a 1-d exposure of five human subjects to 4.3%
CO2, the subjects were unable to exercise (Radziszewski et al., 1988).
In a 9-d exposure to 3.8% CO2, five subjects could exercise only at a
limited capacity (Radziszewski et al., 1988). In contrast, in a 30-d
exposure of six volunteers to 2 % CO2, the volunteers had good ability
to exercise (Radziszewski et al., 1988), and their oxygen consumption
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rate, respiratory rate, and heart rate during the 10-min exercise at a
150-watt workload did not differ from performance of the same ex-
ercise in the normocapnic control period (Guillerm and Radziszewski,
1979). The only small change was that their minute volumes were
raised about 17% when they were breathing 2% CO2 than air (Guillerm
and Radziszewski, 1979). Similarly, the Air Force group showed that
there was no reduction in the ability of four human subjects to perform
45-min of steady state exercise at low, moderate, or heavy workload
during a 15-20 d exposure to 2.8% CO2 (Sinclair et al., 1971). The
oxygen consumption rate and heart rate of the subjects during these
exercises stayed the same in hypercapnic or normocapnic condition.
The minute volumes during these exercises when they were breathing
2.8% CO2 were about 20% higher than that when breathing air. The
Glatte et al. (1967a) Air Force study showed that six out of seven
human volunteers easily tolerated daily 1-h moderate exercises at a 100-
watt workload during a 5-d exposure to 3% CO2. GlaRe et al. reported
that the lone human volunteer who could not tolerate the exercises was
of so small a statute that the exercise bike could not be lowered
sufficiently to fit him. Therefore, the exercise data of this man can be
ignored. The data from the French and Air Force studies (GlaRe et al.,
1967a; Sinclair et al., 1971; Radziszewski et al., 1988) showed that a
subchronic exposure to 2-3% CO2 should have no adverse impact on
the ability of astronauts to exercise or work, so the number of test
subjects used in these studies are pooled, 6 + 4 + 6 = 16, in
estimating the acceptable concentrations based on the ability to exercise.
7-d, 30-d, and 180-d ACs based on exercise ability
= NOAEL x 1/small n factor
= NOAEL x (square root of n)/10
= 2% × (square root of 16)/10
= 2% × 0.40
= 0.8%.
The final factor worth considering is the increased inhalation of air-
borne toxicants caused by CO2-induced hyperventilation. Based on the
consideration of the subjective feeling of tolerability and the exercise
ability, the acceptable concentration is about 0.7%. Radziszewski et al.
(1988) exposed six volunteers to 0.5% and 1% CO2 and they reported
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that 0.5% CO2 failed to produce significant increase in the minute
volume, while 1% CO2 produced a 19% hyperventilation in the first
day of exposure. In 15 human subjects exposed to 1% CO2 for 44 d,
Pingree (1977) showed that the minute volume rose 30% in d 4, but it
returned to the control value on the eighth day. Judging from these
data of Radziszewski et al. and Pingree, the AC of 0.7% will increase
inhalation of airborne toxicants by less than 30% in the first few days
of CO2 exposure. A less than 30% increase is small compared with the
potential respiratory ventilatory increase caused by moderate or heavy
workload. According to the NRC Committee on Toxicology, a man
inhales 7.5 L/min at rest and 20 L/rain at light activity (NRC, 1992).
NRC assumes that a man inhales 20 m3/d, which is approximately
equivalent to the amount of air inhaled in 10 h of rest and 14 h of light
activity per day (NRC, 1992). The minute volume at light activity is
about 170% higher than that at rest. According to the data of Sinclair
et al. (1971), the minute volumes at moderate and heavy workload are
590% and 940% higher than that at rest. Therefore, the less-than-30%
increase in minute volume in the first few days of an exposure to 0.7%
CO2 would be less than the exercise-induced minute volume increase if
the astronauts were to engage in any moderate or heavy exercises.
Especially because the less-than-30% increase in CO2-induced minute
volume will disappear in a few days, in the long run there will not be
any significant increase in the inhalation of airborne toxicants.
From the analysis with these three secondary effects of hyperventi-
lation, 0.7% CO2 is selected to be the acceptable concentration for a
7-d, 30-d, or 180-d exposure based on hyperventilation.
Airway Resistance Increases
In humans, acute CO2 exposures to 5% or 7.5% CO2 in 2 h might
result in increased airway resistance, and increased total lung resistance,
without any lung compliance change, in exposure to 8% CO2 in 3-6
min (Nadel and Widdicombe, 1962; Tashkin and Simmons, 1972).
Theoretically, increased total lung resistance could be caused by an
increase in tissue resistance in the lung or airway resistance. Although
an increased tissue resistance could be produced by CO2 because CO2 is
known to raise the surface tension of the alveolar extract (Schaefer et
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al., 1964a), the increased total lung resistance detected in the human
subjects exposed to 8% CO2 for 3-6 min (Nadel and Widdicombe,
1962) was most probably not due to any raised tissue resistance. This
is because tissue resistance normally contributes only 20% of the total
lung resistance, with airway resistance contributing the remaining 80%
in young adults (West, 1979). As a result, the CO2-induced increase in
total lung resistance was probably due mostly to increased airway
resistance. The finding by Nadel and Widdicombe (1962) that an acute
exposure to 8% CO2 increased the total lung resistance without
changing the lung compliance supports the notion that CO2 increases the
total lung resistance by increasing the airway resistance. Therefore, a
CO2 concentration that does not increase airway resistance should also
prevent any increases in total lung resistance. According to Tashkin
and Simmons (1972), a 2-h exposure of nine human subjects to 2.5%
CO2 did not change the airway resistance. Glatte et al. (1967a) found
that the forced expiratory volume in 1 s failed to change in seven vol-
unteers during a 5-d exposure to 3% CO2. Therefore, 3 % CO2 is con-
sidereal the NOAEL for increases in airway resistance. Because a large
safety margin is not needed in short-term contingencies, no adjustment
is made for using a NOAEL based on only seven human subjects in
deriving the short-term ACs.
1-h and 24-h ACs based on airway resistance increases
= 5-d NOAEL
=3%.
The increase in airway resistance has been postulated to be due to the
local action of hypercapnia in the larynx (Cotes, 1979, pp. 149, 258,
363). Being a local reaction on the upper airway, it is not expected to
increase in severity with time of exposure. Therefore, the 5-d NOAEL
of 3% is used to derive the ACs for 7-d, 30-d, or 180-d exposures
without any time adjustment.
7-d, 30-d, and 180-d ACs based on lung mechanics changes
= 5-d NOAEL x 1/small n factor
= 5-d NOAEL x (square root of n)/10
= 3% x (square root of 7)/10
= 3% x 0.26
= 0.8%.
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Testes
Although an acute exposure of rats to COz at a concentration as low
as 2.5% was found to cause the sloughing of mature spermatids and
Sertoli cells in the testis at 4 or 8 h (but not at 1 or 2 h) (Vandemark et
al., 1972), both the 1-h and 24-h SMACs are not set based on testicular
toxicity. This is because the testicular morphology recovered complete-
ly in these rats in 36 h after the 8-h COz exposure (Vandemark et al.,
1972). So the only potential functional deficit is a 1- or 2-d period of
temporarily reduced fertility within a week of the acute CO2 exposure at
2.5%. Such a temporary reduced fertility is acceptable, considering
that the l-h and 24-h SMACs are aimed at emergency situations.
Although there is no solid proof that subchronic CO2 exposures cause
testicular injuries, for prudence' sake, it is assumed that CO2 is toxic to
the testis subchronically. This is because acute CO2 exposures could
injure the testis, albeit only temporarily (Vandemark et al., 1972). If
the CO2 exposure duration is extended from acute to subchronic, it is
possible that the testicular injury will persist. Even though the study of
Schaefer et al. (1971) was not adequately controlled, the absence of
testicular damage in guinea pigs and rats exposed to 3 % CO2 for 42 d
suggests that 3% could be treated as a NOAEL for subchronic expo-
sures. The NRC Subcommittee on SMACs advised NASA not to apply
the traditional interspecies factor of 10 with CO2's testicular toxicity
because they felt that the toxicity is due to the acidosis and they did not
think that the testes in humans will be more sensitive than the testes in
rodents toward CO2-induced acidosis.
7-d, 30-d, and 180-d AC based on testicular toxicity
= 42-d NOAEL in the rodent studies
=3%.
Establishment of SMACs
The ACs based on these toxic end points are summarized in Table 3-
12. By comparing the ACs, the l-h and 24-h SMACs are set at 1.3%
(9.9 torr), while the 7-d, 30-d, and 180-d SMACs are all established at
0.7% (5.3 torr). For comparison purpose, it should be noted that it has
been the Navy's position that "[h]uman exposures have been safely
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conducted in atmospheres containing up to 5 torr CO2, for up to 90
days. Such exposures are therefore considered safe at this time" (Naval
Submarine Medical Research Laboratory, 1982).
Finally, it should be pointed out that potential influences of micro-
gravity-induced physiological changes on the acceptable concentrations
are not needed in setting the SMACs for CO2. Even though micro-
gravity-induced hypercalciuria is a risk factor for kidney stone forma-
tion (Pak et al., 1989), CO2's SMACs need not be adjusted for hyper-
calciuria because CO2 exposures are not known to increase urinary
calcium excretion in human subjects (in fact CO2 exposures decreased
urinary calcium excretion in human subjects) (Messier et al., 1976;
Schaefer et al., 1963b).
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B4 2-Ethoxyethanol
King Lit Wong, Ph.D.
Johnson Space Center Toxicology Group
Biomedical Operations and Research Branch
Houston, Texas
PHYSICAL AND CHEMICAL PROPERTIES
2-Ethoxyethanol is a colorless liquid with a slightly sweet odor
(ACGIH, 1986). Without giving concentrations, Waite et al. (1930)
reported that the odor of 2-ethoxyethanoi is mild and agreeable in low
concentrations and disagreeable in high concentrations. It is completely
miscible with water and with many organic solvents.
Synonyms:
Formula:
CAS number:
Molecular weight:
Boiling point:
Melting point:
Vapor pressure:
Conversion factors
at 25°C, 1 atm:
Ethylene glycol monoethyi ether; Cellosolve
CH3CH2OCH2CH2OH
110-80-5
90.1
135.6°C
-70°C
3.7 mm Hg at 20°C
1 ppm = 3.68 mg/m 3
1 mg/m 3 = 0.27 ppm
OCCURRENCE AND USE
2-Ethoxyethanol is used as a solvent in synthetic resins and nitrocel-
lulose manufacturing and in varnish removers, cleaning solutions, and
lacquers (ACGIH, 1986). There is no known use of 2-ethoxyethanol in
the spacecraft, but it has been found in the cabin atmosphere during two
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missions (NASA, 1989-1990). The concentrations of 2-ethoxyethanol
detected in these missions varied from 0.8 to 3.0 ppb (NASA, 1989-
1990), and off-gassing is probably the source of it. Based on the off-
gassing data in the Spacelab, it was estimated that 2-ethoxyethanol will
also be generated in the space station (Leban and Wagner, 1989). A
possible source is the off-gassing from paint because 2-ethoxyethanol
has been detected at a geometric mean air concentration of 2.6 ppm
during painting operations in two Belgian shops (Veulemans et al.,
1987).
PHARMACOKINETICS AND METABOLISM
Absorption
In general, about 60% of 2-ethoxyethanol vapor inhaled by human
subjects are absorbed. Groeseneken et al. (1986a) found that in 10 rest-
ing men exposed for 4 h to 2-ethoxyethanol vapor at 10, 20, or 40
mg/m 3 (2.7, 5.4, or 11 ppm), the exhaled concentration was 59-65%
lower than the inspired concentration starting at 10 min into the expo-
sure and remained constant throughout the 4-h exposure. Groeseneken
et al. also found that the degree of respiratory absorption of 2-ethoxy-
ethanol was not substantially affected by light exercise in the subjects.
Metabolism and Excretion
In human volunteers, 2-ethoxyethanol was oxidized to ethoxyacetic
acid (Groeseneken et ai., 1986b). Of the 2-ethoxyethanol absorbed by
the human respiratory tract during a 4-h exposure at 2.7, 5.4, or 11
ppm, 7-8% or 22-24% were excreted as ethoxyacetic acid within 12 or
48 h, respectively (Groeseneken et al., 1986b). After the termination
of the 4-h inhalation exposure in men, the exhaled concentration of
2-ethoxyethanol declined with time bi-exponentially in 4 h (Groese-
neken et al., 1986a). The first phase happened very rapidly, since the
exhaled 2-ethoxyethanol concentration declined more than 98% in 7.5
min after exposure (Groeseneken et al., 1986a). The half-life of the
second phase was calculated to be 102 rain. Integration of the exhaled
concentration curve with time showed that less than 0.4 % of the amount
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of 2-ethoxyethanol absorbed by the human respiratory tract was exhaled
unchanged 4 h after exposure (Groeseneken et al., 1986a). From these
data in humans, the exhalation rate of 2-ethoxyethanot after exposure is
calculated to be 0.1% of the dose per hour, and the elimination rate of
2-ethoxyethanol as ethoxyacetic acid in urine is 0.6% of the dose per
hour. Therefore, it can be concluded that exhalation is less important
than metabolism for 2-ethoxyethanol elimination in humans.
The formation of ethoxyacetic acid is important because it was postu-
lated by Foster et al. (1983) to be the active metabolite of 2-ethoxy-
ethanol. Foster et al. found that an equimolar oral dose of ethoxyacetic
acid was as toxic as 2-ethoxyethanol to the testis of rats.
There are some species differences in the way ethoxyacetic acid is
excreted in the urine. Groeseneken et al. (1986b) discovered that in
resting men exposed for 4 h to 2-ethoxyethanol vapor at 10, 20, or 40
mg/m 3 (equivalent to a dose of 0.25, 0.5, or 1.0 mg/kg), ethoxyacetic
acid was excreted in the urine entirely in its free form. In rats, 2-eth-
oxyethanoi is also oxidized to ethoxyacetic acid, but, unlike in humans,
a part of this metabolite might be first conjugated with glycine before
being excreted in the urine (Groeseneken et al., 1986b). Groeseneken
et al. (1986b) showed that there were significant amounts of glycine-
conjugated ethoxyacetic acid, in addition to the free form, in the urine
of rats after an oral dose of 2-ethoxyethanol at 0.5-100 mg/kg. How-
ever, Medinsky et al. (1990) failed to find the glycine conjugate of
ethoxyacetic acid in the urine of rats exposed to 2-ethoxyethanol in
drinking water for 24 h at a dose of 94, 210, or 1216 #g/kg (equivalent
to 8.5, 19, or 110 mg/kg). The elimination half-life of ethoxyacetic
acid in the urine was 42.0 h in humans and 7.2 h in rats (Groeseneken
et al., 1986b).
Ethoxyacetic acid is not the only metabolite of 2-ethoxyethanol in
rats. Medinsky et al. (1990) reported that in rats given 2-ethoxyethanol
at 8.5, 19, or 110 mg/kg in drinking water for 24 h, 2-ethoxyethanol
was metabolized by two competing pathways to either ethoxyacetic acid
or ethylene glycol. Parts of the ethoxyacetic acid and ethylene glycol
formed were further metabolized to carbon dioxide. Of the absorbed
2-ethoxyethanol, about 18% was excreted as ethylene glycol regardless
of the dose. However, the elimination of 2-ethoxyethanoi as ethoxy-
acetic acid in the urine and as exhaled CO 2 depended on the dose. The
fractions of 2-ethoxyethanol excreted as CO 2 decreased with the doses:
27%, 22%, and 9% in those given 8.5, 19, or 110 mg/kg, respectively
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(Medinsky et al., 1990). In contrast, the fractions of 2-ethoxyethanol
excreted as ethoxyacetic acid, the putative active metabolite of 2-eth-
oxyethanol for testicular toxicity, increased with the doses: 26%, 30%,
and 37% in those given 8.5, 19, or 110 mg/kg, respectively (Medinsky
et al., 1990). Assuming that the 11-12-week-oid male rats used in the
study of Medinsky et al. weighed about 240 g, the ventilation of these
rats is estimated to be 177 mL/min, according to the data of Leong et
al. (1964). It can be calculated that the oral doses of 8.5, 19, or 110
mg/kg used by Medinsky et al. are equivalent to a 6-h inhalation expo-
sure of the 240-g rats to 2-ethoxyethanol at 8.6, 19, or 112 ppm. This
calculation allows us to determine if an inhalation study was conducted
with high concentrations that overly favored the metabolism of 2-eth-
oxyethanol to ethoxyacetic acid, the putative active metabolite for testic-
ular toxicity.
A question of practical importance in evaluating the pharmacokinetic
and metabolic data is whether 2-ethoxyethanol accumulates in the body
during repetitive inhalation exposures. There are no pharmacokinetic
and metabolism data on repetitive exposures to 2-ethoxyethanol. How-
ever, the data from acute exposures seem to indicate that 2-ethoxy-
ethanol is not likely to accumulate during repetitive exposures. As
mentioned above, the exhaled concentration of 2-ethoxyethanol declines
in a bi-exponential fashion after an acute inhalation exposure in hu-
mans, with the half-lives of 7.5 and 102 min, respectively (Groese-
neken et al., 1986a). Since the exhaled concentration correlates with
the blood concentration of organic compounds, such as trichloroethyl-
ene, benzene, and toluene (Stewart et al., 1962; Sato et al., 1974), the
exhaled concentration data on 2-ethoxyethanol suggest that the blood
concentration of 2-ethoxyethanol declines with time rather rapidly after
an inhalation exposure in humans. In other words, there is little accu-
mulation of 2-ethoxyethanol. The data from the rat study of Medinsky
et al. (1990) tend to support this conclusion. Comparing the amount of
2-ethoxyethanol absorbed with the sum of the amounts of it and its me-
tabolites excreted in 48 h after the oral exposure, it appears that the
amount absorbed was almost totally eliminated from the body in 48 h
(Medinsky et al., 1990).
Finally, it should be noted that, in addition to inhalation, cutaneous
absorption is another possible exposure route for 2-ethoxyethanol.
There are data showing that 2-ethoxyethanol is absorbed upon dermal
application in rats (Sabourin et al., 1990).
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TOXICITY SUMMARY
Acute and Short-Term Toxicity
An acute exposure to 2-ethoxyethanol has been known to produce
mucosal irritation, lung congestion, lung edema, and death. Inhalation
exposure of human subjects to 2-ethoxyethanol at 6000 ppm for a few
seconds resulted in moderate eye irritation and a very disagreeable
odor, causing a desire to avoid similar exposures (Waite et al., 1930).
A 24-h exposure at 1000 ppm killed one out of six guinea pigs, and
it caused acute lung congestion and edema, as well as kidney conges-
tion, but a 16-h exposure at 500 ppm failed to produce any gross pa-
thology or death (Waite et al., 1930). Based on the mortality of guinea
pigs exposed for 24 h, the LCs0 was estimated to be about 1400 ppm.
In a study by Werner et al. (1943a), the 7-h LCso of 2-ethoxyethanol in
mice was 1830 ppm, which resulted in dyspnea, weakness, moderate to
marked follicular phagocytosis in the spleen and marked congestion of
the cavernous veins of the spleen. Carpenter et al. (1956) showed that
a 4-h exposure at 4000 ppm or an 8-h exposure at 2000 ppm killed one-
half of the rats.
Foster et al. (1983) showed that oral administration of 2-ethoxy-
ethanol to rats at concentrations of 250-1000 mg/kg failed to change the
weight of the testis, prostate, and seminal vesicles, and it also did not
cause any testicular injury in 24 h. However, because 2-ethoxyethanol
is known to be toxic to the male reproductive system in subchronic
exposure, the finding of Foster et al. cannot rule out the possibility that
2-ethoxyethanol is toxic to the testis after acute exposures. It might take
more than 24 h for the testicular toxicity of 2-ethoxyethanol to appear.
Subchronic and Chronic Toxicity
Testicular Toxicity
Subchronic exposures to 2-ethoxyethanol is known to affect the male
reproductive system. In a cross-sectional study, Ratcliffe et al. (1987)
showed that 80 workers exposed to 2-ethoxyethanol in casting opera-
tions had a lower average sperm count per ejaculation than the unex-
posed controls. The concentration of 2-ethoxyethanol in the breathing
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zone during a full work shift ranged from not detectable to 23.8 ppm
(Ratcliffe et al., 1987).
Welch et al. (1988) conducted a cross-sectional study of 94 shipyard
painters exposed to 2-ethoxyethanol and 2-methoxyethanol and 55 unex-
posed workers. They showed an increased incidence of oligospermia,
which was defined as less than 100 million sperm per ejaculate, in the
exposed painters who did not smoke compared with the unexposed non-
smokers (36% of 33 exposed nonsmokers had oligospermia versus 16%
of 32 unexposed nonsmokers). There was no statistically significant
difference in the average sperm count, however, between the exposed
and unexposed smokers. There were also no statistically significant dif-
ferences in sperm morphology, sperm motility, and testicular size. Due
to no differences in the levels of luteinizing hormone, follicle-stimulat-
ing hormone, and testosterone in the semen of the exposed and the con-
trol groups, Welch et al. concluded that the oligospermia was probably
not due to any perturbation of the hypothalamic-pituitary axis.
The painters had been employed at that site for an average of 8 y (a
standard deviation of 7 y and a range of 0.5 to 33 y) (Welch et al.,
1988). The 8-h time-weighted-average (TWA) concentrations of
2-ethoxyethanol and 2-methoxyethanol, measured during the study,
were 2.6 ppm (standard deviation (SD), 4.2 ppm) and 0.8 ppm (SD,
1.0 ppm), respectively. Welch et al. admitted that the measured expo-
sure concentrations might underestimate the concentrations of 2-ethoxy-
ethanol in previous exposures. The exposure concentrations in the
Welch et al. study were measured with personal samplers, representing
concentrations in the breathing zone of the painters (Sparer et al.,
1988). The painters wore respirators less than 25% of the time. There
were minimal cutaneous exposures of the painters to 2-ethoxyethanol
and 2-methoxyethanol, since 94 % of the painters had no or only a little
paint on them (Sparer et al., 1988). Because these painters had been
rotated from job to job involving exposures to either or both of the eth-
anol ethers, it was impossible to separate the effects of the two in this
study.
In the shipyard study of Welch et al. (1988), the painters potentially
were exposed to many chemicals: ammonia, carbon black, coal-tar-
pitch volatiles, epichlorohydrin, ethyl silicate, lbrmic acid, phosphoric
acid, silica, toluene diisocyanate, 38 organic solvents, and 14 metals.
Among these chemicals, only lead and epichlorohydrin are known to
affect the male reproductive system in humans, but actual sampling and
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analyses demonstrated that the painters were not exposed to these two
reproductive toxicants to any significant extent (Welch et al., 1988). It
thus appears that the male reproductive effects detected in the shipyard
study might be related to exposure to 2-ethoxyethanol, 2-methoxy-
ethanol, or both (Welch et al., 1988).
Both chemicals have been shown to be reproductive toxicants in male
animals. Seminiferous tubule degeneration was detected in rabbits but
not in rats exposed to 2-ethoxyethanol at 400 ppm for 6 h/d, 5 d/w, for
13 w (Barbee et al., 1984). Rats exposed to 2-methoxyethanol at 300
ppm for 6 hid for 3 d showed degenerative changes in spermatocytes of
pachytene and meiotic division at spermatogenic stage XIV (Lee and
Kinney, 1989). By comparing the results of exposures to 2-ethoxy-
ethanol at 400 ppm and exposures to 2-methoxyethanol at 300 ppm, it
appears that, in the rat, 2-ethoxyethanol is less toxic to the testes than
2-methoxyethanol (Barbee et al., 1984; Lee and Kinney, 1989). Such a
conclusion was confirmed by Foster et al. (1983) who showed that oral
administration of 2-ethoxyethanol to rats at 250 mg/kg/d for 11 d did
not affect the testes, and it took an oral dose of 500 mg/kg/d to produce
spermatocyte degeneration of similar severity to that seen with adminis-
tration of 2-methoxyethanol at 100 mg/kg/d.
The adverse effects of 2-ethoxyethanol on the testis do not appear to
be permanent. Oudiz et ai. (1984) showed that five daily oral intuba-
tions of 936, 1872, or 2808 mg/d in rats resulted in sperm-count de-
creases (starting in the second week after exposure for the highest dose
group), with most of the rats exposed to the two highest doses becom-
ing azoospermic by week 7 after exposure. However, partial or com-
plete recovery was seen in the sperm counts and sperm morphology by
week 14 and in histological assessment of the testis and epididymis by
week 16 (Oudiz et al., 1984). Among the spermatogenesis stages,
Oudiz et al. showed that in rats the early-spermatid-late-spermatocyte
stages were most sensitive to 2-ethoxyethanol. Foster et al. (1983)
showed that in rats, daily oral administration of 2-ethoxyethanol at 1000
mg/kg/d for 7 or 11 d led to degeneration of only the late primary
spermatocytes and secondary spermatocytes, with other testicular cell
types unaffected. Finally, it should be noted that the reproductive
toxicity of 2-ethoxyethanol is confined to males. 2-Ethoxyethanol given
in drinking water at 0.5-2% resulted in testicular atrophy and decreased
sperm motility in male CD-I mice, but no reproductive abnormalities
were detected in female mice (Lamb et al., 1984).
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Hematological Toxicity
Other than testicular toxicity, subchronic or chronic exposures to
2-ethoxyethanol also could affect the blood cells. In the cross-sectional
study conducted by Welch et al. (1988), anemia, which was defined as
a condition with the blood hemoglobin concentration below 14.0 g/dL,
was detected in 9 of 94 exposed shipyard male painters, and anemia
was not detected in 55 unexposed subjects in the control group (p con-
centrations in the shipyard painters with anemia ranged from 12.3 to
13.5 g/dL). The shipyard painters with anemia, however, had normal
values for mean corpuscular volume, mean corpuscular hemoglobin,
and mean corpuscular hemoglobin concentration (Welch and Cullen,
1988). In addition, the mean blood hemoglobin concentrations in the
exposed painters and unexposed controls did not differ statistically
(Welch and Cullen, 1988). Therefore, the anemic condition detected in
the shipyard painters was relatively mild. Among the chemicals the
painters were potentially exposed to, benzene and lead can produce he-
matological effects, but there were no significant exposures of the ship-
yard painters to benzene or lead, based on actual sampling and analyses
(Welch and Cullen, 1988). The anemia in the painters, therefore,
might be related to occupational exposures to 2-ethoxyethanol, 2-meth-
oxyethanol, or both, because both chemicals have been shown to pro-
duce hematological abnormalities in laboratory animals. An exposure
to 2-ethoxyethanol at 400 ppm for 6 h/d, 5 d/w, for 13 w reduced the
leukocyte count in female rats, and it reduced the erythrocyte count in
rabbits (Barbee et al., 1984). Exposure of rats to 2-methoxyethanol at
300 ppm for 6 h/d for 9 d resulted in pancytopenia and bone-marrow
hypoplasia (Miller et al., 1981).
A study of lithographers by Cullen et al. (1983) also showed that
occupational exposures to 2-ethoxyethanol might be related to bone-
marrow injury. Myeloid hypoplasia with or without stromal injury was
observed in the bone marrow of six of seven workers who had worked
for 1-6 y with a five-color press, which used solutions containing,
among other chemicals, 2-ethoxyethanol. However, blood counts were
normal for these workers. They were exposed, via inhalation and di-
rect skin contacts, to 2-ethoxyethanol, dipropylene glycol monomethyl
ether, insoluble pigments, acrylic and epoxy resins, C4 and C3 substi-
tuted benzene, dichloromethane, 1,2-dichloroethylene, dichloroethane,
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1,1,l-trichloroethane, 2-butanone, glycerol triacetate, and n-propanol
(Cullen et al., 1983). The airborne concentration of dipropylene glycol
monomethyl ether ranged from 0.6 to 6.4 ppm, but the exposure con-
centration of 2-ethoxyethanol was not measured (Cullen et al., 1983).
There is also evidence of the bone-marrow toxicity of 2-ethoxy-
ethanol in laboratory animals. An exposure of rats at a concentration of
370 ppm for 7 h/d, 5 d/w, for 5 w resulted in fat replacement of cells
in the bone marrow and a decrease in myeloid cells in the spleen
(Werner et al., 1943b). There was also increased hemosiderosis in the
spleen, indicating increased red-blood-cell (RBC) destruction, but the
2-ethoxyethanol exposure had no effects on RBC and reticulocyte
counts, hemoglobin concentration, total white-blood-cell counts, and the
differential counts of granulocytes, lymphocytes, and monocytes
(Werner et al., 1943b).
Carcinogenicity
No results of carcinogenicity testing with 2-ethoxyethanol were found
in the literature.
Genotoxicity
2-Ethoxyethanoi did not cause mutation in four strains of Salmonella
typhimurium (NIOSH, 1983).
Developmental Toxicity
2-Ethoxyethanol is known to affect the embryo and fetus in labora-
tory animals. Exposure of pregnant rats at a concentration of 10 ppm
for 6 h/d on days 6-15 of gestation led to an increased incidence of
limb mairotation in the fetuses, and a similar exposure at 50 ppm re-
duced the litter size (Doe, 1984). No adverse effects were detected in
the mothers in the 10-ppm and 50-ppm groups. An intrauterine expo-
sure of rats at 250 ppm, however, produced late intrauterine death; re-
duction of the mean fetal weight; increased incidence of minor skeletal
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defects, including partial or nonossification of the skull, the thoracic
centra, the lumbar centra, the lumbar vertebrae, and sternebrae; and
increased incidence of 27 presacral vertebrae and sternebrae abnormali-
ties (Doe, 1984). Exposure of the rats at 250 ppm reduced the mean
corpuscular volume, hematocrit, and hemoglobin level in the mothers.
Exposure of pregnant rabbits to 2-ethoxyethanol at 175 ppm for 6 h/d
on days 6-18 of gestation also resulted in an increased incidence of mi-
nor skeletal defects in the fetuses and no maternal toxicity (Doe, 1984).
Exposure of pregnant rats to 2-ethoxyethanoi at 100 ppm for 7 h/d on
days 7-13 of gestation resulted in the following conditions in newborns:
decreased rotorod performance; increased acetylcholine, dopamine, and
norepinephrine in the cerebrum; increased acetylcholine, norepineph-
rine, and protein in midbrain; increased acetylcholine in the cerebellum;
and increased norepinephrine in the brainstem (Nelson et al., 1984).
Because SMACs generally are not set on the basis of developmental
toxicity, these data on the toxicity of 2-ethoxyethanol in the first trimes-
ter are not used here.
Interaction with Other Chemicals
No data on the interaction of 2-ethoxyethanol with other chemicals
have been found in the TOXLINE or MEDLINE data bases of the Na-
tional Library of Medicine (Bethesda, Md.).
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TABLE 4-2
Organization
2-ETHOXYETHANOL
Exposure Limits Set by Other Organizations
Concentration, ppm
203
ACGIH's TLV 5 (TWA)
OSHA's PEL 200 (TWA)
NIOSH's IDLH 6000
TLV = threshold limit value. TWA = time-weighted average. PEL =
permissible exposure limit. IDLH = immediately dangerous to life and health.
TABLE 4-3 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m -_ Target Toxicity
1 h 10 40
24 h 10 40
7 d_ 0.8 3
30 d 0.5 2
180 d 0.07 0.3
Hematological toxicity
Hematological toxicity
Hematological toxicity
Hematological toxicity
Hematological toxicity
aThere is no official 7-d SMAC. The current official 7-d SMAC for 2-
ethoxyethyl acetate is 30 ppm.
RATIONALE FOR
ACCEPTABLE CONCENTRATIONS
Although 2-ethoxyethanoi is known to cause fetal toxicity and minor
teratogenic changes in rats and rabbits (Doe, 1984), SMACs for 2-
ethoxyethanol are not established according to its developmental toxicity
because pregnant astronauts will not be allowed in space. The major
targets of subchronic toxicity of 2-ethoxyethanol are the testes and the
hematological system, but very little is known about its acute toxicity.
Mucosal Irritation
Moderate eye irritation was noted by Waite et al. (1930) in human
subjects exposed for a few seconds to 2-ethoxyethanol at a concentra-
tion of 6000 ppm. However, these data are not relied on in setting the
short-term SMACs because the exposure lasted for only several sec-
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onds. In a 13-w study conducted by Barbee et al. (1984), increased
incidences of lacrimation and mucoid nasal discharge were observed in
rabbits and rats after 2-10 w of exposure to 2-ethoxyethanol at 25, 100,
or 400 ppm, as compared with the controls. Barbee et al. reported that
the lacrimation and nasal discharge failed to show a concentration-
response relationship. Nevertheless, the data indicate that 2-ethoxy-
ethanol vapor at 25 ppm could be irritating to the mucous membranes
in animals. Because Groeseneken et al. (1986c) did not report any
mucosal irritation in 10 human volunteers exposed to 2-ethoxyethanol at
up to 10 ppm for 4 h, the nonirritating concentration appears to be 10
ppm in humans. Because the astronauts are expected to be able to
tolerate mild mucosal irritation during 1-h or 24-h contingencies, the
acceptable concentration (AC), based on irritation, for 1 and 24 h is 25
ppm.
1-h and 24-h ACs based on irritation
= 25 ppm.
7-d, 30-d, and 180-d ACs based on irritation
= 4-h NOAEL x 1/safety factor for small n
= 10 ppm × (square root of n)/10
= 10 ppm x (square root of 10)/10
= 3 ppm.
The 7-d, 30-d, and 180-d ACs are set at the same concentration because
mucosal irritation is not expected to increase with time after the first
hour of exposure.
Testicular Toxicity
Although Welch and co-workers (1988) showed that occupational
exposures to 2-ethoxyethanol at about 2.6 ppm could result in lower
sperm count and mild anemia, the SMACs for testicular toxicity should
not be set relying solely on the data of Welch and co-workers for three
reasons. First, the exact exposure concentrations of 2-ethoxyethanol
were not known in that study. The painters were exposed, several
years before the study began, to 2-ethoxyethanol at concentrations
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potentially higher than 2.6 ppm (Sparer et al., 1988; Welch and Cullen,
1988; Welch et al., 1988). Second, in addition to 2-ethoxyethanol, the
painters were exposed to 2-methoxyethanol at a concentration of 0.8
ppm, which is also known to produce testicular and hematological
toxicity (Miller et al., 1981; Welch and Cullen, 1988; Welch et al.,
1988; Lee and Kinney, 1989). Third, the painters were potentially
exposed to 59 chemicals other than 2-ethoxyethanol and 2-methoxy-
ethanol (Welch and Cullen, 1988; Welch et al., 1988). Altt_ough the
investigators did determine the airborne concentrations of the testicular
or hematological toxicants among those 59 chemicals to reasonably rule
them out, it is possible that some of the chemicals can potentiate the
toxicity of 2-ethoxyethanol. For these reasons, the SMACs are not
derived entirely from the data on the shipyard painters. Rather, the
painter data are used only to check the validity of setting SMACs on the
basis of animal data.
The animal data of Barbee et al. (1984) appeared to be suitable for
the derivation of SMACs for 2-ethoxyethanol. In their 13-w study,
Barbee et al. showed that rabbits were more sensitive than rats to the
testicular and hematological toxicity of 2-ethoxyethanol; therefore, the
SMACs are established using the rabbit data. A 13-w exposure at 400
ppm for 6 h/d, 5 d/w resulted in testicular damage and decreases in
testicular weight in rabbits but not in rats. A similar exposure at 100
ppm failed to cause any changes in the testis in rabbits; thus, the
subchronic toxicity study of Barbee et al. (1984) indicates that 100 ppm
is the 13-w no-observed-adverse-effect level (NOAEL) in animals.
Applying the traditional interspecies extrapolation factor of 10 to the
13-w NOAEL of 100 ppm, it appears that a 13-w occupational exposure
to 2-ethoxyethanol at 10 ppm should be devoid of testicular toxicity in
humans. However, compared with the study of Welch et al. (1988) in
which an 8-y occupational exposure to a mixture of 2-ethoxyethanol
(TWA, 2.6 ppm; SD, 4.2 ppm) and 2-methoxyethanol (TWA, 0.8 ppm;
SD, 1.0 ppm) could result in lower sperm counts, the 13-w exposure
concentration at 10 ppm, predicted to be safe using the 13-w NOAEL
of 100 ppm, does not appear to have any margin of safety. It appears
that humans are even more sensitive than rabbits to the testicular toxic-
ity of 2-ethoxyethanol. Although it can be contended that the painter
study of Welch et al. had flaws enumerated above, prudence dictates
that a 13-w NOAEL lower than 100 ppm should be used to derive the
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SMACs. Consequently, the lower 13-w NOAEL of 25 ppm was cho-
sen (Barbee et al., 1984). Even though 25 ppm lowered the body
weights of rabbits after a 13-w exposure, 25 ppm is still considered a
NOAEL because the higher concentration of 100 ppm did not lower the
body weights of rabbits in the same study (Barbee et al., 1984).
7-d AC for testicular toxicity
= 13-w NOAEL x l/species factor
= 25ppm x 1/10
= 2.5 ppm.
Haber's rule is used to derive the 30-d AC on the basis of testicular
toxicity because it is uncertain whether the testicular injury is reparable.
For prudence sake, the testicular injury caused by 2-ethoxyethanol is
assumed to be irreparable.
30-d AC = 13-w NOAEL x time adjustment x 1/species factor
= 25 ppm x (6 h/d x 5 d/w x 13 w)/(24 h/d x 30 d) x 1/10
= 25 ppm x 390 h/720 h x 1/10
= 25 ppm x 0.54 x 1/10
= 1.4 ppm.
Because the testicular toxicity in a 180-d exposure is not expected to
differ significantly from that in a 30-d exposure, the 180-d AC is set
equal to the 30-d AC. Because an oral administration of 2-ethoxyeth-
anol at a dose of 1000 mg/kg failed to cause any male reproductive
toxicity in rats (Foster et al., 1983), testicular toxicity is not a
consideration in setting the short-term SMACs.
Hematological Toxicity
A subchronic exposure of rabbits to 2-ethoxyethanol at 400 ppm for
6 h/d, 5 d/w, for 13 w reduced the RBC count (Barbee et al., 1984).
No change in the count was observed in rats. In the female rats, there
were lower leukocyte counts and a 15% decrease in the spleen weight.
A similar exposure at 100 or 25 ppm failed to produce any hematologi-
cal changes in either rabbits or rats. However, a 12% decrease in
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spleen weight was detected in female rats after the 13-w exposure at
100 or 25 ppm (Barbee et ai., 1984). Because there were no hemato-
logical and histological changes in female rats exposed to 2-ethoxyeth-
anoi at 100 or 25 ppm, the toxicological meaning of the decreases in
spleen weight is uncertain. The meaning of the decreases in spleen
weight in female rats exposed at 100 ppm is further obscured by the
fact that the spleen/body-weight ratio showed no change in that group
(Barbee et al., 1984). The spleen/body-weight ratio was lowered only
in female rats exposed at 400 or 25 ppm, and body weight showed no
statistically significant changes in female rats exposed at 400, 100, or
25 ppm.
All in all, the data of Barbee et al. (1984) indicate that the NOAEL
for a 13-w exposure to 2-ethoxyethanol is 100 ppm for hematological
toxicity in rabbits and rats. Similar to the analysis of the NOAEL based
on testicular toxicity, the comparison of the subchronic NOAEL of 100
ppm from the animal study with the finding of Welch and co-workers
(1988) in human workers indicates that a NOAEL lower than 100 ppm
should be used. Welch and co-workers found that workers exposed to
a mixture of 2-ethoxyethanol (TWA, 2.6 ppm; S.D., 4.2 ppm) and
2-methoxyethanol (TWA, 0.8 ppm; S.D., 1.0 ppm) developed mild
anemia. As a result, the lower NOAEL of 25 ppm from the 13-w
study is used in setting the SMACs (Barbee et al., 1984).
Microgravity is known to reduce the RBC mass in astronauts
(Huntoon et al., 1989). Consequently, a safety factor of 3 is used to
account for potential interaction of 2-ethoxyethanol and microgravity on
causing anemia.
7-d AC based on hematological toxicity
= 13-w NOAEL x 1/species factor x 1/microgravity factor
= 25 ppm x 1/10 x 1/3
= 10 ppm.
30-d AC based on hematological toxicity
13-w NOAEL × l/species factor x 1/microgravity factor
x time adjustment
25 ppm x 1/10 x 1/3 x (6 h/d x 5 d/w x 13 w)/(24 h/d
x 30 d)
0.5 ppm.
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180-d AC based on hematological toxicity
= 13-w NOAEL × 1/species factor × l/microgravity factor
× time adjustment
= 25ppm × 1/10 × 1/3 x (6h/d x 5d/w × 13w)/(24h/d
x 180 d)
= 0.07 ppm.
Werner et al. (1943b) found that repetitive exposures of rats to 370
ppm for 7 h/d, 5 d/w, for 1 w did not cause any changes in the RBC
count and hemoglobin concentration in blood. The 1-w NOAEL of 370
ppm is used to derive the 1-h and 24-h ACs.
l-h and 24-h ACs based on hematological toxicity
= l-w NOAEL x 1/species factor x l/microgravity factor
= 370ppm × 1/10 × 1/3
= 10 ppm.
Establishment of SMAC Values
The ACs for all toxic end points are tabulated below. By choosing
the lowest AC for each exposure duration, the l-h, 24-h, 7-d, 30-d, and
180-d SMACs are set at 10, 10, 0.8, 0.5, and 0.07 ppm, respectively.
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B5 Hydrazine
Hector D. Garcia, Ph.D., and John T. James, Ph.D.
Johnson Space Center Toxicology Group
Biomedical Operations and Research Branch
Houston, Texas
PHYSICAL AND CHEMICAL PROPERTIES
Hydrazine is a clear, colorless, fuming, oily, hygroscopic, highly po-
lar, flammable liquid with an ammonia-like odor or an extremely irritat-
ing gas that is readily adsorbed or condensed onto surfaces and has a
high affinity for water (Sevin, 1978).
Synonym:
Formula:
CAS number:
Molecular weight:
Boiling point:
Melting point:
Liquid density at
25°C:
Vapor pressure:
Saturated vapor
concentration:
Solubility:
Conversion factors
at 25°C, 1 arm:
Diamine
N2H4
302-01-2
32.05
113.5°C
1.4-1.5°C
1.0045
14.1 nun Hg @ 25°C (10.4 torr at 20°C)
18,900 ppm (25°C) (24,800 mg/m 3)
Miscible with water and methyl, ethyl,
propyl, and isobutyl alcohols; insoluble in
chloroform and ether
1 ppm = 1.31 mg/m 3
1 mg/m 3 = 0.76 ppm
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OCCURRENCE AND USE
Hydrazine occurs naturally as a product of nitrogen fixation by Azo-
tobacter agile. It has been identified in tobacco grown without the use
of maleic hydrazide (Sevin, 1978). Essentially all commercially used
hydrazine is chemically synthesized, usually by one of several processes
involving chemical oxidation of ammonia.
Hydrazine is used commercially as a polymerization catalyst, a blow-
ing agent, a reducing agent, and an oxygen scavenger in boiler-water
treatment; it is also used commerically in the synthesis of maleic hydra-
zide and in the manufacture of drugs. In combination with water, it is
used in the F-16 aircraft emergency power unit as a source of gas to
drive a turbine. The hydrazine bases are used in the production of salts
and hydrazones that are used in surfactants, detergents, plasticizers,
pharmaceuticals, insecticides, and herbicides (Sevin, 1978).
Hydrazine is used as a rocket propellant and for the auxiliary power
unit on the space-shuttle orbiters. Hydrazine might be used on the inter-
national space station. It is theoretically possible for a small amount
(up to a few grams) to be introduced into the spacecraft atmosphere in
the unlikely scenario that, during an extravehicular activity, a crew
member is in the vicinity of an undetected leak leak of a subtantial
amount of hydrazine, which is deposited unnoticed on the surface of the
spacesuit and then is vaporized from the suit alter the crew member re-
enters the spacecraft. During missions in which hydrazine contamina-
tion of the airlock is a risk, a real-time chemical monitor using ion-
mobility spectrometry has been flown to ensure that unsafe concentra-
tions of propellants, including hydrazine, are not present before the
spacecraft is re-entered (Eiceman et al., 1993).
PHARMACOKINETICS AND METABOLISM
Absorption
Hydrazine was detectable in the plasma of anesthetized dogs within
30 s after applying concentrated hydrazine solutions to their intact skin
(Smith and Clark. 1972). No data were found in the literature on the
absorption of hydrazine by inhalation or ingestion.
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Distribution
Hydrazine was distributed rapidly (2 h) to most tissues in mice given
single intraperitoneal (i.p.) doses of hydrazine sulfate at 1 mmole/kg of
body weight and in rats given 60 mg/kg; the highest concentrations ap-
peared in the kidneys (Dambrauskas and Cornish, 1964).
Excretion
Anesthetized dogs administered hydrazine sulfate intravenously (i.v.)
at a concentration of 50 mg/kg excreted 5-11% as hydrazino nitrogen in
the urine within 4 h. Unanesthetized dogs administered hydrazine sul-
fate i.v. at 15 mg/kg excreted 50% as hydrazino nitrogen within 2 d.
Rats given subcutaneous (s.c.) injections of hydrazine at 60 mg/kg ex-
creted it unchanged at the rate of 8% after 2 h, 20% after 20 h, and
50% after 40 h.
Metabolism
Hydrazine injected i.p. into rabbits was shown to undergo a two-step
acetylation. Using _SN-labeled hydrazine to study the metabolic fate of
hydrazine in Sprague-Dawley rats, Springer et al. (1981) found that
within 48 h, 25% was exhaled as N 2 gas, 30% appeared in the urine as
hydrazine, and 20 % appeared as a derivative that was acid hydrolyzable
to hydrazine. The disappearance of hydrazine from the blood was hi-
phasic, with half-times of 0.74 and 26.9 h.
TOXICITY SUMMARY
Hydrazine vapor is extremely irritating to the eyes, nose, and throat.
Quantitative information on worker exposure, however, can only be
estimated from the existing published data (Santodonato et al., 1985).
The median concentration of hydrazine detectable by odor is 3-4 ppm
(Jacobson et al., 1955). Inhalation can cause dizziness, anorexia (Mac-
Ewen et al., 1974), and nausea. Hydrazine can be absorbed dermally
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(Smith and Clark, 1972) or orally and can induce contact dermatitis
(Evans, 1958; van Ketel, 1964; Hovding, 1967), neurological impair-
ment (Kulagina, 1962; Reid, 1965), and kidney, lung, and liver damage
at an i.p. dose of 20 mg/kg for 3 d in rodents (Scales and Timbrell,
1982). Hydrazine is fetotoxic in rats and mice at i.p. doses of 5 mg/kg
and is teratogenic in mice at 12 mg/kg.
The summary of the toxic effects of hydrazine given below applies
also to the salts of hydrazine, such as sulfate and hydrochloride, be-
cause they differ in toxicity from the free base only when the develop-
ment of toxicity is related to differences in pH, solubility, volatility, or
mass (in expression of doses) (Sevin, 1978).
Acute and Short-Term Toxicity
Lethality
The LDs0 for hydrazine injected i.p. into rats is 80-100 mg/kg of
body weight. Rats administered 200 mg/kg went into convulsions with-
in 5 min and died within 3 h of dosing (Scales and Timbreli, 1982). A
2-h exposure to hydrazine vapors at a concentration of 1.0-2.0 mg/L
(7600-15,200 ppm) has been reported to induce convulsions, respiratory
arrest, and death in mice and rats (Kulagina, 1962). The toxicity of
multiple lower doses was cumulative, but surviving animals recovered
and lived normal life spans if exposure was discontinued. The LCs0 for
a 4-h exposure to hydrazine is 750 mg/m 3 (570 ppm) for rats and 330
mg/m 3 (250 ppm) for mice (Jacobson et al., 1955). Continuous inhala-
tion exposure to hydrazine at 0.8 ppm was highly lethal to mice within
1-4 w (House, 1964).
Hepatotoxicity
Rats given i.p. injections of hydrazine at 20 mg/kg exhibited vacuol-
ization of liver cells within 24 h of exposure, and those given 10 mg/kg
showed no histopathology (Scales and Timbrell, 1982), but they did
show increases in triglyceride levels (Timbrell et al., 1982). Those
given hydrazine at 60 mg/kg exhibited ultrastructural changes in liver
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cells 30 min after exposure (Scales and Timbrell, 1982). Methylation
of liver DNA has been shown in rats given oral doses of hydrazine at
30-90 mg/kg (Becker et al., 1981).
Subchronic and Chronic Toxicity
Lethality
Continuous inhalation exposure to hydrazine at 0.8 ppm was highly
lethal to rats within 7-10 w and moderately lethal (20%) to monkeys
within 3-13 w (House, 1964). Dogs, rats, mice, and guinea pigs ex-
posed at 14 ppm for 6 h/d, 5d/w, for up to 6 mo showed varying mor-
talities, mice being the most sensitive species (Comstock et al., 1954).
Rats that survived the exposures were found to have completely recov-
ered with no observable pathology about 6 mo after the last day of ex-
posure (Comstock et al., 1954).
There are a few literature reports of accidental human exposures to
high, but unspecified, doses of hydrazine. In one case, a man drank
between a swallow and half a cup of liquid hydrazine, which induced
vomiting and unconsciousness, followed in a few hours by violent be-
havior and in a few days by ataxia, nystagmus, and paraesthesia (Roe,
1978). No followup report was found. Another case involving 6 mo
of occupational contact exposure once a week to hydrazine by a ma-
chinist culminated in conjunctivitis, tremor, cough, fever, vomiting,
diarrhea, and death (Sotaniemi et al., 1971). There were no deaths due
to acute exposure to hydrazine vapor at a hydrazine factory among all
78 workers exposed for at least 6 mo at an estimated 1-10 ppm (54 of
them were exposed for over 2 y) (Waid et al., 1984).
Hepatotoxicity
Fatty changes in the liver have been reported in rats, mice, dogs, and
monkeys exposed by inhalation at 0.8 ppm for 90 d (Weatherby and
Yard, 1955; House, 1964). Prominent fat vacuoles and pigmentation of
liver Kupffer cells were reported in dogs exposed at 14 ppm, for 6 h/d,
5 d/w, for 39 w (Comstock et al., 1954). Exposure at 1 ppm for 6
218 SMACs FOR SELECTED AIRBORNE CONTAMINANTS
h/d, 5 d/w, for 1 y produced no hepatotoxicity in mice and male rats
but did cause a statistically significant increase (to 60% from an inci-
dence of =40%) in focal liver-cell hyperplasia in female rats (Mac-
Ewen et al., 1981). "Fatty livers" were induced in rats given hydrazine
orally (Weatherby and Yard, 1955).
Carcinogenicity
There are conflicting reports on the carcinogenicity of hydrazine.
The National Institute of Environmental Health Sciences finds that there
is sufficient evidence for the carcinogenicity of hydrazine in experimen-
tal animals but inadequate evidence for its carcinogenicity in humans
(NTP, 1989). Inhaled hydrazine has been reported to induce alveolar-
genic carcinomas in three of eight mice exposed at 0.2 ppm (MacEwen
et al., 1974), malignant nasal tumors in 6 of 99 male rats and 5 of 98
female rats exposed at 5 ppm (MacEwen et al., 1981), and benign nasal
polyps in 16 of 160 hamsters exposed at 5 ppm (Carter et al., 1981).
Unequivocally toxic doses (up to 50 mg/L), however, administered in
drinking water for the lifetime of rats were only weakly carcinogenic
(Steinhoff and Mohr, 1988). In male rats (the most sensitive species
and sex) exposed by inhalation, tumors, which were predominantly be-
nign, occurred only late in life in animals showing many other chronic
toxic effects, including a greatly increased inflammatory response of the
upper airways (Carter et al., 1981).
The epidemiological data available on hydrazine-related cancers in
humans (Karstadt and Bobal, 1982) indicates no excess risk of cancer in
workers occupationally exposed to hydrazine vapors, but the number of
workers having substantial exposure has been too few to detect anything
other than gross carcinogenic hazards (Roe, 1978; Waid et al., 1984).
A NASA-sponsored followup study of the Wald cohort of occupation-
ally exposed workers failed to show any increase in cancer-induced
mortality 20 y after exposures ended (Morris et al., 1995).
Genotoxicity
Hydrazine has been reported to be mutagenic in several test systems
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(Jain and Shukla, 1972; Herbold and Buselmaier, 1976; Kimball,
1977), including the Escherichia coli and Ames Salmonella (+$9) as-
says, the Drosophila-melanogaster-specific locus test, and L5178Y cul-
tured mouse lymphoma cells. Hydrazine induces sister chromatid ex-
changes in vitro (MacRae and Stich, 1979). Hydrazine has been shown
to saturate the 5,6 double bond and degrade the pyrimidine bases in
DNA. DNA from the livers of hydrazine-exposed rats, but not control
rats, has been demonstrated to have methylated guanine bases.
Reproductive Toxicity
Hydrazine induces abnormally shaped spermatocytes in treated male
mice (Wyrobek and London, 1973). In the mouse dominant lethal test,
hydrazine did not induce early fetal deaths or preimplantation losses at
single i.p. doses of 42 mg/kg or 52 mg/kg.
Developmental Toxicity
No information was found on the effects of hydrazine exposure on
developing embryos.
Interaction with Other Chemicals
No reports of toxicologically relevant interactions with other chemi-
cals were found.
220
"7
tsr_
<
U
"-I
.£1
_ _ _ __
OO0 0
.p.- o o $ $ ,_ ......
©
=_ ='-= =.=.
I
_ r_ "7' c_ do ooo O_
oooo
.__ .__ _ _ _-
i 0 0 ¢"
_ o o o
E
0
221
o
0
e_
v- O0
0 0 X
E_
_ NN
_ Z. _.
'_ _, ._
_- u_ _;_ u ....
_'_ " "-5
.-_.=o_ _ -
"_
._o :_. _-
_- :_ _-_ ._ ._
,._'-= _ _ _ _,-'
_ _ _ _._ :':o.__.-._
cO
v,
(j _J
(--.
0
xO C_
C'..I
-o E El
s,_ m _ I _- _C_
("4 14% I/_ c',l
222 SMACs FOR SELECTED AIRBORNE CONTAMINANTS
TABLE 5-2 Exposure Limits Set by Other Organizations
Organization Concentration, ppm
ACGIH's TLV
OSHA's PEL
NIOSH's IDLH
NRC's l-h SPEGL
NRC's 24-h SPEGL
0.1 (TWA) (0.01 proposed TWA)
1 (TWA, 8 h/d, 40 h/w, lifetime)
0.03 (ceiling}
Not established owing to carcinogenicity
2
0.08
TLV = threshold limit value. TWA = time-weighted average. PEL =
permissible exit)sure limit. IDLH = immediately dangerous to life and health.
SPEGL = short-term public emergency guidance level.
TABLE 5-3 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m 3 Target Toxicity
lh 4 5
24 h 0.3 0.4
7 da 0.04 0.05
30 d 0.02 0.03
180 d 0.004 0.005
Lethality
Hepatotoxicity
Hepatotoxicity
Hepatotoxicity, focal-liver-cell
hyperplasia, nasal adenoma
Hepatotoxicity, nasal adenoma
aA temporary 7-d SMAC had been set at 0.04 ppm.
RATIONALE FOR
ACCEPTABLE CONCENTRATIONS
Hydrazine induces a variety of toxic effects including irritation of the
eyes, nose, and throat, contact dermatitis, and, at higher concentrations,
dizziness, anorexia, nausea, vomiting, cough, fever, diarrhea, tempo-
rary blindness, hepatotoxicity, tremors, hyperexcitability, convulsions,
and death. Prolonged exposures to relatively low concentrations have
been reported to induce hepatotoxicity and carcinogenicity (Comstock et
al., 1954; House, 1964; Haun and Kinkead, 1973; MacEwen et al.,
1974; Carter et al., 1980; MacEwen et al., 1981; Vernot et al., 1985).
Of these end points, quantitative data are available only for hepatotoxic-
ity, carcinogenicity, and lethality. SMACs were determined following
the guidelines of the National Research Council for exposure durations
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of 1 h, 24 h, 7 d, 30 d, and 180 d by establishing acceptable concentra-
tions (ACs) for each adverse effect at each exposure duration and se-
lecting the lowest AC at each exposure duration to be the SMAC
(NRC, 1992).
Hepatotoxicity
Liver effects induced by inhalation of airborne hydrazine include
fatty changes in the liver in several species after 90 d of continuous ex-
posure at 0.8 ppm (House, 1964). In calculating an AC, these data
were used rather than data on hyperplasia because the fatty changes
were seen at a much earlier time for similar concentrations of hydra-
zine.
AC values for liver toxicity were calculated for 180-d and 30-d expo-
sures by using Haber's rule on data for fatty changes induced in 7 of 10
monkeys exposed continuously at 0.8 ppm for 90 d (also seen in 2 of
10 control monkeys). An uncertainty factor of 10 was applied for ex-
trapolation from animals to humans, and another factor of 10 was ap-
plied for extrapolation from an effect level to a no-effect level. The use
of Haber's rule to extrapolate from a 90-d exposure to exposure dura-
tions of 7 d or less (i.e., >_ 12-fold extrapolation) was deemed inappro-
priate.
180-d AC = 0.8 ppm x (90 d/180 d) + 10 + 10 = 0.004 ppm.
30-d AC = 0.8 ppm x (90 d/30 d) + 10 + 10 = 0.02 ppm.
An AC for a 24-h exposure can be derived from the data of Timbrell
et al. (1982), which showed that an i.p. dose of 10 mg/kg in rats in-
duced the lowest-observed-adverse-effect level (LOAEL) for increased
liver triglycerides when examined 24 h after dosing. For a 70-kg man
inhaling 20 m3/d, assuming 100% absorption, one can convert from an
i.p. dose to an equivalent inhalation dose and derive a 24-h AC as fol-
lows:
10 mg/kg x 70 kg + 20 m 3 -- 10 (NOAEL) + 10 (species)
x 0.76 (to convert mg/m 3 to ppm) = 0.3 ppm.
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An AC for a 7-d exposure can be calculated from the 24-h AC by
using Haber's rule. Thus,
7-dAC = 24-hAC x (1 d/7d) = 0.3ppm x 1/7 = 0.04ppm.
Focal-Liver-Cell Hyperplasia
Liver effects induced by inhalation of hydrazine include a significant
increase in the incidence of focal-liver-cell hyperplasia in female rats
(but not in male rats, mice, hamsters, or dogs) exposed at 1 ppm or 5
ppm for 6 h/d, 5 d/w, for 1 y (Vernot et al., 1985). (Hyperplasia oc-
curred in 58 of 97 exposed female rats compared with 57 of 147 con-
trols.) Female rats exposed at 0.25 ppm under the same conditions had
no significant increase in focal-liver-cell hyperplasia (36 of 100). Thus,
0.25 ppm is a NOAEL for focal-liver-cell hyperplasia for an exposure
of 1560 h or 65 d. ACs can be calculated for 30 d and 180 d by using
a factor of 10 for species differences and Haber's rule for extrapolating
from 65 d to 180 d. The concentration is not increased for extrapolat-
ing from 65 d to 30 d:
30-d AC = 0.25 ppm + 10 = 0.03 ppm.
180-d AC = 0.25 ppm x (65 d/180 d) + 10 -- 0.009 ppm.
Carcinogenicity
Hydrazine has been found to be carcinogenic in animal model sys-
tems (MacEwen et al., 1981; Carter et al., 1981; Vernot et al., 1985).
The oncogenic changes were mostly benign and observable only at the
microscopic level, producing little or no impairment of respiratory
function and no effect on life expectancy. The nononcogenic toxicities
of hydrazine exposure in animals were more severe in producing debili-
tation and lethal effects. There are, moreover, no known reports of
hydrazine-induced human tumors. Most human exposures to hydrazine
have been accidental or job-related, and dose-response data are not
available. The only clearly demonstrated effect induced by inhalation
of hydrazine is nasal polyps in rodents and, at higher exposures, nasal
adenocarcinomas. The most sensitive species for this effect is rats;
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hence, they are used to make the risk estimate at a risk level of 104.
ACs were calculated by using the linearized multistage model described
below (NRC, 1992).
Based on the data of MacEwen et al. (1981) and using linearized
multistage extrapolation, the NRC Committee on Toxicology (COT)
calculated that the lower 95 % confidence limit on the inhalation dose of
hydrazine that would produce a I% lifetime tumor incidence in rats is
0.055 ppm for a 6 h/d, 5 d/w, 52 w/y for a 1-y exposure (NRC, 1985).
This dose extrapolates to 0.005 ppm for a continuous 2-y exposure:
0.055 ppm × (6 h/24 h) × (5 d/7 d) × (1 y/2 y) = 0.005 ppm.
Extrapolating from the 1% tumor incidence for a continuous 2-y ex-
posure at 0.005 ppm to calculate the expected incidence for a 24-h ex-
posure at the same concentration (0.005 ppm), the COT estimated that
the tumor risk for rats should be less than 10-_ (NRC, 1985, 1992).
The linearized multistage model is considered sufficiently conserva-
tive so that an additional species extrapolation factor is unnecessary (J.
Doull, Committee on Toxicology, personal commun., 1989). There-
fore, the following equation, based on Crump and Howe's (1984) multi-
stage model with only the first stage dose-related, was used to calculate
the exposure concentrations, D, which would yield a tumor risk of 10-4
for exposure durations of 24 h, 7 d, 30 d, and 180 d:
d x (25,600) k x (10-4/risk)
D=
(25,600 - (365 x age)) k - (25,600 - (365 x age) - t) k'
where d is the concentration during a lifetime exposure (0.005 ppm in
this case); 25,600 is the number of days in a 70-y human lifetime; k is
the number of stages in the model (three in this case); 10.4 is the accept-
able risk level; age is the minimum age of an astronaut in years (30 y
in this case); t is the exposure duration in days (1, 7, 30, or 180); risk
is the risk of tumor for lifetime exposure to d (102 in this case).
This equation yields values of
D24h= 1.0 ppm.
DTj = 0.2 ppm.
D3oz = 0.04 ppm.
D,s0d = 0.007 ppm.
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Lethality
Analysis of the lethality data is a difficult and frustrating process.
The data for repeated exposures to hydrazine are highly scattered. A
major factor in the poor reproducibility of results between laboratories
might be the propensity of hydrazine to adhere to surfaces. An early
report (Comstock et al., 1954) showed that, at a nominal concentration
of 20,000 ppm, the recovery of hydrazine vapor from the chamber at-
mosphere decreases from 26% to 4% with dead rats in the chamber; if
the rats are alive, the recovery is decreased to 2%. This clearly indi-
cates that a large fraction of the airborne hydrazine adheres to the rat
fur, probably about 10 times the amount retained in the respiratory sys-
tem. Examination of the methods used for many of the experiments
reveals serious short-comings in some of the study designs (number of
animals tested; not sham-exposing control animals, etc.). Despite these
potential problems in experimental designs and highly scattered rodent
data, the conservative approach would be to use the data for the most
sensitive species (mice). Epidemiological data on workers occupation-
ally exposed to hydrazine vapors over periods of months to years lead
to the conclusion that humans are much less susceptible to hydrazine
toxicity than are mice (Wald et ai.+ 1984). Personal communication
with Dr. Nick Wald (April 1992) confirmed that there were no deaths
seen in his epidemiological study among the 78 factory workers ex-
posed to hydrazine at 1-10 ppm over a period of at least 6 mo. ACs
can be calculated from these data as follows:
For a l-h exposure: The assumption is made that if the hydrazine
concentrations were between 1 and 10 ppm for >6 mo, it would be
highly likely that there would be at least one period during those >6
mo when the hydrazine concentration was 5 ppm for at least 1 h.
Thus, multiplying 5 ppm by the square root of 78 divided by 10 to ad-
just for the use of less than 100 subjects,
1-h AC : 5 ppm × v," _ 4 ppm
10
is a NOAEL for lethality.
For exposures of 24 h, 7 d, and 30 d: AC vatues were calculated
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using the lower end of the concentration range (1 ppm) and assuming a
work schedule of 6 h/d, 5 d/w, for 6 mo (equivalent to 32.5 d continu-
ous exposure) and not increasing the 30-d AC for exposure durations
shorter than 30 d. Thus,
24-h, 7-d, 30-d ACs : 1 ppm x v'v - 0.9 ppm.10
For exposures of 180 d: Using Haber's rule, the AC is
,Tf_30
180-d AC : 1 ppm × -- × v'v - 0.15 ppm.
80 10
Spaceflight Effects
The susceptibility of astronauts to the toxic effects of hydrazine
would not be expected to be affected by the physiological changes in-
duced by spaceflight.
RECOMMENDATIONS
Studies are needed to definitively determine the fate of the large frac-
tion of the hydrazine vapor that disappears during controlled laboratory
exposures. This determination would help eliminate the uncertainty in
the total dose received by exposed animals. Currently, it is not known
whether hydrazine vapor might be undergoing some reaction in the air
or on surfaces that converts it to a form that, although not measured as
hydrazine in analytical measurements of airborne concentrations, might
be the ultimate toxin or carcinogen or that might be metabolized by the
body to the ultimate toxin or carcinogen.
A study on the relative absorption rates for dermal versus inhalation
absorption of hydrazine vapor would aid in estimating the total
absorbed dose during exposures.
A carcinogenicity study using a continuous exposure protocol includ-
ing concentrations that do not produce nasal inflammation or necrosis
would be helpful.
A carcinogenicity study in which animals are continuously exposed to
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high concentrations of hydrazine vapor for l h, 24 h, or 7 d and then
observed for their lifetime would be useful.
229
<
°1
230 SMACs FOR SELECTED AIRBORNE CONTAMINANTS
REFERENCES
Becker, R.A., L.R. Barrows, and R.C. Shank. 1981. Methylation of
liver DNA guanine in hydrazine hepatotoxicity: Dose-response and
kinetic characteristics of 7-methylguanine and O_-methylguanine for-
mation and persistence in rats. Carcinogenesis 2:1181-1188.
Carter, V.L.J., K.C. Back, and JD. MacEwen. 1981. The Oncogenic
Hazard From Chronic Inhalation of Hydrazine. AGARD-CP-309,
B5/I-B5-9, Advisory Group for Aerospace Research and Develop-
ment, AGARD Conference Proceedings, Sept. 15-19, 1980, Toronto.
Comstock, C.C., L.H. Lawson, E.A. Greene, and F.W. Oberst. 1954.
Inhalation toxicity of hydrazine vapor. AMA Arch. Ind. Hyg.
Occup. Med. 10:476-490.
Crump, K.S., and R.B. Howe. 1984. The multistate model with a
time-dependent dose pattern: Applications to carcinogenic risk as-
sessment. Risk Anal. 4: 163-176.
Dambrauskas, T., and H.H. Cornish. 1964. The distribution, metabo-
lism, and excretion of hydrazine in rat and mouse. Toxicol. Appl.
Pharmacol. 6:653-663.
Doull, J. 1989. Letter to Col. Thayer J. Lewis, M.C., Headquarters,
U.S. Air Force, Boiling Air Force Base, Washington, D.C.
Eiceman, G.A., M.R. Salazar, M.R. Rodriguez, T.F. Limero, S.W.
Beck, J.R. Cross, R. Young, and J.T. James. 1993. Ion mobility
spectrometry of hydrazine, monomethylhydrazine, and ammonia in
air with 5-nonanone reagent gas. Anal. Chem. 65:1696-1702.
Evans, D. 1958. Two cases of hydrazine hydrate dermatitis without
systemic intoxication. Br. J. Ind. Med. 16:126-127.
Haun, C.C., and E.R. Kinkead. 1973. Pp. 351-363 in Chronic Inhala-
tion Toxicity of Hydrazine. AMRL-TR-73-125, Paper No. 25. Aero-
space Medical Research Laboratory, Wright-Patterson Air Force
Base, Dayton, Ohio.
Herbold, B., and W. Buselmaier. 1976. Induction of point mutations
by different chemical mechanisms in the liver microsomal assay.
Murat. Res. 40:73-84.
House, W.B. 1964. Tolerance Criteria for Continuous Inhalation Ex-
posure to Toxic Materials, lII. Effects on Animals of 90-Day Expo-
sure to Hydrazine, Unsymmetrical Dimethylhydrazine, Decaborane,
HYDRAZINE 231
and Nitrogen Dioxide. ASD-TR-61-519 (Ill). Wright-Patterson Air
Force Base, Dayton, Ohio.
Hovding, G. 1967. Occupational dermatitis from hydrazine hydrate
used in boiler protection. Acta Derm.-Venereol. 47:293-297.
Jacobson, K.H., J.H. Clem, H.J. Wheelwright, Jr., W.E. Rinehart,
and N. Mayes. 1955. The acute toxicity of the vapors of some
methylated hydrazine vapors. AMA Arch. Ind. Health 12:609-616.
Jain, H.K. and P.T. Shukla. 1972. Locus specificity of mutagens in
Drosophila. Mutat. Res. 14:440-442.
Karstadt, M., and R. Bobal. 1982. Availability of epidemiologic data
on humans exposed to animal carcinogens: 2. Chemical uses and
production volume. Teratogen. Carcinogen. Mutagen. 2:151-168.
Kimball, R.F. 1977. The mutagenicity of hydrazine and some of its
derivatives. Mutat. Res. 39:111-126.
Kulagina, N.K. 1962. The toxicological characteristics of hydrazine.
Toxicology of new industrial chemical substances. Acad. Med. Sci.
USSR 4:65-81.
MacEwen, J.D., E.E. McConnell, and K.C. Back. 1974. Pp. 225-235
in The Effects of 6-Month Chronic Low Level Inhalation Exposures
to Hydrazine on Animals. AMRL-TR-74-125. Paper No. 16.
Aerospace Medical Research Laboratory, Wright-Patterson Air Force
Base, Ohio.
MacEwen, J.D., E.R. Kinkead, E.H. Vernot, C.C. Haun, and A.I.
Hall. 1981. Chronic Inhalation Toxicity of Hydrazine: Oncogenic
Effects. Rep. ISS AFAMRL-TR-81-56, Order AD-AlO1847. Aero-
space Medical Research Laboratory, Wright-Patterson Air Force
Base, Dayton, Ohio.
MacRae, W.D., and H.F. Stich. 1979. Induction of sister-chromatid
exchanges in Chinese hamster ovary cells by thiol and hydrazine
compounds. Mutat. Res. 68:351-365.
Morris, J., J.W. Densem, N.J. Wald, and R. Doll. 1995. Occupa-
tional exposure to hydrazine and subsequent risk of cancer. Occup.
Environ. Med. 52:43-45.
NRC. 1985. P. 5-21 in Emergency and Continuous Exposure Guid-
ance Levels for Selected Airborne Contaminants, Vol. 5. Washing-
ton, D.C.: National Academy Press.
NRC. 1992. Guidelines for Developing Spacecraft Maximum Allow-
232 SMACs FOR SELECTED AIRBORNE CONTAMINANTS
able Concentrations for Space Station Contaminants. Washington,
D.C.: National Academy Press.
NTP. 1989. Fifth Annual Report on Carcinogens: Summary. NTP
89-239: 166-168. National Institute of Environmental Health Sci-
ences, Research Triangle Park, N.C.
Reid, F.J. 1965. Hydrazine poisoning. Br. Med. J. 2:1246.
Roe, F.J.C. 1978. Hydrazine. Ann. Occup. Hyg. 21:323-326.
Santodonato, J., S. Bosch, W. Meylan, J. Becket, and M. Neal. 1985.
P. ii in Monograph on Human Exposure to Chemicals in the Work-
place: Hydrazine. AMRL-TR-84-533. Aerospace Medical Re-
search Laboratory, Wright-Patterson Air Force Base, Dayton, Ohio.
Scales, M.D.C., and J.A. Timbrell. 1982. Studies on hydrazine
hepatotoxicity. 1. Pathological Findings. J. Toxicol. Environ.
Health 10:941-953.
Sevin, I.F. 1978. Criteria for a Recommended Standard Occupational
Exposure to Hydrazines. Publ. No. DHEW-78-172. National
Institute tbr Occupational Safety and Health, Rockville, MD.
Smith, E.B., and D.A. Clark. 1972. Absorption of hydrazine through
canine skin. Toxicol. Appl. Pharmacol. 21:186-193.
Sotaniemi, E.J., J. Hirvonen, H. Isomaki, J. Takkunen, and J. Kaila.
1971. Hydrazine toxicity in the human: Report of a fatal case.
Ann. Clin. Res. 3:30-33.
Springer, D.L., B.M. Krivak, D.J. Broderick, D.J. Reed, and F.N.
Dost. 1981. Metabolic fate of hydrazine. J. Toxicol. Environ.
Health 8:21-29.
Steinhoff, D. and U. Mohr. 1988. The question of carcinogenic
effects of hydrazine. Exp. Pathol. 33:133-143.
Timbrell, J.A., M.D. Scales, and A.J. Streeter. 1982. Studies on
hydrazine hepatotoxicity. 2. Biochemical findings. J. Toxicol.
Environ. Health 10:955-968.
van Ketel, W.G. 1964. Contact dermatitis from a hydrazine derivative
in a stain remover: Cross sensitization to apresoline and isoniazide.
Acta Derm.-Venereol. 44:49-53.
Vernot, E.H., J.D. MacEwen, R.H. Brunet, C.C. Haun, E.R.
Kinkead, D.E. Prentice, A. Hall III, R.E. Schmidt, R.L. Eason,
G.B. Hubbard, and J.T. Young. 1985. Long-term inhalation
toxicity of hydrazine. Fundam. Appl. Toxicol. 5:1050-1064.
Wald, N., J. Boreham, R. Doll, and J. Bonsall. 1984. Occupational
HYORAZINE 233
exposure to hydrazine and subsequent risk of cancer. Br. J. Ind.
Med. 41:31-34.
Weatherby, J.H., and A.S. Yard. 1955. Observations on the subacute
toxicity of hydrazine. AMA Arch. Ind. Health 11:413-419.
Wyrobek, A.J., and S.A. London. 1973. Pp. 417-432 in Effect of
Hydrazines on Mouse Sperm Cells. AMRL-TR-73-125. Paper No.
30. Aerospace Medical Research Laboratory, Wright-Patterson Air
Force Base, Dayton, Ohio.

B6 Indole
Chiu-Wing Lam, Ph.D., and John T. James, Ph.D.
Johnson Space Center Toxicology Group
Biomedical Operations and Research Branch
Houston, Texas
PHYSICAL AND CHEMICAL PROPERTIES
Indole is a colorless crystalline solid. It has an intense fecal odor at
moderate concentrations; however, the odor at very low concentrations
is pleasant (Merck Index, 1989).
Synonym:
Formula:
CAS number:
Molecular weight:
Boiling point:
Melting point:
Vapor pressure:
Conversion factors
at 25°C, 1 atm:
2,3-Benzopyrrole
CsHTN
120-72-9
117.1
130°C
52°C
Not found
1 ppm = 4.8 mg/m 3
1 mg/m 3 = 0.21 ppm
OCCURRENCE AND USE
Indole is a naturally occurring compound, constituting about 2.5 % of
jasmine oil and 1% of orange-blossom oil, and in both cases, it contrib-
utes to their fragrances (Kirk-Othmer Concise Encyclopedia of Chemical
Technology, 1985). lndole is a component of perfumes (Kirk-Othmer
Concise Encyclopedia of Chemical Technology, 1985; Merck Index,
235
236 SMACs FOR SELECTEDAIRBORNE CONTAMINANTS
1989). Paradoxically, indole has an intense fecal odor (Merck Index,
1989), presumably at higher concentrations. It is also a bacterial de-
composition product of tryptophan in the gut (Hammond et al., 1984;
Eisele, 1986). Indole is one of the odorous components found in sew-
age and animal wastes, including human feces (Veber, 1967, as cited in
Sgibnew and Orlova, 1971; Karlin et al., 1985). The compound is also
found in animal tissues where putrefactive processes have occurred,
presumably by the decomposition of tryptophan (Eisele, 1986). Trace
levels of indole are expected to be present in manned spacecraft.
PHARMACOKINETICS AND METABOLISM
Indole, an anaerobic metabolite of tryptophan, can be condensed with
serine by microorganisms to recover tryptophan (Meister, 1965). How-
ever, this biosynthetic pathway for tryptophan has not been observed in
humans and rats. Absorbed indole from the gut is hydroxylated to
form indoxyl, which conjugates with sulfate to produce indican (in-
doxylsulfuric acid) in the liver (Meister, 1965). Indoxyl and indican
are found in human plasma and urine. A mean plasma indican concen-
tration of 3 mg/L was reported in 56 males (range 1.2-4.8 mg/L) and
44 females (range 0.6-5.4 mg/L) (Geigy Pharmaceuticals, 1974). The
daily urinary excretion of indoxylsulfate in normal adults was reported
to average 200 mg (range 140-250 mg) (Haddox and Saslaw, 1963).
Sgibnew and Orlova (1971) reported that indole was not detected in
the blood of rabbits exposed at 10 mg/m 3 for 3 h. When 10 mg of in-
dole was injected intravenously into each of the five rabbits, an average
plasma indole concentration of 0.3 mg % was detected only in the blood
samples taken 15 rain after the injection. Because of the inability to
detect indole in the blood thereafter, Sgibnew and Orlova concluded
that indole was quickly removed and rendered harmless. However, it
should be pointed out that 0.3 rag% was close to the detection limit of
the calormetric method employed by these authors. Indole concentra-
tions in the blood were investigated by Hammond et al. (1980) in cows
dosed orally with the compound at 50, 100, or 200 mg/kg. Plasma
indole concentrations reached peak concentrations of 4.5, 8, and 20
mg/mL, respectively, 3 h after dosing. The plasma concentrations de-
creased to 4.4%, 7.4%, and 38% of the corresponding peak concentra-
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tions after 12 h and to 2%, 0.6%, and 1.4% after 24 h. Indole was not
detected (< 0.02 mg/mL) in plasma of these cows 72 h after injection.
These results indicate that indole was rapidly eliminated from the blood
of the cows.
TOXICITY SUMMARY
Indole at a few parts per million has an unpleasant odor and can eli-
cit toxic symptoms, such as nausea. The consistent toxicological prop-
erty of indole, an aromatic amine, observed in animal studies is its abil-
ity to cause the formation of Heinz bodies, which are known to be pro-
duced by other aromatic amine compounds, such as aniline (Smith,
1986). Chronic studies by the subcutaneous route have shown that in-
dole might have a weak leukemogenic activity in mice, but not in ham-
sters. The toxicity of indole is summarized in the Table 6-1.
Acute and Short-Term Toxicity
The human odor threshold of indole was reported to be 0.45 mg/m 3
(= 0.1 ppm) (Sgibnew and Orlova, 1971). Very unfavorable odor was
perceived in concentrations approaching 9.0 mg/m3; 2 of the 12 test
subjects complained of nausea. According to the authors, brief expo-
sures at this concentration did not produce electrocardiographic and
electroencephalographic changes (exposure length not specified). Ex-
posing 20 mice and 15 rats to indole at a concentration of 9-10 mg/m 3
for 2 h produced no toxic signs except some unrest during the first 15
min; no deaths occurred during the 14-day post-exposure observation
period (Sgibnew and Orlova, 1971).
The hematological effects and subsequent renal lesions induced by
indole were observed in four cows given the compound at a single oral
dose of 100 mg/kg and then 200 mg/kg 2 w later (Hammond et al.,
1980). Hemolysis was observed 24 h after each chemical exposure. At
the high dose, all four cows had blood-colored urine. Necropsy 1 w
later revealed renal tubular epithelial degeneration attributable to hemo-
globinuric nephrosis. There was a grayish-brown discoloration of the
endothelial surfaces of the aorta and other elastic arteries, and a mild
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cloudy swelling in hepatocytes. No lesions were found in the lung.
The dose of indole that produced no observable clinical signs of toxic-
ity, including hemolysis, in these cows was 50 mg/kg given in a single
dose 1 mo before the 200-mg/kg dose.
Subchronic and Chronic Toxicity
Inhalation studies were conducted by Sandage (1961) in 10 rhesus
monkeys, 50 rats, and 100 mice exposed continuously to indole at a
concentration of 10.5 ppm (50 mg/m 3) for 90 d. Hematological exami-
nation of the exposed rodents revealed that numerous Heinz bodies
were present in the blood. Heinz-body occurrence was most prominent
in mice and was observed after 3-4 d of exposure. It was slightly less
prominent in the rats and was observed after 7-10 d of indole exposure.
No Heinz bodies were observed in monkeys until 70 d of exposure. In
the mice, the appearance of Heinz bodies was accompanied by anisocy-
tosis (presence in blood of erythrocytes showing excessive variation in
size) and polychromatophilia, with many erythrocytes exhibiting diffuse
basophilia. There was a general ieukocytosis and marked reticulocyto-
sis with about 80% of the reticulated cells appearing morphologically
atypical. Instead of the fine thread-like reticulum of normal reticulo-
cytes, there was a profuse, densely staining nuclear material that filled
the cell, which appeared to consist of coarse granules. Pathological
studies on 25 % of the exposed mice revealed 95 % of the animals had
pigment in the renal tubular cells. However, renal abnormalities were
not found in any exposed monkeys or rats examined (about 25% of
those exposed).
Significant elevation of serum sodium, cholinesterase, and amylase
levels in monkey blood serum was also noted by Sandage (1961), who
suggested that such elevated levels provided a clue to neurological ef-
fects. However, pathological examination showed no brain damage.
Histopathological studies of the heart, lung, liver, and kidney from the
exposed monkeys revealed no statistical difference from that of control
monkeys. Two monkeys from the exposed group and none from the
controls died. Sandage concluded that the death rate (2 of 10) of the
monkeys exposed to indole could not be considered "significant." The
cause of death was not given.
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Carcinogenicity
There are three studies in mice that provide some evidence that in-
dole might be leukemogenic. Eckhart and Stich (1957) reported that
three of the 50 RFH-bred white mice given indole at 0.5 mg (in 50%
propylene glycol) subcutaneously every 3-4 d for 140 d (weekly dose
approximately 40 mg/kg) developed leukemia and three developed aleu-
kemic myelosis; 10 of the initial 50 mice died in the first 4 w of indole
administration (4 mg per mouse). Leukemia was not observed among
the 100 control mice; however, no indication was given that the control
mice were given sham injections of the vehicle. According to these
authors, the spontaneous rate of leukemia observed in 1000 RFH mice
was 1:500.
A similar study was conducted by Dzioev (1974), who injected in-
dole subcutaneously in mice at a weekly dose of 1 mg for 9 mo. The
author reported that of 60 surviving mice, 13 showed leukosis and 21
had pulmonary adenomas. Exposure to tryptophan (presumably serving
as controls) resulted in tumors in 8 of the 28 surviving animals. Subcu-
taneous injection of indole in mice (C-57) was also conducted by
Rauschenbach et al. (1963), who administered a dose of 2.5 mg per
mouse once a week for 5-10 mo. No leukemia was observed in 17
mice that survived longer than 1 y; however, one mouse developed ade-
nocarcinoma of the breast and seven were leukemoid. Cancer or hema-
topoietic changes were not observed in the 30 mice given tryptophan
(presumably serving as controls) and surviving longer than 1 y (10 died
before 1 y). These carcinogenicity results of indole reported in the lat-
ter two studies (Rauschenbach et al., 1963; Dzioev, 1974) were classi-
fied by NIOSH as equivocal (NIOSH, 1985-86). In addition, the ieuke-
mogenic effect of indole was not observed in hamsters chronically ex-
posed to indole. In a study to investigate the role of indole in the carci-
nogenicity of 2-acetylaminofluorene, 23 male and 30 female Syrian
golden hamsters were given 1.6% indole alone in the diet as controls
for 10 mo (Oyasu et al., 1972). These animals showed no tumors of
the bladder or liver.
240
i
I
: + ..
+-+ _ "m "n
++=++
Q i..+ '_
0
___.=o
"-° _.__, _
• .-_ ,_ ,-_
,,_ _._
o.O o_+_ "_"
.__ _. "_ o
s -- o'_.o_
,g
0 0
241
0 0
0
E o
- o
242 SMACs FOR SELECTED AIRBORNE CONTAMINANTS
TABLE 6-2 Exposure Limits Set by Other Organizations
Organization Concentration, ppm
ACGIH's TLV None set
OSHA's PEL None set
NRC 1.0 ppm (10 and 60 min)"
NRC 0.1 ppm (90 and 180 dy
TLV = threshold limit value. PEL = permissible exposure limit.
aValues recommended to NASA by the NRC in 1972.
TABLE 6-3 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m 3 Target Toxicity
1 h 1 5 Nausea
24 h 0.3 1.5 Nausea, hematological
changes
7 d 0.05 0.25 Nausea, hematological
changes
30 d 0.05 0.25 Mortality
180 d 0.05 0.25 Mortality
RATIONALE FOR
ACCEPTABLE CONCENTRATIONS
The SMACs for indole depend not only on the toxicological effects
induced, but also on the interactions with spaceflight-induced changes
and the normal turnover of indole in man. The toxicological effects
induced by indole include nausea, hematological changes, mortality,
and possibly leukemogenic effects. Because spaceflight was known to
induce approximately a 10% reduction in red-cell mass (Huntoon et al.,
1989), this finding was considered when the hematological effects of
indole were used to set an acceptable concentration (AC) for effects on
red cells. Inhaled indole is not known to induce effects on the respira-
tory system; therefore, systemically mediated effects, produced by an
absorbed dose from inhalation or other route of administration, might
be considered equivalent. Moderate amounts of indole are normally ab-
sorbed from the gastrointestinal tract, so there is a significant systemic
body burden. If the amount of indole entering the body via respiration
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is small compared with the normal load, then there will be no toxic ef-
fects from the inhaled indole.
Nausea
Brief exposures at 2 ppm indole induced nausea in 2 of 12 test sub-
jects (Sgibnew and Orlova, 1971). Slight nausea is tolerable for brief
periods as long as crew-member performance is not affected; however,
interpretation of the duration of exposure is difficult from the original
study. It was estimated that reducing the exposure concentration by a
factor of 2 would have caused no more than slight nausea in a few peo-
ple even if the exposure were for 1 h. Hence, the 1-h AC (nausea) was
set at 1 ppm. Since nausea induced by odorous compounds is a thresh-
old effect, and nausea would be less tolerable for a 24-h period, the
24-h AC (nausea) was set at 0.5 ppm to minimize the chance of nausea.
For longer exposures, nausea is not acceptable, so the 7-d, 30-d, and
180-d ACs were calculated from the 2-ppm lowest-observed-adverse-
effect level (LOAEL) as follows:
,1/35
7-d, 30-d, 180-d ACs : 2 ppm x 1 x v-- _ 0.07 ppm.
10 10
The factor of 10 was applied to estimate a no-observed-adverse-effect
level (NOAEL) from the LOAEL, and the factor of the square root of
12 divided by 10 was applied to account for a small number of test sub-
jects (12 subjects). This value is about one-third the concentration that
gave a sweet odor when inhaled by test subjects for the first time, but
not during the second exposure (Sgibnew and Orlova, 1971).
Hematological Effects
The key study for this toxic end point was the continuous 90-d inha-
lation study reported by Sandage (1961). Many toxic end points were
assessed in the exposures of mice, rats, and monkeys to indole at a con-
centration of 10.5 ppm. For human risk assessment, the study has sev-
eral shortcomings, but represents the best available data. The control
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animals were not sham exposed; they were kept in a separate room that
was not environmentally the same as the exposure chambers; and the
findings were reported statistically as increases or decreases compared
with control groups rather than numerically (except mortality). Favor-
able points of the study were that several species were exposed, the
concentrations were measured analytically (the actual measurements
were not reported), and the data were apparently subjected to statistical
analysis.
In this 90-d continuous inhalation study (Sandage, 1961), exposures
at 10.5 ppm, which was the only concentration tested, produced Heinz
bodies in mice, rats, and monkeys after 3, 7, and 70 d of exposure,
respectively. Because only a single concentration was used, the con-
ventional derivation of a LOAEL from a dose-response curve could not
be applied. However, employing an unconventional species-based ap-
proach, it was noted that 3 x 10.5, 7 × 10.5, and 70 x 10.5 d-ppm
induced Heinz bodies in one, two, and three animal species, respec-
tively. Hence, 3 x 10.5 d-ppm was estimated to be the LOAEL. Using
the NRC guideline, the LOAEL was divided by 10 to get a NOAEL of
1 ppm. The 7-d NOAEL of 0.4 ppm, which is equal to 1 ppm x 3/7,
was then divided by 10 (species factor) and 3 (spaceflight factor, see
below) to obtain the 7-d AC of 0.015 ppm. The hematological effect
was not observed 24 h after the exposure; therefore, 10.5 ppm was the
NOAEL for the 24-h exposure. By applying the same safety factors
(species and spaceflight), the 24-h AC would be 0.3 ppm. Because
only one exposure concentration was tested in the study, the LOAEL
for 30-d and 180-d exposures could not be obtained or extrapolated,
and 30-d and 180-d ACs could not be established based on these data.
The factor of 3 for spaceflight-induced effects was appropriate be-
cause the magnitude of the red-cell mass changes observed in astronauts
has been about 10% (Huntoon et al., 1989). This change has caused no
clinically detectable effects and could be considered adaptive in nature.
The mechanism of this change might be due to microgravity effects on
the kidney resulting from fluid shifts. Kidneys, which produce erythro-
poietin, play an important role in red-cell production. However, the
mechanism of the red-cell-mass changes has not been clearly elucidated
at this time. The hematology factor should be smaller than the factor of
5 used for cardiac effects because cardiac effects have actually caused a
cosmonaut to be returned early from a mission (Gazenko et al., 1990).
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Mortality
The same study used to set the ACs for hematology was used to set
the ACs for mortality because it is the only long-term inhalation study
available (Sandage, 1961). The author reported that there was no statis-
tically significant increase in mortality in the exposed groups compared
with the control groups; however, there were more deaths in the ex-
posed groups by the end of the 90-d study. A comparison is given be-
low for mortality incidences.
TABLE 6-4 Mortality in Control and Exposed Groups
Species Control Deaths Deaths at 10.5-ppm Exposure
Mice 16 of 100 22 of 100
Rats 2 of 50 5 of 50
Monkeys 0 of 9 2 of 10
Because the study did not provide information on the cause of death,
and it appears that more deaths occurred in the exposed groups, mortal-
ity was considered in setting the SMACs. The 30- and 180-d ACs for
mortality were set by dividing the exposure at a concentration of 10.5
ppm by factors of 10 to get to a NOAEL for mortality and 10 for inter-
species extrapolation. Haber's rule (90 d/180 d) was used to decrease
the 180-d exposure concentration. The ACs for 30 and 180 d were 0.1
and 0.05 ppm, respectively.
Leukemogenic Effects
As described in the Toxicity Summary, there are several reports that
indole is leukemogenic when given by injection. NIOSH (1985-1986)
has classified two of the studies (Rauschenbach et al., 1963; Dzioev,
1974) as equivocal, and the remaining study (Eckhart and Stich, 1957)
appears positive for leukemogenic effects. However, the study control
groups might not have been given injections of the vehicle used when
indole was administered, and the results of the study are difficult to ex-
trapolate to inhalation exposures. The injection dosages were highly
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toxic bolus quantities, whereas inhalation dosages of an equivalent
amount would be through long-term, low-level administrations. Fur-
thermore, it is difficult to estimate the risk of carcinogenesis from a
study in which only one exposure group was used. It also appears that
mortality is a more important end point because in the study in which 6
of 40 mice showed leukemogenic changes, 10 of 50 died before any
animals showed these changes. Because the inhalation data have been
used to estimate ACs for mortality, it was not necessary to establish
ACs for cancer based on injection data, which were obtained for pur-
poses other than estimating an inhalation risk.
Normal Indole Uptake
Daily urinary excretion of indican averages 200 mg in normal adults,
and this is equivalent to 110 mg of indole absorbed from the gastroin-
testinal tract. It is reasonable to assume that a 5% increase in this in-
dole input from an inhalation source would be toxicologically insignifi-
cant. Hence, 5 mg/d could enter through the respiratory system with-
out causing an effect. For a 70-kg man breathing 20 m_/d, an indole
concentration of 0.25 mg/m 3 (0.05 ppm) would cause an additional up-
take of 5 mg/d, assuming 100% of the inhaled dose is absorbed. Thus,
0.05 ppm should be a lower bound on any SMAC value selected. The
7-, 30-, 180-d SMACs were set at the metabolic load threshold of 0.05
ppm based on these considerations.
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B7 Mercury
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PHYSICAL AND CHEMICAL PROPERTIES
Elemental mercury is a heavy, silvery-white, slightly volatile liq-
uid at room temperature (Stokinger, 1981; ACGIH, 1986).
Synonym:
Formula:
CAS number:
Atomic weight:
Boiling point:
Melting point:
Vapor pressure:
Solubility:
Conversion factors
at 25°C, 1 arm:
Quicksilver
Hg
7439-97-6
200.6
356.6°C
-38.9°C
0.0018 torr (25°C)
Insoluble in H20, soluble in non-polar sol-
vents, vapor soluble in blood than in H20
1 ppm = 8.2 mg/m 3
1 mg/m 3 = 0.12 ppm
OCCURRENCE AND USE
Mercury occurs in three chemical forms in the environment: (1)
elemental (metallic) mercury (Hg°); (2) inorganic mercurous (Hg ÷) and
mercuric (Hg ++) compounds or ions; and (3) organic mercury com-
pounds (Stokinger, 1981). Although this document is concerned with
mercury vapor, data on inorganic or organic forms also are included
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when relevant to the toxicity of mercury vapor. The major sources of
mercury vapor and compounds of mercury are both natural (degassing
of earth's crust, emissions from volcanoes, evaporation of natural bod-
ies of water) and man-made (mining, smelting, refuse incineration,
combustion of fossil fuel) (WHO, 1991).
Mercury has many diverse uses because of its properties. Liquid
elemental mercury is a common component of thermometers, barome-
ters, manometers, and other laboratory and medical measuring instru-
ments (Stokinger, 1981). It is also widely used in electrical devices,
including lamps, switches, rectifiers and batteries. The breakage of any
of these instruments or devices inside the spacecraft cabin could result
in the release and volatilization of liquid mercury and the subsequent
exposure of crew members to potentially toxic levels of the vapor.
Containment of mercury in such devices is strictly controlled by NASA
based on mercury's SMACs and the ability of the air revitalization sys-
tem to remove mercury vapor from spacecraft air. No method has been
developed to monitor mercury vapor in spacecraft air. Recently, there
has been much debate over possible health hazards from the inhalation,
and ingestion, of elemental mercury released from dental amalgams in
the mouth (WHO, 1991). Reported intraoral vapor concentrations
range from 0.003 to 0.029 mg/m 3 (Vimy and Lorscheider, 1985).
PHARMACOKINETICS AND METABOLISM
Inhalation of mercury vapor is the most important route of uptake for
elemental mercury (WHO, 1991). Human subjects retained approxi-
mately 70-80% of inhaled mercury vapor, retention occurring almost
entirely in the alveoli (Nielsen-Kudsk, 1965; Hursch et al., 1976). Ox-
idation of elemental mercury to the mercuric ion is the primary meta-
bolic pathway (Hursch et al., 1976). Mercury accumulates in many
tissues, but the most important are the brain and kidneys. Clearance
half-times of mercury inhaled by human test subjects vary from 1.7 d
for the lungs to 64 d for the kidney region (Hursch et al., 1976).
Absorption
Experimental results indicated that absorption of mercury vapor by
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the skin poses a very minor hazard compared with that by inhalation.
In human volunteers exposed via the forearm skin, the rate of uptake by
the total body skin was estimated to be 2.2% of that by the lung
(Hursch et al., 1989). Approximately one-half of the mercury retained
by the skin was shed by desquamation of epidermal cells, and the
remainder was slowly released into the body (Hursch et al., 1989).
Metabolism and Distribution
Mercury vapor rapidly passes from the inspired air in the alveoli into
the bloodstream because of its high lipophilicity (Aschner and Aschner,
1990). The dissolved elemental mercury (Hg °) is soon oxidized to
mercuric ions (Hg++), partly in red blood cells and partly after
diffusion into other tissues of the body (Hursch et al., 1988). This
oxidation occurs under the influence of the catalase-hydrogen peroxide
complex (Complex I) in mammalian tissues (Nielsen-Kudsk, 1969).
Catalase inhibitors, such as ethanol and aminotriazole, inhibit the
oxidation reaction, which can change the distribution, retention, and
excretion of inhaled mercury vapor (Magos et al., 1974; Hursch et al.,
1980; Khayat and Dencker, 1984).
Following the inhalation of mercury vapor, mercury quickly
accumulates within the brain, but to a much lesser extent than in the
kidneys (Magos, 1967). Despite its rapid oxidation by red blood cells,
some solubilized vapor persists in the bloodstream sufficiently long to
reach and diffuse across the blood-brain barrier into the brain, where it
is oxidized by the catalase-hydrogen peroxide system to the divalent
mercuric form (Dunn et al., 1978). The mercuric ions, which traverse
the blood-brain barrier less freely than elemental mercury, bind to sulf-
hydryl-containing ligands and are retained within the brain. Because of
this greater diffusibility of the vapor, the mercury content in the brains
of animals exposed to the vapor was ten times greater than that of
animals injected with an equivalent dose of mercuric salts (Berlin et al.,
1969).
Excretion
The principal routes of elimination of inhaled mercury vapor are the
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urine and feces; a small portion (7%) of the retained mercury is ex-
creted in the expired air as elemental mercury vapor (Dunn et al.,
1981). A small amount of the exhaled vapor is formed by the reduction
of divalent mercury produced by the oxidation of the elemental
mercury. This reduction occurs both in animals (mice and rats) and hu-
mans (Berlin et al., 1969; Sugata and Clarkson, 1979; Dunn et al.,
1981). The exhalation of mercury vapor is increased in catalase-defi-
cient mice and by ethanol in mice and humans (Dunn et al., 1981;
Ogata et al., 1987). The clearance of inhaled mercury vapor from
tissues of the body follows a complicated pattern; biological half-times
differ according to the tissue and the time after exposure (WHO, 1991).
Tracer studies on human volunteers and animals indicate that, after a
short exposure to mercury vapor, the first phase of elimination from
blood has a half-time of approximately 2-4 d and accounts for about
90% of the retained mercury (WHO, 1991). This is followed by a
second phase with a half-time of 15-30 d. After inhalation by human
volunteers of a mixture of stable and radioactive mercury vapor for 14-
24 min, elimination from the body followed a single exponential pro-
cess, with an average half-time of 58 d (Hursch et ai., 1976). Average
half-times for mercury clearance from different parts of the body were
the following: lungs, 1.7 d; brain, 21 d; kidneys, 64 d; and chest, 43
d. It is probable that a fraction of the mercury in the brain and the
kidneys has a longer biological half-life, particularly when exposures
are prolonged (WHO, 1991).
TOXICITY SUMMARY
Acute Toxicity
In humans, acute inhalation of mercury vapor might cause irritation
and inflammation of the respiratory tract, resulting in tracheo-bronchi-
tis, bronchiolitis, pneumonitis, and various neuropsychiatric reactions or
symptoms (Milne et al., 1970; McFarland and Reigel, 1978; WHO,
1991). Accidental exposure of four workers for 2-5 h to mercury vapor
at 1.1-2.9 mg/m 3 (determined by simulating the exposure conditions)
caused minimal discomfort during exposure, but fever, cough, dyspnea,
and mild chest tightness developed 4 h later (Milne et al., 1970). In
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another accident, exposure of workers for less than 8 h to the vapor at
a calculated maximum concentration of 44 mg/m 3 caused fever, chills,
chest pain, and weakness, and, in some, impaired pulmonary function
and evidence of interstitial pneumonitis (McFarland and Reigei, 1978).
Various symptoms characteristic of chronic mercurialism developed
later, including tremor, nervousness, irritability, lack of ambition, and
loss of sexual drive.
Animal studies of the acute toxicity of mercury vapor are limited in
number and scope and were mostly conducted with high concentrations.
In a pharmacokinetic study in which monkeys, rabbits, and rats were
exposed to mercury vapor at 1 mg/m 3 for 4 h, signs of toxicity (in-
creased irritability, aggressiveness, decreased food intake for 24 h)
were observed only in rats (Berlin et al., 1969). An 8-h exposure of a
dog at 20 mg/m 3 caused dyspnea and weakness; death occurred on the
day of exposure (Fraser et al., 1934). In rabbits, a 1-h exposure at
28.8 mg/m 3 caused moderate histopathological changes to the kidneys
and brain and mild changes to the lungs and heart (Ashe et al., 1953).
With 2-, 4-, or 6-h exposures, damage to the kidneys and brain was se-
vere (extensive cellular degeneration and necrosis) and mild to moderate
in the lungs, liver, colon, and heart. In rats exposed to mercury vapor
at 0.55 mg/m 3 for 12, 14, or 24 h (four rats per group), it was reported
that one animal from each group died with neurological signs. Only
small peripheral hemorrhages were found in lung tissues (Moiler-
Madsen, 1992). These deaths might not have been from mercury since
this result is at variance with many other reports (Ernst et al., 1993).
Short-Term and Subchronic Toxicity
In squirrel monkeys exposed to mercury vapor at 1 and 2 mg/m 3, 5
d/w (hours per day not specified), for 6-69 d, no pathological changes
were evident in the brain, although some brain structures contained up
to 8 ppm of mercury (Berlin, 1976). Exposure of dogs at 15-20
mg/m 3, 8 h/d, for 2 or 3 d caused dyspnea, often with cyanosis, ex-
treme weakness or lassitude, occasional vomiting and diarrhea, and
death (Fraser et al., 1934). After exposures at 12.5 and 6 mg/m 3, these
effects were less severe and deaths were delayed. Daily 8-h exposures
at 3 and 4.4 mg/m 3 for 20-32 d caused gingivitis, loss of appetite, and
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diarrhea, without death. In two dogs exposed at 1.9 mg/m 3, 8 h/d, for
40 d, no toxic effects were evident except for a transient redness of the
gums of one animal (Fraser et al., 1934). in rabbits, repeated expo-
sures at 28.8 mg/m 3 for 1, 2, or 4 h for 5 d or for 6 h for 2 or 3 d
caused severe damage to the kidneys and brain and less damage to the
lungs, liver, colon, and heart (Ashe et al., 1953). After exposures at 6
mg/m 3, 7 h/d, 5 d/w, for 1-5 w, tissue damage to the kidneys, brain,
heart and lungs was mild to moderate and more severe when exposures
were 6-11 w. At 0.86 mg/m 3, 7 h/d, 5 d/w, for 2-5 w, histopathologi-
cal changes were generally mild and evident only in the kidneys and
brain; for exposures of 6-12 w, changes were moderate in the kidneys
and mild in the brain, liver, heart, and lungs. Localized concentrations
of mercury in the brain have been studied in rats exposed at up to 0.4
mg/m 3, 6 h/d, for 2 w (Ernst et ai., 1993). In Wistar rats exposed to
mercury vapor at O. 1 mg/m 3, 6 h/d, 5 d/w, fi)r 7 w, the mercury con-
tent in the kidney was found to be about 50-fold higher than in any
other organ (Eide and Wesenberg, 1993). Autoimmune glomerulone-
phritis and proteinuria were found in Brown-Norway rats exposed to
mercury vapor at 1 mg/m 3, 24 h/d for 5 w (Hua et al., 1993). A less-
exposed group from the same study (5 h/d for 5 w) showed autoim-
mune glomeruionephritis without proteinuria.
Repeated exposure to mercury vapor also causes decrements in oper-
ant behavior of the pigeon and the rat. In eight pigeons exposed to
mercury vapor at 17 mg/m 3, 2 h/d, 5 d/w, response rates (key pecking
for food reward) were reduced 50% in one of the eight in the first
week, in six of the eight in the fifth week, and in all eight by the four-
teenth week (Armstrong et al., 1963). Tremors in the head, neck, and
wings appeared during the fifth week of exposure and were the only
toxic signs.
In rats, exposure to mercury vapor at 17 mg/m _. 2 h/d, 5 d/w, over
30 d decreased shock-avoidance responses and increased escape-re-
sponse latency time in a conditioned operant test (Bellies et al., 1968).
Escape-response latency increased after 15 d of exposure and was 7
times that of controls at 30 d. Tremor and weight loss were evident
during the last 5 d. Recovery of operant behavior began at 14 d post-
exposure and was almost complete at 45 d. Histopathologicai changes
were not evident in the kidneys, liver, or lungs: but in the brain, two of
three rats had lymphocytic cuffing around capillaries of the medulla
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oblongata. The same exposure regimen exacerbated shock-induced re-
flexive fighting behavior of rats and increased spontaneous fighting,
requiring termination of the experiment after 18 d (Beliles et al., 1968).
Chronic Toxicity
In humans, tile principal target organs of chronic exposure to mer-
cury vapor are the central nervous system (CNS) and the kidneys. The
classic symptoms of chronic inhalation of the vapor include (1) intention
tremor; (2) erethism, a neuropsychiatric syndrome that includes irrita-
bility, excitability, loss of memory, loss of self-confidence, insomnia,
and depression; and (3) gingivitis (Cragle et al., 1984). Less-common
effects on the kidneys, including the nephrotic syndrome, proteinuria,
and other signs of renal dysfunction, have been attributed to chronic
exposure (Kazantzis et al., 1962; Foa et al., 1976; Buchet et al., 1980;
Roels et al., 1982; Rosenman et al., 1986).
One major study reported no significant signs or symptoms of chron-
ic mercury exposure in 479 workers whose time-weighted average ex-
posures were at or below 0.1 mg/m 3, some symptoms (tremor, insom-
nia, loss of appetite and weight) among 88 workers exposed at 0.11-
0.27 mg/m 3, and no evidence of kidney damage or other organ injury
(Smith et al., 1970). In a followup study of these and other workers,
no correlation was found between adverse health effects in workers and
exposure to mercury vapor at levels between 0.05 and 0.1 mg/m 3
(McGiii et al., 1964; Danzinger and Possick, 1973). Other investiga-
tors also reported no cases of classic mercury toxicity or evidence of
significant exposure-related abnormalities when average concentrations
did not exceed 0.1 mg/m 3 (McGill et al., 1964; Danzinger and Possick,
1973). In contrast, other studies attributed various toxic signs, includ-
ing erethism, tremor, decreased nerve conduction velocity, decreased
red-blood-cell cholinesterase, and renal dysfunction, in workers to ex-
posure to mercury vapor below 0.1 mg/m 3, or even below 0.05 mg/m 3
(Bidstrup et al., 1951; Fawer et al., 1983; Verberk et al., 1986; WHO,
1991).
Peak or time-integrated average urinary mercury levels in workers
were reported to be associated with neurological dysfunction, increased
tremor, impaired psychomotor performance, decreased coordination,
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verbal intelligence and memory, renal dysfunction, and other effects
(Langolf et ai., 1978, 1981; Buchet et al., 1980; Roels et al., 1982;
Smith et al., 1983; Rosenman et al., 1986).
Based on its review of the literature, the World Health Organization
(WHO, 1991) concluded that, at mercury vapor concentrations above
0.08 mg/m 3 (corresponding to urinary mercury of 0.1 mg/g creatinine),
the probability of developing neurological signs (tremor, erethism) is
high. At 0.025-0.08 mg/m 3 (corresponding to urinary mercury of 0.03-
0.10 mg/g creatinine), the incidence of certain less severe toxic effects
is increased. These subtle effects include impaired psychomotor perfor-
mance, measurable tremor, impaired nerve conduction velocity, fatigue,
irritability, loss of appetite, and possibly proteinuria.
Continuous low-level exposure to mercury vapor also occurs as a
result of the release of vapor from amalgam fillings in the mouth
(WHO, 1991). Several studies have shown a correlation between the
number of amalgam fillings or surfaces with mercury content in brain
and kidney tissue from human autopsy (WHO, 1991). However, in an
epidemiological study of 1024 women, there were no positive correla-
tions between the number of fillings and the symptoms reported
(Ahlqwist et al., 1988).
In 2 dogs, 18 rabbits, and 25 rats exposed to mercury vapor at 0.1
mg/m 3, 7 h/d, 5 d/w, for up to 83 w, there was no histopathology in
organs of rats at 72 w, in organs of rabbits and a dog at 83 w, or in
kidney biopsy samples from 2 dogs taken at 38 and 48 w (Ashe et al.,
1953). Kidney function tests in the 2 dogs at 41 or 43 w and 60 or 83
w also were normal.
Mercury vapor at 3 mg/m 3, 5 d/w, caused a 50% reduction in shock-
avoidance response rate in two of seven rats after 15 w and in avoid-
ance after 41 w and escape rates after 35 w in all seven rats (Kishi et
al., 1978). Response rates were normal within 12 w after termination
of exposure. No histological changes were evident in the brain, lungs,
or liver, but there was a slight degenerative change to the tubular epi-
thelium of the kidneys.
Exposure to mercury vapor at 4 mg/m 3, 6 h/d, 4 d/w, for 13 w
caused occasional tremor and clonus of the fore- and hind-legs of two
of six rabbits (Fukuda, 1971). Highest mercury concentrations in brain
structures were in the cerebellum, tegmentum, and thalamus.
MERCURY 2 $ 9
Genotoxicity and Carcinogenicity
An increased incidence of chromosome aberrations was reported in
four asymptomatic workers who had been exposed to mercury vapor at
0.15-0.44 mg/m 3 and had elevated urinary mercury levels during the
preceding year (Popescu et al., 1979). Another study did not find an
increase of structural aberrations in peripheral blood lymphocytes in
workers exposed to the mercury vapor (Mabille et al., 1984).
There are no reports, to our knowledge, that mercury vapor is carci-
nogenic. An epidemiological study of 2400 workers exposed to mer-
cury vapor for several years did not find excess deaths from diseases or
cancers of the brain and CNS, kidneys, liver, or lungs due to mercury
vapor exposure (Cragle et al., 1984).
Reproductive and Developmental Toxicity
The reproductive and developmental toxicities of mercury vapor will
be considered together since studies often address both end points. The
database consists primarily of epidemiological studies of workers ex-
posed as a result of employment in a factory or as dental professionals
and rodent inhalation studies. The potential for developmental toxicity
is high because elemental mercury readily crosses the placenta and ac-
cumulates in many fetal organs, but at concentrations below those typi-
cally found in the mother (Clarkson et al., 1972; Khayat and Dencker,
1982).
The reproductive toxicity of mercury has been evaluated in both male
and female industrial workers exposed to concentrations that were often
incompletely characterized. Female workers (n = 153) in a mercury
vapor lamp factory exposed to concentrations mostly below a time-
weighted average of 0.05 mg/m 3 reported higher rates of menstrual dis-
orders and adverse pregnancy outcomes than unexposed workers did;
however, the authors conclude that their findings neither proved nor
excluded the possibility that mercury causes adverse effects on repro-
duction (De Rosis et al., 1985). Male workers (n = 103) from various
industrial plants where mercury vapor exposures increased urinary con-
centrations to 50 _g/g of creatinine (1 _g/g of creatinine in controls)
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showed no statistically significant difference in the observed number of
offspring compared with a matched control population (Lauwerys et al,
1985). In another study of male workers (n = 247) with exposures to
mercury vapor and average urinary concentrations over a 20-y period
ranging from 27 to 107/xg/L, there was no association between the fa-
ther's mercury exposure and decreased fertility, increased malforma-
tions in offspring, or childhood illness. Furthermore, the father's mer-
cury exposure was not a significant risk factor for miscarriage after
controlling for previous history (Alcser et al., 1989). In a result that
seems to contradict this finding, a doubling of the rate of spontaneous
abortions was found in the wives of 152 workers with average urinary
mercury concentrations above 50 #g/L before pregnancy (Cordier et
al,. 1991).
A number of studies have focused on potential adverse effects in den-
tal professionals who receive exposure to mercury vapor during amal-
gam restorations. In a questionnaire study of nearly 60,000 dental
workers divided into two groups according to the frequency of amalgam
restorations performed, there was no significant increase in the rate of
spontaneous abortion or congenital malformations with the presumed
increase in exposure to mercury vapor (Brodsky et al, 1985). In con-
trast, Sikorski et al. (1987) found that the rate of reproductive failures
and menstrual cycle disorders in 81 female dental workers was associ-
ated with the mercury content of their hair. In a study of over 8000
infants born to dental workers in Sweden, the frequency of perinatal
death, low birth weight, and malformations was comparable to the inci-
dence in the general population (Ericson and Kailen, 1989). On the
whole, data from worker studies must be considered inconclusive about
the potential for mercury vapor to cause reproductive or developmental
toxicity at concentrations experienced in occupational settings.
Studies in rodents exposed to concentrations well above those experi-
enced by workers have demonstrated mercury vapor's potential for re-
productive and developmental toxicity. The estrus cycle was prolonged
in rats exposed at 2.5 mg/m 3, 6 h/d, 5 d/w for 21 d; however, during
the latter weeks of the exposure, CNS signs were observed (Baranski
and Szymczyk, 1973). In the same study, offspring of females exposed
3 w before mating and during gestational days 7-20 were reduced in
number and all died by the sixth day after birth. In a study reported by
abstract only, rats were exposed on gestational days 15-20 or 1-20 to
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concentrations of 0.1, 0.5, and 1.0 mg/m 3 (Steffek et al., 1987). No
effects were seen at 0.1 mg/m3; however, increased resorptions and
cranial defects (2 of 84) were found in offspring from the 0.5-mg/m 3
group. Relative to the control group, maternal toxicity was evident in
the high-exposure group as decreased weight gain (Steffek et al., 1987).
Several behavioral effects were found in offspring of dams exposed to
mercury vapor for 1 or 3 h/d at 1.8 mg/m 3 for 7 d (days 11-14 and 17-
20 of gestation) (Danielsson et al., 1993).
Interactions with Other Chemicals
Catalase inhibitors, such as ethanol and aminotriazole, inhibit the
oxidation of elemental mercury to mercuric ion in blood and tissues
(Nielsen-Kudsk, 1969; Magos et al., 1974). Pretreatment with ethyl
alcohol (rat and marmoset monkey) or aminotriazole (rat) caused de-
creased mercury retention in most organs and in the whole body, in-
creased blood concentrations of elemental mercury, and increased reten-
tion of mercury in most liver and adrenal cells (Khayat and Dencker,
1984). Ingestion of moderate amounts of ethanol by three human vol-
unteers decreased mercury uptake by red blood cells and retention of
mercury by the body and increased the rapid phase of vapor expiration
and mercury storage in the liver (Hursch et al., 1980).
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TABLE 7-2 Exposure Limits Set by Other OrgaJlizations
Organization Concentration, mg/m 3
ACGIH's TLV
OSHA's PEL
NIOSH's REL
NIOSH's IDLH
NRC's EEGL
NRC's CEGL
0.05, TWA (skin)
0.1, TWA (ceiling)
0.05, TWA (skin)
28
0.2, 24 h a
0.01, 90 d"
aNRC, 1984.
TLV = threshold limit value. TWA = time-weighted average. PEL =
permissiblc cxposure limit. REL = recommended cxposure limit. IDLH =
immediately daqgerous to life and health. EEGL = emergency exposure guid-
ance level. CEGL = continuous exposure guidance level.
TABLE 7-3 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m 3 Target Toxicity
l h 0.01 0.08 Respiratory tract
24 h 0.002 0.02 Respiratory tract
7 d 0.001 0.01 CNS, kidney
30 d 0.001 0.01 CNS, kidney
180 d 0.001 0.01 CNS, kidney
RATIONALE FOR
ACCEPTABLE CONCENTRATIONS
In setting SMAC values for mercury vapor, the toxic effects on the
respiratory tract, the brain and CNS, and the kidney must be consid-
ered. Few well-controlled animal studies have been conducted with
observations and measurements of toxic end points in adequate numbers
of animals and at more than one concentration of vapor. In most re-
ports of human exposures, analytical data are lacking. Guidelines from
the Committee on Toxicology have been used to structure the rationale
below (NRC, 1992).
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Respiratory System Toxicity
For single, brief exposures to mercury vapor, it appears that the re-
spiratory system is the most sensitive target organ in human beings
(Milne et al., 1970; McFarland and Reigel, 1978). A few hours after
exposure, cough, shortness of breath, and tightness of the chest devel-
op, and when clinical evaluations have been conducted, a diffuse pul-
monary infiltrate has been found. There are no well-characterized hu-
man exposures; however, data from two accidental industrial exposures
were used to estimate an acceptable concentration (AC) for the lung. In
one accident, nine workers were exposed for about 5 h to a mercury
concentration that could have been as much as 40 mg/m 3 (McFarland
and Reigel, 1978). Even though three of the workers complained of no
illness, six had moderate respiratory symptoms like those indicated
above. It is possible that human genetic variations in catalase activity
and enzymes related to endogenous peroxide supply might affect human
responses to inhaled mercury (Clarkson et al., 1980). All six injured
workers recovered from respiratory injury; however, in some there
were lingering subjective symptoms including fatigue, irritability, and
sexual disinterest. Two of the exposed workers had lingering tremors,
which never fully disappeared in one subject. In another report of acci-
dental human exposures at 1-3 mg/m 3 for 2.5-5 h, similar respiratory
symptoms were reported in three-fourths of the exposed workers and
one-fourth of the workers reported minimal respiratory symptoms
(Milne et al., 1970). Authors of the first study assert that all nine
workers had approximately equal exposures to mercury vapor even
though there was a wide range in apparent lung injury. An estimate of
short-term human exposure limits was made as follows: A LOAEL was
estimated from the 13 exposed workers as an exposure of 2 mg/m 3 for
5 h. For the 1-h AC to protect the lung, the estimate was 2 mg/m 3 x
0.4 (the square root of 13 divided by 10 for the small number of sub-
jects) x 1/10 (LOAEL to NOAEL), or 0.08 mg/m 3. For the 24-h AC,
the estimate was 2 mg/m 3 x 0.4 x 1/10 x 5/24 (Haber's rule), or
0.02 mg/m 3.
The above estimates of safe mercury concentrations were based on
incomplete human data and should not be adopted without comparison
with available animal data on lung injury. From short-term exposures
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of rabbits at concentrations of 30 mg/m 3 for 1-4 h, the degree of histo-
logically detected injury was reported as mild (Ashe et al., 1953).
From these data, the 1-h AC to protect the lung was 30 mg/m 3 x 1/10
(species extrapolation) x 1/10 (LOAEL to NOAEL), or 0.3 mg/m 3.
This was about fourfold above the estimate from human data, so the
lower 1-h AC of 0.08 mg/m 3 was adopted. For the 24-h AC to protect
the lung, as estimated from the rabbit data, the value was 30 mg/m 3 ×
1/10 x 1/10 x 4/24 (Haber's rule), or 0.05 mg/m 3. Again, this was
above the estimate from human data, so the 24-h AC for the lung of
0.02 mg/m 3 was adopted.
Nephrotoxicity
Data were available for subchronic and chronic exposures of animals
to mercury vapor. No more than mild histopathological changes were
seen in the kidneys of rabbits exposed at 0.86 mg/m 3, 7 h/d, 5 d/w, for
up to 4 w, and no histopathological changes were seen in the kidneys of
rabbits, rats, and two dogs exposed at 1 mg/m 3 for 83 w (Ashe et al.,
1953). Applying a species factor of 10 to the long-term NOAEL of 0.1
mg/m 3 gave an AC for nephrotoxicity of 0.01 mg/m 3 for exposures of
7, 30, and 180 d. Haber's rule was not applied because mercury con-
centrations in kidneys of exposed rabbits did not increase after the
fourth week of exposures (Ashe et al., 1953).
Neurotoxicity
Animal data for estimating potential neurotoxicity in humans were
available from the same study that provided data on nephrotoxicity.
Mild histopathologicai changes in the brains of rabbits resulted from
exposure at 0.86 mg/m 3, 7 h/d, 5 d/w, for 2-4 w, but no histopatholog-
ical changes were detected when rabbits, rats, and two dogs were ex-
posed at 0.1 mg/m 3 for 83 w (Ashe et al., 1953). In the 83-w study,
the tissue concentrations of mercury in the brain were roughly an order
of magnitude below the concentrations found in the kidney, but do not
conclusively show that mercury is not accumulating in brain tissue.
However, the exposures at 0.86 mg/m _ show no increased accumulation
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between the fifth and twelfth weeks of exposure, nor does the extent of
tissue damage increase (Ashe et al., 1953). Hence, the concentration of
0.1 mg/m 3 was considered a NOAEL, and a species factor of 10 was
applied, without using Haber's rule, to derive an AC for neurotoxicity
of 0.01 mg/m 3 for 7-, 30-, and 180-d exposures.
A large epidemiological study reported no significant toxic effects
below 0.1 mg/m 3 in workers chronically exposed to mercury vapor, but
there were some complaints of symptoms (Smith et al., 1970). A few
much smaller studies suggest occasional complaints, symptoms, or sub-
clinical effects at exposures below 0.1 mg/m 3 and even possibly below
0.05 mg/m 3 (Bidstrup et al., 1951; Fawer et al., 1983; Verberk et al.,
1986). Consequently, 0.1 mg/m 3 is considered a LOAEL and a factor
of 10 was applied to estimate a human NOAEL.
No adjustments to the AC values were necessary for any microgra-
vity-induced physiological changes.
RECOMMENDATIONS
The most important SMACs for mercury in spacecraft air are the
short-term values because this chemical would be removed from the air
after release and because a continuous slow-release source is unlikely to
be accidentally created. The long-term effects of mercury have been
studied thoroughly in occupationally exposed populations; however, the
short-term effects in human beings can only be approximated from the
few accidental exposures that have occurred. Only one animal study
was found on short-term effects of mercury vapor inhalation and it left
unanswered several questions important to the setting of short-term
SMACs. The time-vs.-concentration relationships need better definition
for brief continuous exposures lasting from 1 h to a few days. The re-
lationships need to be defined for each apparent target site in animal
models: brain, kidney, liver, colon, heart, and lung. In addition, the
mechanism of the damage needs exploration to improve extrapolations
from animal models to humans. Because the lung appears to be the
target site in humans after acute exposure, future research should be
focused on understanding biochemical and microscopic changes in that
organ. Appropriate animal models should be selected carefully, with
the initial experiments involving exposure of several species.
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B8 Methylene Chloride
King Lit Wong, Ph.D.
Johnson Space Center Toxicology Group
Biomedical Operations and Research Branch
Houston, Texas
PHYSICAL AND CHEMICAL PROPERTIES
Methylene chloride is a volatile and colorless liquid (ACGIH, 1986).
Its vapor is not flammable or explosive (Merck, 1989).
Synonyms:
Formula:
CAS number:
Molecular weight:
Boiling point:
Melting point:
Vapor pressure:
Conversion factors
at 25°C, 1 atm:
Dichloromethane
CH2C12
75-09-2
84.9
39.8°C
-96.7 °C
440 torr 25°C
1 ppm = 3.47 mg/m 3
1 mg/m 3 = 0.29 ppm
OCCURRENCE AND USE
Methylene chloride is a widely used solvent (NTP, 1986). Examples
of its use are as a paint remover and a degreasing agent. There is no
known use of methylene chloride in spacecraft, but methylene chloride
has been shown to off-gas in space shuttles reaching typically 0.1 ppm
in a few days (NASA, 1989).
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PHARMACOKINETICS AND METABOLISM
Absorption
The blood equilibrates with inhaled methylene chloride sooner at rest
than at exercise. DiVincenzo et al. (1972) showed that the methylene
chloride concentration in blood in 11 human volunteers, who exercised
during one-third of the exposure duration, did not plateau 2 h into an
exposure to methylene chloride at a concentration of 100 or 200 ppm.
Similarly, in a study conducted by Astrand et al. (1975) with five hu-
man subjects who were exposed to methylene chloride at 500 ppm for 2
h, with the first 30 rain at rest, followed by 30 min of exercise at a 50-
watt workload, 30 rain of exercise at a 100-watt workload, and 30 min
of exercise at a 150-watt workload, both the arterial and venous concen-
trations of methylene chloride did not reach a plateau in 2 h (Astrand
et. al., 1975). In contrast, DiVincenzo and Kaplan (1981) showed that
the methylene chloride concentration in venous blood reached a plateau
in 2 h during a 7.5-11 exposure of four to six sedentary human volun-
teers to methylene chloride at 50-150 ppm. However, when exposed to
methylene chloride at 200 ppm, the blood concentration failed to pla-
teau in 7.5 h (DiVincenzo and Kaplan, 1981).
Experiments demonstrated that methylene chloride is quite well ab-
sorbed during inhalation exposures. DiVincenzo et al. (1972) reported
that methylene chloride vapor was rapidly absorbed by the lung during
the first few minutes of exposure of 11 human volunteers to methylene
chloride at 100 or 200 ppm. Astrand et al. (1975) showed that human
subjects at rest absorbed 55% of the amount of methylene chloride in-
haled in a 30-min exposure at 250 or 500 ppm. The absorption de-
creased to 409_ when the subjects were working at a load of 50 watts,
which is equivalent to light exercise (Astrand et al., 1975). In a study
conducted by DiVincenzo and Kaplan (1981), up to 70% of the methy-
lene chloride inhaled in a 7.5-11 exposure at 50-200 ppm was absorbed
by resting human subjects.
Distribution
In rats, methylene chloride is distributed, after a 1-h exposure at 560
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ppm, mainly to white adipose tissue (Carlsson and Hultengren, 1975).
The tissues, ranked according to methylene chloride concentrations in
decreasing order, are white adipose tissue, liver, kidneys, and brain.
Metabolism
Methylene chloride is metabolized by two enzyme pathways in ro-
dents (Kubic et al., 1974; Ahmed and Anders, 1978). The glutathione
transferase pathway metabolizes methylene chloride into hydrogen chlo-
ride, formaldehyde, and carbon dioxide. Methylene chloride is also
metabolized by the cytochrome P-450 system into hydrogen chloride,
carbon monoxide, and carbon dioxide. McKenna et al. (1982) showed
that metabolism of methylene chloride was saturable in rats; the per-
centage that was metabolized in 48 h after a 6-h methylene chloride
exposure decreased from 95 % to 69% to 45 % as the exposure concen-
tration increased from 50 ppm to 500 ppm to 1500 ppm, respectively.
McKenna et al. reported that the major metabolites of methylene chlo-
ride in rats were carbon monoxide and carbon dioxide, which were ex-
haled.
DiVincenzo and Kaplan (1981) showed that, in a 7.5-h exposure of
four to six sedentary human subjects to methylene chloride at 50-200
ppm, about 30% of the absorbed methylene chloride was converted into
carbon monoxide, leading to a carboxyhemoglobin (COHb) concentra-
tion of 1.9-6.8% in blood. Even though the methylene chloride con-
centration in blood was approaching a plateau 2 h into the exposure at
50-150 ppm, the increase in COHb concentration did not slow down in
the same period. According to Stewart et al. (1972), formation of 2.6-
8% COHb in blood occurred in 11 men alter a l-2-h inhalation expo-
sure to methylene chloride at 515-986 ppm.
Excretion
DiVincenzo and Kaplan (1981) reported that, after a 7.5-h methylene
chloride exposure at 50-200 ppm in four to six human subjects, less
than 5 %, of the absorbed methylene chloride was excreted unchanged in
the expired air, and 25-34% was excreted as carbon monoxide during
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and after the exposure. DiVincenzo et al. (1972) showed that methy-
lene chloride's blood concentration lollows a bi-exponential decay in
humans. The first phase of the decay is very rapid, followed by a slow-
er phase with a half-life of about 40 rain. A physiologically based
pharmacokinetic model has been developed by Andersen et al. (1987).
The model's predictions of the blood concentration of methylene chlo-
ride in mice, rats, hamsters, and humans agreed quite well with experi-
mental data. Peterson (1978) also modeled the uptake, metabolism,
excretion of methylene chloride in man. The model was used to predict
the exhaled concentration of methylene chloride and the blood COHb
concentration after an acute methylene chloride exposure.
After a methylene chloride exposure ends, the COHb concentration
in blood might continue to rise, depending on the length of the expo-
sure. In two studies in which humans were exposed to methylene chlo-
ride at 250-986 ppm for 1 or 2 h, the COHb concentration rose an av-
erage of 33% within 1 or 2 h after the exposure ended and then de-
creased with time (Stewart et al., 1972; Astrand et al., 1975) This
suggests that, after the 1-2 h exposure, methylene chloride is released
from some of the tissues and metabolized into carbon monoxide, lead-
ing to a }emporary accumulation of COHb in blood. It is interesting
that such a phenomenon does not occur in longer methylene chloride
exposures. Serial samplings failed to demonstrate any further increase
in COHb concentrations after a 7.5-8-h exposure of methylene chloride
in two human studies (DiVincenzo et al., 1981: Andersen et al., 1987).
TOXICITY SUMMARY
Acute and Short-Term Toxicity
Acute exposures to methylene chloride are known to adversely affect
the central nervous system (CNS) and the liver. These adverse effects
are summarized below.
CNS Effects
Because carbon monoxide is one of methylene chloride's metabolites,
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the acute toxicity of methylene chloride resembles that of carbon mon-
oxide. Putz et al. (1979) showed that a 4-11 exposure to methylene
chloride at 200 ppm, resulting in 5% COHb in the fourth hour, im-
paired the hand-eye coordination and increased the reaction time in 12
human volunteers. In the same study, these CNS effects were repro-
duced by a carbon monoxide exposure that yielded 5% COHb.
Acute methylene chloride exposures could impair vigilance perfor-
mance in humans. In the 4-h exposure of [2 human volunteers to
methylene chloride at 200 ppm conducted by Putz et al. (1979), im-
paired auditory vigilance was found. Winneke and Fodor (1976) also
studied visual vigilance in eight women by measuring their abilities to
correctly detect random drops in the intensity of a train of pulses of
white noise. The vigilance performance started to deteriorate 1 h into
the exposure to methylene chloride at 500 ppm. The eight women also
subjectively felt a more rapid decline in their soberness, and they felt
tired more rapidly during the 2-h and 20-rain exposure to methylene
chloride at 500 ppm than during the sham exposure to air. Winneke
(1981) reported that visual vigilance was impaired by acute methylene
chloride exposures as low as 300 ppm, so he concluded that "prolonged
monotonous observation-tasks are easily disturbed by" methylene chlo-
ride.
Methylene chloride also could impair visual or CNS alertness in hu-
man subjects. In the study of Winneke and Fodor (1976), there was
decreased visual or CNS alertness as early as 50 min into an exposure
of 12 women to methylene chloride at 500 ppm for 2 h and 20 rain, as
measured by a drop in the monocular critical flicker frequency. Similar
drops in the crifica! flicker frequency were detected by Winneke (1981)
in a 95-rain exposure to methylene chloride at 300 ppm. Stewart et al.
(1972) also reported that a 2-h exposure to methylene chloride at 986
ppm, resulting in 10.1% COHb in the blood, changed the amplitude of
visual-evoked potentials triggered by 100 strobe flashes in three out of
three human volunteers.
Unlike other aspects of CNS function, Winneke's group showed that
cognitive performances of human subjects were quite resistant to methy-
lene chloride's depressive effect on the CNS (Winneke and Fodor,
1976; Winneke, 1981). DiVincenzo et al. (1972) exposed ll men to
methylene chloride at 100 and 200 ppm for 2 to 4 h, with the men ex-
ercising approximately one-third of the exposure duration. The expo-
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sure did not change the time for the men to complete tests of adding
single-digit numerals. Winneke and Fodor (1976) showed that, in an
exposure of 12 women to methylene chloride at 500 ppm for 2 h and 20
rain, there were no differences in their performances in an addition test
and a letter-canceling test. Even a 2-h exposure at 1000 ppm failed to
reduce cognitive performances in human subjects, as determined by an
addition test, the learning and retention of nonsense syllables, and the
reproduction of visual patterns (a test of short-term memory) (Winneke,
1981).
As the exposure concentration increases, methylene chloride pro-
duces more overt CNS depression. Winneke (1981) reported that a 4-h
methylene chloride exposure at 800 ppm results in depressive mood and
motor impairment. As the concentration approached 1000 ppm, Stew-
art et al. (1972) reported that two of three human subjects complained
of mild light-headedness after 1 h of exposure; one of the two devel-
oped a sensation of "thick tongue." Moskowitz and Shapiro (1952) re-
ported four cases of accidental exposures to unknown but presumably
very high concentrations of methylene chloride for 1-3 h, which pro-
duced unconsciousness in all the victims: three men finally recovered
after 3-6 h and one man never regained consciousness and died.
Hepatic Effect
Other than acting on the CNS, methylene chloride might also affect
the liver. A 6-h exposure at 5000 ppm or higher increases the hepatic
triglyceride concentration in guinea pigs tBalmer et al., 1976).
Subchronic and Chronic Toxicity
Subchronic exposures to methylene chloride have been reported to
produce COHb and toxic effects in the liver, kidney, and the respira-
tory system.
Carboxyhemoglobin Formation
Kim and Carlson (1986) compared COHb fl_rmation in rats exposed
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to the same concentrations of methylene chloride at 200, 550, or 960
ppm for either 8 h/d for 5 d or 12 h/d fl_r 4 d. They found no signifi-
cant difference in the COHb concentrations in rats exposed to the same
concentration for 8 h/d or 12 h/d after tile first and last exposures of
the week. Similar results were found ill mice. The half-lives of the
disappearance of COHb in the 8-h or 12-h groups of rats also did not
differ. However, the half-lives depended on the exposure concentra-
tion: the half-lives were 50 and 130 rain in rats exposed to 550 ppm for
8 h or 960 ppm for 8 h, respectively. They concluded that unusual
workshift would probably not change methylene chloride's toxicity me-
diated via COHb formation.
Non-neoplastic Effects on the Liver and Kidney
Subchronic exposure to methylene chloride could produce liver and
kidney toxicity. MacEwen et al. (1972b) reported cellular vacuoliza-
tion, nuclear enlargement, and iron pigmentation in portal areas of the
liver and cortical tubular-cell degeneration in the kidney of rats exposed
to methylene chloride at 1000 ppm, 24 h/d, for 100 d. In similarly
exposed mice, ductal proliferation and large masses of brown pigment
were found in or around the portal areas. In addition, a mild balloon-
ing degeneration of cytoplasm and chromatin clumping were noted in
the livers of these mice. In the kidneys, a very faint granular staining
with hemosiderin was observed in some tubules of half of the mice ex-
amined. MacEwen et al. (1972b) also reported marked fatty liver in
four dogs and mild fat accumulation in the liver of four monkeys ex-
posed to methylene chloride at 1000 ppm for 100 d, but the kidney was
not affected in the dogs and monkeys.
In 20 rats continuously exposed to methylene chloride at 25 ppm for
100 d, Haun et al. (1972) detected fatty changes and cytoplasmic vacu-
olization in the liver, as well as nonspecific tubular degeneration and
regeneration in the kidney. In 20 mice exposed at 100 ppm, the only
pathology discovered was fatty liver. No histopathoiogy was found in
any tissues of four dogs and four monkeys exposed at 100 ppm. At a
lower concentration of 25 ppm, the only species affected was rats,
which had fatty liver and nonspecific tubular degeneration in their kid-
neys.
Evaluation of these data indicates that the liver is more sensitive than
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the kidney to methylene chloride. These data also revealed species dif-
ferences in the sensitivity toward methylene chloride's hepatic effects.
The sensitivity of four test species ranked in decreasing order as rats,
mice, dogs, and monkeys is shown in Table 8-1.
TABLE 8-1 Species Differences in Sensitivity for Hepatic Effects _
lO0-d Exposure Hepatic Changes
Concentration, ppm Rat Mouse Dog Monkey
1000 Marked Marked Marked Mild
100 Mild LOAEL NOAEL NOAEL
25 LOAEL NOAEL None None
_Data from Haun et al. (1972) and MacEwen et al. (1972b).
The National Toxicology Program (NTP, 1986) sponsored subchron-
ic and chronic toxicity studies conducted at exposure concentrations
much higher than those in studies performed by MacEwen et al.
(1972b) and Haun et al. (1972). The NTP's studies failed to show that
rats were clearly more sensitive toward the non-neoplastic effects of
methylene chloride than mice. In the NTP's subchronic toxicity study,
rats and mice were exposed to methylene chloride at 1000, 2100, or
4200 ppm, 6 h/d, 5 d/w, for 90 d (NTP, 1986). The exposure at 1000
or 2100 ppm did not cause any histopathology, and the exposure at
4200 ppm produced mild centrilobular hydropic degeneration in mice
but not in rats.
In the NTP's chronic toxicity study, rats were exposed at 1000,
2000, or 4000 ppm, and mice were exposed at 2000 or 4000 ppm, 6
h/d, 5 d/w, for 2 y (NTP, 1986). Rats and mice suffered different
types of histopathology in the liver; rats were afflicted with more types
of histopathology than mice. Mice in both the 2000- and 4000-ppm
groups developed only cytological degeneration in the liver. In com-
parison, several types of hepatic pathology were found in the 1000-,
2000-, and 4000-ppm groups: focal granulomatous inflammation, focal
necrosis, hemosiderosis, and cytoplasmic vacuolization.
In a chronic toxicity study sponsored by several chemical companies,
Burek et al. (1984) exposed rats and hamsters to methylene chloride at
500, 1500, or 3500 ppm, 6 h/d, 5 d/w, for 2 y, and showed differences
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in the sensitivities between the two species. The methylene chloride
exposures failed to increase the incidence of liver or kidney histopathol-
ogy in hamsters, and some of the exposures affected the liver and kid-
ney in rats. Similar to the findings of the NTP (1986), Burek et al.
found that chronic methylene chloride exposures were more damaging
to the liver than the kidney in rats. Methylene chloride did not cause
any concentration-dependent increases in the incidence of glomerulone-
phropathy in female rats. In male rats, however, chronic methylene
chloride exposures led to glomerulonephropathy at 1500 and 3500 ppm.
In terms of liver injuries, chronic methylene chloride exposures at 500,
1500, or 3500 ppm produced vacuolization consistent with fatty liver in
both male and female rats and they also caused multinucleared hepato-
cytes in female rats. Exposures at 1500 or 3500 ppm resulted in necro-
sis of individual hepatocytes in male rats, and the exposure at 3500 ppm
produced coagulation necrosis and foci of altered hepatocytes in female
rats.
Non-neoplastic Effects on the Respiratory System
Repetitive exposures of mice to methylene chloride at 4000 ppm, 6
h/d, 5 d/w, for up to 13 w, have been shown by Foster et al. (1992) to
produce cytoplasmic vacuoles in bronchiolar Clara cells. The lesion
appeared only on the second day of each week of exposure and resolved
after the second day. The disappearance of the lesion correlated with a
decrease in cytochrome P-450 monooxygenase activity in Clara cells,
suggesting that Clara cells developed tolerance to methylene chloride
with time by the inactivation of one of the pathways of methylene chlo-
ride metabolism. In contrast to mice, rats are not susceptible to this
toxicity of methylene chloride (Foster et al., 1986). Since the Clara
cell lesion did not appear to be too serious and disappeared with time,
SMACs are not set according to the Clara cell lesion.
In the chronic toxicity study by the NTP (1986), exposures at 4000
ppm, 6 h/d, 5 d/w, for 2 y have been shown to cause squamous meta-
plasia in the nasal cavities of female rats but not those of male rats or
female and male mice. Similar exposures at 2000 ppm failed to pro-
duce such a change. Squamous metaplasia in the nose is not relied on
in setting methylene chloride's SMACs because it is a toxic effect seen
only at very high exposure concentrations.
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Neoplastic Effects
Two 2-y bioassays showed that methylene chloride was carcinogenic
in rats and mice, but not in hamsters (Burek et al., 1984; NTP, 1986).
In a chronic exposure of rats and hamsters to methylene chloride at
3500 ppm conducted by Burek et al. (1984), salivary gland sarcomas
were the only kind of tumor found, and these sarcomas were observed
only in the male rats. In the NTP's chronic toxicity study (1986),
methylene chloride produced leukemia and benign mammary tumors in
female rats and alveolar and bronchiolar adenomas and carcinomas in
mice, as well as hepatocellular adenomas and carcinomas in mice. The
incidences of lung tumors in female mice were 3 of 50, 16 of 48, and
40 of 48 in the 0-, 2000-, and 4000-ppm groups, respectively. The
corresponding incidences of liver tumors were 3 of 50, 30 of 48, and
41 of 48. According to the NTP, methylene chloride shows clear evi-
dence of carcinogenicity in female F344/N rats and male and female
B6C3F_ mice. An epidemiological study did not find any significant
increase in cancer-related mortality in workers exposed to methylene
chloride at 30-1200 ppm for up to 30 y (Friedlander et al., 1978). The
ACGIH (1986) has classified it as a suspected human carcinogen.
The methylene chloride metabolites via the glutathione transferase
pathway have been postulated to be the active metabolites in causing its
carcinogenicity (Andersen et al., 1987). One of the metabolites formed
is formaldehyde. Casanova et al. (1992) studied DNA-protein cross-
links in rodents exposed to methylene chloride. They exposed mice and
hamsters to methylene chloride at 4000 ppm, 6 h/d, for 2 d and then to
_4C-methylene chloride on the third day for 6 h at a concentration de-
caying from 4500 to 2500 ppm. They found DNA-protein cross-links
in mouse liver, but not in mouse lung, while the cross-links failed to
show up in either organs of hamsters. Casanova et al. stated that the
failure to detect DNA-protein cross-links in mouse lung did not rule out
the possibility that the cross-links existed ill subpopulations of lung
cells. The}' attributed the DNA-protein cross-links to formaldehyde
formed from methylene chloride's metabolism via the glutathione trans-
ferase pathway.
Genotoxicity
Methylene chloride is mutagenic in Salmonella o,phimurium (Jongen
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et al., t978). It has been shown to cause chronaosomal aberrations, but
not sister chromatid exchange, in Chinese hamster ovary cells in vitro
(Thilager and Kumaroo, 1983). It also failed to produce micronuclei in
mice (Gocke et al., 1981).
Developmental Toxicity
It should be noted that methylene chloride has not been found to be
teratogenic. Schwetz et al. (1975) exposed rats and mice to methylene
chloride at 1225 ppm, 6 h/d, on gestation days 6-15 and failed to find
any malformations in the fetuses. Because the exposure duration used
by Schwetz et al. might not be long enough for a chemical that acts via
its metabolites, Hardin and Manson (1980) exposed five female rats to
methylene chloride at 4500 ppm, 6 h/d, 7 d/w, for 12-14 d before
breeding and on days 1-17 of gestation. Hardin and Manson did not
detect any increases in the incidence of skeletal or soft-tissue malforma-
tions or external anomalies.
Interaction with Other Chemicals
No evidence of interaction involving methylene chloride and other
chemicals has been found in the literature.
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TABLE 8-3 E×posure Limits Set by Other Organizations
Organization Concentration, ppm
ACGIH's TLV 50 (TWA)
OSHA's PEL 500 (TWA)
1000 (ceiling)
NIOSH's REL 75 (TWA)
500 (ceiling)
N1OSH's IDLtt 5000
TIN = threshold limit value. TWA = time-weighted average.
permissible exposure limit. REL = recommended exposure limit.
immediately dangerous to life and health.
PEL =
IDLH =
TABLE 8-4 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m _ Target Toxicity
1 h i00 350
24 h 35 120
7 d _' t 5 50
30 d 5 20
180 d 3 10
CNS depression
CNS depression
CNS depression
laver
Liver
"Former 7-d SMAC = 25 ppm.
RATIONALE FOR
ACCEPTABLE CONCENTRATIONS
The acceptable concentrations (ACs) for the three major toxic end
points of CNS depression, liver toxicity, and carcinogenicity are esti-
mated for continuous exposures lasting 1 h, 24 h, 7 d, 30 d, or 180 d.
The lowest AC among the three end points will be chosen as the SMAC
for each exposure duration.
CNS Depression
As discussed in the Toxicity Summary, one of the major acute effects
of methylene chloride is CNS depression, which appears to be due to
carbon monoxide formed from methylene chloride's metabolism A 4-h
exposure to methylene chloride at 200 ppm, which yields 5 % COHb in
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blood, impairs the hand-eye coordination and auditory vigilance (Peter-
son et al., 1978), but there are no data on the no-observed-adverse-
effect level (NOAEL) of methylene chloride. It makes sense to adopt
the NOAEL of COHb used in setting the l-h and 24-h SMACs of car-
bon monoxide as a potential basis for setting the l-h and 24-h SMACs
of methylene chloride. Three percent COHb is the target COHb con-
centration used to set both the 1-h and 24-11 SMACs for carbon monox-
ide (Wong, 1990). The task here is to determine the methylene chlo-
ride concentrations that produce about 3% COHb in 1 and 24 h. As-
suming a baseline COHb concentration of 0.6% due to endogenous CO
production, the task is to determine the methylene chloride concentra-
tions that would increase the COHb concentration by 2.4%. The in-
creases in COHb concentrations produced by various methylene chlo-
ride exposure scenarios are shown in Table 8-5.
To derive the 1-h AC based on CO formation, a linear regression
line was fitted through the data of percent COHb increase versus C x
T by forcing the fitted lille through the origin. All the data in the
above table were used except the data points at 3750 and 1972 ppm-h
because their corresponding responses of 10% and 9.3% increases in
COHb were too far away from the region of interest, 2.4%. The linear
regression yielded a line with a slope of 0.0038, r: of 0.74, and a 95 %
confidence limit of 100 ppm-h at a 2.4% increase in COHb. Accord-
ingly, 100 ppm is selected as the 1-11AC based on CO formation.
To derive the ACs based on CO formation for a 24-h, 7-d, 30-d, or
180-d methylene chloride exposure, the physiologically based
pharmacokinetic (PB-PK) model of Andersen et al. (1991) was used.
For a 70-kg man with a starting COHb of 0.6%, this model predicted
that an exposure to methylene chloride at 35 ppm would produce a final
COHb of 3 % in 24 h, so 35 ppm is chosen to be the 24-h AC based on
CO formation.
To calculate the acceptable 7-d, 30-d, and 180-d methylene chloride
concentrations based on the carbon monoxide metabolite, the target
COHb concentrations of 1.6% were adopted from the 7-d, 30-d, and
180-d carbon monoxide SMACs. According to the PB-PK model of
Andersen et al. (1991), a continuous exposure to methylene chloride at
14 ppm would raise the COHb concentration from 0.6% to 1.6% in a
70-kg man in 7, 30, or 180 d. The 7-d, 30-d, and 180-d ACs based on
CO formation are all set at 14 ppm.
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TABLE 8-5 Increases in COHb Produced by Methylene Chloride Exposures
MeCI Concen- Exposure C × T" Increase in
tration, ppm Time, h (ppm x h) No. % COHb Reference
50 7.5 375 11 1.6
50 7.5 375 4-6 0.8
100 5 500 6 3.9
100 7.5 750 11 3.2
100 7.5 750 4-6 2.2
150 7.5 1125 4-6 4.0
180 8 1440 4 4.5
200 l 200 4-6 2.2
200 2 400 4-6 3.3
200 4 800 12 4.2
200 7.5 1500 4-6 5.8
250 2 500 4 3.2
250 7.5 1875 35 7
350 5 1750 6 6.0
500 2 1000 5 4.0
500 7.5 3750 5 10
515 1 515 8 1.8
691 _ 1382 3 4.8
986 2 1972 3 9.3
Peterson, 1978
DiVincenzo and
Kaplan, 1981
Andersen et al., 1981
Peterson, 1978
DiVincenzo and
Kaplan, 1981
DiVincenzo and
Kaplan, 1981
Ratney et al., 1974
DiVincenzo and
Kaplan, 1981
DiVincenzo and
Kaplan, 1981
Putz et al., 1979
DiVincenzo and
Kaplan, 1981
Astrand et al., 1975
Peterson, 1978
Andersen et al., 1981
Astrand et al., 1975
Peterson, 1978
Stewart et al., 1972
Stewart et al., 1972
Stewart et al., 1972
aConcentration x Time.
It should be noted that the National Research Council's Subcommit-
tee on SMACs recognized the potential that methylene chloride's toxic-
ity due to COHb formation could be aggravated by a reduction in the
mass of red blood cells (RBCs) in the bodies of astronauts in microgra-
vity. However, the ACs based on CO formation derived from data
gathered on earth should be valid because microgravity reduces astro-
nauts' RBC mass by only about 10%. Thus, any aggravation on the
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COHb concentration formed in astronauts during methylene chloride
exposures will not be significant.
Liver Toxicity
Subchronic or chronic exposures of rats to methylene chloride have
been shown to produce these hepatic changes: fatty liver in the studies
of MacEwen et al. (1972a,b) and Haun et al. (1972); cytoplasmic vacu-
olization (which might reflect fatty changes) and necrosis in the studies
of Burek et al. (1984) and NTP (1986): and hemosiderosis and focal
granulomatous inflammation in the NTP (1986) study.
Methylene chloride's hepatic effects depend on exposure duration to
a certain extent. MacEwen et al. (1972b) reported that livers of rats
exposed to methylene chloride at 5000 ppm, 24 h/d, 7 d/w, for 4 w
exhibited the same degree of cellular vacuolization, nuclear enlarge-
ment, and iron pigmentation as that in rats exposed at 5000 ppm, 24
h/d, 7 d/w, for 14 w. However, the NTP (1986) study showed that a
subchronic exposure of rats at 2100 ppm, 6 h/d, 5 d/w, for 13 w was
not hepatotoxic, but a chronic exposure at 2000 ppm, 6 h/d, 5 d/w, for
2 y produced liver injuries. Similarly, in a comparison of methylene
chloride's hepatic effects in mice exposed at 100 ppm, 24 h/d, for 3 d,
for 1, 2, 3, 4, or 10 w, Weinstein and Diamond (1972) showed that
liver histopathology became somewhat more severe as the exposure was
lengthened, but the hepatic triglyceride concentration did not increase
linearly with the exposure duration. Their results are summarized in
Table 8-6.
Therefore, the bulk of the data indicate that methylene chloride's
liver toxicity is somewhat time-dependent in rats. As a result, the pru-
dent approach in deriving an AC based on hepatic toxicity would be to
lower the AC as the exposure time is lengthened.
Instead of using the data gathered by MacEwen et al. (1972b) and
Haun et al. (1972) to derive the ACs, data from the NTP (1986) study
and the Burek et al. (1984) study were used. These studies are more
recent and they were peer-reviewed, but the studies of MacEwen et al.
and Haun et al. were not. The NTP study, showed that repetitive expo-
sures to methylene chloride at 2100 ppm, 6 h/d, 5 d/w, for 13 w
caused 11ohistopathology in rats.
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TABLE 8-6 Temporal Pattern of Methylene Chloride's Hepatic Effects in
Mice
Exposure Time Triglyceride Level Histopathology
3 d No significant change
1 w No significant change
2 w 240% of control's
3 w 420% of control's
4 w 190% of control's
10 w 140% of control's
No changes
Small fat droplets
Increase in fat-droplet size
Fatty changes, enlarged nuclei,
small autophagic vacuoles
Fatty changes, enlarged nuclei,
small autophagic vacuoles
Fatty changes, enlarged nuclei, large
autophagic vacuoles
7-d AC based on liver toxicity
= 90-d NOAEL x 1/species factor
= 2100ppm x 1/10
= 210 ppm.
The NTP (1986) study also showed that exposures to rats at 1000,
2000, or 4000 ppm, 6 h/d, 5 d/w, for 2 y could lead to cytoplasmic
vacuolization, hemosiderosis, and focal granulomatous inflammation in
liver. Burek et al. (1984) found that a similar 2-y exposure of rats to
methylene chloride produced cytoplasmic vacuolization, indicative of
fatty liver, at as low as 500 ppm, so the LOAEL for non-neoplastic
hepatotoxicity is 500 ppm.
30-d AC based on liver toxicity
= 2-y LOAEL x 1/NOAEL factor × 1/species factor
= 500ppm x 1/10 x 1/10
= 5 ppm.
180-d AC based on liver toxicity
= 2-y LOAEL × 1/NOAEL factor × l/species factor x time
adjustment
= 500ppm × 1/10 × 1/10 x
(6h/d × 5d/w x 104w)/(24h/d x 180d)
= 3.6 ppm.
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No evidence of liver toxicity has been found in the literature for
acute methylene chloride exposures; therefore, 1-h and 24-h ACs based
on liver toxicity are not derived.
Carcinogenicity
A 2-y exposure to methylene chloride at 0, 2000, and 4000 ppm pro-
duced 3 of 50, 30 of 48, and 41 of 48 cases of lung tumors and 3 of
50, 16 of 48, and 40 of 48 cases of liver tumors, respectively, in fe-
male B6C3F_ mice in the NTP study (1986). Instead of using the air-
borne methylene chloride concentrations to calculate the 10 .4 tumor
dose, it is better to use the doses of active metabolite produced by the
glutathione transferase pathway in the lung and liver, as estimated by a
physiologically based pharmacokinetic model (Andersen et al., 1987).
According to this pharmacokinetic model, 2000 and 4000 ppm of air-
borne methylene chloride are equivalent to 123 and 256 mg of methy-
lene chloride metabolized per liter of lung per exposure day. Similarly,
2000 and 4000 ppm are equivalent to 851 and 1811 mg of methylene
chloride metabolized per liter of liver per exposure-day. By substitut-
ing these values in the linearized multistage model using GLOBAL86
(Howe and Crump, 1986), 0.011 mg of methylene chloride metabolized
per liter of lung per day and 0.24 mg of methylene chloride metabo-
lized per liter of liver per day are the lower 95% confidence limit of
the dose that will yield a 10 .4 lung and liver tumor risk, respectively.
Based on the pharmacokinetic model (Andersen et al., 1987), 0.011
mg/L lung and 0.24 mg/L liver are equivalent to about 6 and 12 ppm
of methylene chloride for humans, respectively. The lower concentra-
tion of 6 ppm is used in the risk assessment.
The continuous exposure concentration to get a lung tumor risk of 10 .4
= 6 ppm × (6 h/d × 5 d/w)/(24 h/d × 7 d/w)
= 1.1 ppm.
Instead of the physiologically based pharmacokinetics model, EPA
(1990) used the body-surface-area ratio to extrapolate the tumor data in
mice to humans. With the linearized multistage model, EPA estimated
that a continuous lifetime exposure to methylene chloride at 0.02 mg/m 3
or 5.8 × 10 3 ppm would produce an excess tumor risk of 1 in 10,000
298 SMACs FOR SELECTED AIRBORNE CONTAMINANTS
in humans. In comparison, EPA's estimate is 190 times more conser-
vative than the risk assessment estimate based on the physiologically
based pharmacokinetics model.
According to the Committee on Toxicology, setting k = 3 (the num-
ber of stages in the carcinogenic process affected by methylene chlo-
ride), t = 25,550 d (lifetime of 70 y), and t,, = 10,950 d (an initial
exposure age of 30 y), the adjustment factor for a near instantaneous
exposure is calculated to be 26,082 (NRC, 1992).
24-h exposure level that would produce a 10 _ excess tumor risk
= 1.1 ppm × 26,082
= 29,000 ppm.
Similarly, by setting k = 3, t = 25,550 d, and to = 10,950 d, the
adjustment factor for estimating the 7-d exposure concentration that
would yield the same excess tumor risk as that for a lifetime exposure
is 3728 (NRC, 1992).
7-d exposure level that would produce a 10 4 excess tumor risk
= 1.1 ppm × 3728
= 4100 ppm
With a similar approach, 871 and 146.7 are calculated to be the ad-
justment factors for converting a lifetime exposure concentration to 30-d
and 180-d exposure concentrations for the same excess tumor risk
(NRC, 1992).
30-d exposure level that would produce a 10 4 excess tumor risk
= 1.1 ppm × 871
= 960 ppm.
180-d exposure level that would produce a 10 _ excess tumor risk
= 1.1 ppm x 146.7
= 160 ppm.
Establishment of SMAC Values
The ACs h_r the three toxic end points are listed in Table 8-7. The
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lowest AC for each exposure duration is selected to be the SMAC. As
a result, the l-h, 24-h, 7-d, 30-d, and 180-d SMACs are set at 100, 35,
15, 5, and 3 ppm, respectively.
No adjustments of the SMACs are needed for any micro-
gravity-induced physiological changes. The reason is that the in-flight
hemoglobin concentrations obtained in Skylabs were higher than the
preflight values by only 10%, so the carbon monoxide produced from
methylene chloride metabolism is not going to be significantly more
toxic in-flight than on earth.
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B9 Methyl Ethyl Ketone
King Lit Wong, Ph.D.
Johnson Space Center Toxicology Group
Biomedical Operations and Research Branch
Houston, Texas
PHYSICAL AND CHEMICAL PROPERTIES
Methyl ethyl ketone (MEK) is a flammable, colorless liquid with an
acetone-like odor (ACGIH, 1991).
Synonyms:
Formula:
CAS number:
Molecular weight:
Boiling point:
Melting point:
Vapor pressure:
Conversion factors
at 25°C, 1 atm:
2-butanone, methyl acetone
CH3COCH2CH3
78-93-3
72
79.6°C
-85.9°C
71.2 mm Hg at 20°C
1 ppm = 2.94 mg/m 3
1 mg/m 3 = 0.34 ppm
OCCURRENCE AND USE
MEK is used as a solvent in synthetic resins manufacturing and in
the surface-coating industry (ACGIH, 1991). We are not aware of any
use of MEK in the spacecraft, but MEK has been found in the cabin
atmosphere during several space-shuttle missions, ranging from 0.3 to
69 ppb (Huntoon, 1993). Off-gassing is probably the source of MEK
in space shuttles. Based on the off-gassing data in the Spacelab, it was
estimated that 3.8 g of MEK will be generated in the space station each
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day (J. Perry, Marshall Space Flight Center, personal commun., 1989).
PHARMACOKINETICS AND METABOLISM
Absorption
Most disposition studies of MEK were performed on humans, so the
following review refers to human results unless specified otherwise.
The average pulmonary uptake rate of MEK was 1.05 mg/min in work-
ers exposed to MEK at a concentration of 100 ppm (Perbellini et al.,
1984). In resting male volunteers exposed to MEK at 200 ppm for 4 h,
the expired MEK concentration was about 53 % of the inhaled MEK all
through the exposure (Liira et al., 1988a). It remained unchanged at
53% when the volunteers performed three 10-min, 100-watt-workload
exercises during the 4-h MEK exposure beginning at 5, 95, and 225
min (Liira et al., 1988a). At the end of the 4-h MEK exposure at 200
ppm, the venous blood concentration reached 80 #mol/L (5.8 #g/mL)
in the resting volunteers, and the venous blood concentration was 80%
higher in the volunteers who did the exercises (Liira et al., 1988a). In
another study, during a 4-h exposure to MEK at 100 or 200 ppm, the
venous blood concentrations of MEK reached about 1.8 or 3.5 #g/mL,
respectively, at 4 h (Liira et al., 1988a; Dick et al., 1988). The ve-
nous blood concentrations at 4 h were approximately 10-30% higher
than those at 2 h (Brown et al., 1987; Liira et al., 1988a; Dick et al.,
1988).
Metabolism and Excretion
In guinea pigs, MEK is reduced to 2-butanol or oxidized to 3-hy-
droxy-2-butanone and 2,3-butanediol (DiVincenzo et al., 1976). In hu-
man volunteers exposed to MEK at 200 ppm, Liira et al. (1988a) dis-
covered 2,3-butanediol in the urine. In contrast, Perbellini et al. (1984)
did not find 2-butanol or 2,3-butanediol in the urine of workers exposed
to MEK at concentrations equal to or lower than 300 mg/m 3 (100 ppm);
they found only 3-hydroxy-2-butanone in the urine. Liira et al. (1988a)
reported that 3 % of the absorbed MEK was exhaled unchanged and 2%
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was excreted as 2,3-butanediol in the urine during the 4 h of exposure
and 20 h after exposure. Miyasaka et al. (1982) found that only ap-
proximately 0.1% of MEK absorbed during an inhalation exposure was
excreted unchanged in the urine after the exposure in humans. These
data suggest that most of the absorbed MEK apparently entered into
intermediary metabolism (Liira et al., 1988a), so that, had these investi-
gators used radioactively labeled MEK, they would have found that
most of the MEK absorbed is eliminated from the body as CO2. Using
a physiologically based pharmacokinetic model, Liira et al. (1990a) esti-
mated that MEK metabolism would be saturated at an airborne MEK
concentration of 100 ppm at rest or 50 ppm during exercise. The satu-
rable metabolism of MEK explains why the MEK concentrations in
blood tend to vary nonlinearly with exposure concentrations above 100
ppm: the peak MEK concentrations in blood during a 4-h exposure of
resting human volunteers at 25,200, or 400 ppm were 0.3 _g/mL, 7.5
_g/mL, or 23.0 _g/mL, respectively (Liira et al., 1990a).
In humans exposed to MEK at a concentration of 200 ppm, MEK
was cleared from the blood in two exponential phases (Liira et al.,
1988a). The initial phase had a 30-rain half-life and the second phase
had an 81-min half-life. One and a half hours after a 4-h MEK expo-
sure at 200 ppm, the venous blood concentration of MEK dropped from
3.5 _g/mL to 1.0 #g/mL, and it decreased to below detectable concen-
trations 20 h after exposure in 22 volunteers (Dick et al., 1988). In
guinea pigs given MEK intraperitoneally at 450 mg/kg (a much higher
dose than the estimated dose of 28 mg/kg used in the inhalation study
by Liira et al. (1988a)), MEK was cleared from the blood monoexpo-
nentially with a much longer half-life of 270 min (DiVincenzo et al.,
1976).
TOXICITY SUMMARY
Acute and Short-Term Toxicity
Mucosal Irritation
The major acute toxicity of MEK is mucosal irritation. Nelson et al.
(1943) exposed 10 human subjects lk_r 3-5 rain to MEK or to 1 of 15
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other organic solvents and told them to rank the effects on the eye,
nose, and throat as either no irritation, slightly irritating, or very irritat-
ing. They were not told of the exposure concentrations. Unfortunate-
ly, Nelson et al. did not report whether they analytically determined the
exposure concentrations, and it appears that the exposures were done
using nominal concentrations. In the study, MEK at a concentration of
100 ppm resulted in slight nose and throat irritation. Mild eye irritation
was reported by some subjects at 200 ppm. Most, if not all of the sub-
jects, rejected the vapor at 300 ppm. In a mouse model of sensory irri-
tation, a 5-min exposure to MEK at 10,745 ppm reduced the respiratory
rate by 50% (De Ceaurriz et al., 1981).
Subchronic and Chronic Toxicity
In subchronic exposures, MEK is known to cause death, hepatic ef-
fects, and central-nervous-system (CNS) impairment.
Neural Studies
Although methyl n-butyl ketone is neurotoxic, MEK has been found
not to cause peripheral neuropathy in rats. A continuous exposure of
rats to MEK at 1125 ppm, 24 h/d. for up to 55 d in one study (Saida et
al., 1976) or a repetitive exposure to MEK at 700 ppm, 8 h/d, 5 d/w,
for 16 w in another (Duckett et al., 1979) failed to cause any peripheral
neuropathy. An exposure of five rats to MEK at 10,000 ppm in the
first few days and 6000 ppm thereafter for 8 h/d, 7 d/w, for 7 w re-
sulted in no neurological signs (Altenkirch et al., 1978). During the
MEK exposure, all the rats were excited in the initial several minutes,
but they became somnolent within 5-10 min (Altenkirch et al., 1978).
In the seventh week, all the rats died of severe bronchopneumonia as
determined by gross pathological and histological examinations (Alten-
kirch et al., 1978). Electron microscopic examination revealed no al-
terations of the sciatic, tibial, peroneal, and sural nerves (Altenkirch et
al., 1978).
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Mortality
As mentioned earlier, all five rats died after an exposure to MEK for
8 h/d, 7 d/w, for 7 w (Altenkirch et al., 1978). The exposure concen-
trations were 10,000 ppm in the first several days and 6000 ppm for the
balance of the 7 w. The 100% mortality was again obtained when the
experiment was repeated (Altenkirch et al., 1978). The mortality at
6000-ppm MEK seen in that study was probably of little significance at
lower exposure concentrations, because a 90-d study showed that expo-
sures of rats to MEK at 1250, 2500, or 5000 ppm, 6 h/d, 5 d/w, for 13
w failed to cause any increase in mortality compared with the control
group (Cavender et al., 1983).
Hepatic Effects
A 90-d exposure to MEK at 5000 ppm, 6 h/d, 5 d/w did not change
the morphology of any tissues, but it increased the liver weight and the
liver-to-body-weight ratio (Cavender et al., 1983). A similar exposure
at 2500 ppm increased the liver weight in the female rats but not in the
male rats, and it had no effect on the liver-to-body-weight ratio (Caven-
der et al., 1983). It can be concluded that a subchronic MEK exposure
could have a mild effect on the liver. In the same study, MEK at 5000
ppm decreased the SGPT slightly, and it increased the serum potassium,
glucose, and alkaline phosphatase levels in the females. A similar ex-
posure to MEK at 1250 ppm failed to elicit any toxic effects (Cavender
et al., 1983).
CNS Effects
Like most organic solvents, MEK might also impair the CNS at rela-
tively high concentrations (Patty et al., 1935; Altenkirch et al., 1978).
In an exposure of rats to MEK at 6000 ppm, 8 h/d, 7 d/w for 7 w, it
was discovered that the rats developed transient excitation in the first
few minutes of exposure followed by somnolence (Altenkirch et al.,
1978). After the somnolence set in, the rats were still arousable. An
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exposure of guinea pigs to MEK at 10,000 ppm for 13.5 h resulted in
incoordination in 90 min and narcosis in about 250 rain (Patty et al.,
1935).
Carcinogenicity
No carcinogenicity bioassay of inhaled MEK was found in the litera-
ture (EPA, 1990). A study with only 10 C3H/He mice per group
showed that a cutaneous application, twice a week for 1 y, of 50 mL of
a solution containing 25 % MEK resulted in no skin tumors, whereas a
skin tumor was found in 1 of 10 mice after a similar application of 29%
MEK (Horton, 1965). The animal data to assess the carcinogenicity of
MEK are inadequate..
Likewise, there are insufficient epidemiological data to determine
MEK's carcinogenicity, if any, in humans. Generally, uncertainties on
the exposure history of the study populations make it difficult to inter-
pret the epidemiological data reported in the literature.
In a retrospective cohort mortality study of 14,067 aircraft manufac-
turing workers who have spent, on the average, 15.8 y in the facility,
there was no significant excess of mortality from cancer of various or-
gans (Garabrandt et al., 1988). These workers were exposed to various
substances on their jobs, including aluminum alloy dusts, welding
fumes, methylene chloride, trichloroethylene, MEK, lubricating oils and
greases, and metal cutting fluids (Garabrandt et al., 1988). Forty-seven
percent of their jobs had a potential for MEK exposure (Garabrandt et
al., 1988). In another retrospective cohort mortality study, the stan-
dardized mortality ratio (SMR) for all cancers was much lower than
unity in 1008 male oil-refinery workers, and the SMR for prostate can-
cer was 1.82, which was not statistically significant (Wen et al., 1985).
These workers have been working in a lubricating-dewaxing process
with exposures to various solvents, primarily MEK and toluene, at con-
centrations below OSHA's standards (Wen et al., 1985).
In an historical prospective study of 446 men who had worked in two
MEK dewaxing plants, where they had been followed for 13.9 y on the
average, there was a statistically significant excess of deaths from buc-
cal cavity and pharynx cancers and fewer deaths from lung cancer
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(Alderson and Rattan, 1980). The investigators concluded that "there is
no clear evidence of a cancer hazard in these workers." Finally, child-
hood leukemia might be related to parents' occupational exposure to
MEK. A case-control study of children less than 10 y old showed a
statistically significant increase of leukemogenic risk in children whose
fathers had been occupationally exposed, after the children's birth, to
MEK, chlorinated solvents, spray paint, dyes, pigments, and cutting oil
(Lowengart et al., 1987). Because of exposure to a wide mixture of
chemicals, these epidemiology studies failed to demonstrate carcinoge-
nicity specifically associated with MEK in humans.
Genotoxicity
MEK was not mutagenic for several strains of Salmonella typhimu-
rium (Douglas et al., 1980; Florin et al., 1980), but it induced aneu-
ploidy in Saccharomyces cerevisiae strain M (Zimmermann et ai.,
1985). MEK was not found to be genotoxic in the mouse lymphoma
assay, unscheduled DNA synthesis assay, and micronucleus assay
(O'Donoghue et al., 1988).
Developmental Toxicity
MEK exposure at a concentration of 3000 ppm for 7 h/d on gestation
days 6-15 was not teratogenic in rats (Deacon et al., 1981). However,
a similar MEK exposure was mildly teratogenic in mice because a con-
centration-related trend of increases in misaligned sternebrae was found,
but no increase in any single malformation was seen at exposure con-
centrations up to 3000 ppm (Schwetz et al., 1991). MEK exposure at
3000 ppm for 7 h/d on gestation days 6-15 is slightly toxic to the fetus
by delaying ossification in the rat and reducing fetal weight in the
mouse (Deacon et al., 1981; Schwetz et al., 1991). It also decreased
the body-weight gain and increased the water consumption in the preg-
nant rats (Deacon et al., 1981), and it increased the maternal liver-to-
body-weight ratio in the mouse (Schwetz et al., 1991). It can be con-
cluded that MEK has only very slight developmental toxicity.
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Interaction with Other Chemicals
Ethanol has been found to affect MEK metabolism. In humans, in-
gestion of ethanol at 0.8 g/kg just before a 4-h exposure to MEK at 200
ppm resulted in increased blood concentrations of MEK and 2-butanol
and decreased blood concentrations of 2,3-butanediol (Liira et al.,
1990b).
Although MEK is not neurotoxic, it potentiates the neurotoxicity of
n-hexane. A weekly exposure of rats to n-hexane at 10,000 ppm, 8
h/d, 7 d/w led to slight weakness and severe paresis in some of the rats
in the eighth week (Altenkirch et al., 1978). A similar exposure to a
mixture of 1000-ppm MEK with 9000-ppm n-hexane hastened the neu-
rotoxicity development by the third week and caused a higher percent
of the rats to be inflicted with slight weakness and severe paresis
(Altenkirch et al., 1978). Exposure to the MEK and n-hexane mixture
also caused hypersalivation not produced by an exposure to n-hexane
alone (Altenkirch et al., 1978).
An explanation tbr the potentiation is that co-exposure to MEK and
n-hexane reduced the clearance of methyl n-butyl ketone, n-hexane's
neurotoxic metabolite, in rats (Shibata et al., 1990a), although MEK
also inhibited the oxidation of n-hexane to 2,5-hexanedione, another
neurotoxic metabolite (Shibata et al., 1990b). These findings were
made by the same investigators by exposing rats for 8 h to n-hexane at
a concentration of 2000 ppm plus MEK at concentrations of 0, 200,
630, or 2000 ppm (Shibata et al, 1990a,b). Because MEK reduced the
clearance of methyl n-butyl ketone, it is reasonable that an exposure of
rats to 1125-ppm MEK and 225-ppm methyl n-butyl ketone, 24 h/d for
35 or 55 d resulted in more severe nerve injuries than an exposure to
methyl n-butyl ketone alone at 225 ppm (Saida et al., 1976).
In addition to affecting n-hexane's metabolism, MEK also has an in-
fluence on xylene's metabolism. Exposure of male volunteers to MEK
at 200 ppm and m-xylene at 100 ppm for 4 h resulted in higher xylene
concentrations in the blood than an exposure to m-xylene alone at 100
ppm, because MEK inhibited m-xylene metabolism (Liira et al.,
1988b). However, m-xylene did not change the blood concentration of
MEK and the urinary excretion of 2,3-butanediol, an MEK metabolite
(Liira et al., 1988b).
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In conclusion, the interaction findings indicate that NASA needs to
be aware of the possibility that ethanol ingestion might potentiate
MEK's toxicity and MEK inhalation could potentiate the toxicity of
n-hexane, methyl n-butyl ketone, and m-xylene during combined expo-
sure. Due to the large number of possible combinations of these chemi-
cals, MEK's SMACs are not set based on the interaction information.
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TABLE 9-2 Exposure Limits Set by Other Organizations
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Organization Concentration, ppm
ACGIH's TLV 200 (TWA)
ACGIH's STEL 300
OSHA's PEL 200 (TWA)
TLV = threshold limit value. TWA = time-weighted average. STEL =
short-term exposure limit. PEL = permissible exposure limit.
TABLE 9-3 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m 3 Target Toxicity
1 h 50 150 Mucosal irritation
24 h 50 150 Mucosal irritation
7 da 10 30 Mucosal irritation
30 d 10 30 Mucosal irritation
180 d 10 30 Mucosal irritation
_The current 7-d SMAC = 20 ppm.
RATIONALE FOR
ACCEPTABLE CONCENTRATIONS
To set MEK's SMACs, the maximum acceptable concentrations
(ACs) for the various exposure durations, according to the different
toxic end points, are compared. The noncarcinogenic end points pro-
duced by MEK include mucosal irritation (Nelson et al., 1943), hepato-
megaly (Cavender et al., 1983), and CNS impairment (Altenkirch et
al., 1978). The NRC's Committee on Toxicology advised that MEK's
SMACs need not be set using hepatomegaly as an end point because of
doubtful clinical significance of a mild increase in liver weight absent
any histological hepatic damages. Accordingly, ACs are derived for
only mucosal irritation and CNS impairment.
Mucosal Irritation
A 3-5 min exposure at 100-ppm MEK produced slight nose and
throat irritation, but not eye irritation, in 10 human subjects (Nelson et
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al., 1943). There are no data on MEK's irritancy at 1 h. The best
time-response data on mucosal irritants are those gathered by Weber-
Tschopp et al. (1977) with acrolein. They showed that the nose irrita-
tion at 0.3-ppm acrolein increased from no irritation in the first few
minutes to mild irritation at 40 min, and the degree of throat irritation
went from no irritation in the first few minutes to very mild irritation at
40 rain. The severity of nasal and throat irritation did not change from
40 to 60 min of the 1-h exposure (Weber-Tschopp et al., 1977). As-
suming that MEK's irritancy develops with time like that of acrolein,
the nose and throat irritation produced by 100-ppm MEK at 1 h proba-
bly would be only mild to moderate.
There are no time-response data on MEK's mucosal irritation. How-
ever, if the exposure to MEK at 100 ppm were prolonged to more than
1 h, the degree of nose and throat irritation would most likely remain
mild to moderate because mucosal irritation, being a surface response,
is not expected to increase with time after the first hour. This is sup-
ported by the time-response data of two other irritants, acrolein and
formaldehyde. The mucosal irritancy of acrolein did not increase from
40 to 60 min into a l-h exposure (Weber-Tschopp et al., 1977), and the
mucosal irritancy in volunteers exposed to formaldehyde at 3 ppm was
mild to moderate at 1 or 3 h (Sauder et al., 1986; Green et al., 1987).
The 1-h and 24-h ACs based on mucosal irritation should be lower
than 100 ppm, because NASA should not subject the crew to more than
mild mucosal irritation in a 1-h or 24-h contingency. MEK's irritancy
appears to have quite a steep concentration-response curve. Although
all the subjects found a 3-5 min exposure to MEK at 300 ppm not toler-
able, only slight nose and throat irritation was felt at 100 ppm (Weber-
Tschopp et al., 1977). Therefore, a factor of 3 applied to the mildly to
moderately irritating concentration of 100 ppm should yield a nonirritat-
ing concentration of 33 ppm. Since some degree of nose and throat
irritation is acceptable in a 1-h or 24-h contingency, the 1-h and 24-h
ACs should be set slightly higher than the nonirritating concentration of
33 ppm, so the 100-ppm concentration is divided by an extrapolation
factor of 2 instead of 3.
1-h and 24-h ACs based on mucosal irritation
= mildly to moderately irritating level x l/extrapolation factor
= 100 ppm x 1/2
= 50 ppm.
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For the 7-d, 30-d, and 180-d ACs, it is important that mucosal irrita-
tion be prevented completely, so an extrapolation factor of 3 is used to
derive a nonirritating concentration from a mildly to moderately irritat-
ing concentration. To compensate for the relatively small number of
subjects used in getting the mildly to moderately irritating concentra-
tion, a safety factor is also used.
7-d, 30-d, and 180-d ACs based on mucosal irritation
= mildly to moderately irritating level x l/extrapolation factor
x l/small n factor
= 100 ppm × 1/3 x (square root of n)/10
= 100 ppm x 1/3 x (square root of 10)/10
= 10 ppm.
CNS Impairment
Dick et al. (1984, 1988) showed that a 4-h exposure of 137 human
volunteers to MEK at a concentration of 200 ppm had no effects on the
choice reaction time, visual vigilance, auditory tone tracking, auditory
discrimination, memory scanning, and postural sway test. Thus, the
NOAEL for CNS impairment is 200 ppm for a 4-h MEK exposure.
Classical pharmacokinetics analysis is used instead of the conserva-
tive Haber's rule to derive ACs for MEK on the basis of CNS impair-
ment. A pharmacokinetic technique is used to predict an MEK concen-
tration in blood during an inhalation exposure of humans to MEK. By
assuming that MEK's CNS effect is dependent on its concentration in
the blood, the pharmacokinetic technique can predict an acceptable ex-
posure concentration based on the prevention of CNS impairment. The
assumption is probably valid for two reasons. First, only 2% of the
absorbed MEK is excreted in the urine as 2,3-butanediol in human sub-
jects within a day of an MEK exposure (Liira et al., 1988a). This sug-
gests that only a very small fraction of absorbed MEK is converted into
organic metabolites in the body, with the majority going into intermedi-
ary metabolism (Liira et al., 1988a). Second, even when MEK is con-
verted into organic metabolites, such as 3-hydroxy-2-butanone and
2,3-butanediol, they are more polar than MEK and should be eliminated
much faster than MEK. From the data of Liira et al. (1988a) on the
rate of urinary excretion of 2,3-butanediol in human subjects after an
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MEK exposure, it can be estimated that the elimination half-life of 2,3-
butanediol is about 1 h, which is less than MEK's elimination half-life
of 81 rain determined in that study. Therefore, the organic metabolites
are not expected to contribute much to the CNS effect of MEK.
According to classical pharmacokinetics, during a continuous expo-
sure in which the subject is exposed to the same dose throughout, the
blood concentration would reach 87.5 % or 99% of the final steady-state
value at 3 or 7 elimination half-lives, respectively, past the start of the
exposure (Gibaldi and Perrier et al., 1975). It follows that the blood
concentration, expressed in percent of the final steady-state value that is
reached at a given time, expressed in number of elimination half-lives,
after the start of a continuous exposure, can be calculated with the fol-
lowing formula:
Concentration reached at time t = 100% - (100%/2"),
where t = n x elimination half-life.
Although the absorption rate might not stay constant in an inhalation
exposure (in fact as the body gradually absorbs a vapor, the absorption
rate should decrease with time of exposure), to simplify the analysis
and to err slightly on the conservative side, the absorption rate is as-
sumed to be constant throughout a continuous inhalation exposure.
With MEK, for instance, the expired MEK concentration was about
53 % of the inhaled MEK concentration all through a 4-h exposure of
human subjects at 200 ppm, indicating that the MEK absorption rate
remained constant through at least 4 h of an inhalation exposure. It is,
therefore, safe to assume that the blood concentration of the vapor will
be no higher than the concentration predicted by the formula above.
According to the formula, when an individual inhales a constant con-
centration of a vapor for time t equaled to 3 times the chemical's elimi-
nation half-life, the blood concentration will be 87.5 %, or about 90%,
of the steady-state concentration. The half-life of the elimination phase
of MEK is 81 min in humans (Liira et al., 1988a). In other words, the
blood concentration at 3 x 81 min, or 4 h, into an MEK inhalation ex-
posure is about 90% of the steady-state concentration. It can be calcu-
lated with the formula that the MEK concentrations in blood achieved
in a 4-h inhalation exposure should be 37% higher than those in a 2-h
exposure. Because measurements done in 70 male and female human
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subjects exposed to MEK at 100 or 200 ppm showed that the 4-h blood
concentration was, on the average, 35 % higher than that at 2 h, the for-
mula predicts the blood concentration quite well (Brown et al., 1987).
As predicted by the formula, the blood concentration will reach 99%
of the steady-state concentration if the inhalation exposure is extended
to time t equaled to 7 elimination half-lives. That means at 7 x 81
min, or 9.5 h, into an inhalation exposure to a fixed airborne MEK
concentration, the MEK concentration in blood would practically reach
steady state. If MEK's CNS effect is proportional to its blood concen-
tration, as assumed above, an airborne MEK concentration acceptable
for 9.5 h should also be acceptable for up to 180 d.
Dick et al. (1984, 1988) showed that a 4-h exposure to MEK at 200
ppm does not cause CNS impairment. Since the elimination half-life of
MEK is 81 min, 4 h is 3 elimination half-lives. As shown previously,
at 3 elimination half-lives into an inhalation exposure, the blood con-
centration should be about 90% of the final steady-state concentration.
So the data of Dick et al. can be interpreted to mean that a blood MEK
concentration of 90% the steady-state blood concentration produced by
a long-term continuous exposure to MEK at 200 ppm does not cause
CNS impairment. Therefore, the steady-state blood concentration of
MEK produced by a long-term continuous exposure to MEK at 180
ppm, which is equal to 90 % of 200 ppm, should also be devoid of CNS
effects. Because it only takes an MEK exposure of 9.5 h for the blood
concentration to reach steady state, the ACs based on CNS impairment
for 24 h, 7 d, 30 d, and 180 d are all estimated to be 180 ppm.
The l-h AC can be derived as follows: The pharmacokinetic for-
mula shows that, during an inhalation exposure to MEK, the MEK con-
centration in blood reached in 1 h should be 40% of that reached in 4
h. So a 1-h exposure to twice the 4-11 no-observed-adverse-effect level
(NOAEL) of 200 ppm should also yield an MEK blood concentration
that would not impair the CNS. Therefore, 400 ppm, which is twice
the 4-h NOAEL, is selected as the 1-h AC on the basis of CNS impair-
ment.
Establishment of SMAC Values
The various ACs are given in Table 9-4. Comparison of the ACs for
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mucosal irritation and CNS impairment shows that the l-h, 24-h, 7-d,
30-d, and 180-d SMACs are set at 50, 50, 10, 10, and 10 ppm, respec-
tively. Because neither irritation nor CNS impairment is expected to be
affected by microgravity-induced physiological changes, no micro-
gravity adjustments are needed for the SMACs.
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B10 Nitromethane
King Lit Wong, Ph.D.
Johnson Space Center Toxicology Group
Biomedical Operations and Research Branch
Houston, Texas
PHYSICAL AND CHEMICAL PROPERTIES
Nitromethane is a colorless liquid with a fruity odor (Sax, 1984).
Synonyms:
Formula:
CAS number:
Molecular weight:
Boiling point:
Melting point:
Vapor pressure:
Conversion factors
at 25°C, 1 arm:
Nitrocarbol
CH3NO2
75-52 -5
61
101.2°C
-29 °C
27.8 mm Hg at 20°C
1 ppm = 2.62 mg/m _
1 mg/m 3 = 0.38 ppm
OCCURRENCE AND USE
Nitromethane is used as a solvent, an intermediate in the chemical
synthesis of pharmaceuticals and pesticides, as a rocket fuel, and a sta-
bilizer for halogenated alkanes (EPA, 1985; ACGIH, 1986). Nitro-
methane is not known to be used in spacecraft, but it has been predicted
to be off-gassed in the Space Station Freedom (Leban and Wagner,
1989).
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PHARMACOKINETICS AND METABOLISM
No pharmacokinetic data have been found in the literature search.
Because nitromethane has been found to be toxic in rabbits after oral or
inhalation exposures, but not after cutaneous applications on closely
clipped abdominal skin (the liquid nitromethane applied was allowed to
remain on the skin until totally evaporated) (Machle et al., 1940), it
could be inferred that nitromethane is absorbed via the intestinal and
respiratory tracts and nitromethane might not be very well absorbed
through the skin.
There are no in vivo data on nitromethane metabolism. However, a
few studies have been performed with liver microsomal preparations.
Incubation of nitromethane with rat liver microsomes under oxidative
conditions has been shown to produce nitrite in one study (Marietta and
Stuehr, 1983) and to form nitrite and formaldehyde in a stoichiometric
fashion in another study (Sakurai et al., 1980). Anaerobic incubation
of rat liver microsomes with nitromethane produced only formaldehyde,
but not nitrite (Sakurai et al., 1980).
There is no study on the excretory pathways of nitromethane. How-
ever, nitromethane has been detected in the urine of mice not exposed
to nitromethane (Miyashata and Robinson, 1980).
TOXICITY SUMMARY
In in vitro systems, nitromethane is known to interact with certain
heme proteins. Incubation of cytochrome P-450, myoglobin, or hemo-
globin with nitromethane has been shown to form nitro complexes of
these heme proteins (Mansuy, 1977a,b). Nevertheless, it is unknown
whether these interactions contribute to any toxicity in the body during
nitromethane exposures.
Acute and Short-Term Toxicity
Nitromethane is known to produce certain symptoms and death in
laboratory animals. However, whether nitromethane is toxic to the
liver is a controversy.
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Lethality
The oral LDso of nitromethane in mice is 1.44 g/kg (Weatherby,
1955). There are very few inhalation studies with nitromethane.
Machle et al. exposed two rabbits and two guinea pigs per group to nit-
romethane vapor at concentrations ranging from 0.1% to 5 % in cumu-
lative exposure durations of 0.25-140 h (the cumulative exposure dura-
tions above 6 h consisted of daily 6-h exposures) (Machle et al., 1940).
The lethal responses of the two rabbits and two guinea pigs combined
varied with concentration x time (C x T) (Machle et ai., 1940). Clos-
er scrutiny of the data shows that the lethal response followed Haber's
rule only for exposures at concentrations of 0.10% or higher. No mor-
tality was recorded in the group exposed cumulatively to 0.05% nitro-
methane for 140 h, which is equivalent to a CxT of 7 %-h. The fact
that the group exposed at 0.05% for 140 h was an outlier was apparent
after the mortality data were tabulated (see Tables 10-1 and 10-2).
Miscellaneous Symptoms
Without reference to specific exposure concentrations, Machle et al.
(1940) reported that restlessness, slight mucosal irritation (no occular
TABLE 10-1 Mortality in Single Exposures (Machle et al., 1940)
Exposure Exposure
Concentration, % Time, h C x T Mortality
3 0.25 0.75 0/4
1 1 1 0/4
3 0.5 1.5 1/4
0.50 3 t.5 1/4
2.25 I 2.25 1/4
3 1 3 2/4
1 3 3 2/4
0.50 6 3 2/4
5 I 5 4/4
1 6 6 4/4
3 2 6 4/4
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TABLE 10-2 Mortality in Repetitive Exposures (Machle et al., 1940)
Exposure Exposure
Concentration, % Time, h C × T Mortality
0.25 12 3 3/4
0.10 30 3 2/4
0.05 140 7 0/4
discharge, coughing, or sneezing), slight narcosis, salivation, weakness,
ataxia, incoordination, circus movements, convulsions, and twitching
were produced by the exposures. In addition, the animals appeared un-
comfortable or ill. They reported that it took exposures at 3% or 5%
nitromethane for more than 1 h or 1% nitromethane for 5 h or more to
cause CNS symptoms in rabbits and guinea pigs.
Hepatic Toxicity
Weatherby (1955) showed that an oral administration of nitromethane
at 500 mg/kg in dogs produced marked fatty changes in the periportal
and midzonal regions of the liver 32 h after the administration. How-
ever, Dayal et al. (1989) reported that nitromethane injected intraperi-
toneally at 550 mg/kg failed to cause any liver histopathology or any
changes in the plasma levels of alanine transaminase, aspartate transam-
inase, and sorbitol dehydrogenase in mice. Similarly, no evidence of
hepatic toxicity has been found with inhalation exposure of nitrometh-
ane. Lewis et al. (1979) exposed 10 rats to nitromethane at 98 or 745
ppm, 7 h/d, tbr 2 d. The level of serum glutamic-pyruvic transaminase
(alanine transaminase) did not increase and no histopathology was de-
tected in various tissues, including the liver, in these animals. There-
fore, there is no evidence that nitromethane, at least via inhalation ex-
posures, is hepatotoxic.
Subchronic and Chronic Toxicity
Hepatic Toxicity
Subchronic nitromethane exposures might result in liver changes, but
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there is no evidence of any liver toxicity when animals inhaled nitro-
methane repetitively. Subcutaneous injections of nitromethane at 290
mg/kg every other day for 18 d in rats led to an 80% reduction of he-
patic histidase activity and two- to three-fold increases in the histidine
levels in the plasma and liver (Wang and Lee, 1973). There were no
changes in the levels of other amino acids in the plasma and liver, the
liver protein content, and the body-weight gain in these rats. Because it
is doubtful whether increases in the histidine levels in the plasma and
liver have any adverse health impacts, the SMACs are not set according
to these biochemical changes.
Weatherby (1955) exposed male rats at 0.1% or 0.25% nitromethane
in drinking water for 15 w. Cells with enlarged, prominent nuclei and
cytoplasm more granular than in the controls in both the 0.1% and
0.25% groups were observed in the liver. In the rats exposed at 0.25%
nitromethane, numerous lymphocytes were observed in the periportal
regions of the liver. In both nitromethane groups, the light microscopic
morphology of other tissues appeared normal. The National Research
Council Subcommittee on SMACs doubted the clinical significance of
these minor light microscopic changes in the liver. The subcommittee
advised that NASA disregard the hepatic end point in setting nitrometh-
ane's SMACs, especially because Lewis et al. (1979) failed to find any
increase in alanine transaminase or histopathology in the livers of rats
exposed to nitromethane at a concentration of 745 ppm, 7 h/d, 5 d/w,
for 10 d or 1, 3, or 6 mo. The hepatic findings of Weatherby (1955)
also had doubtful meaning in inhalation exposures of nitromethane be-
cause Griffin (1990) also did not detect any increases in the level of
alanine transaminase, aspartate transaminase, bilirubin or protein, or
any hepatic histopathology in rats exposed to nitromethane at 100 or
200 ppm, 7 h/d, 5 d/w, for 2 y.
Thyroid Toxicity
Exposures of rats to nitromethane have been shown to result in thy-
roid toxicity. An exposure of 10 rats at 98 or 745 ppm, 7 h/d, 5 d/w,
for 6 mo resulted in an increase in thyroid weight by 19% or 26%, re-
spectively, but no change in the thyroxine level in plasma (Lewis et al.,
1979). In contrast, an exposure of five rabbits to nitromethane at 98
ppm, 7 h/d, 5 d/w, for 6 mo caused a 48% reduction in the thyroxine
336 SMACs FOR SELECTED AIRBORNE CONTAMINANTS
level in plasma, but no change in the thyroid weight. However, a simi-
lar exposure of five rabbits at 745 ppm increased the thyroid weight by
38% and reduced the plasma thyroxine level by 52%. No thyroid
weight or thyroxine level changes were detected in 10 rats exposed at
98 or 745ppm, 7h/d, 5d/2, for2d, 10d, 1 mo, or3mo. Similarly,
no thyroid weight or thyroxine level changes were found in five rabbits
exposed to nitromethane at 98 ppm, 7 h/d, 5 d/w, for 1 or 3 mo (Lewis
et al., 1979). The thyroid data of Lewis et al. are summarized in Table
10-3.
Unfortunately, in the 2-y study conducted by Griffin (1990), he did
not weigh the thyroid or measure the serum levels of thyroid hormones
in rats exposed to nitromethane at up to 200 ppm. Despite a close to
50% reduction in thyroxine level and a 20-40% increase in thyroid
weight caused by a 6-too exposure to nitromethane at 98 or 745 ppm in
rabbits, the subcommittee on SMACs advised that nitromethane's
SMACs need not be set to prevent the thyroid toxicity. The subcom-
mittee's reasoning is that the thyroid changes are not clinically signifi-
cant in humans and that quite a number of chemicals known to produce
thyroid changes of similar magnitude in rodents do not produce any
thyroid disease in humans. It should be noted that nitromethane's effect
on thyroxine is opposite to that of microgravity. Studies done by
NASA showed that the blood concentrations of thyroxine and thyroid-
stimulating hormone were increased on the day astronauts returned to
earth after several Skylab and space-shuttle missions (Huntoon et al.,
1989).
TABLE 10-3 Thyroid Data from Rats and Rabbits
Nitromethane Concentration
Animal and 98 ppm 745 ppm
Parameter 3 mo 6 mo 3 mo 6 mo
Rats
Thyroxine level -t- _+ _ --I-
Thyroid weight + + 19% ___ +26%
Rabbits
Thyroxine level + -48% _+ --52%
Thyroid weight _ + 19% + +38%
NITROMETHANE 3 3 7
Hematological Changes
As mentioned earlier, nitromethane is metabolized in vitro to nitrite,
so there is a possibility that nitromethane produces methemoglobin.
Despite the fact that nitrite was found in the lung, heart, kidney, and
spleen of rats exposed to nitromethane at 13,000 ppm for 6 h, no met-
hemoglobin was detected (Dequidt et al., 1973). Similarly, Lewis et al.
(1979) did not find methemoglobinemia in rats and rabbits exposed to
nitromethane at 745 ppm, 7 h/d, 5 d/w, for 6 mo.
In the study of rats and rabbits exposed to nitromethane for 7 h/d, 5
d/w, the hematocrit and hemoglobin levels were reduced 5-12% in rats
exposed at 745 ppm for 10 d or 1, 3, or 6 too, but not in the rats ex-
posed for 2 d (Lewis et al., 1979). The rabbits appeared to be less sen-
sitive than rats to nitromethane's effects in causing anemia because a
13% reduction in hemoglobin levels was found in the rabbits only at 1
mo and not after 3 or 6 mo of repetitive exposures to nitromethane at
745 ppm. In addition, repetitive exposures of rabbits to nitromethane at
745 ppm for 1, 3, or 6 mo did not decrease the hematocrit.
There is evidence that chronic nitromethane inhalation exposures are
devoid of any hematological effects at up to 200 ppm. Griffin (1990)
exposed rats to nitromethane at 100 or 200 ppm, 7 h/d, 5 d/w, for 2 y
and found no changes in the red- or white-blood-cell counts, hemoglo-
bin concentration, hematocrit, and platelet count.
Pulmonary Toxicity
Lewis et al. (1979) showed that nitromethane caused pulmonary dam-
age in one group of rabbits at one time point. They observed moderate
to moderately severe focal lung hemorrhages and congestion, associated
with interstitial lung edema, in rabbits exposed to nitromethane at 745
ppm, 7 h/d, 5 d/w, for 1 mo. The interstitial pulmonary edema evi-
dently must not be severe because no increase in the wet-weight-to-
dry-weight ratio was found in the lung of these rabbits. These changes
in the pulmonary morphology were absent in the rabbits exposed to
nitromethane at 98 ppm. No lung histopathology was detected in
groups of 10 rats each exposed at 745 ppm, 7 h/d, 5 d/w, for 2 or 10 d
or 1, 3, or 6 mo. The apparent pulmonary toxicity discovered in these
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rabbits was not relied on in setting the SMACs for three reasons. First,
only five rabbits were exposed at 745 ppm for 1 mo. For lung mor-
phological evaluation, something highly susceptible to artifacts, more
animals are required to make the result more reliable. Second, the lung
changes were seen in the rabbit only at 1 mo but not at 3 or 6 mo. It is
highly suspicious that the morphological changes resolved after further
repetitive nitromethane exposures. Third, the lung changes have never
been reported by other investigators, including Weatherby (1955), who
exposed rabbits, rats, and dogs to nitromethane, and Griffin (1990),
who exposed rats to nitromethane at up to 200 ppm for 2 y (Machle et
al., 1940).
Effects on Reproductive Function
Nitromethane did not produce reproductive toxicity in female rats.
Intraperitoneal injections of nitromethane with 0.5 mL (equivalent to 46
mg) every third day, begun 1 w before the rats were bred and contin-
ued throughout gestation, failed to produce any changes in the percent-
age of successful matings, litter size, pup death rate, birth weights, or
maternal behavior (Whitman et al., 1977). The negative finding of re-
productive toxicity in rats exposed to nitromethane does not prove that
nitromethane is devoid of adverse effects on reproduction. According
to the subcommittee on SMACs, the rat is not an ideal model to test for
some classes of reproductive toxicity, and both male and female effects
can be difficult to detect in the absence of histopathological examina-
tion. This is particularly germane in an experiment such as this where
treatment began only 1 w before mating.
Carcinogenesis
Although an exposure to 2-nitropropane at 207 ppm, 7 h/d, 5 d/w,
for only 6 mo produced liver tumors in 10 out of 10 rats, a similar ex-
posure to nitromethane at 745 ppm failed to show any carcinogenicity
(Lewis et al., 1979). The lack of carcinogenic response to nitro-
methane has been proven by Griffin (1990) in rats exposed to nitro-
methane at 200 or 100 ppm, 7 h/d, 5 d/w, for 2 y.
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Genotoxicity
Nitromethane does not appear to be genotoxic. An exposure of Sal-
monella typhimurium (strains TA98, TA100, and TA102) to nitro-
methane at up to 200 /xmol per plate did not increase the mutation
frequency (Dayal et al., 1989).
Developmental Toxicity
No data on nitromethane's developmental toxicity were found in the
Toxline and Toxlit databases of the National Library of Medicine.
Interaction with Other Chemicals
No data on nitromethane's interaction with other chemicals were
found.
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TABLE 10-5 Exposure Limits Set by Other Organizations
343
Organization Concentration, ppm
ACGIH's TLV 100 (TWA)
NIOSH's IDLH 1000
OSHA's PEL 100 (TWA)
TLV = threshold limit value. TWA = time-weighted average. IDLH =
immediately dangerous to life and health. PEL --- permissible exposure limit.
TWA = time-weighted average.
TABLE 10-6 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m 3 Target Toxicity
1 h 25 65 Anemia
24 h 15 40 Anemia
7 da 7 18 Anemia
30 d 7 18 Anemia
180 d 5 13 Anemia
aThere was no 7-d SMAC.
RATIONALE FOR
ACCEPTABLE CONCENTRATIONS
The SMACs are set to protect the astronauts against the following
toxic end points: CNS symptoms and anemia. For a given exposure
duration, the SMACs are set by selecting the lowest acceptable
concentration (AC) among the two toxic end points. An acceptable
concentration for a toxic end point for a given exposure duration is de-
rived from the no-observed-adverse-effect level (NOAEL) for that end
point and that duration. Because all the NOAELs are estimated from
animal data, an interspecies factor of 10 is applied on all of them.
Other than the AC for anemia, no microgravity safety factor is needed
for other toxic end points because they are not known to be affected by
microgravity.
Miscellaneous Symptoms
Machle et al. (1940) reported that inhalation exposures of rabbits or
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guinea pigs led to slight mucosal irritation, but they did not report the
exposure concentration at which they detected mucosal irritation in the
animals. Similarly, both the ACGIH (1986) and Lewis et al. (1979)
commented that nitromethane is a mucosal irritant not supported by any
quantitative data. The SMACs are not set based on mucosal irritation
because there are no data on the irritating concentrations of nitrometh-
ane. Lewis et al., however, did state that the current permissible expo-
sure limit (PEL) of 100 ppm is sufficiently low to prevent respiratory
irritation based on animal data and industrial health experience. Be-
cause the SMACs are set below 100 ppm, it appears that mucosal irrita-
tion will not be a problem if Lewis et al. are correct.
Machle et al. (11940) also stated, without reference to any specific
exposure concentration, that nitromethane could produce restlessness,
narcosis, ataxia, incoordination, and convulsions in the rabbits and gui-
nea pigs they exposed. Since Lewis et al. (1979) did not mention these
symptoms in rats exposed to nitromethane at 98 or 745 ppm in a 90-d
study, the NOAEL for CNS symptoms is estimated to be 745 ppm.
l-h, 24-h, 7-d, 30-d, and 180-d ACs based on CNS symptoms
= 90-d NOAEL x 1/species factor
= 745 ppm x 1/10
= 75 ppm.
The 180-d AC based on CNS symptoms is set equal to the 30-d AC
because if CNS symptoms fail to develop in an exposure at 75 ppm for
30 d, it is highly unlikely that the symptoms will occur when the expo-
sure is extended to 180 d. The reason is that the CNS should equili-
brate with nitromethane in blood in 30 d.
Anemia
Exposures of rats to nitromethane at 98 ppm, 7 h/d, 5 d/w, caused
no anemia in 2 d to 6 mo, but a similar exposure at 745 ppm produced
anemia, as shown in Table 10-7, in 10 d to 6 mo (Lewis et al., 1979).
The 7% increase in the RBC count seen in the rat after 2 d of expo-
sure to nitromethane at 745 ppm (Lewis et ai., 1979) is not considered
important because it did not repeat itself in all the later time points. Be-
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TABLE 10-7 Changes in Red Blood Cells in Rats Exposed at 745 pp (Lewis
et al., 1979)
Parameter 2 d 10 d 1 mo 3 mo 6 mo
Hematocrit + -- 5 % -- 5 % -- 7 % -- 7 %
Hemoglobin "Jr- --7% --6% --12% -12%
concentration
RBC count + 7 % -- 7 % ___ + Jr"
cause no anemia was found in the rat after a 2-d exposure at 745 ppm,
745 ppm is chosen to be the 1-h NOAEL for anemic effects.
To derive the acceptable concentrations based on nitromethane's in-
duction of anemia, a microgravity safety factor of 3 is applied because
microgravity is known to reduce the RBC mass by 10-20% (Huntoon et
al., 1989). Three is chosen because 5 has been used for microgravity-
induced arrhythmia in the derivation of the ACs of other compounds.
The anemic effect is not as serious as the arrhythmic effect for the rea-
son that anemia is usually not life threatening, and some arrhythmia
could be. So a smaller safety factor is justified for the anemic effect
than that for the arrhythmic effect.
With the microgravity safety factor and the traditional interspecies
extrapolation factor, the 1-h and 24-h ACs are derived from the fact
that a 2-d exposure of rats to nitromethane at 745 ppm at 7 h/d did not
produce anemia in the study by Lewis et ai. (1979).
1-h AC based on anemic effects
= 2-d NOAEL x 1/species factor x 1/microgravity factor
= 745 ppm x 1/10 × 1/3
= 25 ppm.
Haber's rule is used to derive the 24-h AC.
24-h AC based on anemic effects
= 2-d NOAEL x time adjustment x 1/species factor
x 1/microgravity factor
= 745 ppm x (7 h/d x 2 d)/24 h x 1/10 x 1/3
= 745 ppm x 0.58 x 1/10 x 1/3
= 15 ppm.
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Lewis et al. (1979) showed that an exposure to nitromethane at 98
ppm, 7 h/d, 5 d/w, for 10 d, 1 mo, or 6 mo failed to produce any
changes in the hematocrit, hemoglobin concentration, and RBC count in
rats. However, based on Griffin's (1990) finding that an exposure of
rats to nitromethane at 200 ppm, 7 h/d, 5 d/w for 2 y, did not produce
any changes in the hematocrit, hemoglobin concentration, and RBC
count, 200 ppm is selected to be the NOAEL for anemia in a continu-
ous exposure lasting 7, 30, or 180 d.
7-d and 30-d ACs based on anemic effects
= 2-y NOAEL x 1/species factor × l/microgravity factor
= 200 ppm × 1/10 x 1/3
-- 7 ppm.
180-d AC based on anemic effects
= 2-y NOAEL x time adjustment x l/species factor
x 1/microgravity factor
= 200ppm x (7h/d x 5d/w x 104w)/(24h/d x 180d)
x 1/10 x 1/3
= 200 ppm x 0.84 x 1/10 x 1/3
= 5.6 ppm.
Establishment of SMAC Values
From the comparison of the various ACs at each time point, the l-h,
24-h, 7-d, 30-d, and 180-d SMACs are set at 25, 15, 7, 7, and 5 ppm,
respectively. As reported in the Toxicity Summary, acute exposures of
rabbits and guinea pigs to nitromethane by inhalation have been known
to cause death, according to Machle et al (1940). However, those mor-
tality data are not relied on in setting ACs because Machle et al. used
only two rabbits and two guinea pigs per combination of exposure con-
centration and duration. It is of interest, nevertheless, to assess wheth-
er exposures at the short-term SMACs are likely to be lethal using the
benchmark dose approach as follows (Beck et al., 1993).
The mortality data of rabbits and guinea pigs are combined and
grouped together in terms of C x T, which is the product of exposure
concentration in percent and exposure duration in hours. But the data
of the outlier group (animals exposed at 0.05 % nitromethane, 6 h/d for
NITROMETHANE 3 4 7
more than 23 d) are excluded. The mortality rates are plotted against
the logarithms of C x T of the exposure groups. Via probit analysis
according to Finney (1971), the lower 95% confidence limit of the LDs0
is estimated to be 0.49 %-h.
Acceptable C x T based on lethality for acute exposure
= Benchmark dose x 1/species factor
= 0.49 %-h z 1/10
= 490 ppm-h.
Acceptable concentration for a 24-h exposure
= 490 ppm-h x 1/24 h
= 20 ppm.
Acceptable concentration for a l-h exposure
= 490 ppm.
Because the 24-h and 1-h SMACs are lower than 20 and 490 ppm,
respectively, it is highly unlikely that any deaths will result from expo-
sures at these SMACs.
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Bll 2-Propanol
John T. James, Ph.D., and Harold L. Kaplan, Ph.D.
Johnson Space Center Toxicology Group
Biomedical Operations and Research Branch
Houston, Texas
PHYSICAL AND CHEMICAL PROPERTIES
Isopropyl alcohol is a colorless, volatile liquid at room temperature
(Rowe and McCollister, 1982).
Synonyms:
Formula:
CAS number:
Molecular weight:
Boiling point:
Melting point:
Specific gravity:
Vapor pressure:
Solubility:
Conversion factors
at 25°C, 1 atm:
Isopropanol, 2-propanol
CH3CHOHCH._
67-63-0
60.09
82.5°C
-89.5°C
0.79
44 mm Hg at 25°C
Miscible with water and most organic solvents
1 ppm = 2.45 mg/m 3
1 mg/m 3 = 0.41 ppm
OCCURRENCE AND USE
Isopropyl alcohol (IPA) is used commercially in the manufacture of
acetone, as a solvent, and in skin lotions, cosmetics, and pharma-
ceuticals (Rowe and McCollister, 1982). It is widely used by the public
in a 70% solution in water as rubbing alcohol to reduce fever and as a
disinfectant.
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The odor threshold in air is 22 ppm (Amoore and Hautala, 1983).
Isopropanol is consistently found in air samples taken during shuttle
flights at concentrations in the range of 0.1 to 10 mg/m 3 (James et al.,
1994). It originates from flight-hardware off-gassing and the use of
IPA as a disinfectant and cleaner.
PHARMACOKINETICS AND METABOLISM
Absorption
The pharmacokinetics and metabolism of IPA have been studied in
animals using oral and intravenous (i.v.) administration and, to a lim-
ited extent, using inhalation. Acute toxicity inhalation studies show that
IPA at high concentrations (near 20,000 ppm) is absorbed by the lungs
rapidly and in sufficient quantities to cause central-nervous-system
(CNS) depression and lethality within a few hours (Starrek, 1938 (cited
by Lehman and Flurry, 1943; Rowe and McCollister, 1982); Carpenter
et al., 1949). Apparently, sufficient IPA can be absorbed by rats in 4 h
at 2000 ppm to induce what the authors report as slight anesthesia ef-
fects (Nakaseko et al., 1991a). Studies of anesthetized dogs given IPA
injections into isolated segments of their alimentary tract showed that
absorption is more rapid from the intestine than from the stomach and
occurs rapidly (82% complete in 30 rain) (Wax et al., 1949). In four
workers exposed at a mean concentration of 410 ppm, the alveolar air
contained an average of only 100 ppm, whereas nine workers exposed
at an average of 140 ppm had an alveolar air concentration of only 56
ppm (Folland et al., 1976). This suggests a respiratory absorption of
60-75% in these concentration ranges. In a study of printing-plant
workers exposed to IPA in a range of concentrations up to 260 ppm,
the ratio of the alveolar concentration to the ambient concentration aver-
aged 0.4, suggesting an uptake of about 60% (Brugnone et al., 1983).
Distribution
Once IPA reaches the blood, it is distributed to the spinal fluid and
brain, liver, kidney, and skeletal muscle in dogs (Wax et al., 1949).
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The results did not suggest any pattern of preferential uptake by any of
these organs, nor did the distribution depend on concentration of IPA.
Excretion
The exact metabolic fate of IPA has not been established. Perfusion
experiments with isolated rabbit liver demonstrated that the liver con-
verts 30-50% of IPA to acetone (Ellis, 1952). Also in rabbits, IPA is
conjugated with glucuronic acid, but only 10% of the intragastrically
(i.g.) administered dose was accounted for in the urine as the gtucuro-
nide (Kamil et al., 1953). Acetone (19 ppm) was found in the expired
air of four workers exposed to IPA at an average of 410 ppm, and an
acetone concentration of 7.5 ppm was found in nine workers exposed at
an average of 140 ppm (Folland et al., 1976). In another study involv-
ing 12 printing-plant workers exposed to IPA at 3-260 ppm for 7 h the
elimination of acetone from the lungs reached a steady state in 6-7 h,
suggesting that blood concentrations of 1PA and acetone had also
reached steady-state concentrations (Brugnone et al., 1983).
Metabolism
Limited data are available on the metabolism of IPA in animals and
in humans. At the end of a 4-h exposure of rats to IPA at 8000 ppm,
the blood concentrations of IPA and acetone were nearly equal; how-
ever, at exposures at 500 to 1000 ppm, the acetone-to-IPA ratio was
about 3 (Laham et al., 1980). Twenty-four hours after ending the 8-h
exposure to 8000 ppm, the blood concentrations of IPA and acetone
were 0.008 and 0.110 mg/mL, respectively. In another study, after i.v.
administration of 1 or 2 g/kg to pigeons, rats, rabbits, cats, and dogs,
the rate of disappearance of alcohol from the blood during the 6 h after
equilibration depended on the dose as well as the species (Lehman et
ai., 1945). In contrast to the linear disappearance of ethanol, the disap-
pearance of IPA from the blood of dogs given large fractions of the
fatal dose was more rapid a few hours after administration than at times
approaching 24 h (Lehman et al., 1944). In two humans, who had in-
gested large doses of rubbing alcohol, and reportedly were heavy users
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of alcoholic beverages, the concentrations of blood IPA were consistent
with an exponential model with half-lives of 155 and 187 min (Daniel et
al., 1981).
Studies with enzyme inhibitors indicate that oxidation of IPA to ace-
tone is catalyzed by alcohol dehydrogenase (ADH). Pyrazole, an inhib-
itor of ADH and catalase, reduced the clearance of IPA from the blood
of rats and slowed the rate of acetone production (Lester and Benson,
1970; Nordmann et al., 1973). In contrast, pre-exposure of rats to 3-
amino-l,2,4-triazole, an inhibitor of catalase, did not result in blood
alcohol or acetone concentrations that were different from concentra-
tions in control animals (Nordmann et al., 1973).
TOXICITY SUMMARY
Acute Toxicity
Isopropyl alcohol vapor is irritating to the eyes and upper respiratory
tract, and is a CNS depressant at higher concentrations. At 400 ppm,
human volunteers exposed for 3-5 min experienced mild irritation of the
eyes, nose, and throat (Nelson et al., 1943). At 800 ppm, the effects
were not severe but were considered unsuitable for an 8-h workday.
Most subjects estimated 200 ppm as the highest concentration satisfac-
tory for 8 h.
No reports of CNS depressant effects in humans solely from inhala-
tion of IPA vapor were found in the scientific literature; however, many
cases of acute poisoning in humans from ingestion of IPA have been
reported (Adelson, 1962; King et al., 1970). Common manifestations
are nausea, vomiting, headache, and varying degrees of CNS depres-
sion, soon followed by coma with or without shock (Nelson et al.,
1943). When shock is present, death might occur within the first 24 h.
In a study of seven subjects given 10-15 cc IPA orally, Fuller and Hun-
ter (1927) found increased blood pressure, sensations of warmth, and
various degrees of dizziness and numbness. Tolerance was evident by
reduced responses on successive days of administration.
Animals exposed to vapors of IPA exhibit signs of CNS depression,
with the severity dependent on the concentration and duration of
exposure. In mice, ataxia was produced in 12-26 rain at a concentra-
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tion of 24,000 ppm and was increasingly delayed with decreasing con-
centrations until, at 3250 ppm, 180-195 rain of exposure were required
(Starrek, 1938). Prostration of mice occurred in 37-46 min at a con-
centration of 24,000 ppm but required almost 6 h at 3250 ppm. The
onset of narcosis ranged from 100 rain at a concentration of 24,000
ppm to almost 8 h at 3250 ppm. Exposure at 12,800 ppm for 200 min
or at 19,200 ppm for 160 min caused death in mice (Weese, 1928 (cited
by Rowe and McCollister, 1982)). Mice exposed for 8 h at 2050 ppm
did not show adverse effects (Starrek, 1938). The ability of IPA to
induce CNS depression in rats appears to be comparable to its ability in
mice. In rats, an 8-h exposure to IPA vapor at 16,000 ppm resulted in
the deaths of four of six animals (Smyth and Carpenter, 1948). In rats
exposed to IPA vapor for 4 h at 400, 2000, 4000, or 12,000 ppm, the
CNS effects (reduced reaction to sound and dragging hind legs) were
obvious only at the highest concentration. In the 2000- and 4000-ppm
groups, the authors reported reduced activity and the possibility that
anesthesia-type effects might have appeared in some rats during expo-
sures as low as 2000 ppm (Nakaseko et al., 1991a).
The anesthetic dose (elimination of corneal reflect) and lethal dose of
IPA by slow i.v. infusion were 2.5 and 6.5 g/kg, respectively, in rab-
bits and 2.7 and 4.1 g/kg, respectively, in dogs (Lehman and Chase,
1944). Although the anesthetic dose for the two species is almost iden-
tical, the anesthetic dose is about 40% of the fatal dose for the rabbit
and 65 % for the dog.
The principal effect of IPA administered intragastrically to rats, rab-
bits, and dogs was depression of the CNS, with salivation, retching,
and vomiting (Lehman and Chase, 1944). The LDs0 values for the rat,
rabbit, and dog were 5.3, 5.1, and 4.9 g/kg, respectively. Surviving
animals recovered rapidly from the depressant effects completely re-
turned to normal behavior. In another study, the oral LDso in young
adult rats was 4.7 g/kg, and the first observable toxic signs were at a
dose of 2.4 g/kg (Kimura et al., 1971).
Subchronic and Short-Term Toxicity
Rats were unaffected except tor slight intoxication when exposed in-
termittently over a week (total number of exposure hours not given) to
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air supposedly saturated with IPA vapor (Macht, 1922). Mice exposed
to IPA at 10,900 ppm, 4 h/d, for a total of 123 h of exposure were nar-
cotized but survived (Weese, 1928). Slight, reversible fatty changes
were observed in the liver. Pregnant rats were exposed to IPA at
10,000, 7000, and 3500 ppm, 7 h/d, for 19 d. No effects were ob-
served clinically at 3500 ppm; however, unsteady gait was observed at
the end of early 7000-ppm exposures but was not noticeable after the
later exposures (Nelson et al., 1988). The rats were narcotized at the
end of early 10,000-ppm exposures, but the effect diminished in later
exposures. Since the goal of the study was teratogenic effects, the dams
were not subjected to pathology evaluation.
Daily ingestion by human volunteers of IPA at 2.6 or 6.4 mg/kg in a
flavored syrup diluted with water for 6 w did not result in adverse signs
or symptoms (Wills et al., 1969). There were also no significant
changes in clinical chemistry measurements of blood or urine, BSP ex-
cretion, optical properties of the eyes, or the general well-being of the
subjects.
Chronic Toxicity
Rats exposed to IPA vapor at 8.4 ppm, 24 h/d, for 3 mo showed
alterations in reflexes, enzyme activities, BSP retention, leukocyte
count, total nucleic acids, urine coproporphyrin, and morphology of the
lung, liver, spleen, and CNS (Baykov et al., 1974). At 1.0 ppm, there
were lesser changes in some of these end points, and at 0.27 ppm, there
were no alterations. These findings are difficult to evaluate in view of
their variance with other data and inadequate details on experimental
design and statistical analysis.
Ingestion by rats of IPA in drinking water at 0.5-5% for 27 w did
not result in any definite toxic signs other than a slight retardation of
growth and the probable accidental death of some animals (Lehman and
Chase, 1944). There were no gross or microscopic abnormalities in the
brain, pituitary, lungs, heart, liver, spleen, kidneys, or adrenals.
Ingestion by three dogs of IPA in drinking water at 4% for 1 h daily
(average of 1.3 g/kg/d) over 6 mo produced inebriation for 3-5 h daily
but otherwise normal, healthy behavior (Lehman et al., 1945). At the
end of 6 too, an i.v. test dose indicated the development of tolerance
manifested by a decreased response to IPA and an increased rate of
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removal of alcohol from the blood. Histopathological changes were
limited to the kidneys of one and the brains of two of the three dogs.
In contrast to the report by Baykov et al. (1974), 3-mo intermittent
exposures of rats to IPA were without adverse effect up to 1000 ppm
(Nakaseko et al., 1991b). Rats were exposed 4 h/d, 5 d/w, and were
evaluated for hematological, clinical chemistry, and organ-weight
changes. At concentrations of 4000 and 8000 ppm, mucous membrane
irritation was evident, and a decrease in red-blood-cell (RBC) count
occurred. At 8000 ppm, there was an increase in liver enzymes, and
liver and spleen weights were reduced. Using 8-h daily exposures, 5
d/w for 20 w, the authors found delayed transmission velocity in the
tail peripheral nerve in rats exposed at 8000 ppm but not in rats
exposed at 1000 ppm (Nakaseko et al., 1991b).
Reproductive and Developmental Toxicity
The reproductive and developmental effects were studied in rats
given 2.5% IPA in their drinking water over two generations (Lehman
et al., 1945). First-generation males and females had retarded growth
early in life, but nearly caught up with the control group by the 13th
week. The second-generation rats showed no retardation of growth in
either sex. The study is certainly incomplete by modern standards; how-
ever, the authors conclude that IPA does not produce deleterious effects
on reproductive function or embryonic development.
Developmental effects have been reported in rats, but only at IPA
concentrations that are toxic to the dams (Nelson et al., 1988). There
were increased resorptions and decreased fetal weights from dams
exposed at 10,000 ppm, 7 h/d, for 19 d. These results might have been
due to IPA's being administered excessively early in gestation. Only
decreased fetal weights were seen after exposures to IPA at 7000 ppm,
and no effects were seen after exposures at 3500 ppm. The dams were
narcotized at 10,000 ppm and showed mild CNS effects at 7000 ppm.
Genotoxicity
Recently, a Tier 1 (Toxic Substances Control Act) mutagenicity
evaluation has been completed in response to recognition that regulatory
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risk assessment on IPA was hampered by insufficient data. In eight
strains of Salmonella tested with and without S-9 activation, IPA was
not found to be mutagenic (Zeigler et al., 1992). In vitro sister chrom-
atid exchange assays using V79 cells, with and without S-9 activation,
were also negative for mutagenic activity (Vonder Hude et al., 1987).
Further demonstration of the lack of mutagenic activity of IPA was re-
ported in a Chinese hamster ovary gene mutation assay and in a bone-
marrow micronucleus test (Kapp et al., 1993).
Carcinogenicity
In the early 1940s, suspicion was raised that a carcinogen was in-
volved in the industrial process used to produce isopropanol. Eventu-
ally, studies in mice showed that isopropyl oil, a waste product of the
production, was most likely the cause of the observed human cancers
(Weil et al., 1952). No tumorigenic activity was observed in mice ex-
posed to IPA vapor at 4000 ppm, 3-7 h/d, 5 d/w, for 5-8 mo or when
IPA was administered by skin painting or subcutaneous injection (Weil
et al., 1952). Epidemiological studies of workers in isopropyl alcohol
plants in the United States and United Kingdom have not shown a sig-
nificant excess of mortalities or malignant diseases (Alderson and Rat-
tan, 1986).
Interaction with Other Chemicals
Isopropyl alcohol has been shown to potentiate the toxicity of several
halogenated hydrocarbons. In rats, intubation of IPA at 2.3 g/kg for
16-18 h before exposure to carbon tetrachloride vapor at 1000 ppm
caused significantly greater serum SGOT activity than that produced by
carbon tetrachloride alone (Cornish and Adefuin, 1967). Pre-exposure
of rats with IPA before intraperitoneally injected carbon tetrachloride
resulted in increased serum SGPT activity, hepatic triglyceride content,
and total serum bilirubin and in decreased hepatic glucose-6-phospha-
tase activity (Traiger and Plaa, 1971). Suggested mechanisms for the
potentiation include lysosomal alterations, changes in the endoplasmic
reticulum, stimulation of drug-metabolizing enzymes, and increased
sensitivity of hepatocytes to carbon tetrachloride (Cot6 et al., 1974).
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In mice, pre-exposure with IPA or acetone by gavage potentiated the
hepatotoxic response to chloroform, l,l,2-trichloroethane, and trichlo-
roethylene, as measured by serum SGPT activity, but not to 1,1,1-tri-
chloroethane (Traiger and Plaa, 1974).
In an industrial exposure of workers, toxic effects, including renal
failure and hepatitis, were attributed to the potentiation of carbon tetra-
chloride toxicity by IPA, following the inhalation of vapors of the two
chemicals (Folland et al., 1976).
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TABLE 11-2 Exposure Limits Set by Other Organizations
Organization Concentration, ppm
ACGIH's TLV 400 (TWA)
ACGIH's STEL 500
OSHA's PEL 400 (TWA)
OSHA's STEL 500
NIOSH's REL 400 (TWA)
NIOSH's STEL 500
NIOSH's IDLH 12,000
NRCs 1-h EEGL 400
NRC's 24-h EEGL 200
NRC's 90-d CEGL 1
TLV = threshold limit value. TWA = time-weighted average. STEL =
short-term exposure limit. PEL = permissible exposure limit. REL = recom-
mended exposure limit. IDLH = immediately dangerous to life and death.
EEGL = emergency exposure guidance level. CEGL = continuous exposure
guidance level.
TABLE 11-3 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m 3 Target Toxicity
1 h 400 1000 CNS depression, irritation
24 h 100 240 CNS depression, irritation, hepatoxicity
7 d a 60 150 CNS depression, irritation, hepatoxicity
30 d 60 150 CNS depression, irritation, peripheral
nerve damage
180 d 60 150 CNS depression, irritation
"Previous 7-d SMAC was 50 ppm.
RATIONALE FOR
ACCEPTABLE STANDARDS
CNS depression should be of primary concern in setting SMAC val-
ues for IPA vapor; however, hepatotoxicity must also be considered
because of early reports of fatty liver in mice (Weese, 1928) and liver
enzyme elevation after prolonged exposures at high concentrations
(Nakaseko et al., 1991b). One investigator has also reported conduc-
tion decreases in peripheral nerves after prolonged high exposure
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(Nakaseko et al., 1991b). Additionally, the vapor has the potential to
cause irritation of the eyes and upper respiratory passages. Although
mild irritation might be acceptable under emergency short-term
conditions, long-term SMACs should protect against all adverse effects
during prolonged exposure. Finally, in setting acceptable
concentrations (ACs), the Baykov et al. (1974) report will be
disregarded because it is not consistent with the weight of evidence
from other studies. Guidelines from the National Research Council's
Committee on Toxicology have been used to structure the rationale for
astronaut exposure limits (NRC, 1984).
CNS Depression
A combination of animal inhalation studies, structure-activity
arguments, and human-worker studies were used to derive ACs to
protect against CNS effects. Based on graphical data derived from mice
exposed to various IPA concentrations up to 8 h, a no-observed-
adverse-effect level (NOAEL) for ataxia (first instability) could be
estimated (Lehman and Flury, 1943). For a 1-h exposure, that value
was 12,000 ppm (30 mg/L); however, clinically evident ataxia is not a
sensitive end point for CNS effects. The question is what factor would
be suitable to correct the ataxia NOAEL to a true NOAEL? A factor of
2 appears to be suitable based on two arguments. First, it was noted
that increasing the 1-h IPA concentration to 22,000 ppm (approximately
doubling the 12,000 ppm value) resulted in more serious CNS effects;
specifically, the mice became prone. That result suggests that halving
the 12,000-ppm value would greatly reduce the magnitude of any CNS
effects. Second, ethanol appears to have approximately the same
capacity as IPA to induce CNS effects in mice by inhalation (ethanol at
13,300 ppm in 100 rain induces ataxia) (Rowe and McCollister, 1982).
The CNS effects of ethanol are such that doubling the concentration
from 0.06-0.08% to 0.12-0.15% causes the CNS effect to increase from
"beginning of uncertainty" to "stupor" (Rowe and McCollister, 1982).
Using this NOAEL correction factor of 2, the 1-h AC based on CNS
effects was calculated as follows:
1-h AC based on CNS effects
= 12,000 ppm x 1/10 (species factor) x I/2 (NOAEL)
= 600 ppm.
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This value is consistent with rat data from Nakeseko et al. (1991b) in
which they report that animals exposed to IPA at 8000 ppm did not
show effects of anesthesia resulting from the first half of 4-h (or 8-h)
exposures. In 4-h exposures, Nakeseko et al. (1991a) clearly observed
CNS effects in less than 1 h at a concentration of 12,000 ppm, but no
definite CNS effects were reported after a 4-h exposure at 2000 ppm.
To protect against CNS depression for exposure periods longer than
1 h, an exposure concentration must be found that avoids accumulation
of blood concentrations of IPA or acetone that is associated with CNS
depression. In nine workers exposed during a 7-h work shift to average
concentrations between 40 and 200 ppm (average 110 ppm), Brugnone
et al. (1983) made the following observations:
• The uptake of IPA from the air was about 60%.
• IPA was not detectable in blood or urine (limit of detection was 1
mg/L).
• In three workers exposed to IPA at 193-202 ppm, the blood ace-
tone average was 7.2-8.2 mg/L.
• Blood acetone concentrations with IPA exposures were highly cor-
related.
• The slope of the regression lines (IPA exposure vs. blood acetone
concentration) suggested a steady state alter 3 h of exposure.
These data indicate that any CNS effects would correlate with blood
acetone concentrations rather than IPA concentrations. In 22 subjects
exposed to acetone at 250 ppm, the blood concentrations after 4 h aver-
aged 15 mg/L, and there were slight psychomotor perIbrmance decre-
ments; however, at exposures to acetone at 125 ppm (plus methyl ethyl
ketone at 100 ppm) the blood acetaldehyde concentration averaged 10
rag/L, and no performance decrements could be deleted (Dick et al.,
1988). This latter blood acetone concentration (10 mg/L) is slightly
above that seen in the three most heavily exposed workers (7-8 mg/L)
from the Brugnone IPA study. Since a steady state is reached between
IPA exposure and blood acetone after 3 h of exposure, it may be con-
cluded that 100-ppm IPA is a safe concentration to avoid CNS effects
even during prolonged exposure.
This conclusion is consistent with mouse data showing no ataxia at
2050 ppm after an 8-h exposure (Starrek, 1938). Using the factor of 2
to correct the ataxia NOAEL to a true NOAEL (see discussion above)
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and noting that accumulation after 8 h would be negligible, the AC to
avoid CNS effects for long exposures was calculated as follows:
AC based on CNS effects
= 2050 ppm x 1/10 (species factor) x 1/2(NOAEL)
= 100 ppm.
Peripheral Nerve Damage
Prolonged exposure of a total of 800 h induced decreases in periph-
eral nerve conduction velocity in rats exposed to IPA at 8000 ppm but
not in those exposed at 1000 ppm (Nakaseko et al., 1991b). This find-
ing was used to set a 30-d (720 h) AC as follows:
30-d AC based on peripheral nerve damage
= 1000 ppm x 1/10 (species factor)
= 100 ppm.
Irritation
Exposures of approximately 10 human subjects to IPA at concentra-
tions of 200, 400, and 800 ppm for 3-5 min resulted in mild irritation
at 400 ppm and the conclusion, by the test subjects, that 200 ppm
would be satisfactory for 8 h (Nelson et al., 1943). Even though the
study leaves some doubt about how such conclusions were reached, it
appears that 400 ppm would be acceptable for 1-h exposures because
tolerance to the irritating sensation of alcohols develops quickly. The
200-ppm value would be more suitable for a 24-h exposure where the
risk of irritation would have to be minimal. Irritation would not be
acceptable for long-term exposure; hence, a long-term NOAEL was
calculated using the recommended approach for studies involving a
small number (n = 10) of test subjects. Specifically,
AC based on irritation
= 200 ppm x (square root of 10)/10 (small n factor)
= 60 ppm.
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Hence, the 7-, 30-, and 180-d ACs to prevent irritation from IPA were
all set at 60 ppm.
Hepatotoxicity
Liver injury is not usually thought of as an important effect of IPA
exposure; however, an early study involving repeated inhalation expo-
sure of mice reported reversible fatty changes in the liver (Weese,
1928). A lowest-observed-adverse-effect level (LOAEL) for liver
effects was a cumulative exposure of 123 h (in 4-h segments) at 11,000
ppm. Based on this observation, the 24-h AC was 110 ppm with
uncertainty factors of 10 for LOAEL to NOAEL and 10 for species
extrapolation. This may be extended to 7 d by reducing the value by
168 + 123 to give 80 ppm. Extending estimates to longer times was
based on the 4000-ppm NOAEL reported in rats exposed 20 h/w for 13
w (Nakeseko et al., 1991b).
The 7-d AC based on liver injury calculated that way gave an AC of
400 ppm. The 30-d AC was calculated by applying a time factor based
on Haber's rule (720 + 260) to derive an AC of 140 ppm.
RECOMMENDATIONS FOR
ADDITIONAL RESEARCH
Many of the IPA toxicity studies, particularly the inhalation studies,
were completed 40 or more years ago. Over that time, many new
regulatory guidelines have been developed to provide data that are more
useful for setting human-exposure standards. In addition, methods of
measuring CNS effects in animals, and performance decrements in
humans have improved considerably over the past 40 years. Hence,
standardized inhalation studies in rodents, including a long-term,
continuous-exposure study with multiple end-point assessments (to
determine the accuracy of Baykov et al., 1974), are needed to resolve
questions of dose-response and target organs. Short-term human
inhalation studies are needed to better understand IPA irritancy and
tolerance phenomena. Finally, metabolic studies are needed to better
define the adsorption, metabolism, and fate of inhaled IPA.
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NOTE ADDED IN PROOF
As this document was going to press, two studies were published that address
many of the recommendations above. Slauter et al. (Slauter, R.W., D.P.
Coleman, N.F. Gaudette, R.H. McKee, L.W. Masten, T.H. Gardiner, D.E.
Strother, T.R. Tyler, and A.R. Jeffcoat. 1994. Fundam. Appl. Toxicol 23:
407-420) reported valuable data on the distribution, metabolism, and excre-
tion of IPA in rats and mice exposed for 6 h at a concentration of 500 or
5000 ppm. Burleigh-Flayer et al. (Burleigh-Flayer, H.D., M.W. Gill, D.E.
Strother, L.W. Masten, R.H. McKee, T.R. Tyler, T. Gardiner. 1994.
Fundam. Appl. Toxicol 23:421-428)showed that repeated exposures to IPA
for 13 w produced clearly toxic effects in rats and mice only at a concen-
tration of 5000 ppm. Nephropathy was found in male rats at lower expo-
sures, but this type of lesion has questionable relevance to human risk assess-
ment. Clinical signs of CNS effects (narcosis, ataxia, and hypoactivity) were
reported in some mice during, but not immediately after, exposures at 1500
ppm; however, later exposures of mice at 2500 ppm did not fully confirm
the presence of CNS effects such as ataxia at 1500 ppm (H.D. Burleigh-
Flayer, Busby Run Research Center, Union Carbide Chemicals and Plastics
Co., Export, Pa., personal commun., 1995). Additonal new studies on IPA
will be published soon and a re-evaluation of the SMACs in light of the new
data should be completed at that time.
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B12 Toluene
Hector D. Garcia, Ph.D.
Johnson Space Center Toxicology Group
Biomedical Operations and Research Branch
Houston, Texas
PHYSICAL AND CHEMICAL PROPERTIES
Toluene is a clear, colorless, non-corrosive, flammable liquid with a
sweet, pungent, "aromatic" odor. Values reported for the odor thresh-
old range from 0.2 to 16 ppm (Sandmeyer, 1981).
Synonyms:
Formula:
Structure:
CAS number:
Molecular weight:
Boiling point:
Melting point:
Liquid density:
Vapor pressure:
Solubility:
Conversion factors
at 25°C, 1 atm:
Antisal, phenyl methane, methacide, methyl
benzene, methylbenzol, NCI-C07272, tolueen,
toluen, toluol, toluolo, tolu-sol, UN 1294
C7H 8
//_ ,,\
,/
108-88-3
92.14
110.62°C
-95°C
0.8869
36.7 mm Hg at 30°C
Insoluble in water
Very soluble in alcohol and ether
1 ppm = 3.77 mg/m 3
1 mg/m 3 = 0.265 ppm
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OCCURRENCE AND USE
Toluene has been measured in urban air at 0.01-0.05 ppm, probably
stemming from production facilities, automobile and coke-oven emis-
sions, gasoline evaporation, and cigarette smoke, and can occur in hu-
man respiratory air in smokers and nonsmokers (Sandmeyer, 1981). It
is used extensively as a component of gasoline, as a solvent in the
chemical, rubber, paint, and drug industries, as a thinner for inks, per-
fumes and dyes, and as a nonclinical thermometer liquid and suspension
solution for navigational instruments (Sandmeyer, 1981). Intentional in-
halation of toluene vapors from glue was popular among some youth
during the last few decades because of toluene's effects on the central
nervous system (CNS). Toluene has been detected in spacecraft air in
numerous missions at levels of up to 64 ppm.
PHARMACOKINETICS AND METABOLISM
Absorption
The major route of absorption of toluene is by inhalation. During in-
halation, arterial blood concentrations of toluene in humans reach 60%
of maximum in 10-15 min (Benignus, 1981a). A linear relationship was
found between toluene concentrations in alveolar air and arterial blood
in human subjects exposed to toluene at 100, 300, 500, and 714 ppm
for 20 rain per concentration (Gamberale and Hultengren, 1972). Re-
ports of uptake rates (to 95% of asymptote) in humans exposed at up
to 500 ppm vary from 10 to 80 rain (Gamberale and Hultengren, 1972;
Veulemans and Masschelein, 1978; Benignus, 1981a). Exercise in-
creases the rate of uptake (Benignus, 198la). Retention, including from
cigarette smoke, was 86-96% (Sandmeyer, 1981). In mice, however,
Peterson and Bruckner (1978) reported that the arterial blood concentra-
tion did not approach maximum values until about 2 h after the onset of
exposure to toluene at 4000 ppm and was still rising slightly after 3 h.
Distribution
Inhaled toluene is distributed widely throughout the body, most rap-
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idly into highly vascularized tissues, with fatty tissues acting as reser-
voirs. During exposure, the concentrations of toluene are highest in the
liver, then the brain and blood (Bruckner and Peterson, 1981a).
Excretion
The majority of inhaled toluene is exhaled unchanged. Toluene con-
centrations fall off rapidly after cessation of exposure, dropping to 30%
of maximum in humans in 40 rain and near zero levels in 4 h when
subjects are at rest (Benignus et al., 1981). In rats, toluene blood
concentrations fall to 50% of maximum about 60 min after termination
of exposure (Benignus, 1981b). In humans, about 80-85% of total
toluene is excreted in the urine as conjugates of benzoic acid. Of this,
about 80% is hippuric acid (the glycine conjugate of benzoic acid) and
20% is benzoylglucuronide (the glucuronic acid conjugate of benzoic
acid). In 23 male volunteers inhaling toluene vapor for 3 h or 7 h
(with a break of 1 h), the excretion of urinary hippuric acid over an 18-
h period was equivalent to 68% of the toluene absorbed (Ogata et al.,
1971). In humans exposed to toluene at up to 200 ppm, the total
amount of hippuric acid excreted was proportional to the total exposure
(ppm / h) (Ogata et al., 1971).
Metabolism
Toluene is metabolized in several ways, but mainly it is converted by
oxidation of the methyl group to benzoic acid via benzyl alcohol and
benzaldehyde in the microsomes of the liver parenchymal cells
(Benignus et al., 1981). Benzoic acid is conjugated with glycine to
form hippuric acid (80%) and with glucuronic acid to form benzoylglu-
curonide (20%), which are excreted in the urine (Benignus et al.,
1981). Possible ethnic differences in toluene metabolism were reported
for Chinese, Turkish, and Japanese solvent workers; the male Japanese
excreted almost twice as much hippuric acid as the male Chinese under
similar exposure conditions, although the difference was less marked
between female Chinese and Japanese workers, and there were no
differences in the excretion of o-cresol (lnoue et al., 1986).
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TOXICITY SUMMARY
Acute and Short-Term Toxicity
Lethality
The LCso in Fischer rats for a 60-rain inhalation exposure to toluene
vapors is 26,700 ppm, and the LC_(x) for a 60-rain inhalation exposure
is about 40,000 ppm (Pryor et al., 1978). During inhalation studies in
which continuous exposure and fixed concentrations of toluene vapor
were used, the LCs0 was a function of both the concentration of toluene
and the duration of exposure. A group of pregnant rats (n = 9) ex-
posed to toluene at 400 ppm continuously for 8 d had a 28% mortality,
but no mortality was seen at 266 ppm (n = 10) (Hudfik and Ungv_iry,
1978). A later publication from the same laboratory indicated that rats
could be exposed to toluene at 950 ppm for 48 h, starting on d 10 of
pregnancy without significant maternal mortality (Ungvfiry et al.,
1982).
Irritation and CNS Effects
In 16 volunteers, 21-32 y old, exposure to toluene at 40 ppm for 6 h
has been shown to be a no-observed-adverse-effect level (NOAEL) for
irritation and CNS effects, including vigilance, visual perception,
psychomotor functions, and higher cortical functions (Andersen et al.,
1983). In the same study, 100 ppm was lound to cause slight irritation
of eyes and nose and increased headaches, dizziness, and a feeling of
intoxication: in another study (Gamberale and Hultengren, 1972), 100
ppm was found to be a NOAEL for impairment of reaction time.
In a Danish study, 20 printers previously occupationally exposed for
%25 y to a mixture of solvents containing toluene at 0-20% and 22
naive control subjects were exposed to toluene at 100 ppm for 6 h. All
42 exposed subjects complained of low air quality, strong odor, fatigue,
sleepiness, a feeling of intoxication, and irritation of the eyes, nose, and
throat. The exposed naive control subjects showed a statistically signifi-
cant 1% decrease in manual dexterity, decreased color discrimination,
and slightly decreased accuracy in visual perception compared with un-
exposed naive controls (Bzelum et al., 1985).
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Male rats and mice exposed to toluene at 12,000 ppm for 5 min ex-
hibited marked depression, but recovered fully after breathing fresh air
for 10 min (Bruckner and Peterson, 1981a). A study by Guillot et al.
(1982) reported that a 1-h exposure to liquid toluene using several pro-
tocols irritated rabbits' eyes, but the irritation was reduced to slight ir-
ritation if the eyes were rinsed 30 s alter instillation.
Subchronic and Chronic Toxicity
Histopathology, Clinical Chemistry, and Hematology
A well-executed chronic inhalation study in F344 rats performed by
the Chemical Industry Institute of Toxicology in 1980 failed to show
any adverse effects at the doses tested (Gibson et ai., 1983). Groups of
120 male and 120 female F344 rats were exposed to toluene at 30, 100,
or 300 ppm (>99.98% pure), 6 h/d, 5 d/w, for 24 mo. An unexposed
group of 120 male and 120 female rats served as a control. Clinical
chemistry, hematology, and urinalysis tests were conducted at 18 and
24 mo. All parameters measured at the termination of the study were
normal except for a dose-related reduction in hematocrit values in fe-
males exposed to toluene at 100 and 300 ppm. Forty-one tissues from
each animal (5-76 animals per group) sacrificed at 6, 12, 18, and 24
mo were examined grossly and histopathologically. The authors consid-
ered the highest dose of 300 ppm to be a NOAEL.
Hepatotoxicity and Nephrotoxicity
Evidence for liver and kidney toxicity by toluene is weak and incon-
sistent. Rats exposed to toluene at 5000 ppm for 7 h/d for 25 expo-
sures showed reversible increases in kidney and liver weights (Von
Oettingen, 1942). Mice exposed at 40,000 ppm for 3 h/d for 40 expo-
sures and rats exposed at 1000 ppm for 6 h/d for 65 exposures showed
no evidence of kidney or liver damage. Clinical case reports on hu-
mans who have either accidentally or intentionally been exposed to long
durations or high levels or both of toluene also show reversible kidney
and liver pathology symptoms, but the reports are not consistent in their
findings of pathology (Benignus, 1981a).
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CNS Effects
Chronic inhalation abuse of pure toluene produces irreversible cere-
bellar, brain-stem, and pyramidal-tract dysfunction (Spencer and
Schaumberg, 1985), but comparable changes have not been found in
solvent workers (n = 43) occupationally exposed for 22 y (SD = 7.4)
to toluene at a mean concentration of 117 ppm (Barium et al., 1985;
Juntunen et al., 1985).
Rats exposed to toluene at 1000 ppm, 6 h/d, 5 d/w, for 30 d exhib-
ited a small but significant alteration in brain function (flash-evoked
potentials) 18-26 h after the last exposure (Dyer et al., t984).
Lethality
In an extensive study conducted by the National Toxicology Program
(NTP) on nonpregnant animals, mice (n -- 120) and rats (n = 100)
exposed to toluene at 1200 ppm for 2 y had no significant differences in
survival compared with unexposed controls (Huff, 1990).
Carcinogenicity
In a 1989 NTP study (Huff, 1990), groups of 60 male and 60 female
F344 rats were exposed to toluene at 0, 600, or 1200 ppm and 60 male
and 60 female B6C3F_ mice were exposed at 0, 120, 600, or 1200
ppm for 6.5 h/d, 5 d/w, for 2 y. At 15 too, an interim sacrifice re-
vealed an increased incidence and severity of nonneoplastic lesions of
the nasal cavity of exposed rats. Minimal hyperplasia of the bronchial
epithelium was seen in 4 of 10 female mice at 1200 ppm. There were
also effects on the olfactory and respiratory epithelia of exposed rats.
There was no evidence of carcinogenicity for any group of animals in
this study.
Genotoxicity
Chromosome studies on peripheral blood lymphocytes of 34 workers
of a rotogravure plant found no significant differences between toluene-
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exposed workers and a group of 34 matched controls (Forni et al.,
1971). A similar study found no increases in the frequencies of sister
chromatid exchanges (SCEs) or chromosomal aberrations (CAs) (Maki-
Paakkanen et al., 1980). No increases in SCEs or CAs were found in
vitro in toluene-treated human lymphocytes (Gerner-Smidt and Fried-
rich, 1978). Toluene was found to be nonmutagenic in the Ames assay
(Bos et al., 1981). Toluene was found to be a potent mitotic arrestant
in the grasshopper embryo system, but it did not induce an accumula-
tion of colchicine-like mitoses (Liang et al., 1983).
Reproductive Toxicity
Wives (n = 28) of men with high or frequent occupational exposure
to toluene had an increased odds ratio of spontaneous abortion com-
pared with 29 referents (controls), but there was no association with
congenital malformations (Taskinen et al., 1989). No increases were
seen for intermediate or low or rare exposures.
A study examining occupational exposure to chemicals in the work-
place compared 301 working women who had recently given birth to a
child with congenital defects with 301 matched working women whose
most recent child was born normal (McDonald et al., 1987). The au-
thors' analysis indicated that, of nine categories of chemical exposures
examined, only in those women exposed to aromatic solvents, primarily
toluene, were there a suspicious excess number of cases of defects. Six
mothers of children with congenital defects were exposed to toluene and
two of these were also exposed to other solvents. The authors state that
the statistical significance of this result (Z = 1.77; one sided p = 0.04)
might be an overestimate.
Developmental Toxicity
There are conflicting reports of the teratogenicity of toluene. Expo-
sure to toluene at 399 ppm for 24 h/d during various portions of preg-
nancy was not teratogenic to rats, but there was considerable retardation
of fetal development (Hud_k and Ungv_lry, 1978). In mice, however,
exposure at 400 ppm from gestation days 6-15 indicated teratogenicity
(a significant shift in the rib profile) but no fetotoxicity (Courtney et
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al., 1986). Continuous exposure at 266 ppm from gestation days 6-15
caused spontaneous abortion in rabbits, while maternal-weight gain de-
creased (Ungvfiry and Tfi.trai, 1985). Toluene was found to be negative
in the Chernoff/Kavlock developmental toxicity screen in mice
(Taskinen et al., 1989).
The offspring of pregnant mice given toluene at 400 ppm in drinking
water and maintained at that concentration after weaning showed a
decreased habituation or open-field activity at 35 d of age and depressed
rotorod performance at 45-55 d of age, but no change in surface-
righting response (Kostas and Hotchin, 1981).
Interaction with Other Chemicals
Toluene and trichloroethylene have been shown to noncompetitively
inhibit each other's metabolism in rats. Trichloroethylene suppresses
the urinary excretion of hippuric acid, a main metabolite of toluene,
and toluene reduces the amount of urinary total trichloro-compounds,
the metabolites of trichloroethylene (Ikeda, 1974). lkeda also reported
suppression of benzene and styrene oxidation in vivo by co-adminis-
tration of toluene in rats (Ikeda et al., 1972). Benzene and toluene mu-
tually inhibit each other's metabolism, with toluene more effectively
inhibiting benzene metabolism than the reverse (Purcell et al., 1990). A
drastic increase in toluene concentration in the blood of rats was re-
ported after combined inhalation with acetone (Freundt and Schneider
1986). Inhalation of toluene at 954 ppm by pregnant rats combined
with acetylsalicylic acid at 500 mg/kg resulted in increased maternal
and fetal toxicity and teratogenicity (Tfitrai et al., 1979).
Simultaneous exposure of human volunteers to toluene and ethanol
has been shown to reduce the urinary excretion of hippuric acid and
o-cresol, metabolites of toluene, to less than half of the value for expo-
sure to toluene alone (Dossing et al., 1984).
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TABLE 12-2 Exposure Limits Set by Other Organizations
383
Organization Concentration, ppm
ACGIH's TLV 100 (TWA)
(proposed TLV = 50 ppm)
ACGIH's STEL 150
OSHA's PEL 200 (TWA) (8 h/d, 40 h/2, lifetime)
OSHA's PEL 300 (ceiling)
OSHA's 10-min PEL 500 (ceiling)
NIOSH's l-h REL 100 (TWA)
NIOSH's 10- min REL 200 (ceiling)
NRCs 1-h EEGL 200
NRC's 24-h EEGL 100
NRC's 90-d CEGL 20 (continuous)
TLV = threshold limit value. TWA = time-weighted average. STEL =
short-term exposure limit. PEL = permissible exposure limit. REL = recom-
mended exposure limit. EEGL = emergency exposure guidance level. CEGL
= continuous exposure guidance level.
TABLE 12-3 Spacecraft Maximum Allowable Concentrations
Duration ppm mg/m 3 Target Toxicity
I h 16 60 Neurotoxicity
24 h 16 60 Neurotoxicity
7 d" 16 60 Neurotoxicity,
irritation
30 d 16 60 Neurotoxicity,
irritation
180 d 16 60 Neurotoxicity,
irritation
"Temporary 7-d SMAC was set at 20 ppm.
RATIONALE FOR
ACCEPTABLE CONCENTRATIONS
The SMAC values listed above were set based on the lowest accept-
able concentration (AC) for any adverse effect at each exposure dura-
tion using guidelines established jointly by the National Research Coun-
cil and NASA (NRC, 1992). The evidence and logic used to determine
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the ACs for each adverse effect and exposure duration are documented
below.
Irritation
A NOAEL of 40-ppm toluene vapor lbr irritation of the eyes and
nose during a 6-h exposure was established in 16 young male volun-
teers. Because irritation is dependent on concentration but not on expo-
sure duration, the ACs for all exposure durations from 7 d to 180 d
were based on the 40-ppm NOAEL, adjusting for the low number of
subjects by a factor equal to one-tenth the square root of the number of
subjects tested:
7-d, 30-d, and 180-d ACs based on irritation
--- NOAEL x l/small n factor
= 40 ppm x (square root of 16)/10
= 16 ppm.
Some irritation is acceptable for short-term SMACs; therefore, the
irritancy ACs for 1 h and 24 h were set equal to the LOAEL:
1-h and 24-h ACs based on irritation
= LOAEL
= 100 ppm.
Neurotoxicity
A variety of CNS effects in humans have been reported in the litera-
ture, and ACs were calculated separately for each set of end points or
experiment. These ACs were not adjusted for duration of exposure be-
cause the CNS depressant effects of toluene have been shown to be re-
versible within a few minutes of cessation of exposure (Bruckner and
Peterson, 1981b), except possibly after chronic exposure to high con-
centrations, indicating that the effects are dependent on blood concen-
trations but not exposure duration. Pharmacokinetic experiments have
shown that arterial blood concentrations reach 60% of maximum in 10-
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15 min and decrease rapidly after cessation of exposure (Benignus et
al., 1981).
Although there are a number of reports in the literature that have
examined the effects on humans of exposure to toluene vapors at con-
centrations in the range of the threshold limit value (TLV) of 100 ppm,
the ACs have been set using the study that yields the lowest values of
the ACs: In 16 young subjects, exposure at 10 or 40 ppm for 6 h did
not result in any adverse effects for any of the end points examined (na-
sal mucus flow, lung function, subjective response, and psychometric
performance), but exposure at 100 ppm produced irritation of eyes and
nose and borderline significance in reduced performance in a battery of
eight psychometric tests for visual perception, vigilance, psychomotor
functions and higher cortical functions (Andersen et al., 1983). Accept-
able concentrations for vigilance, visual perception, psychomotor func-
tions, higher cortical functions, headache, dizziness, and a feeling of in-
ebriation were calculated. The ACs for 7 d, :_0 d, and 180 d were
based on the 40-ppm NOAEL, adjusting for the number of subjects.
7-d, 30-d, and 180-d ACs based on CNS effects
= NOAEL × 1/small n factor
= 40 ppm × (square root of 16)/10
= 16 ppm.
Although headaches, irritation, and insignificant decrements in psy-
chometric tests would be acceptable for short-term contingency expo-
sures, dizziness would not be acceptable, even for brief exposures dur-
ing contingency operations. Thus, the ACs for 1 h and 24 h were also
based on the 40-ppm NOAEL, adjusting for the number of subjects.
1-h and 24-h ACs based on CNS effects
= NOAEL × 1/small n factor
= 40 ppm × (square root of 16)/10
= 16 ppm.
ACs for clinical, neuropsychological, or autonomic nervous system
effects that persist after long-term occupational exposure were calcu-
lated on the basis of the 117-ppm NOAEL, correcting it for the number
of subjects.
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180-d AC based on neurotoxicity
= NOAEL × 1/small n factor
= 117 ppm × (square root of 43)/10
= 77 ppm.
ACs for exposure periods shorter than 180 d were not based on these
persistent effects because the effects involve anatomical lesions pro-
duced after long-term exposures rather than a blood-concentration-de-
pendent functional impairment.
High-frequency hearing loss and appropriate cochlear changes were
found in weanling rats exposed to toluene at 1200-1400 ppm, 14 h/d, 7
d/w, for 5 w (Rebert et al., 1982; Pryor and Rebert, 1984). In adult
animals, however, no solvent-induced alterations in the structure of
brain or peripheral nerves were seen after exposure at 1500 ppm, 6 h/d,
5 d/w, for 6 mo (Spencer et al., 1985). Thus, this finding was not
used to set an AC.
One study (Dyer et al., 1984) reported that a 30-d intermittent expo-
sure of rats to toluene at 1000 ppm led to subtle changes in brain-wave
activity, which was measured a day after exposure. This report was not
used in setting an AC for neurotoxicity for the following reasons:
First, the time course for this effect was not studied, and, second, the
brain-wave changes were not correlated with any functional deficit.
Similarly, the study of mice (Kostas and Hotchin, 1981) exposed to to-
luene in the womb through 35 d of age at a concentration of 400 ppm
in drinking water indicated a CNS effect that could not easily be corre-
lated with effects in humans (that is, decreased habituation or open-field
activity at 35 d of age and depressed rotorod performance at 45-55 d of
age).
Reproductive Toxicity
There are inconclusive reports concerning toluene's reproductive tox-
icity. In rabbits, continuous exposure at 266 ppm for gestation days 6-
15 caused a decrease in maternal-weight gain and a slight, but not sta-
tistically significant, increase in spontaneous abortion (Ungv_iry and
Tfitrai, 1985). A study of spontaneous abortion rates in the wives (n =
28) of men who were occupationally exposed to toluene suggested an
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increased risk for spontaneous abortion, but the exposure concentrations
could not be quantitated (Taskinen et al., 1989). Thus, no AC could be
set for reproductive toxicity.
Hepatotoxicity and Nephrotoxicity
Even at high but unmeasured concentrations and long exposure dura-
tions in humans (such as chronic glue sniffers), liver and kidney toxic-
ity is variable and reversible. Subchronic intermittent exposure of rats
to toluene at 5000 ppm produced reversible weight gains in the liver
and kidneys, which is not considered an adverse effect. Thus, an AC
was not set for hepatotoxicity and nephrotoxicity.
Lethality
A NOAEL of 1200-ppm toluene was seen in a 2-y exposure of mice
(n = 120) and rats (n = 100), 6.5 h/d, 5 d/w (equivalent to 140 d con-
tinuous exposure). Thus, applying Haber's rule for 180-d exposures
(but not increasing the AC for exposures shorter than the experimental
exposure) and using a species extrapolation factor of 10, the 30-d and
180-d ACs are the following:
30-d AC based on lethality
= NOAEL x 1/species factor
= 1200 ppm x 1/10
= 120 ppm.
180-d AC based on lethality
= NOAEL x time adjustment x 1/species factor
= 1200 ppm x (140 d/180 d) x 1/10
= 93 ppm (rounded to 90 ppm).
ACs for shorter exposures are not justified from this data set.
For 1-h exposures, the l-h rat LC_0 of 27,000 ppm was reduced by
factors of 10 for species extrapolation and 10 for estimating an LC_
from an LCs_).
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1-h AC based on lethality
= LCs0 x 1/species factor x I/LC_o to LC 0 factor
= 27,000ppm x 1/10 x 1/10
= 270 ppm.
Spaceflight Effects
The toxicity of toluene is not expected to be altered by the conditions
of spaceflight.
RECOMMENDATIONS
The molecular mechanisms of action of toluene in producing its CNS
effects and other toxic effects are poorly understood. Multi-species
studies (including humans) are needed to elucidate the role of metabo-
lites in the pharmacokinetics of toluene toxicity and offer results for
comparison between species.
The development and validation of neurobehavioral tests, which mea-
sure effects relevant to the ability of humans to function competently in
space or on earth, are needed to quantitate the effects of toluene expo-
sure. Studies using such validated tests should include measurements at
several vapor concentrations and with and without exercise at light and
heavy workloads.
Although the data would not be applicable to spaceflight under cur-
rent NASA guidelines, which prohibit spaceflight by pregnant astro-
nauts, more data are needed on the developmental and reproductive tox-
icity of inhaled toluene, particularly with regard to teratogenicity and
spontaneous abortion. Although some data are available on tests con-
ducted in rats and mice that support suggestive results from epidemio-
logical studies in female workers, these data are not compelling and
require replication and extension.
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